	
Approximately	O
60	O
%	O
of	O
the	O
treated	O
patients	O
were	O
male	O
,	O
with	O
a	O
mean	O
age	O
of	O
55.1	O
years	O
.	O
	
The	O
table	O
below	O
lists	O
the	O
adverse	O
drug	O
reactions	O
that	O
occurred	O
in	O
at	O
least	O
1	O
%	O
of	O
patients	O
treated	O
with	O
Ferriprox	O
in	O
clinical	O
trials	O
.	O
	
5.9	O
Progressive	O
Multifocal	O
Leukoencephalopathy	O
JC	B
virus	I
infection	I
resulting	O
in	O
PML	B
and	O
death	B
has	O
been	O
reported	O
in	O
ADCETRIS-treated	O
patients	O
.	O
	
If	O
a	O
patient	O
develops	O
skin	O
discoloration	O
,	O
serious	O
consideration	O
should	O
be	O
given	O
to	O
changing	O
to	O
an	O
alternate	O
medication	O
.	O
	
5.8	O
Hepatotoxicity	O
Serious	O
cases	O
of	O
hepatotoxicity	B
,	O
including	O
fatal	B
outcomes	O
,	O
have	O
occurred	O
in	O
patients	O
receiving	O
ADCETRIS	O
.	O
	
*	O
Tissue	O
inflammation	O
as	O
well	O
as	O
prostatic	O
hyperplasia	O
have	O
been	O
associated	O
with	O
false	O
positive	O
11	O
C-choline	O
PET	O
images	O
.	O
	
Interrupt	O
or	O
discontinue	O
Zydelig	O
as	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
923	O
patients	O
to	O
TANZEUM	O
and	O
a	O
mean	O
duration	O
of	O
exposure	O
to	O
TANZEUM	O
of	O
93	O
weeks	O
.	O
	
Table	O
2	O
:	O
Severe	O
to	O
Fatal	B
Immune-mediated	B
Adverse	I
Reactions	I
in	O
Study	O
1	O
a	O
Including	O
fatal	B
outcome	O
.	O
	
(	O
5.1	O
)	O
item	O
{	O
Cataracts-	O
Use	O
of	O
corticosteroids	O
may	O
result	O
in	O
posterior	B
subcapsular	I
cataract	I
formation	O
.	O
	
5.4	O
Tumor	O
Lysis	O
Syndrome	O
Tumor	B
lysis	I
syndrome	I
(	O
TLS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
has	O
been	O
observed	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
*	O
Hepatic	B
toxicity	I
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.5	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Patients	O
received	O
GILOTRIF	O
40	O
mg	O
daily	O
until	O
documented	O
disease	O
progression	O
or	O
intolerance	O
to	O
the	O
therapy	O
.	O
	
5.8	O
Contact	O
Lens	O
Wear	O
DUREZOL	O
should	O
not	O
be	O
instilled	O
while	O
wearing	O
contact	O
lenses	O
.	O
	
(	O
5.1	O
)	O
*	O
Hemorrhage	B
:	O
Severe	O
,	O
sometimes	O
fatal	B
,	O
hemorrhage	B
including	O
hemoptysis	B
and	O
gastrointestinal	B
hemorrhage	I
occurred	O
in	O
3	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
of	O
Volume	B
DepletionVolume	O
depletion	B
includes	O
reports	O
of	O
dehydration	B
,	O
hypovolemia	B
,	O
orthostatic	B
hypotension	I
,	O
or	O
hypotension	B
.	O
	
To	O
adjust	O
for	O
normal	O
growth	O
,	O
z-scores	O
were	O
derived	O
(	O
measured	O
in	O
standard	O
deviations	O
[	O
SD	O
]	O
)	O
,	O
which	O
normalize	O
for	O
the	O
natural	O
growth	O
of	O
pediatric	O
patients	O
by	O
comparisons	O
to	O
age-	O
and	O
sex-matched	O
population	O
standards	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Patients	O
with	O
MCL	O
who	O
develop	O
lymphocytosis	O
greater	O
than	O
400,000/mcL	O
have	O
developed	O
intracranial	O
hemorrhage	O
,	O
lethargy	O
,	O
gait	O
instability	O
,	O
and	O
headache	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
treated	O
with	O
DALVANCE	O
was	O
47	O
years	O
,	O
ranging	O
between	O
16	O
and	O
93	O
years	O
old	O
.	O
	
Cervical	O
Dystonia	O
About	O
3	O
%	O
of	O
subjects	O
developed	O
antibodies	O
(	O
binding	O
or	O
neutralizing	O
)	O
over	O
time	O
with	O
DYSPORT	O
(	O
r	O
)	O
treatment	O
.	O
	
(	O
6.2	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Janssen	O
Products	O
,	O
LP	O
at	O
1-800-JANSSEN	O
(	O
1-800-526-7736	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
laboratory	O
abnormality	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
was	O
neutropenia	B
.	O
	
Serious	O
,	O
life-threatening	O
events	O
of	O
herpes	B
simplex	I
infections	I
,	O
including	O
cases	O
of	O
encephalitis	B
and	O
multiorgan	B
failure	I
,	O
have	O
occurred	O
with	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
postmarketing	O
setting	O
.	O
	
In	O
general	O
,	O
limiting	O
the	O
dose	O
injected	O
into	O
the	O
sternocleidomastoid	O
muscle	O
may	O
decrease	O
the	O
occurrence	O
of	O
dysphagia	O
.	O
	
Use	O
of	O
SIMPONI	O
ARIA	O
in	O
patients	O
under	O
18	O
years	O
of	O
age	O
has	O
not	O
been	O
established	O
.	O
	
5.3	O
Interstitial	O
Lung	O
Disease	O
(	O
ILD	O
)	O
ILD	B
or	O
ILD-like	B
adverse	I
reactions	I
(	O
e.g.	O
,	O
lung	B
infiltration	I
,	O
pneumonitis	B
,	O
acute	B
respiratory	I
distress	I
syndrome	I
,	O
or	O
alveolitis	B
allergic	I
)	O
occurred	O
in	O
1.5	O
%	O
of	O
the	O
3865	O
patients	O
who	O
received	O
GILOTRIF	O
across	O
clinical	O
trials	O
;	O
of	O
these	O
,	O
0.4	O
%	O
were	O
fatal	B
.	O
	
The	O
incidence	O
of	O
adverse	O
reactions	O
associated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
is	O
shown	O
in	O
Table	O
2	O
.	O
	
These	O
metabolic	B
changes	I
include	O
hyperglycemia	B
,	O
dyslipidemia	B
,	O
and	O
weight	B
gain	I
.	O
	
Pulmonary	B
embolism	I
was	O
fatal	B
in	O
2	O
%	O
(	O
1/55	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
cardiomyopathy	B
in	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
was	O
86	O
days	O
(	O
range	O
:	O
27	O
to	O
253	O
days	O
)	O
.	O
	
For	O
ULORIC	O
40	O
mg	O
,	O
559	O
patients	O
were	O
treated	O
for	O
>	O
=6	O
months	O
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
with	O
neutrophil	O
counts	O
of	O
<	O
=1,500	O
cells/mm	O
3	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
received	O
a	O
transfusion	O
for	O
the	O
management	O
of	O
anemia	O
was	O
3	O
%	O
of	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
less	O
than	O
1	O
%	O
in	O
subjects	O
who	O
received	O
PegIntron/REBETOL	O
alone	O
.	O
	
*	O
Perform	O
test	O
for	O
latent	O
TB	O
;	O
if	O
positive	O
,	O
start	O
treatment	O
for	O
TB	O
prior	O
to	O
starting	O
SIMPONI	O
ARIA	O
(	O
5.1	O
)	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
*	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=	O
5	O
%	O
)	O
in	O
clinical	O
trials	O
were	O
hypersensitivity	B
reactions	I
and	O
included	O
:	O
anaphylaxis	B
,	O
rash	B
,	O
pyrexia	B
,	O
flushing/feeling	O
hot	B
,	O
urticaria	B
,	O
headache	B
,	O
hyperhidrosis	B
,	O
nausea	B
,	O
cough	B
,	O
decreased	B
oxygen	I
saturation	I
,	O
tachycardia	B
,	O
tachypnea	B
,	O
chest	B
discomfort	I
,	O
dizziness	B
,	O
muscle	B
twitching	I
,	O
agitation	B
,	O
cyanosis	B
,	O
erythema	B
,	O
hypertension/increased	O
blood	B
pressure	I
,	O
pallor	B
,	O
rigors	B
,	O
tremor	B
,	O
vomiting	B
,	O
fatigue	B
,	O
and	O
myalgia	B
(	O
6.1	O
)	O
.	O
	
5.2	O
Concomitant	O
Use	O
of	O
CYP3A4	O
Inhibitors	O
STENDRA	O
metabolism	O
is	O
principally	O
mediated	O
by	O
the	O
CYP450	O
isoform	O
3A4	O
(	O
CYP3A4	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Endophthalmitis	B
and	O
retinal	B
detachments	I
may	O
occur	O
following	O
intravitreal	O
injections	O
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
alopecia	B
,	O
angio-edema	B
,	O
dermatitis	B
,	O
dermographism	B
,	O
ecchymosis	B
,	O
eczema	B
,	O
hair	B
color	I
changes	I
,	O
hair	B
growth	I
abnormal	I
,	O
hyperhidrosis	B
,	O
peeling	B
skin	I
,	O
petechiae	B
,	O
photosensitivity	B
,	O
pruritus	B
,	O
purpura	B
,	O
skin	B
discoloration	I
,	O
skin	B
lesion	I
,	O
skin	B
odor	I
abnormal	I
,	O
urticaria	B
.	O
	
Call	O
your	O
doctor	O
for	O
medical	O
advice	O
about	O
side	O
effects	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
PROMACTA	O
.	O
	
In	O
addition	O
,	O
one	O
DALVANCE-treated	O
subject	O
in	O
a	O
Phase	O
1	O
trial	O
had	O
post-baseline	O
ALT	B
elevations	I
greater	O
than	O
20	O
times	O
ULN	O
.	O
	
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
arthritis	B
,	O
joint	B
stiffness	I
,	O
joint	B
swelling	I
,	O
muscle	B
spasms	I
,	O
musculoskeletal	B
pain	I
,	O
myalgia	B
.	O
	
If	O
such	O
a	O
reaction	O
occurs	O
,	O
therapy	O
with	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
stopped	O
at	O
once	O
and	O
alternative	O
treatments	O
should	O
be	O
considered	O
.	O
	
There	O
were	O
no	O
differences	O
in	O
efficacy	O
or	O
safety	O
between	O
patients	O
with	O
or	O
without	O
immunoreactivity	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Risk	O
of	O
Thyroid	O
C-cell	O
Tumors	O
Carcinogenicity	O
of	O
albiglutide	O
could	O
not	O
be	O
assessed	O
in	O
rodents	O
due	O
to	O
the	O
rapid	O
development	O
of	O
drug-clearing	O
,	O
anti-drug	O
antibodies	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
Higher	O
than	O
recommended	O
dosing	O
or	O
repeated	O
dosing	O
appears	O
to	O
increase	O
the	O
risk	O
(	O
5.1	O
)	O
*	O
hypersensitivity	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
,	O
including	O
death	B
,	O
have	O
occurred	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
,	O
and	O
treat	O
promptly	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Most	O
commonly	O
reported	O
adverse	O
reactions	O
were	O
flushing	B
(	O
2	O
%	O
)	O
,	O
headache	B
(	O
1	O
%	O
)	O
,	O
increased	B
blood	I
pressure	I
(	O
2	O
%	O
)	O
,	O
nausea	B
(	O
1	O
%	O
)	O
,	O
and	O
dizziness	B
(	O
1	O
%	O
)	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
DaTscan	O
administration	O
.	O
	
No	O
neutralizing	O
antibodies	O
were	O
detected	O
.	O
	
Patients	O
were	O
between	O
the	O
ages	O
of	O
18	O
and	O
69	O
on	O
the	O
date	O
of	O
the	O
first	O
dose	O
of	O
CERDELGA	O
,	O
and	O
included	O
87	O
females	O
and	O
72	O
males	O
.	O
	
Psoriasis	O
Clinical	O
Trials	O
The	O
safety	O
of	O
OTEZLA	O
(	O
r	O
)	O
was	O
assessed	O
in	O
1426	O
subjects	O
in	O
3	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trials	O
in	O
adult	O
subjects	O
with	O
moderate	O
to	O
severe	O
plaque	O
psoriasis	O
who	O
were	O
candidates	O
for	O
phototherapy	O
or	O
systemic	O
therapy	O
.	O
	
The	O
incidence	O
of	O
ILD	B
appeared	O
to	O
be	O
higher	O
in	O
patients	O
of	O
Asian	O
ethnicity	O
(	O
2.1	O
%	O
)	O
as	O
compared	O
to	O
non-Asians	O
(	O
1.2	O
%	O
)	O
.	O
	
Monitor	O
patients	O
during	O
and	O
for	O
an	O
appropriate	O
period	O
of	O
time	O
after	O
administration	O
of	O
BENLYSTA	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
at	O
risk	O
for	O
gastrointestinal	O
perforation	O
or	O
fistula	O
.	O
	
Adverse	O
Reactions	O
in	O
Pediatric	O
Patients	O
During	O
clinical	O
trials	O
,	O
141	O
pediatric	O
patients	O
(	O
7	O
aged	O
<	O
24	O
months	O
,	O
33	O
aged	O
2	O
-	O
5	O
years	O
,	O
58	O
aged	O
6	O
-	O
11	O
years	O
and	O
43	O
aged	O
12	O
-	O
17	O
)	O
received	O
DOTAREM	O
.	O
	
(	O
5.14	O
,	O
8.1	O
)	O
5.1	O
Cardiac	O
Toxicities	O
worsening	B
of	I
pre-existing	I
cardiac	I
failure	I
(	O
e.g.	O
,	O
congestive	B
heart	I
failure	I
,	O
pulmonary	B
edema	I
,	O
decreased	B
ejection	I
fraction	I
)	O
,	O
restrictive	B
cardiomyopathy	I
,	O
myocardial	B
ischemia	I
,	O
and	O
myocardial	B
infarction	I
including	O
fatalities	B
have	O
occurred	O
following	O
administration	O
of	O
Kyprolis	O
.	O
	
In	O
some	O
cases	O
,	O
hyperglycemia	O
has	O
resolved	O
when	O
the	O
atypical	O
antipsychotic	O
was	O
discontinued	O
;	O
however	O
,	O
some	O
patients	O
required	O
continuation	O
of	O
anti-diabetic	O
treatment	O
despite	O
discontinuation	O
of	O
the	O
antipsychotic	O
drug	O
.	O
	
Patients	O
with	O
unstable	O
or	O
poorly	O
controlled	O
hypertension	O
,	O
a	O
recent	O
history	O
of	O
cardiovascular	O
or	O
cerebrovascular	O
events	O
may	O
be	O
at	O
an	O
increased	O
risk	O
of	O
adverse	B
cardiovascular	I
effects	I
.	O
	
In	O
the	O
patients	O
with	O
AP	O
CML	O
and	O
BP	O
CML	O
,	O
the	O
median	O
duration	O
of	O
BOSULIF	O
treatment	O
was	O
10	O
months	O
and	O
3	O
months	O
,	O
respectively	O
.	O
	
Administration	O
of	O
cabazitaxel	O
to	O
patients	O
with	O
mild	O
and	O
moderate	O
hepatic	O
impairment	O
should	O
be	O
undertaken	O
with	O
caution	O
and	O
close	O
monitoring	O
of	O
safety	O
.	O
	
Patients	O
treated	O
with	O
DALVANCE	O
were	O
predominantly	O
male	O
(	O
60	O
%	O
)	O
and	O
Caucasian	O
(	O
78	O
%	O
)	O
.	O
	
Patients	O
with	O
acute	O
respiratory	O
illness	O
may	O
be	O
at	O
risk	O
of	O
serious	O
acute	O
exacerbation	O
of	O
their	O
respiratory	O
compromise	O
due	O
to	O
hypersensitivity	O
reactions	O
,	O
and	O
require	O
additional	O
monitoring	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
The	O
population	O
was	O
almost	O
entirely	O
Caucasian	O
(	O
99	O
%	O
)	O
with	O
a	O
median	O
age	O
of	O
51	O
years	O
(	O
range	O
18-82	O
years	O
)	O
.	O
	
Although	O
there	O
were	O
few	O
non-Caucasian	O
patients	O
,	O
no	O
differences	O
in	O
the	O
incidences	O
of	O
adverse	O
reactions	O
compared	O
to	O
Caucasian	O
patients	O
were	O
observed	O
.	O
	
5.7	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TRULICITY	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
*	O
XIAFLEX	O
is	O
available	O
for	O
the	O
treatment	O
of	O
Peyronie	O
's	O
disease	O
only	O
through	O
a	O
restricted	O
program	O
called	O
the	O
XIAFLEX	O
REMS	O
Program	O
(	O
5.3	O
)	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
YERVOY	O
.	O
	
Appropriate	O
prophylactic	O
measures	O
,	O
including	O
pretreatment	O
nontoxic	O
cytoreduction	O
and	O
on-treatment	O
hydration	O
,	O
should	O
be	O
used	O
for	O
the	O
prevention	O
of	O
TLS	O
during	O
BLINCYTO	O
treatment	O
.	O
	
Immunogenicity	O
Antibodies	O
directed	O
against	O
the	O
belatacept	O
molecule	O
were	O
assessed	O
in	O
398	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
in	O
Studies	O
1	O
and	O
2	O
(	O
212	O
of	O
these	O
patients	O
were	O
treated	O
for	O
at	O
least	O
2	O
years	O
)	O
.	O
	
If	O
this	O
product	O
is	O
used	O
for	O
10	O
days	O
or	O
longer	O
,	O
IOP	O
should	O
be	O
monitored	O
.	O
	
(	O
5.5	O
)	O
*	O
QT	B
prolongation	I
:	O
QT	O
interval	O
should	O
be	O
monitored	O
in	O
patients	O
taking	O
concomitant	O
medications	O
known	O
to	O
increase	O
the	O
QT	O
interval	O
or	O
with	O
certain	O
heart	O
conditions	O
.	O
	
Beta-agonist	O
medications	O
may	O
produce	O
transient	O
hyperglycemia	B
in	O
some	O
patients	O
.	O
	
Amyvid	O
caused	O
no	O
serious	O
adverse	O
reactions	O
in	O
the	O
studies	O
and	O
the	O
reported	O
adverse	O
reactions	O
were	O
predominantly	O
mild	O
to	O
moderate	O
in	O
severity	O
.	O
	
However	O
,	O
an	O
earlier	O
onset	O
can	O
not	O
be	O
ruled	O
out	O
,	O
and	O
it	O
is	O
possible	O
that	O
retinal	B
abnormalities	I
were	O
present	O
earlier	O
in	O
the	O
course	O
of	O
exposure	O
to	O
POTIGA	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
from	O
NORTHERA	O
were	O
hypertension	B
or	O
increased	B
blood	I
pressure	I
and	O
nausea	B
.	O
	
5.6	O
Effects	O
on	O
Ability	O
to	O
Drive	O
and	O
Use	O
Machines	O
Due	O
to	O
the	O
potential	O
for	O
neurologic	B
events	I
,	O
including	O
seizures	B
,	O
patients	O
receiving	O
BLINCYTO	O
are	O
at	O
risk	O
for	O
loss	B
of	I
consciousness	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
6.3	O
Immunogenicity	O
During	O
clinical	O
studies	O
in	O
Dupuytren	O
's	O
contracture	O
and	O
Peyronie	O
's	O
disease	O
,	O
patients	O
were	O
tested	O
at	O
multiple	O
time	O
points	O
for	O
antibodies	O
to	O
the	O
protein	O
components	O
of	O
XIAFLEX	O
(	O
AUX-I	O
and	O
AUX-II	O
)	O
.	O
	
Withhold	O
then	O
dose	O
reduce	O
,	O
or	O
permanently	O
discontinue	O
ZYKADIA	O
.	O
	
The	O
most	O
common	O
reasons	O
for	O
interruption	O
or	O
discontinuations	O
were	O
diarrhea	B
(	O
11	O
%	O
)	O
,	O
pneumonia	B
(	O
11	O
%	O
)	O
,	O
and	O
elevated	B
transaminases	I
(	O
10	O
%	O
)	O
.	O
	
First	O
onset	O
of	O
symptoms	O
occurred	O
at	O
various	O
times	O
from	O
initiation	O
of	O
ADCETRIS	O
therapy	O
,	O
with	O
some	O
cases	O
occurring	O
within	O
3	O
months	O
of	O
initial	O
exposure	O
.	O
	
Among	O
patients	O
in	O
whom	O
the	O
status	O
of	O
both	O
mucous	B
membrane	I
discoloration	I
and	O
retinal	B
pigmentary	I
abnormalities	I
are	O
reported	O
,	O
approximately	O
a	O
quarter	O
of	O
those	O
with	O
mucous	B
membrane	I
discoloration	I
had	O
concurrent	O
retinal	B
pigmentary	I
abnormalities	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Patients	O
who	O
have	O
been	O
previously	O
maintained	O
on	O
20	O
mg	O
or	O
more	O
of	O
prednisone	O
(	O
or	O
its	O
equivalent	O
)	O
may	O
be	O
most	O
susceptible	O
,	O
particularly	O
when	O
their	O
systemic	O
corticosteroids	O
have	O
been	O
almost	O
completely	O
withdrawn	O
.	O
	
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
:	O
myositis	B
,	O
chondropathy	B
,	O
trismus	B
.	O
	
Monitor	O
lipase	O
and	O
amylase	O
prior	O
to	O
treatment	O
and	O
periodically	O
thereafter	O
as	O
clinically	O
indicated	O
.	O
	
Consider	O
the	O
diagnosis	O
of	O
PML	O
in	O
any	O
patient	O
presenting	O
with	O
new-onset	O
signs	O
and	O
symptoms	O
of	O
central	O
nervous	O
system	O
abnormalities	O
.	O
	
Liver	O
Function	O
Test	O
Abnormalities	O
:	O
Among	O
patients	O
with	O
Grade	O
0	O
or	O
1	O
ALT	O
levels	O
at	O
baseline	O
,	O
18	O
%	O
of	O
HALAVEN-treated	O
patients	O
experienced	O
Grade	O
2	O
or	O
greater	O
ALT	B
elevation	I
.	O
	
RE-COVER	O
and	O
RE-COVER	O
II	O
studies	O
compared	O
PRADAXA	O
150	O
mg	O
twice	O
daily	O
and	O
warfarin	O
for	O
the	O
treatment	O
of	O
deep	O
vein	O
thrombosis	O
and	O
pulmonary	O
embolism	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactionsare	O
discussed	O
elsewhere	O
in	O
the	O
labeling	O
:	O
*	O
Nephrogenic	B
systemic	I
fibrosis	I
(	O
NSF	B
)	O
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Hypersensitivity	B
reactions	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
0.5	O
%	O
)	O
are	O
nausea	B
,	O
headache	B
,	O
feeling	B
hot	I
,	O
dizziness	B
,	O
and	O
back	B
pain	I
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bayer	O
HealthCare	O
Pharmaceuticals	O
Inc.	O
at	O
1-888-84-BAYER	O
(	O
1-888-842-2937	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
infection	O
and	O
treat	O
appropriately	O
.	O
	
Monitor	O
laboratory	O
parameters	O
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
white	O
blood	O
cell	O
count	O
and	O
absolute	O
neutrophil	O
count	O
)	O
during	O
BLINCYTO	O
infusion	O
.	O
	
Three	O
of	O
these	O
6	O
patients	O
tested	O
positive	O
for	O
neutralizing	O
antibodies	O
.	O
	
The	O
mean	O
age	O
of	O
participants	O
was	O
55	O
years	O
,	O
1	O
%	O
of	O
participants	O
were	O
75	O
years	O
or	O
older	O
and	O
53	O
%	O
of	O
participants	O
were	O
male	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
any	O
neurological	O
toxicity	O
was	O
7	O
days	O
.	O
	
Signs	O
and	O
symptoms	O
of	O
hyponatremia	B
include	O
headache	B
,	O
difficulty	B
concentrating	I
,	O
memory	B
impairment	I
,	O
confusion	B
,	O
weakness	B
,	O
and	O
unsteadiness	B
,	O
which	O
can	O
lead	O
to	O
falls	B
.	O
	
(	O
5.6	O
)	O
*	O
Extravasation	B
:	O
Assure	O
good	O
venous	O
access	O
and	O
monitor	O
infusion	O
site	O
during	O
and	O
after	O
administration	O
.	O
	
Table	O
6	O
:	O
Weight	O
Change	O
Results	O
Categorized	O
by	O
BMI	O
at	O
Baseline	O
:	O
Comparator-Controlled	O
52-Week	O
Study	O
in	O
Adults	O
with	O
Schizophrenia	O
BMI	O
<	O
23	O
SAPHRIS	O
N=295	O
BMI	O
23	O
-	O
<	O
=27	O
SAPHRIS	O
N=290	O
BMI	O
>	O
27	O
SAPHRIS	O
N=302	O
Mean	O
change	O
from	O
Baseline	O
(	O
kg	O
)	O
1.7	O
1	O
0	O
%	O
with	O
>	O
=7	O
%	O
increase	B
in	I
body	I
weight	I
22	O
%	O
13	O
%	O
9	O
%	O
Pediatric	O
Patients	O
:	O
Data	O
on	O
mean	O
changes	B
in	I
body	I
weight	I
and	O
the	O
proportion	O
of	O
pediatric	O
patients	O
meeting	O
a	O
weight	B
gain	I
criterion	O
of	O
>	O
=7	O
%	O
of	O
body	O
weight	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
trial	O
are	O
presented	O
in	O
Table	O
7	O
.	O
	
5.5	O
Genital	O
Mycotic	O
Infections	O
INVOKANA	O
increases	O
the	O
risk	O
of	O
genital	B
mycotic	I
infections	I
.	O
	
Table	O
1	O
Investigator	O
Assessment	O
of	O
Maximal	O
Local	B
Skin	I
Reactions	I
in	O
the	O
Treatment	O
Area	O
during	O
the	O
57	O
Days	O
Post	O
Treatment	O
Period	O
(	O
face/scalp	O
trials	O
)	O
Face	O
and	O
Scalp	O
(	O
n=545	O
)	O
Picato	O
(	O
r	O
)	O
gel	O
,	O
0.015	O
%	O
once	O
daily	O
for	O
3	O
days	O
Skin	B
reactions	I
Any	I
Gradea	I
>	I
Baseline	I
Grade	I
4	I
87	O
(	O
32	O
%	O
)	O
3	O
(	O
1	O
%	O
)	O
1	O
(	O
0	O
%	O
)	O
0	O
(	O
0	O
%	O
)	O
a	O
Mild	O
(	O
grade	O
1	O
)	O
,	O
Moderate	O
(	O
grade	O
2-3	O
)	O
or	O
Severe	O
(	O
grade	O
4	O
)	O
.	O
	
The	O
median	O
daily	O
dose	O
of	O
TAFINLAR	O
was	O
300	O
mg	O
(	O
range	O
:	O
118	O
to	O
300	O
mg	O
)	O
.	O
	
5.5	O
Metabolic	O
Changes	O
Atypical	O
antipsychotic	O
drugs	O
have	O
been	O
associated	O
with	O
metabolic	B
changes	I
that	O
may	O
increase	B
cardiovascular/cerebrovascular	I
risk	I
.	O
	
Pain	B
increases	I
occurring	O
during	O
patch	O
application	O
usually	O
began	O
to	O
resolve	O
after	O
patch	O
removal	O
.	O
	
5.4	O
Tardive	O
Dyskinesia	O
A	O
syndrome	O
of	O
potentially	O
irreversible	O
,	O
involuntary	B
,	I
dyskinetic	I
movements	I
can	O
develop	O
in	O
patients	O
treated	O
with	O
antipsychotic	O
drugs	O
.	O
	
Increases	O
in	O
Low-Density	O
Lipoprotein	O
Cholesterol	O
(	O
LDL-C	O
)	O
and	O
non-High-Density	O
Lipoprotein	O
Cholesterol	O
(	O
non-HDL-C	O
)	O
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
trials	O
,	O
dose-related	O
increases	B
in	I
LDL-C	I
with	O
INVOKANA	O
were	O
observed	O
.	O
	
Upper	O
Limb	O
Spasticity	O
From	O
230	O
subjects	O
treated	O
with	O
DYSPORT	O
(	O
r	O
)	O
and	O
tested	O
for	O
the	O
presence	O
of	O
binding	O
antibodies	O
,	O
5	O
subjects	O
were	O
positive	O
at	O
baseline	O
and	O
17	O
developed	O
antibodies	O
after	O
treatment	O
.	O
	
*	O
Use	O
with	O
caution	O
in	O
patients	O
with	O
compromised	O
respiratory	O
function	O
or	O
dysphagia	O
(	O
5.4	O
)	O
.	O
	
All	O
other	O
chemotherapy	O
was	O
continued	O
according	O
to	O
the	O
patient	O
's	O
prescribed	O
treatment	O
regimen	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.Study	O
2	O
enrolled	O
30	O
patients	O
[	O
29	O
were	O
being	O
treated	O
for	O
ALL	O
and	O
one	O
for	O
lymphoblastic	O
lymphoma	O
(	O
LBL	O
)	O
]	O
following	O
allergy	O
to	O
native	O
E.	O
coli	O
asparaginase	O
or	O
pegaspargase	O
.	O
	
The	O
risk	O
of	O
developing	O
tardive	O
dyskinesia	O
and	O
the	O
likelihood	O
that	O
it	O
will	O
become	O
irreversible	O
are	O
believed	O
to	O
increase	O
as	O
the	O
duration	O
of	O
treatment	O
and	O
the	O
total	O
cumulative	O
dose	O
of	O
antipsychotic	O
administered	O
increases	O
.	O
	
One	O
of	O
these	O
events	O
was	O
fatal	B
.	O
	
In	O
unapproved	O
uses	O
,	O
including	O
spasticity	O
in	O
children	O
and	O
adults	O
,	O
and	O
in	O
approved	O
indications	O
,	O
symptoms	O
consistent	O
with	O
spread	B
of	I
toxin	I
effect	I
have	O
been	O
reported	O
at	O
doses	O
comparable	O
to	O
or	O
lower	O
than	O
doses	O
used	O
to	O
treat	O
cervical	O
dystonia	O
.	O
	
5.3	O
Neuroleptic	O
Malignant	O
Syndrome	O
(	O
NMS	O
)	O
A	O
potentially	O
fatal	O
symptom	O
complex	O
sometimes	O
referred	O
to	O
as	O
Neuroleptic	B
Malignant	I
Syndrome	I
(	O
NMS	B
)	O
has	O
been	O
reported	O
in	O
association	O
with	O
administration	O
of	O
antipsychotic	O
drugs	O
,	O
including	O
FANAPT	O
.	O
	
Withhold	O
GILOTRIF	O
during	O
evaluation	O
of	O
patients	O
with	O
suspected	O
ILD	O
,	O
and	O
discontinue	O
GILOTRIF	O
in	O
patients	O
with	O
confirmed	O
ILD	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
belimumab	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
6.2	O
Immunogenicity	O
Across	O
repeated	O
treatment	O
in	O
the	O
controlled	O
trials	O
,	O
4	O
patients	O
tested	O
positive	O
for	O
anti-icatibant	O
antibodies	O
.	O
	
In	O
addition	O
,	O
the	O
incidence	O
of	O
Grade	O
1-3	O
palmar-plantar	B
erythrodysesthesia	I
syndrome	I
was	O
7	O
%	O
.	O
	
Two	O
percent	O
(	O
4	O
of	O
183	O
)	O
of	O
subjects	O
had	O
a	O
Grade	O
3	O
to	O
4	O
treatment-emergent	O
hematology	O
laboratory	O
abnormality	O
,	O
with	O
neutropenia	B
(	O
2	O
%	O
[	O
3	O
of	O
183	O
]	O
)	O
being	O
the	O
most	O
frequently	O
reported	O
.	O
	
5.9	O
Infusion	O
Reactions	O
Infusion	B
reactions	I
,	O
including	O
life-threatening	O
reactions	O
,	O
have	O
occurred	O
in	O
patients	O
receiving	O
Kyprolis	O
.	O
	
5.2	O
Effects	O
on	O
Serum	O
Liver	O
Biochemistries	O
in	O
Patients	O
with	O
Hepatitis	O
B	O
or	O
C	O
Co-infection	O
Patients	O
with	O
underlying	O
hepatitis	O
B	O
or	O
C	O
may	O
be	O
at	O
increased	O
risk	O
for	O
worsening	O
or	O
development	O
of	O
transaminase	B
elevations	I
with	O
use	O
of	O
TIVICAY	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
(	O
6	O
)	O
SJIA	O
:	O
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
greater	O
than	O
10	O
%	O
reported	O
by	O
patients	O
with	O
SJIA	O
treated	O
with	O
ILARIS	O
are	O
infections	B
(	O
nasopharyngitis	B
and	O
upper	B
respiratory	I
tract	I
infections	I
)	O
,	O
abdominal	B
pain	I
and	O
injection	B
site	I
reactions	I
.	O
	
The	O
most	O
frequently	O
observed	O
adverse	O
drug	O
reactions	O
in	O
subjects	O
receiving	O
Neuraceq	O
were	O
injection	B
site	I
reactions	I
.	O
	
For	O
these	O
patients	O
,	O
a	O
reduction	O
in	O
the	O
quantity	O
of	O
concurrently	O
administered	O
lipids	O
may	O
be	O
necessary	O
to	O
compensate	O
for	O
the	O
amount	O
of	O
lipid	O
infused	O
as	O
part	O
of	O
the	O
Cleviprex	O
formulation	O
.	O
	
The	O
majority	O
of	O
these	O
reports	O
have	O
occurred	O
in	O
patients	O
who	O
received	O
concomitant	O
immunosuppressants	O
.	O
	
Some	O
patients	O
with	O
hypersensitivity	B
reactions	I
also	O
reported	O
a	O
history	O
of	O
allergy	O
to	O
other	O
macrolides	O
.	O
	
For	O
cases	O
of	O
Grade	O
3	O
non-infectious	O
pneumonitis	O
interrupt	O
AFINITOR	O
until	O
resolution	O
to	O
less	O
than	O
or	O
equal	O
to	O
Grade	O
1	O
.	O
	
*	O
Increased	O
risk	O
for	O
developing	O
post-transplant	B
lymphoproliferative	I
disorder	I
(	O
PTLD	B
)	O
,	O
predominantly	O
involving	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O
	
WARNING	O
:	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
ELIQUIS	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	B
EVENTS	I
(	O
B	O
)	O
EPIDURAL	B
HEMATOMA	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
For	O
ULORIC	O
80	O
mg	O
,	O
1377	O
subjects	O
were	O
treated	O
for	O
>	O
=6	O
months	O
,	O
674	O
patients	O
were	O
treated	O
for	O
>	O
=1	O
year	O
and	O
515	O
patients	O
were	O
treated	O
for	O
>	O
=2	O
years	O
.	O
	
*	O
Hepatotoxicity	B
:	O
Monitor	O
liver	O
enzymes	O
and	O
bilirubin	O
(	O
5.8	O
)	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Genzyme	O
at	O
1-800-745-4447	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
peginterferon	O
alfa	O
and	O
ribavirin	O
for	O
additional	O
information	O
regarding	O
dose	O
reduction	O
or	O
discontinuation	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
)	O
include	O
headache	B
,	O
flushing	B
,	O
nasal	B
congestion	I
,	O
nasopharyngitis	B
,	O
and	O
back	B
pain	I
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
1-877-663-0412	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
*	O
Talk	O
with	O
your	O
healthcare	O
provider	O
regularly	O
about	O
whether	O
you	O
should	O
continue	O
taking	O
DUAVEE	O
.	O
	
Ribavirin	O
dose	O
reduction	O
is	O
recommended	O
for	O
the	O
initial	O
management	O
of	O
anemia	O
.	O
	
Patients	O
should	O
be	O
instructed	O
about	O
non-pharmacologic	O
interventions	O
that	O
help	O
to	O
reduce	O
the	O
occurrence	O
of	O
orthostatic	O
hypotension	O
(	O
e.g.	O
,	O
sitting	O
on	O
the	O
edge	O
of	O
the	O
bed	O
for	O
several	O
minutes	O
before	O
attempting	O
to	O
stand	O
in	O
the	O
morning	O
and	O
slowly	O
rising	O
from	O
a	O
seated	O
position	O
)	O
.	O
	
If	O
bilirubin	O
is	O
elevated	O
,	O
perform	O
fractionation	O
.	O
	
Laboratory	O
Parameters	O
:	O
activated	B
partial	I
thromboplastin	I
time	I
prolonged	I
,	O
creatine	B
increased	I
,	O
bicarbonate	B
decreased	I
,	O
sodium	B
increased	I
,	O
EEG	B
abnormal	I
,	O
glucose	B
increased	I
,	O
cholesterol	B
increased	I
,	O
triglycerides	B
increased	I
,	O
amylase	B
increased	I
,	O
potassium	B
increased	I
,	O
TSH	B
increased	I
,	O
platelet	B
count	I
decreased	I
,	O
hematocrit	B
decreased	I
,	O
hemoglobin	B
decreased	I
,	O
MCV	B
increased	I
,	O
RBC	B
decreased	I
,	O
creatinine	B
increased	I
,	O
blood	B
urea	I
increased	I
,	O
BUN/creatinine	B
ratio	I
increased	I
,	O
CPK	B
)	I
increased	I
,	O
alkaline	B
phosphatase	I
increased	I
,	O
LDH	B
increased	I
,	O
PSA	B
increased	I
,	O
urine	B
output	I
increased	I
,	O
lymphocyte	B
count	I
decreased	I
,	O
neutrophil	B
count	I
decreased	I
,	O
WBC	B
increased	I
,	O
coagulation	B
test	I
abnormal	I
,	O
LDL	B
)	I
increased	I
,	O
prothrombin	B
time	I
prolonged	I
,	O
urinary	B
casts	I
,	O
urine	B
positive	I
for	I
white	I
blood	I
cells	I
.	O
	
Severe	O
hypersensitivity	B
reactions	I
require	O
immediate	O
discontinuation	O
of	O
the	O
JEVTANA	O
infusion	O
and	O
appropriate	O
therapy	O
.	O
	
Do	O
not	O
use	O
DUAVEE	O
for	O
a	O
condition	O
for	O
which	O
it	O
was	O
not	O
prescribed	O
.	O
	
Adverse	O
reactions	O
led	O
to	O
treatment	O
discontinuation	O
in	O
32	O
%	O
of	O
ADCETRIS-treated	O
patients	O
in	O
Study	O
3	O
.	O
	
In	O
a	O
3-week	O
,	O
bipolar	O
mania	O
pediatric	O
trial	O
,	O
the	O
incidence	O
of	O
adverse	O
events	O
related	O
to	O
abnormal	B
prolactin	I
levels	I
were	O
0	O
%	O
in	O
the	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
treatment	O
group	O
,	O
2	O
%	O
in	O
the	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
treatment	O
group	O
,	O
and	O
1	O
%	O
in	O
the	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
treatment	O
group	O
versus	O
to	O
1	O
%	O
for	O
patients	O
treated	O
with	O
placebo	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Potassium	O
levels	O
should	O
be	O
within	O
the	O
normal	O
range	O
prior	O
to	O
administration	O
of	O
MULTAQ	O
and	O
maintained	O
in	O
the	O
normal	O
range	O
during	O
administration	O
of	O
MULTAQ	O
.	O
	
5.2	O
Bleeding	O
ELIQUIS	O
increases	O
the	O
risk	O
of	O
bleeding	B
and	O
can	O
cause	O
serious	O
,	O
potentially	O
fatal	B
,	O
bleeding	B
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
andAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.3	O
Hypoglycemia	O
with	O
Concomitant	O
Use	O
of	O
Insulin	O
Secretagogues	O
or	O
Insulin	O
The	O
risk	O
of	O
hypoglycemia	B
is	O
increased	O
when	O
TANZEUM	O
is	O
used	O
in	O
combination	O
with	O
insulin	O
secretagogues	O
(	O
e.g.	O
,	O
sulfonylureas	O
)	O
or	O
insulin	O
.	O
	
The	O
risk	O
of	O
these	O
events	O
may	O
be	O
increased	O
by	O
the	O
postoperative	O
use	O
of	O
indwelling	O
epidural	O
catheters	O
or	O
the	O
concomitant	O
use	O
of	O
medicinal	O
products	O
affecting	O
hemostasis	O
.	O
	
*	O
The	O
risk	O
for	O
NSF	B
appears	O
highest	O
among	O
patients	O
with	O
:	O
oChronic	O
,	O
severe	O
kidney	O
disease	O
(	O
GFR	O
<	O
30	O
mL/min/1.73m2	O
)	O
,	O
oroAcute	O
kidney	O
injury	O
.	O
	
Rapid	O
intravenous	O
infusions	O
of	O
DALVANCE	O
can	O
cause	O
reactions	O
that	O
resemble	O
``	O
Red-Man	B
Syndrome	I
,	O
''	O
including	O
flushing	B
of	I
the	I
upper	I
body	I
,	O
urticaria	B
,	O
pruritus	B
,	O
and/or	O
rash	B
.	O
	
This	O
trial	O
involved	O
SAPHRIS	O
doses	O
of	O
5	O
mg	O
,	O
10	O
mg	O
,	O
15	O
mg	O
,	O
and	O
20	O
mg	O
twice	O
daily	O
,	O
and	O
placebo	O
,	O
and	O
was	O
conducted	O
in	O
151	O
clinically	O
stable	O
patients	O
with	O
schizophrenia	O
,	O
with	O
electrocardiographic	O
assessments	O
throughout	O
the	O
dosing	O
interval	O
at	O
baseline	O
and	O
steady	O
state	O
.	O
	
*	O
Tumor	B
lysis	I
syndrome	I
:	O
Closely	O
monitor	O
patients	O
with	O
rapidly	O
proliferating	O
tumor	O
or	O
high	O
tumor	O
burden	O
(	O
5.5	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Neonatal	B
toxicity	I
:	O
Risk	O
of	O
gasping	B
syndrome	I
if	O
benzyl	O
alcohol	O
is	O
used	O
in	O
neonates	O
.	O
	
Laboratory	O
,	O
ECG	O
and	O
vital	O
sign	O
changes	O
observed	O
in	O
MDD	O
clinical	O
studies	O
The	O
following	O
changes	O
were	O
observed	O
in	O
pre-marketing	O
placebo-controlled	O
,	O
short-term	O
MDD	O
studies	O
with	O
PRISTIQ	O
.	O
	
The	O
incidence	O
and	O
severity	O
of	O
pyrexia	B
are	O
increased	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
6	O
.	O
	
5.4	O
Venous	O
Thromboembolism	O
Venous	B
thromboembolism	I
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Given	O
the	O
similarity	O
in	O
hypersensitivity	O
symptoms	O
and	O
acute	O
HAE	O
symptoms	O
,	O
patients	O
should	O
be	O
monitored	O
closely	O
in	O
the	O
event	O
of	O
a	O
hypersensitivity	O
reaction	O
.	O
	
Nervous	O
system	O
disorders	O
-	O
Syncope	B
,	O
convulsion	B
,	O
dystonia	B
.	O
	
All	O
patients	O
should	O
be	O
tested	O
for	O
HBV	O
infection	O
before	O
initiating	O
TNF-blocker	O
therapy	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
treatment	O
with	O
STRIBILD	O
(	O
elvitegravir	O
150	O
mg/cobicistat	O
150	O
mg/emtricitabine	O
200	O
mg/tenofovir	O
DF	O
300	O
mg	O
)	O
;	O
ATRIPLA	O
(	O
efavirenz	O
600	O
mg/emtricitabine	O
200	O
mg/tenofovir	O
DF	O
300	O
mg	O
)	O
;	O
or	O
atazanavir	O
(	O
ATV	O
)	O
+	O
ritonavir	O
(	O
RTV	O
)	O
+	O
TRUVADA	O
(	O
emtricitabine	O
200	O
mg/tenofovir	O
DF	O
300	O
mg	O
)	O
due	O
to	O
adverse	O
events	O
,	O
regardless	O
of	O
severity	O
,	O
was	O
6.0	O
%	O
,	O
7.4	O
%	O
and	O
8.5	O
%	O
,	O
respectively	O
.	O
	
TIVICAY	O
is	O
contraindicated	O
in	O
patients	O
who	O
have	O
experienced	O
a	O
previous	O
hypersensitivity	O
reaction	O
to	O
dolutegravir	O
.	O
	
FANAPT	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
Dementia-Related	O
Psychosis	O
.	O
	
Monitor	O
weight	O
.	O
	
Grade	O
2	O
ADRs	O
reported	O
in	O
at	O
least	O
1	O
subject	O
were	O
rash	B
(	O
n	O
=	O
1	O
)	O
,	O
abdominal	B
pain	I
(	O
n	O
=	O
1	O
)	O
,	O
and	O
diarrhea	B
(	O
n	O
=	O
1	O
)	O
.	O
	
In	O
Study	O
1	O
,	O
the	O
overall	O
incidence	O
of	O
cutaneous	B
reactions	I
consisting	O
of	O
rash	B
,	O
erythema	B
,	O
and	O
acneiform	B
rash	I
was	O
90	O
%	O
,	O
and	O
the	O
incidence	O
of	O
Grade	O
3	O
cutaneous	B
reactions	I
was	O
16	O
%	O
.	O
	
The	O
600-mg	O
dose	O
was	O
studied	O
in	O
2	O
of	O
the	O
3	O
studies	O
.	O
	
In	O
this	O
trial	O
,	O
the	O
safety	O
profile	O
of	O
FIRAZYR	O
in	O
patients	O
who	O
self-administered	O
FIRAZYR	O
was	O
similar	O
in	O
nature	O
and	O
frequency	O
to	O
that	O
of	O
patients	O
whose	O
therapy	O
was	O
administered	O
by	O
healthcare	O
professionals	O
.	O
	
These	O
reactions	O
were	O
more	O
likely	O
to	O
occur	O
with	O
higher	O
infusion	O
rates	O
.	O
	
Macular	O
Edema	O
in	O
Patients	O
with	O
History	O
of	O
Uveitis	O
or	O
Diabetes	O
Mellitus	O
Patients	O
with	O
a	O
history	O
of	O
uveitis	O
and	O
patients	O
with	O
diabetes	O
mellitus	O
are	O
at	O
increased	O
risk	O
of	O
macular	B
edema	I
during	O
GILENYA	O
therapy	O
.	O
	
VZV	O
vaccination	O
of	O
antibody-negative	O
patients	O
is	O
recommended	O
prior	O
to	O
commencing	O
treatment	O
with	O
GILENYA	O
,	O
following	O
which	O
initiation	O
of	O
treatment	O
with	O
GILENYA	O
should	O
be	O
postponed	O
for	O
1	O
month	O
to	O
allow	O
the	O
full	O
effect	O
of	O
vaccination	O
to	O
occur	O
.	O
	
In	O
the	O
controlled	O
portions	O
of	O
clinical	O
trials	O
of	O
TNF-blockers	O
including	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
more	O
cases	O
of	O
lymphoma	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
anti-TNF	O
treatment	O
compared	O
with	O
patients	O
in	O
the	O
control	O
groups	O
.	O
	
Fourteen	O
(	O
24	O
%	O
)	O
patients	O
stopped	O
therapy	O
prior	O
to	O
completion	O
;	O
seven	O
due	O
to	O
allergic	B
reactions	I
,	O
five	O
due	O
to	O
physician	O
or	O
patient	O
choice	O
,	O
one	O
due	O
to	O
disease	O
progression	O
,	O
and	O
one	O
due	O
to	O
discontinuation	O
during	O
frontline	O
protocol	O
.	O
	
Monitor	O
renal	O
function	O
with	O
regular	O
measurement	O
of	O
the	O
serum	O
creatinine	O
and/or	O
estimated	O
creatinine	O
clearance	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypertension	B
including	O
hypertensive	B
crisis	I
has	O
been	O
observed	O
.	O
	
Although	O
the	O
prevalence	O
of	O
the	O
syndrome	O
appears	O
to	O
be	O
highest	O
among	O
the	O
elderly	O
,	O
especially	O
elderly	O
women	O
,	O
it	O
is	O
impossible	O
to	O
rely	O
upon	O
prevalence	O
estimates	O
to	O
predict	O
,	O
at	O
the	O
inception	O
of	O
antipsychotic	O
treatment	O
,	O
which	O
patients	O
are	O
likely	O
to	O
develop	O
the	O
syndrome	O
.	O
	
These	O
metabolic	B
changes	I
include	O
hyperglycemia	B
,	O
dyslipidemia	B
,	O
and	O
body	B
weight	I
gain	I
.	O
	
The	O
median	O
dose	O
intensity	O
was	O
483	O
mg/day	O
,	O
and	O
500	O
mg/day	O
,	O
in	O
the	O
AP	O
CML	O
and	O
BP	O
CML	O
cohorts	O
,	O
respectively	O
.	O
	
Monitor	O
liver-related	O
laboratory	O
tests	O
.	O
	
Increases	B
in	I
creatinine	I
1.5	O
to	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
9	O
%	O
of	O
patients	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reaction	O
leading	O
to	O
treatment	O
discontinuation	O
was	O
subdural	B
hematoma	I
(	O
1.8	O
%	O
)	O
.	O
	
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=4	O
%	O
Patients	O
Treated	O
with	O
NESINA	O
25	O
mg	O
and	O
More	O
Frequently	O
Than	O
in	O
Patients	O
Given	O
Placebo	O
in	O
Pooled	O
Studies	O
Number	O
of	O
Patients	O
(	O
%	O
)	O
NESINA25	O
mg	O
Placebo	O
Active	O
Comparator	O
N=5902	O
N=2926	O
N=2257	O
Nasopharyngitis	B
257	O
(	O
4.4	O
)	O
89	O
(	O
3.0	O
)	O
113	O
(	O
5.0	O
)	O
Headache	B
247	O
(	O
4.2	O
)	O
72	O
(	O
2.5	O
)	O
121	O
(	O
5.4	O
)	O
Upper	B
Respiratory	I
Tract	I
Infection	I
247	O
(	O
4.2	O
)	O
61	O
(	O
2.1	O
)	O
113	O
(	O
5.0	O
)	O
Pancreatitis	O
In	O
the	O
clinical	O
trial	O
program	O
,	O
pancreatitis	B
was	O
reported	O
in	O
11	O
of	O
5902	O
(	O
0.2	O
%	O
)	O
patients	O
receiving	O
NESINA	O
25	O
mg	O
daily	O
compared	O
to	O
five	O
of	O
5183	O
(	O
<	O
0.1	O
%	O
)	O
patients	O
receiving	O
all	O
comparators	O
.	O
	
(	O
5.2	O
,	O
5.3	O
,	O
5.4	O
)	O
*	O
Hyponatremia	B
:	O
Monitor	O
sodium	O
levels	O
in	O
patients	O
at	O
risk	O
or	O
patients	O
experiencing	O
hyponatremia	O
symptoms	O
.	O
	
Discontinuation	O
of	O
PRISTIQ	O
should	O
be	O
considered	O
in	O
patients	O
with	O
symptomatic	O
hyponatremia	O
and	O
appropriate	O
medical	O
intervention	O
should	O
be	O
instituted	O
.	O
	
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
reporting	O
severe	O
adverse	O
gastrointestinal	O
reactions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
]	O
.	O
	
POTIGA	O
causes	O
mucous	B
membrane	I
discoloration	I
and	O
it	O
is	O
not	O
clear	O
whether	O
this	O
discoloration	B
is	O
related	O
to	O
retinal	B
abnormalities	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
In	O
healthy	O
subjects	O
,	O
large	O
doses	O
of	O
inhaled	O
fluticasone	O
furoate/vilanterol	O
(	O
4	O
times	O
the	O
recommended	O
dose	O
of	O
vilanterol	O
,	O
representing	O
a	O
12-	O
or	O
10-fold	O
higher	O
systemic	O
exposure	O
than	O
seen	O
in	O
subjects	O
with	O
COPD	O
or	O
asthma	O
,	O
respectively	O
)	O
have	O
been	O
associated	O
with	O
clinically	O
significant	O
prolongation	B
of	I
the	I
QTc	I
interval	I
,	O
which	O
has	O
the	O
potential	O
for	O
producing	O
ventricular	B
arrhythmias	I
.	O
	
Eight	O
(	O
2	O
%	O
)	O
patients	O
developed	O
antibodies	O
during	O
treatment	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
.	O
	
5.6	O
Thyroid	O
Accumulation	O
Failure	O
to	O
block	O
thyroid	O
uptake	O
of	O
iodine	O
123	O
may	O
result	O
in	O
an	O
increased	O
long	O
term	O
risk	O
for	O
thyroid	O
neoplasia	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Particular	O
care	O
should	O
be	O
taken	O
in	O
observing	O
patients	O
postoperatively	O
or	O
during	O
periods	O
of	O
stress	O
for	O
evidence	O
of	O
inadequate	O
adrenal	O
response	O
.	O
	
Delay	O
in	O
stopping	O
INTELENCE	O
(	O
r	O
)	O
treatment	O
after	O
the	O
onset	O
of	O
severe	O
rash	O
may	O
result	O
in	O
a	O
life-threatening	O
reaction	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
AGRANULOCYTOSIS/NEUTROPENIA	O
WARNING	O
:	O
AGRANULOCYTOSIS/NEUTROPENIA	O
*	O
Ferriprox	O
can	O
cause	O
agranulocytosis	B
that	O
can	O
lead	O
to	O
serious	O
infections	B
and	O
death	B
.	O
	
Patients	O
with	O
unstable	O
cardiac	O
disease	O
,	O
narrow-angle	O
glaucoma	O
,	O
or	O
symptomatic	O
prostatic	O
hypertrophy	O
or	O
bladder	O
outlet	O
obstruction	O
were	O
excluded	O
from	O
these	O
trials	O
.	O
	
There	O
was	O
fatal	B
pneumonia	B
in	O
1	O
subject	O
receiving	O
BREO	O
ELLIPTA	O
100/25	O
and	O
in	O
7	O
subjects	O
receiving	O
BREO	O
ELLIPTA	O
200/25	O
(	O
less	O
than	O
1	O
%	O
for	O
each	O
treatment	O
group	O
)	O
.	O
	
Data	O
from	O
this	O
safety	O
study	O
indicate	O
that	O
the	O
greatest	O
risk	O
of	O
VTE	B
is	O
present	O
after	O
initially	O
starting	O
a	O
COC	O
or	O
restarting	O
(	O
following	O
a	O
4	O
week	O
or	O
greater	O
pill-free	O
interval	O
)	O
the	O
same	O
or	O
a	O
different	O
COC	O
.	O
	
One	O
published	O
report	O
of	O
18	O
F-methylcholine	O
PET	O
imaging	O
indicated	O
that	O
discontinuation	O
of	O
colchicine	O
for	O
two	O
weeks	O
resolved	O
the	O
colchicine	O
effect	O
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TRULICITY	O
.	O
	
Reports	O
of	O
penile	O
``	O
popping	O
''	O
sounds	O
or	O
sensations	O
A	O
popping	B
sensation	I
in	I
the	I
penis	I
''	O
,	O
and	O
sometimes	O
accompanied	O
by	O
detumescence	B
,	O
hematoma	B
and/or	O
pain	B
,	O
were	O
reported	O
in	O
73/551	O
(	O
13.2	O
%	O
)	O
XIAFLEX-treated	O
patients	O
and	O
1/281	O
(	O
0.3	O
%	O
)	O
placebo-treated	O
patients	O
.	O
	
A	O
total	O
of	O
741	O
patients	O
have	O
been	O
treated	O
with	O
AMPYRA	O
for	O
over	O
six	O
months	O
,	O
501	O
for	O
over	O
one	O
year	O
and	O
352	O
for	O
over	O
two	O
years	O
.	O
	
If	O
such	O
effects	O
occur	O
,	O
BREO	O
ELLIPTA	O
may	O
need	O
to	O
be	O
discontinued	O
.	O
	
(	O
5.8	O
,	O
8.1	O
,	O
8.7	O
)	O
5.1	O
Severe	O
or	O
Persistent	O
Gastrointestinal	O
Toxicity	O
Diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
or	O
abdominal	B
pain	I
occurred	O
in	O
96	O
%	O
of	O
255	O
patients	O
including	O
severe	O
cases	O
in	O
14	O
%	O
of	O
patients	O
treated	O
with	O
ZYKADIA	O
in	O
Study	O
1	O
.	O
	
Monitor	O
liver	O
enzymes	O
and	O
bilirubin	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Interrupt	O
Ferriprox	O
if	O
infection	O
develops	O
,	O
and	O
monitor	O
the	O
ANC	O
more	O
frequently	O
.	O
	
The	O
most	O
frequent	O
(	O
>	O
=2	O
%	O
)	O
serious	O
adverse	O
reactions	O
reported	O
for	O
subjects	O
treated	O
with	O
Zydelig	O
were	O
pneumonia	B
(	O
17	O
%	O
)	O
,	O
pyrexia	B
(	O
9	O
%	O
)	O
,	O
sepsis	B
(	O
8	O
%	O
)	O
,	O
febrile	B
neutropenia	I
(	O
5	O
%	O
)	O
and	O
diarrhea	B
(	O
5	O
%	O
)	O
.	O
	
The	O
safety	O
evaluation	O
of	O
GILOTRIF	O
is	O
based	O
on	O
the	O
data	O
from	O
more	O
than	O
3800	O
patients	O
,	O
including	O
2135	O
NSCLC	O
patients	O
receiving	O
GILOTRIF	O
monotherapy	O
at	O
or	O
above	O
the	O
recommended	O
dose	O
.	O
	
5.5	O
Renal	O
Impairment	O
In	O
patients	O
treated	O
with	O
GLP-1	O
receptor	O
agonists	O
,	O
there	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
renal	I
failure	I
and	O
worsening	O
of	O
chronic	B
renal	I
failure	I
,	O
which	O
may	O
sometimes	O
require	O
hemodialysis	O
.	O
	
In	O
many	O
cases	O
,	O
this	O
hyponatremia	B
appears	O
to	O
be	O
the	O
result	O
of	O
the	O
syndrome	B
of	I
inappropriate	I
antidiuretic	I
hormone	I
secretion	I
(	O
SIADH	B
)	O
.	O
	
(	O
5.1	O
)	O
*	O
Corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
or	O
other	O
serious	O
injury	B
to	I
the	I
penis	I
:	O
Avoid	O
injecting	O
into	O
the	O
urethra	O
,	O
nerves	O
,	O
blood	O
vessels	O
,	O
corpora	O
cavernosa	O
or	O
other	O
collagen-containing	O
structures	O
of	O
the	O
penis	O
.	O
	
In	O
general	O
,	O
discontinuation	O
events	O
occurred	O
more	O
frequently	O
with	O
longer	O
duration	O
of	O
therapy	O
.	O
	
If	O
signs	O
and	O
symptoms	O
fail	O
to	O
improve	O
after	O
2	O
days	O
,	O
the	O
patient	O
should	O
be	O
re-evaluated	O
.	O
	
Grade	O
3	O
or	O
higher	O
(	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
)	O
neurological	B
toxicities	I
following	O
initiation	O
of	O
BLINCYTO	O
administration	O
occurred	O
in	O
approximately	O
15	O
%	O
of	O
patients	O
and	O
included	O
encephalopathy	B
,	O
convulsions	B
,	O
speech	B
disorders	I
,	O
disturbances	B
in	I
consciousness	I
,	O
confusion	B
and	O
disorientation	B
,	O
and	O
balance	B
disorders	I
.	O
	
In	O
clinical	O
studies	O
,	O
555	O
patients	O
were	O
exposed	O
to	O
Amyvid	O
.	O
	
*	O
Renal	B
toxicity	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
All	O
patients	O
treated	O
with	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
tested	O
positive	O
for	O
neutralizing	O
antibodies	O
capable	O
of	O
inhibiting	O
the	O
drug	O
from	O
binding	O
to	O
the	O
mannose-6-phosphate	O
receptor	O
at	O
least	O
once	O
during	O
the	O
trial	O
.	O
	
The	O
increased	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
AEDs	O
was	O
observed	O
as	O
early	O
as	O
one	O
week	O
after	O
starting	O
treatment	O
with	O
AEDs	O
and	O
persisted	O
for	O
the	O
duration	O
of	O
treatment	O
assessed	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
elevations	B
in	I
triglycerides	I
>	O
=200	O
mg/dL	O
(	O
at	O
Endpoint	O
)	O
was	O
15.2	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
11.4	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Skin	B
reactions	I
including	O
SJS	B
and	O
TEN	B
have	O
occurred	O
when	O
TREANDA	O
was	O
administered	O
concomitantly	O
with	O
allopurinol	O
and	O
other	O
medications	O
known	O
to	O
cause	O
these	O
syndromes	O
.	O
	
(	O
2.6	O
,	O
5.7	O
)	O
*	O
Drug	B
Induced	I
Liver	I
Injury	I
:	O
Discontinue	O
APTIOM	O
in	O
patients	O
with	O
jaundice	O
or	O
evidence	O
of	O
significant	O
liver	O
injury	O
.	O
	
The	O
safety	O
population	O
(	O
received	O
at	O
least	O
1	O
dose	O
of	O
BOSULIF	O
)	O
included	O
546	O
CML	O
patients	O
:	O
*	O
287	O
patients	O
with	O
CP	O
CML	O
previously	O
treated	O
with	O
imatinib	O
only	O
who	O
had	O
a	O
median	O
duration	O
of	O
BOSULIF	O
treatment	O
of	O
24	O
months	O
,	O
and	O
a	O
median	O
dose	O
intensity	O
of	O
484	O
mg/day	O
.	O
	
The	O
safety	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
KALBITOR	O
in	O
255	O
patients	O
with	O
HAE	O
treated	O
with	O
either	O
intravenous	O
or	O
subcutaneous	O
KALBITOR	O
.	O
	
Of	O
these	O
6	O
ADA	O
positive	O
patients	O
,	O
one	O
experienced	O
a	O
hypersensitivity	B
reaction	I
during	O
Study	O
1	O
(	O
2	O
%	O
,	O
1	O
of	O
56	O
)	O
.	O
	
*	O
Using	O
estrogens	O
may	O
increase	O
your	O
chance	O
of	O
getting	O
cancer	O
of	O
the	O
uterus	O
(	O
womb	O
)	O
.	O
	
Ensure	O
that	O
patients	O
are	O
well	O
hydrated	O
before	O
administration	O
of	O
Kyprolis	O
in	O
Cycle	O
1	O
,	O
and	O
in	O
subsequent	O
cycles	O
as	O
needed	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
who	O
are	O
treated	O
with	O
atypical	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
and	O
cerebrovascular-related	B
adverse	I
events	I
,	O
including	O
stroke	B
.	O
	
5.7	O
Hypertension	O
Hypertension	B
,	O
including	O
hypertensive	B
crisis	I
and	O
hypertensive	B
emergency	I
,	O
has	O
been	O
observed	O
with	O
Kyprolis	O
.	O
	
If	O
supine	O
hypertension	O
can	O
not	O
be	O
managed	O
by	O
elevation	O
of	O
the	O
head	O
of	O
the	O
bed	O
,	O
reduce	O
or	O
discontinue	O
NORTHERA	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Obtain	O
periodic	O
liver	O
testing	O
in	O
patients	O
during	O
treatment	O
with	O
GILOTRIF	O
.	O
	
6.2	O
Clinical	O
Trials	O
Experience	O
in	O
Pediatric	O
Subjects	O
IMPAACT	O
P1093	O
is	O
an	O
ongoing	O
multicenter	O
,	O
open-label	O
,	O
non-comparative	O
trial	O
of	O
approximately	O
160	O
HIV-1-infected	O
pediatric	O
subjects	O
aged	O
6	O
weeks	O
to	O
less	O
than	O
18	O
years	O
,	O
of	O
which	O
23	O
treatment-experienced	O
,	O
INSTI-naive	O
subjects	O
aged	O
12	O
to	O
less	O
than	O
18	O
years	O
were	O
enrolled	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
,	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Treatment	O
of	O
cervical	O
dystonia	O
with	O
botulinum	O
toxins	O
may	O
weaken	B
neck	I
muscles	I
that	O
serve	O
as	O
accessory	O
muscles	O
of	O
ventilation	O
.	O
	
Macular	B
edema	I
occurred	O
predominantly	O
during	O
the	O
first	O
3	O
to	O
4	O
months	O
of	O
therapy	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
of	O
MTC	O
with	O
the	O
use	O
of	O
TANZEUM	O
and	O
inform	O
them	O
of	O
the	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g.	O
,	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
persistent	O
hoarseness	O
)	O
.	O
	
Heart	O
Rate	O
Increase	O
In	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
,	O
mean	B
heart	I
rate	I
in	I
patients	I
treated	I
with	I
TANZEUM	I
was	I
higher	I
by	I
an	I
average	I
of	I
1	I
to	I
2	I
bpm	I
compared	O
with	O
mean	O
heart	O
rate	O
in	O
patients	O
treated	O
with	O
placebo	O
across	O
study	O
visits	O
.	O
	
To	O
aid	O
in	O
the	O
management	O
of	O
such	O
patients	O
,	O
consider	O
consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
invasive	O
fungal	O
infections	O
.	O
	
In	O
the	O
postmarketing	O
experience	O
,	O
hypersensitivity	B
reactions	I
have	O
been	O
reported	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hepatotoxicity	B
:	O
Monitor	O
liver	O
function	O
before	O
and	O
during	O
therapy	O
.	O
	
Blood	O
and	O
lymphatic	O
system	O
disorders	O
:	O
febrile	B
neutropenia	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
*	O
Do	O
not	O
place	O
DUAVEE	O
in	O
pill	O
boxes	O
or	O
pill	O
organizers	O
.	O
	
Overall	O
,	O
a	O
higher	O
rate	O
of	O
APTC	O
events	O
was	O
observed	O
in	O
ULORIC	O
than	O
in	O
allopurinol-treated	O
patients	O
.	O
	
*	O
Perform	O
test	O
for	O
latent	O
TB	O
;	O
if	O
positive	O
,	O
start	O
treatment	O
for	O
TB	O
prior	O
to	O
starting	O
CIMZIA	O
(	O
5.1	O
)	O
.	O
	
5.3	O
Worsening	O
of	O
Narrow-Angle	O
Glaucoma	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
narrow-angle	O
glaucoma	O
.	O
	
Patients	O
with	O
abnormal	O
LVEF	O
,	O
history	O
of	O
acute	O
coronary	O
syndrome	O
within	O
6	O
months	O
,	O
current	O
evidence	O
of	O
Class	O
II	O
or	O
greater	O
congestive	O
heart	O
failure	O
(	O
New	O
York	O
Heart	O
Association	O
)	O
,	O
history	O
RVO	O
or	O
RPED	O
,	O
QTc	O
interval	O
>	O
=480	O
msec	O
,	O
treatment	O
refractory	O
hypertension	O
,	O
uncontrolled	O
arrhythmias	O
,	O
history	O
of	O
pneumonitis	O
or	O
interstitial	O
lung	O
disease	O
,	O
or	O
a	O
known	O
history	O
of	O
G6PD	O
deficiency	O
were	O
excluded	O
.	O
	
Discontinue	O
ELIQUIS	O
in	O
patients	O
with	O
active	O
pathological	O
hemorrhage	O
.	O
	
The	O
effects	O
of	O
tenofovir	O
DF-associated	O
changes	O
in	O
BMD	O
and	O
biochemical	O
markers	O
on	O
long-term	O
bone	O
health	O
and	O
future	O
fracture	O
risk	O
are	O
unknown	O
.	O
	
Treatment	O
of	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
therapy	O
with	O
TNF-blocking	O
agents	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
tuberculosis	O
reactivation	O
during	O
therapy	O
.	O
	
The	O
incidence	O
of	O
reported	O
thromboembolic	B
events	I
in	O
wet	O
AMD	O
studies	O
during	O
the	O
first	O
year	O
was	O
1.8	O
%	O
(	O
32	O
out	O
of	O
1824	O
)	O
in	O
the	O
combined	O
group	O
of	O
patients	O
treated	O
with	O
EYLEA	O
.	O
	
Optic	B
atrophy	I
and	O
optic	B
nerve	I
disorder	I
have	O
been	O
reported	O
as	O
potential	O
causes	O
of	O
vision	B
loss	I
.	O
	
5.6	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
trials	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TANZEUM	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Other	O
clinically	O
important	O
adverse	O
reactions	O
observed	O
in	O
<	O
10	O
%	O
of	O
patients	O
(	O
N	O
=	O
586	O
)	O
treated	O
with	O
TAFINLAR	O
were	O
:	O
Gastrointestinal	O
Disorders	O
:	O
Pancreatitis	B
.	O
	
*	O
CIMZIA	O
should	O
be	O
discontinued	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
or	O
sepsis	O
(	O
5.1	O
)	O
.	O
	
In	O
the	O
long-term	O
extension	O
studies	O
,	O
the	O
incidences	O
of	O
adjudicated	O
APTC	O
events	O
were	O
:	O
ULORIC	O
80	O
mg	O
0.97	O
(	O
95	O
%	O
CI	O
0.57-1.56	O
)	O
,	O
and	O
allopurinol	O
0.58	O
(	O
95	O
%	O
CI	O
0.02-3.24	O
)	O
.	O
	
Report	O
any	O
diagnosis	O
of	O
NSF	O
following	O
EOVIST	O
administration	O
to	O
Bayer	O
HealthCare	O
(	O
1-888-842-2937	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
)	O
.	O
	
6.1	O
Clinical	O
Study	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
is	O
recommended	O
to	O
aid	O
in	O
the	O
decision	O
whether	O
initiating	O
anti-tuberculosis	O
therapy	O
is	O
appropriate	O
for	O
an	O
individual	O
patient	O
.	O
	
Beta-blockers	O
should	O
be	O
withdrawn	O
only	O
after	O
a	O
gradual	O
reduction	O
in	O
dose	O
.	O
	
Recommended	O
doses	O
of	O
immunosuppressants	O
should	O
not	O
be	O
exceeded	O
.	O
	
Physicians	O
and	O
patients	O
should	O
be	O
aware	O
of	O
the	O
increased	O
risk	O
of	O
infection	O
with	O
AFINITOR	O
.	O
	
The	O
long-term	O
clinical	O
effects	O
of	O
the	O
increase	B
in	I
heart	I
rate	I
have	O
not	O
been	O
established	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Renal	O
function	O
should	O
be	O
evaluated	O
prior	O
to	O
initiating	O
JARDIANCE	O
and	O
periodically	O
thereafter	O
.	O
	
For	O
patients	O
who	O
develop	O
prolonged	O
Grade	O
2	O
diarrhea	O
lasting	O
more	O
than	O
48	O
hours	O
or	O
greater	O
than	O
or	O
equal	O
to	O
Grade	O
3	O
diarrhea	O
,	O
withhold	O
GILOTRIF	O
until	O
diarrhea	O
resolves	O
to	O
Grade	O
1	O
or	O
less	O
,	O
and	O
resume	O
GILOTRIF	O
with	O
appropriate	O
dose	O
reduction	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Table	O
6	O
compares	O
the	O
incidence	O
of	O
treatment-emergent	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
10	O
mg	O
daily	O
versus	O
placebo	O
.	O
	
In	O
clinical	O
trials	O
where	O
ethnicity	O
was	O
recorded	O
the	O
ethnic	O
distribution	O
was	O
74	O
%	O
Caucasian	O
,	O
12	O
%	O
Asian	O
,	O
4	O
%	O
Black	O
,	O
and	O
10	O
%	O
others	O
.	O
	
No	O
cases	O
of	O
transmission	O
of	O
viral	B
diseases	I
or	O
CJD	B
have	O
ever	O
been	O
reported	O
for	O
albumin	O
.	O
	
Discontinue	O
Kyprolis	O
if	O
PRES	O
is	O
suspected	O
and	O
evaluate	O
.	O
	
Table	O
7	O
:	O
Key	O
Laboratory	O
Abnormalities	O
Reported	O
in	O
Patients	O
with	O
RCC	O
at	O
a	O
Higher	O
Rate	O
in	O
the	O
AFINITOR	O
Arm	O
than	O
the	O
Placebo	O
Arm	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Reflects	O
corresponding	O
adverse	O
drug	O
reaction	O
reports	O
of	O
anemia	B
,	O
leukopenia	B
,	O
lymphopenia	B
,	O
neutropenia	B
,	O
and	O
thrombocytopenia	B
(	O
collectively	O
pancytopenia	B
)	O
,	O
which	O
occurred	O
at	O
lower	O
frequency	O
.	O
	
5.3	O
Ischemic	O
Heart	O
Disease	O
,	O
Arrhythmias	O
,	O
and	O
Congestive	O
Heart	O
Failure	O
NORTHERA	O
may	O
exacerbate	B
existing	I
ischemic	I
heart	I
disease	I
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
reactions	I
characterized	O
by	O
rash	B
,	O
constitutional	O
findings	O
,	O
and	O
sometimes	O
organ	B
dysfunction	I
,	O
including	O
liver	B
injury	I
,	O
have	O
been	O
reported	O
.	O
	
Of	O
these	O
1368	O
patients	O
,	O
safety	O
data	O
were	O
received	O
for	O
940	O
patients	O
with	O
a	O
median	O
age	O
of	O
9	O
years	O
(	O
0	O
to	O
76	O
years	O
)	O
,	O
63	O
%	O
were	O
male	O
,	O
91	O
%	O
with	O
leukemia	O
,	O
3	O
%	O
with	O
lymphoma	O
,	O
and	O
6	O
%	O
with	O
unknown	O
disease	O
information	O
.	O
	
While	O
adequate	O
hydration	O
is	O
required	O
prior	O
to	O
each	O
dose	O
in	O
Cycle	O
1	O
,	O
all	O
patients	O
should	O
also	O
be	O
monitored	O
for	O
evidence	O
of	O
volume	O
overload	O
,	O
especially	O
patients	O
at	O
risk	O
for	O
cardiac	O
failure	O
.	O
	
One	O
patient	O
developed	O
PML	B
after	O
taking	O
GILENYA	O
for	O
approximately	O
2.5	O
years	O
.	O
	
Deaths	B
as	O
a	O
complication	O
of	O
severe	O
dysphagia	B
have	O
been	O
reported	O
after	O
treatment	O
with	O
botulinum	O
toxin	O
.	O
	
They	O
are	O
not	O
interchangeable	O
with	O
other	O
preparations	O
of	O
botulinum	O
toxin	O
products	O
and	O
,	O
therefore	O
,	O
units	O
of	O
biological	O
activity	O
of	O
DYSPORT	O
(	O
r	O
)	O
can	O
not	O
be	O
compared	O
to	O
or	O
converted	O
into	O
units	O
of	O
any	O
other	O
botulinum	O
toxin	O
products	O
assessed	O
with	O
any	O
other	O
specific	O
assay	O
method	O
[	O
seeDescription	O
(	O
11	O
)	O
]	O
.	O
	
5.5	O
Skin	O
Reactions	O
Skin	B
reactions	I
have	O
been	O
reported	O
with	O
TREANDA	O
treatment	O
in	O
clinical	O
trials	O
and	O
postmarketing	O
safety	O
reports	O
,	O
including	O
rash	B
,	O
toxic	B
skin	I
reactions	I
and	O
bullous	B
exanthema	I
.	O
	
A	O
RCAPTA	O
NEOHALER	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
asthma	O
.	O
	
Serious	O
Infections	O
Receptor	O
activator	O
of	O
nuclear	O
factor	O
kappa-B	O
ligand	O
(	O
RANKL	O
)	O
is	O
expressed	O
on	O
activated	O
T	O
and	O
B	O
lymphocytes	O
and	O
in	O
lymph	O
nodes	O
.	O
	
There	O
were	O
four	O
suicides	B
in	O
drug-treated	O
patients	O
in	O
the	O
trials	O
and	O
none	O
in	O
placebo-treated	O
patients	O
,	O
but	O
the	O
number	O
of	O
events	O
is	O
too	O
small	O
to	O
allow	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	B
.	O
	
Hepatic	O
Transaminases	O
An	O
increased	O
incidence	O
of	O
elevations	B
of	I
hepatic	I
transaminases	I
in	O
patients	O
treated	O
with	O
TECFIDERA	O
was	O
seen	O
primarily	O
during	O
the	O
first	O
six	O
months	O
of	O
treatment	O
,	O
and	O
most	O
patients	O
with	O
elevations	O
had	O
levels	O
<	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O
	
However	O
,	O
some	O
of	O
these	O
cases	O
were	O
in	O
the	O
setting	O
of	O
disease	O
progression	O
.	O
	
However	O
,	O
epidemiological	O
studies	O
suggest	O
an	O
increased	O
risk	O
of	O
treatment-emergent	O
hyperglycemia-related	B
adverse	I
events	I
in	O
patients	O
treated	O
with	O
the	O
atypical	O
antipsychotics	O
included	O
in	O
these	O
studies	O
.	O
	
Injection	O
into	O
these	O
structures	O
may	O
result	O
in	O
possible	O
permanent	O
injury	O
,	O
such	O
as	O
tendon	O
rupture	O
or	O
ligament	O
damage	O
,	O
or	O
skin	O
laceration	O
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
in	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
through	O
Week	O
24	O
was	O
3.5	O
%	O
for	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
0.5	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
The	O
demographic	O
characteristics	O
were	O
similar	O
among	O
the	O
4	O
pivotal	O
studies	O
and	O
between	O
the	O
treatment	O
groups	O
within	O
these	O
studies	O
.	O
	
Immune	O
system	O
disorders	O
:	O
anaphylactic	B
shock	I
,	O
hypersensitivity	B
.	O
	
If	O
chickenpox	O
develops	O
,	O
treatment	O
with	O
antiviral	O
agents	O
may	O
be	O
considered	O
.	O
	
Table	O
2	O
:	O
Laboratory	O
Abnormalities	O
of	O
Interest	O
in	O
Study	O
1	O
Abiraterone	O
(	O
N=791	O
)	O
Placebo	O
(	O
N=394	O
)	O
Laboratory	O
Abnormality	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3-4	O
(	O
%	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3-4	O
(	O
%	O
)	O
Hypertriglyceridemia	B
62.5	O
0.4	O
53.0	O
0	O
High	B
AST	I
30.6	O
2.1	O
36.3	O
1.5	O
Hypokalemia	B
28.3	O
5.3	O
19.8	O
1.0	O
Hypophosphatemia	B
23.8	O
7.2	O
15.7	O
5.8	O
High	B
ALT	I
11.1	O
1.4	O
10.4	O
0.8	O
High	B
Total	I
Bilirubin	I
6.6	O
0.1	O
4.6	O
0	O
Study	O
2	O
:	O
Metastatic	O
CRPC	O
Prior	O
to	O
Chemotherapy	O
Study	O
2	O
enrolled	O
1088	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
not	O
received	O
prior	O
cytotoxic	O
chemotherapy	O
.	O
	
Such	O
monitoring	O
may	O
increase	O
the	O
risk	O
of	O
unnecessary	O
procedures	O
,	O
due	O
to	O
the	O
low	O
test	O
specificity	O
for	O
serum	O
calcitonin	O
and	O
a	O
high	O
background	O
incidence	O
of	O
thyroid	O
disease	O
.	O
	
The	O
most	O
frequent	O
(	O
>	O
=	O
0.5	O
%	O
)	O
adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
EOVIST	O
were	O
nausea	B
,	O
headache	B
,	O
feeling	B
hot	I
,	O
dizziness	B
,	O
and	O
back	B
pain	I
.	O
	
Respiratory	O
,	O
Thoracic	O
and	O
Mediastinal	O
Disorders	O
:	O
non-infectious	B
pneumonitis	I
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Advise	O
patients	O
taking	O
Ferriprox	O
to	O
report	O
immediately	O
any	O
symptoms	O
indicative	O
of	O
infection	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
CORPORAL	B
RUPTURE	I
(	O
PENILE	B
FRACTURE	I
)	O
OR	O
OTHER	O
SERIOUS	O
PENILE	B
INJURY	I
IN	O
THE	O
TREATMENT	O
OF	O
PEYRONIE	O
'S	O
DISEASE	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
*	O
Corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
5	O
of	O
1044	O
(	O
0.5	O
%	O
)	O
XIAFLEX-treated	O
patients	O
in	O
clinical	O
studies	O
.	O
	
Preexisting	O
liver	O
disease	O
,	O
elevated	O
baseline	O
liver	O
enzymes	O
,	O
and	O
concomitant	O
medications	O
may	O
also	O
increase	O
the	O
risk	O
.	O
	
Adverse	O
reactions	O
during	O
exposure	O
were	O
obtained	O
by	O
general	O
inquiry	O
and	O
recorded	O
by	O
clinical	O
investigators	O
using	O
their	O
own	O
terminology	O
.	O
	
Investigations	O
:	O
blood	B
bilirubin	I
increased	I
,	O
blood	B
creatinine	I
phosphokinase	I
increased	I
.	O
	
Also	O
,	O
patients	O
taking	O
diuretics	O
or	O
who	O
are	O
otherwise	O
volume	O
depleted	O
can	O
be	O
at	O
greater	O
risk	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.6	O
)	O
]	O
.	O
	
All	O
infections	B
,	O
and	O
other	O
organisms	O
.	O
	
There	O
was	O
no	O
apparent	O
pattern	O
with	O
respect	O
to	O
the	O
anatomic	O
site	O
of	O
fracture	B
.	O
	
Renal	O
and	O
urinary	O
disorders	O
:	O
Nephrotic	B
syndrome	I
and	O
renal	B
failure	I
.	O
	
(	O
5.4	O
)	O
*	O
Hypertension	B
:	O
Monitor	O
blood	O
pressure	O
regularly	O
.	O
	
The	O
clinical	O
impact	O
of	O
anti-belatacept	O
antibodies	O
(	O
including	O
neutralizing	O
anti-belatacept	O
antibodies	O
)	O
could	O
not	O
be	O
determined	O
in	O
the	O
studies	O
.	O
	
EXCERPT	O
:	O
Rule	O
out	O
infectious	O
etiologies	O
of	O
diarrhea	O
before	O
starting	O
crofelemer	O
.	O
	
The	O
clinical	O
significance	O
of	O
small	O
changes	O
in	O
BMD	O
with	O
regard	O
to	O
long-term	O
consequences	O
such	O
as	O
fracture	O
is	O
unknown	O
.	O
	
5.15	O
Coexisting	O
Conditions	O
BREO	O
ELLIPTA	O
,	O
like	O
all	O
medicines	O
containing	O
sympathomimetic	O
amines	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
convulsive	O
disorders	O
or	O
thyrotoxicosis	O
and	O
in	O
those	O
who	O
are	O
unusually	O
responsive	O
to	O
sympathomimetic	O
amines	O
.	O
	
(	O
5.4	O
)	O
*	O
Arthralgia	B
:	O
Severe	O
and	O
disabling	O
arthralgia	B
has	O
been	O
reported	O
in	O
patients	O
taking	O
DPP-4	O
inhibitors	O
.	O
	
Before	O
initiating	O
INVOKANA	O
in	O
patients	O
with	O
one	O
or	O
more	O
of	O
these	O
characteristics	O
,	O
volume	O
status	O
should	O
be	O
assessed	O
and	O
corrected	O
.	O
	
5.3	O
Hyperkalemia	O
INVOKANA	O
can	O
lead	O
to	O
hyperkalemia	B
.	O
	
5.2	O
Myelosuppression	O
Thrombocytopenia	B
,	O
anemia	B
and	O
neutropenia	B
occur	O
with	O
BOSULIF	O
treatment	O
.	O
	
(	O
5.2	O
)	O
Avoidance	O
of	O
Contact	O
Lenses	O
.	O
	
Patients	O
with	O
RA	O
and	O
other	O
chronic	O
inflammatory	O
diseases	O
,	O
particularly	O
patients	O
with	O
highly	O
active	O
disease	O
and/or	O
chronic	O
exposure	O
to	O
immunosuppressant	O
therapies	O
,	O
may	O
be	O
at	O
higher	O
risk	O
(	O
up	O
to	O
several	O
fold	O
)	O
than	O
the	O
general	O
population	O
for	O
the	O
development	O
of	O
lymphoma	B
,	O
even	O
in	O
the	O
absence	O
of	O
TNF-blocking	O
therapy	O
.	O
	
Isolated	O
delayed	O
onset	O
events	O
,	O
including	O
transient	O
asystole	B
and	O
unexplained	O
death	B
,	O
have	O
occurred	O
within	O
24	O
hours	O
of	O
the	O
first	O
dose	O
.	O
	
These	O
exclusion	O
criteria	O
included	O
a	O
history	O
of	O
seizure	O
,	O
underlying	O
brain	O
injury	O
with	O
loss	O
of	O
consciousness	O
,	O
transient	O
ischemic	O
attack	O
within	O
the	O
past	O
12	O
months	O
,	O
cerebral	O
vascular	O
accident	O
,	O
brain	O
metastases	O
,	O
and	O
brain	O
arteriovenous	O
malformation	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
acute	B
pancreatitis	I
,	O
cholecystitis	B
,	O
cholelithiasis	B
,	O
arterial	B
thrombotic	I
events	I
and	O
reflex	B
sympathetic	I
dystrophy	I
.	O
	
Patients	O
with	O
multiple	O
myeloma	O
and	O
a	O
high	O
tumor	O
burden	O
should	O
be	O
considered	O
to	O
be	O
at	O
greater	O
risk	O
for	O
TLS	O
.	O
	
The	O
overall	O
exposure	O
in	O
the	O
controlled	O
trials	O
was	O
equivalent	O
to	O
1716	O
person-years	O
.	O
	
The	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
Postmarketing	O
reports	O
indicate	O
that	O
the	O
effects	O
of	O
DYSPORT	O
(	O
r	O
)	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	I
produce	I
symptoms	I
consistent	I
with	I
botulinum	I
toxin	I
effects	I
.	O
	
*	O
You	O
and	O
your	O
healthcare	O
provider	O
should	O
talk	O
regularly	O
about	O
whether	O
you	O
still	O
need	O
treatment	O
with	O
DUAVEE	O
.	O
	
Death	B
due	O
to	O
cardiac	B
arrest	I
has	O
occurred	O
within	O
a	O
day	O
of	O
Kyprolis	O
administration	O
.	O
	
c	O
The	O
1,200-mg	O
dose	O
of	O
HORIZANT	O
was	O
a	O
treatment	O
arm	O
in	O
each	O
of	O
the	O
3	O
double-blind	O
,	O
placebo-controlled	O
,	O
12-week	O
clinical	O
trials	O
.	O
	
(	O
5.1	O
)	O
*	O
Serious	O
anaphylactic	B
)	I
reactions	I
have	O
been	O
reported	O
with	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
If	O
a	O
patient	O
experiences	O
anticholinergic	O
CNS	O
effects	O
,	O
dose	O
reduction	O
or	O
drug	O
discontinuation	O
should	O
be	O
considered	O
.	O
	
Monitor	O
renal	O
function	O
,	O
blood	O
glucose	O
,	O
lipids	O
,	O
and	O
hematologic	O
parameters	O
prior	O
to	O
treatment	O
and	O
periodically	O
thereafter	O
.	O
	
(	O
2.2	O
)	O
(	O
4	O
)	O
*	O
Severe	O
hypersensitivity	B
can	O
occur	O
and	O
may	O
include	O
generalized	B
rash/erythema	O
,	O
hypotension	B
and	O
bronchospasm	B
.	O
	
Prior	O
to	O
initiating	O
SIMPONI	O
ARIA	O
,	O
assess	O
if	O
treatment	O
for	O
latent	O
tuberculosis	O
is	O
needed	O
;	O
An	O
induration	O
of	O
5	O
mm	O
or	O
greater	O
is	O
a	O
positive	O
tuberculin	O
skin	O
test	O
,	O
even	O
for	O
patients	O
previously	O
vaccinated	O
with	O
Bacille	O
Calmette-Guerin	O
(	O
BCG	O
)	O
.	O
	
Do	O
not	O
use	O
NULOJIX	O
in	O
transplant	O
recipients	O
who	O
are	O
EBV	O
seronegative	O
or	O
with	O
unknown	O
serostatus	O
.	O
	
5.7	O
Pheochromocytoma	O
There	O
is	O
no	O
information	O
to	O
guide	O
use	O
of	O
Cleviprex	O
in	O
treating	O
hypertension	O
associated	O
with	O
pheochromocytoma	O
.	O
	
Invasive	O
Fungal	O
Infections	O
If	O
patients	O
develop	O
a	O
serious	O
systemic	O
illness	O
and	O
they	O
reside	O
or	O
travel	O
in	O
regions	O
where	O
mycoses	O
are	O
endemic	O
,	O
consider	O
invasive	O
fungal	O
infection	O
in	O
the	O
differential	O
diagnosis	O
.	O
	
In	O
the	O
event	O
of	O
recrudescent	O
P.	O
falciparum	O
infection	O
after	O
treatment	O
with	O
Coartem	O
Tablets	O
,	O
patients	O
should	O
be	O
treated	O
with	O
a	O
different	O
antimalarial	O
drug	O
.	O
	
Most	O
cases	O
occurred	O
in	O
association	O
with	O
sepsis	B
,	O
dehydration	B
,	O
or	O
obstructive	B
uropathy	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
most	O
common	O
cause	O
of	O
deaths	B
occurring	O
in	O
patients	O
(	O
%	O
)	O
in	O
the	O
two	O
arms	O
(	O
KRd	O
versus	O
Rd	O
)	O
included	O
renal	B
0	I
(	I
0	I
%	I
)	I
versus	I
1	I
(	I
<	I
1	I
%	I
)	I
,	I
and	I
other	I
adverse	I
events	I
9	O
(	O
2	O
%	O
)	O
versus	O
10	O
(	O
3	O
%	O
)	O
.	O
	
Galactorrhea	B
,	O
amenorrhea	B
,	O
gynecomastia	B
,	O
and	O
impotence	B
have	O
been	O
reported	O
in	O
patients	O
receiving	O
prolactin-elevating	O
compounds	O
.	O
	
Such	O
monitoring	O
may	O
increase	O
the	O
risk	O
of	O
unnecessary	O
procedures	O
,	O
due	O
to	O
the	O
low	O
specificity	O
of	O
serum	O
calcitonin	O
testing	O
for	O
MTC	O
and	O
a	O
high	O
background	O
incidence	O
of	O
thyroid	O
disease	O
.	O
	
In	O
clinical	O
trials	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
5	O
%	O
)	O
following	O
alglucosidase	O
alfa	O
treatment	O
were	O
hypersensitivity	B
reactions	I
,	O
and	O
included	O
anaphylaxis	B
,	O
rash	B
,	O
pyrexia	B
,	O
flushing/feeling	O
hot	B
,	O
urticaria	B
,	O
headache	B
,	O
hyperhidrosis	B
,	O
nausea	B
,	O
cough	B
,	O
decreased	B
oxygen	I
saturation	I
,	O
tachycardia	B
,	O
tachypnea	B
,	O
chest	B
discomfort	I
,	O
dizziness	B
,	O
muscle	B
twitching	I
,	O
agitation	B
,	O
cyanosis	B
,	O
erythema	B
,	O
hypertension/increased	O
blood	B
pressure	I
,	O
pallor	B
,	O
rigors	B
,	O
tremor	B
,	O
vomiting	B
,	O
fatigue	B
,	O
and	O
myalgia	B
.	O
	
There	O
is	O
no	O
experience	O
with	O
antifibrinolytic	O
agents	O
(	O
tranexamic	O
acid	O
,	O
aminocaproic	O
acid	O
)	O
in	O
individuals	O
receiving	O
apixaban	O
.	O
	
Two	O
of	O
the	O
patients	O
(	O
1	O
%	O
)	O
with	O
persistently	O
positive	O
antibodies	O
experienced	O
adverse	O
reactions	O
consistent	O
with	O
infusion	B
reactions	I
that	O
led	O
to	O
discontinuation	O
of	O
treatment	O
.	O
	
5.10	O
Women	O
of	O
Childbearing	O
Potential	O
Premenopausal	O
women	O
who	O
have	O
not	O
undergone	O
a	O
hysterectomy	O
or	O
oophorectomy	O
must	O
use	O
effective	O
contraception	O
while	O
using	O
MULTAQ	O
.	O
	
Overall	O
,	O
a	O
higher	O
incidence	O
of	O
infusion	B
related	I
reactions	I
was	O
observed	O
in	O
patients	O
who	O
developed	O
persistently	O
positive	O
antibodies	O
.	O
	
The	O
median	O
age	O
was	O
54	O
years	O
,	O
57	O
%	O
were	O
male	O
,	O
and	O
>	O
99	O
%	O
were	O
white	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Evaluation	O
of	O
erectile	O
dysfunction	O
(	O
ED	O
)	O
should	O
include	O
an	O
appropriate	O
medical	O
assessment	O
to	O
identify	O
potential	O
underlying	O
causes	O
,	O
as	O
well	O
as	O
treatment	O
options	O
.	O
	
If	O
liver	O
injury	O
is	O
found	O
,	O
institute	O
appropriate	O
treatment	O
and	O
investigate	O
the	O
probable	O
cause	O
.	O
	
Premedicate	O
all	O
patients	O
prior	O
to	O
the	O
initiation	O
of	O
the	O
infusion	O
of	O
JEVTANA	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
5.4	O
Pancytopenia	O
(	O
Use	O
with	O
Ribavirin	O
and	O
Peginterferon	O
Alfa	O
)	O
Serious	O
cases	O
of	O
pancytopenia	B
have	O
been	O
reported	O
postmarketing	O
in	O
patients	O
receiving	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
*	O
Hepatotoxicity	B
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
*	O
See	O
you	O
healthcare	O
provider	O
right	O
away	O
if	O
you	O
get	O
vaginal	O
bleeding	O
while	O
taking	O
DUAVEE	O
.	O
	
In	O
two	O
controlled	O
clinical	O
trials	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
and	O
thrombocytopenia	O
,	O
ascites	B
and	O
encephalopathy	B
occurred	O
more	O
frequently	O
on	O
the	O
arm	O
receiving	O
treatment	O
with	O
PROMACTA	O
plus	O
antivirals	O
(	O
7	O
%	O
)	O
than	O
the	O
placebo	O
plus	O
antivirals	O
arm	O
(	O
4	O
%	O
)	O
.	O
	
5.4	O
Renal	O
Failure	O
In	O
the	O
randomized	O
clinical	O
trial	O
,	O
renal	B
failure	I
of	O
any	O
grade	O
occurred	O
in	O
4	O
%	O
of	O
the	O
patients	O
being	O
treated	O
with	O
JEVTANA	O
,	O
including	O
four	O
cases	O
with	O
fatal	B
outcome	O
.	O
	
Thromboembolic	B
events	I
were	O
reported	O
in	O
clinical	O
trials	O
with	O
VICTRELIS	O
among	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
,	O
and	O
among	O
those	O
receiving	O
PegIntron/REBETOL	O
alone	O
,	O
regardless	O
of	O
ESA	O
use	O
.	O
	
Given	O
the	O
similarity	O
in	O
hypersensitivity	O
symptoms	O
and	O
acute	O
HAE	O
symptoms	O
,	O
monitor	O
patients	O
closely	O
for	O
hypersensitivity	O
reactions	O
(	O
5	O
)	O
.	O
	
AMPLIFY	O
Study	O
The	O
mean	O
duration	O
of	O
exposure	O
to	O
ELIQUIS	O
was	O
154	O
days	O
and	O
to	O
enoxaparin/warfarin	O
was	O
152	O
days	O
in	O
the	O
AMPLIFY	O
study	O
.	O
	
Neutropenic	B
deaths	B
have	O
been	O
reported	O
.	O
	
Discontinue	O
JEVTANA	O
immediately	O
if	O
severe	O
reactions	O
occur	O
and	O
administer	O
appropriate	O
therapy	O
.	O
	
In	O
clinical	O
studies	O
,	O
there	O
were	O
uncommon	O
reports	O
of	O
ischemic	B
cardiac	I
adverse	I
reactions	I
,	O
including	O
myocardial	B
ischemia	I
,	O
myocardial	B
infarction	I
,	O
and	O
coronary	B
occlusion	I
requiring	O
revascularization	O
;	O
these	O
patients	O
had	O
multiple	O
underlying	O
cardiac	O
risk	O
factors	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
BENLYSTA	O
.	O
	
Consider	O
interrupting	O
therapy	O
with	O
BENLYSTA	O
if	O
patients	O
develop	O
a	O
new	O
infection	O
during	O
treatment	O
with	O
BENLYSTA	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Diarrhea	O
Diarrhea	B
has	O
resulted	O
in	O
dehydration	B
with	O
or	O
without	O
renal	B
impairment	I
;	O
some	O
of	O
these	O
cases	O
were	O
fatal	B
.	O
	
b	O
The	O
600-mg	O
dose	O
of	O
HORIZANT	O
was	O
a	O
treatment	O
arm	O
in	O
2	O
of	O
the	O
3	O
double-blind	O
,	O
placebo-controlled	O
,	O
12-week	O
clinical	O
trials	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
psoriatic	O
arthritis	O
who	O
discontinued	O
treatment	O
due	O
to	O
any	O
adverse	O
reaction	O
was	O
4.6	O
%	O
for	O
patients	O
taking	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
and	O
1.2	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
In	O
clinical	O
studies	O
with	O
Kyprolis	O
,	O
these	O
events	O
typically	O
occurred	O
early	O
in	O
the	O
course	O
of	O
Kyprolis	O
therapy	O
(	O
<	O
5	O
cycles	O
)	O
.	O
	
In	O
the	O
presence	O
of	O
binding	O
and	O
neutralizing	O
antibodies	O
to	O
DYSPORT	O
(	O
r	O
)	O
some	O
patients	O
continue	O
to	O
experience	O
clinical	O
benefit	O
.	O
	
During	O
the	O
controlled	O
portion	O
of	O
the	O
Phase	O
3	O
trial	O
in	O
RA	O
for	O
SIMPONI	O
ARIA	O
,	O
the	O
incidence	O
of	O
malignancies	B
other	O
than	O
lymphoma	O
and	O
NMSC	O
per	O
100-patient-years	O
of	O
follow-up	O
was	O
0.56	O
(	O
95	O
%	O
CI	O
:	O
0.01	O
,	O
3.11	O
)	O
in	O
the	O
SIMPONI	O
ARIA	O
group	O
compared	O
with	O
an	O
incidence	O
of	O
0	O
(	O
95	O
%	O
CI	O
:	O
0.00	O
,	O
3.79	O
)	O
in	O
the	O
placebo	O
group	O
.	O
	
Table	O
1	O
presents	O
adverse	O
reactions	O
reported	O
in	O
>	O
=10	O
%	O
patients	O
who	O
received	O
INLYTA	O
or	O
sorafenib	O
.	O
	
Table	O
9	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
2	O
%	O
or	O
More	O
of	O
Adult	O
Patients	O
in	O
Any	O
SAPHRIS	O
Dose	O
Group	O
and	O
Which	O
Occurred	O
at	O
Greater	O
Incidence	O
Than	O
in	O
the	O
Placebo	O
Group	O
in	O
3-Week	O
Bipolar	O
Mania	O
Trials	O
*	O
SAPHRIS	O
5	O
mg	O
to	O
10	O
mg	O
twice	O
daily	O
with	O
flexible	O
dosing	O
.	O
	
These	O
events	O
were	O
confounded	O
by	O
concomitant	O
medications	O
and/or	O
preexisting	O
disease	O
,	O
and	O
the	O
relationship	O
to	O
GILENYA	O
is	O
uncertain	O
.	O
	
Vaginal	O
bleeding	O
after	O
menopause	O
may	O
be	O
a	O
warning	O
sign	O
of	O
cancer	O
of	O
the	O
uterus	O
(	O
womb	O
)	O
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
.	O
	
Patients	O
with	O
pre-existing	O
swallowing	O
or	O
breathing	O
difficulties	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
complications	O
.	O
	
Patients	O
who	O
are	O
carriers	O
of	O
HBV	O
and	O
require	O
treatment	O
with	O
TNF-blockers	O
should	O
be	O
closely	O
monitored	O
for	O
clinical	O
and	O
laboratory	O
signs	O
of	O
active	O
HBV	O
infection	O
throughout	O
therapy	O
and	O
for	O
several	O
months	O
following	O
termination	O
of	O
therapy	O
.	O
	
Severe	O
hypoglycemia	O
was	O
defined	O
as	O
an	O
event	O
consistent	O
with	O
hypoglycemia	O
where	O
the	O
patient	O
required	O
the	O
assistance	O
of	O
another	O
person	O
to	O
recover	O
,	O
lost	O
consciousness	O
,	O
or	O
experienced	O
a	O
seizure	O
(	O
regardless	O
of	O
whether	O
biochemical	O
documentation	O
of	O
a	O
low	O
glucose	O
value	O
was	O
obtained	O
)	O
.	O
	
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
clinical	O
trials	O
,	O
male	B
genital	I
mycotic	I
infections	I
(	O
e.g.	O
,	O
candidal	B
balanitis	I
,	O
balanoposthitis	B
)	O
occurred	O
in	O
0.6	O
%	O
,	O
4.2	O
%	O
,	O
and	O
3.7	O
%	O
of	O
males	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
S	O
Includes	O
subjects	O
treated	O
with	O
flexible	O
dose	O
of	O
SAPHRIS	O
5	O
or	O
10	O
mg	O
twice	O
daily	O
(	O
N=90	O
)	O
.	O
	
Four	O
placebo-controlled	O
and	O
one	O
active-controlled	O
trials	O
of	O
16	O
weeks	O
up	O
through	O
two	O
years	O
in	O
duration	O
were	O
conducted	O
in	O
combination	O
with	O
metformin	O
,	O
in	O
combination	O
with	O
pioglitazone	O
and	O
with	O
pioglitazone	O
added	O
to	O
a	O
background	O
of	O
metformin	O
therapy	O
.	O
	
The	O
frequency	O
of	O
2+	O
proteinuria	B
was	O
similar	O
between	O
the	O
two	O
treatment	O
groups	O
between	O
one	O
and	O
three	O
years	O
after	O
transplantation	O
(	O
<	O
10	O
%	O
in	O
both	O
studies	O
)	O
.	O
	
The	O
data	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
positive	O
for	O
antibodies	O
to	O
belatacept	O
in	O
specific	O
assays	O
.	O
	
5.13	O
Reduction	O
in	O
Bone	O
Mineral	O
Density	O
Decreases	B
in	I
bone	I
mineral	I
density	I
)	O
have	O
been	O
observed	O
with	O
long-term	O
administration	O
of	O
products	O
containing	O
inhaled	O
corticosteroids	O
.	O
	
The	O
need	O
for	O
continued	O
treatment	O
should	O
be	O
reassessed	O
periodically	O
.	O
	
The	O
safety	O
evaluation	O
of	O
NORTHERA	O
is	O
based	O
on	O
two	O
placebo-controlled	O
studies	O
1	O
to	O
2	O
weeks	O
in	O
duration	O
(	O
Studies	O
301	O
and	O
302	O
)	O
,	O
one	O
8-week	O
placebo-controlled	O
study	O
(	O
Study	O
306	O
)	O
,	O
and	O
two	O
long-term	O
,	O
open-label	O
extension	O
studies	O
(	O
Studies	O
303	O
and	O
304	O
)	O
.	O
	
Psychiatric	O
disorders	O
:	O
Anxiety	B
,	O
bipolar	B
disorder	I
,	O
and	O
suicide	B
attempt	I
.	O
	
(	O
5.3	O
)	O
*	O
Wound	B
Complications	I
:	O
Withhold	O
COMETRIQ	O
for	O
dehiscence	O
or	O
complications	O
requiring	O
medical	O
intervention	O
.	O
	
For	O
infectious	B
adverse	I
reactions	I
,	O
the	O
causative	O
organism	O
is	O
reported	O
if	O
specified	O
by	O
the	O
physician	O
in	O
the	O
clinical	O
trials	O
.	O
	
Perioperative	O
Hypertension	O
The	O
placebo-controlled	O
experience	O
with	O
Cleviprex	O
in	O
the	O
perioperative	O
setting	O
was	O
both	O
small	O
and	O
brief	O
(	O
about	O
30	O
minutes	O
)	O
.	O
	
Metabolism	O
and	O
nutrition	O
disorders	O
:	O
metabolic	B
acidosis	I
,	O
dehydration	B
.	O
	
If	O
a	O
patient	O
is	O
exposed	O
to	O
chickenpox	O
,	O
prophylaxis	O
with	O
varicella	O
zoster	O
immune	O
globulin	O
(	O
VZIG	O
)	O
may	O
be	O
indicated	O
.	O
	
Overall	O
,	O
4	O
%	O
of	O
subjects	O
reported	O
one	O
or	O
more	O
adverse	O
reactions	O
following	O
EOVIST	O
administration	O
.	O
	
5.2	O
Allergic	O
Reactions	O
As	O
with	O
any	O
injectable	O
drug	O
product	O
,	O
allergic	B
reactions	I
and	O
anaphylaxis	B
may	O
occur	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
TRULICITY	O
.	O
	
Table	O
4	O
provides	O
the	O
adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
10	O
%	O
of	O
subjects	O
receiving	O
Zydelig	O
monotherapy	O
,	O
and	O
Table	O
5	O
provides	O
the	O
treatment-emergent	O
laboratory	O
abnormalities	O
.	O
	
In	O
Study	O
1	O
,	O
pneumonitis	B
was	O
reported	O
in	O
4	O
%	O
of	O
255	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Hematologic	O
Toxicity	O
Beleodaq	O
can	O
cause	O
thrombocytopenia	B
,	O
leukopenia	B
(	O
neutropenia	B
and	O
lymphopenia	B
)	O
,	O
and/or	O
anemia	B
;	O
monitor	O
blood	O
counts	O
weekly	O
during	O
treatment	O
,	O
and	O
modify	O
dosage	O
as	O
necessary	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.3	O
Liver	O
Disease	O
Discontinue	O
Natazia	O
if	O
jaundice	O
develops	O
.	O
	
One	O
(	O
0.2	O
%	O
)	O
patient	O
died	B
as	O
a	O
result	O
of	O
toxic	B
epidermal	I
necrolysis	I
and	O
one	O
additional	O
patient	O
required	O
hospitalization	O
for	O
severe	O
dermatitis	B
.	O
	
The	O
increased	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
AEDs	O
was	O
observed	O
as	O
early	O
as	O
one	O
week	O
after	O
starting	O
drug	O
treatment	O
with	O
AEDs	O
and	O
persisted	O
for	O
the	O
duration	O
of	O
treatment	O
assessed	O
.	O
	
5.5	O
Gallbladder	O
Disease	O
Studies	O
suggest	O
a	O
small	O
increased	O
relative	O
risk	O
of	O
developing	O
gallbladder	B
disease	I
among	O
COC	O
users	O
.	O
	
Adverse	O
reactions	O
of	O
Grade	O
3	O
or	O
higher	O
were	O
reported	O
in	O
80	O
%	O
of	O
patients	O
.	O
	
Protamine	O
sulfate	O
and	O
vitamin	O
K	O
are	O
not	O
expected	O
to	O
affect	O
the	O
anticoagulant	O
activity	O
of	O
dabigatran	O
.	O
	
(	O
5.1	O
)	O
*	O
Some	O
patients	O
with	O
retinal	O
abnormalities	O
have	O
been	O
found	O
to	O
have	O
abnormal	O
visual	O
acuity	O
.	O
	
(	O
5.1	O
,	O
6.1	O
)	O
*	O
Impairment	B
in	I
renal	I
function	I
:	O
Monitor	O
renal	O
function	O
during	O
therapy	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Merz	O
Pharmaceuticals	O
,	O
LLC	O
at	O
888-493-6646	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
All	O
patients	O
taking	O
POTIGA	O
should	O
have	O
baseline	O
and	O
periodic	O
(	O
every	O
6	O
months	O
)	O
systematic	O
visual	O
monitoring	O
by	O
an	O
ophthalmic	O
professional	O
.	O
	
In	O
this	O
study	O
,	O
76	O
%	O
(	O
44	O
of	O
58	O
)	O
completed	O
all	O
planned	O
therapy	O
.	O
	
*	O
Neurological	B
toxicities	I
,	O
which	O
may	O
be	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
Alternatively	O
,	O
administration	O
of	O
non-enteric	O
coated	O
aspirin	O
(	O
up	O
to	O
a	O
dose	O
of	O
325	O
mg	O
)	O
30	O
minutes	O
prior	O
to	O
TECFIDERA	O
dosing	O
may	O
reduce	O
the	O
incidence	O
or	O
severity	O
of	O
flushing	B
[	O
see	O
Dosing	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
The	O
most	O
frequent	O
second	B
primary	I
malignancy	I
was	O
non-melanoma	B
skin	I
cancer	I
(	O
range	O
,	O
4	O
to	O
11	O
%	O
)	O
.	O
	
5.2	O
Hypersensitivity	O
Clinically	O
significant	O
hypersensitivity	B
including	O
anaphylaxis	B
has	O
been	O
reported	O
with	O
Prolia	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Vertex	O
Pharmaceuticals	O
Incorporated	O
at	O
1-877-634-8789	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Events	O
related	O
to	O
visual	B
changes	I
were	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
The	O
impact	O
of	O
treatment	O
with	O
CIMZIA	O
on	O
the	O
development	O
and	O
course	O
of	O
malignancies	O
,	O
as	O
well	O
as	O
active	O
and/or	O
chronic	O
infections	O
,	O
is	O
not	O
fully	O
understood	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
,	O
5.5	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Fatal	B
pulmonary	B
embolism	I
was	O
reported	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
none	O
of	O
the	O
patients	O
receiving	O
sorafenib	O
.	O
	
In	O
most	O
cases	O
the	O
reactions	O
were	O
of	O
mild	O
or	O
moderate	O
intensity	O
.	O
	
The	O
sudden	O
drop	O
in	O
estrogen	O
levels	O
causes	O
``	O
surgical	O
menopause	O
.	O
	
Monitor	O
patients	O
periodically	O
.	O
	
The	O
most	O
frequently	O
reported	O
of	O
these	O
adverse	O
reactions	O
were	O
headache	B
,	O
nasopharyngitis	B
,	O
injection	B
site	I
pain	I
,	O
sinusitis	B
,	O
URI	B
,	O
injection	B
site	I
bruising	I
,	O
and	O
injection	B
site	I
reaction	I
)	O
.	O
	
6.2	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
a	O
potential	O
for	O
immunogenicity	O
.	O
	
Adverse	O
reactions	O
with	O
GILENYA	O
0.5	O
mg	O
in	O
Study	O
2	O
,	O
the	O
1-year	O
active-controlled	O
(	O
versus	O
interferon	O
beta-1a	O
)	O
study	O
were	O
generally	O
similar	O
to	O
those	O
in	O
Studies	O
1	O
and	O
3	O
.	O
	
Screen	O
all	O
patients	O
for	O
renal	O
impairment	O
by	O
obtaining	O
a	O
history	O
and/or	O
laboratory	O
tests	O
.	O
	
Grade	O
3	O
and	O
higher	O
adverse	O
reactions	O
were	O
reported	O
among	O
47	O
%	O
of	O
XTANDI-treated	O
patients	O
and	O
53	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
The	O
adverse	O
events	O
occurring	O
in	O
>	O
=5	O
%	O
of	O
XEOMIN-treated	O
patients	O
and	O
greater	O
than	O
placebo	O
in	O
the	O
Phase	O
3	O
study	O
were	O
eyelid	B
ptosis	I
,	O
dry	B
eye	I
,	O
dry	B
mouth	I
,	O
diarrhea	B
,	O
headache	B
,	O
visual	B
impairment	I
,	O
dyspnea	B
,	O
nasopharyngitis	B
,	O
and	O
respiratory	B
tract	I
infection	I
.	O
	
*	O
Hypersensitivity	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Toviaz	O
,	O
like	O
other	O
antimuscarinic	O
drugs	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
decreased	O
gastrointestinal	O
motility	O
,	O
such	O
as	O
those	O
with	O
severe	O
constipation	O
.	O
	
AEDs	O
increase	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
in	O
patients	O
taking	O
these	O
drugs	O
for	O
any	O
indication	O
.	O
	
5.2	O
Serious	O
Infections	O
Serious	O
and	O
sometimes	O
fatal	B
infections	B
have	O
been	O
reported	O
in	O
patients	O
receiving	O
immunosuppressive	O
agents	O
,	O
including	O
BENLYSTA	O
.	O
	
Analysis	O
of	O
seventeen	O
placebo-controlled	O
trials	O
(	O
modal	O
duration	O
10	O
weeks	O
)	O
,	O
largely	O
in	O
patients	O
taking	O
atypical	O
antipsychotic	O
drugs	O
,	O
revealed	O
a	O
risk	O
of	O
death	B
in	O
the	O
drug-treated	O
patients	O
of	O
between	O
1.6	O
to	O
1.7	O
times	O
the	O
risk	O
of	O
death	O
in	O
placebo-treated	O
patients	O
.	O
	
5.6	O
Other	O
Immune-mediated	O
Adverse	O
Reactions	O
,	O
Including	O
Ocular	O
Manifestations	O
The	O
following	O
clinically	O
significant	O
immune-mediated	B
adverse	I
reactions	I
were	O
seen	O
in	O
less	O
than	O
1	O
%	O
of	O
YERVOY-treated	O
patients	O
in	O
Study	O
1	O
:	O
nephritis	B
,	O
pneumonitis	B
,	O
meningitis	B
,	O
pericarditis	B
,	O
uveitis	B
,	O
iritis	B
,	O
and	O
hemolytic	B
anemia	I
.	O
	
The	O
majority	O
of	O
the	O
most	O
common	O
adverse	O
reactions	O
presented	O
inTable	O
2occurred	O
within	O
the	O
first	O
2	O
weeks	O
of	O
treatment	O
and	O
tended	O
to	O
resolve	O
over	O
time	O
with	O
continued	O
dosing	O
.	O
	
5.2	O
Hypotension	O
and	O
Reflex	O
Tachycardia	O
Cleviprex	O
may	O
produce	O
systemic	B
hypotension	I
and	O
reflex	B
tachycardia	I
.	O
	
Advise	O
patients	O
to	O
contact	O
their	O
healthcare	O
provider	O
if	O
they	O
become	O
pregnant	O
,	O
or	O
if	O
pregnancy	O
is	O
suspected	O
,	O
while	O
taking	O
TAFINLAR	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Bleeding	B
was	O
assessed	O
in	O
each	O
study	O
beginning	O
with	O
the	O
first	O
dose	O
of	O
double-blind	O
study	O
drug	O
.	O
	
For	O
patients	O
receiving	O
Cleviprex	O
and	O
all	O
active	O
comparators	O
the	O
incidence	O
of	O
serious	O
adverse	O
events	O
within	O
one	O
hour	O
of	O
drug	O
infusion	O
discontinuation	O
was	O
similar	O
.	O
	
5.11	O
Fluid	O
Retention	O
Estrogens	O
may	O
cause	O
some	O
degree	O
of	O
fluid	B
retention	I
.	O
	
For	O
patients	O
with	O
SEGA	O
and	O
severe	O
hepatic	O
impairment	O
,	O
reduce	O
the	O
starting	O
dose	O
of	O
AFINITOR	O
Tablets	O
or	O
AFINITOR	O
DISPERZ	O
by	O
approximately	O
50	O
%	O
and	O
adjust	O
subsequent	O
doses	O
based	O
on	O
therapeutic	O
drug	O
monitoring	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
,	O
2.5	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
treatment	O
discontinuation	O
in	O
the	O
JEVTANA	O
group	O
was	O
neutropenia	B
(	O
2	O
%	O
)	O
.	O
	
Since	O
many	O
of	O
the	O
patients	O
in	O
the	O
Phase	O
3	O
trial	O
were	O
also	O
taking	O
medications	O
that	O
cause	O
liver	O
enzyme	O
elevations	O
(	O
e.g.	O
,	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
[	O
NSAIDs	O
]	O
,	O
methotrexate	O
[	O
MTX	O
]	O
,	O
or	O
isoniazid	O
prophylaxis	O
)	O
,	O
the	O
relationship	O
between	O
SIMPONI	O
ARIA	O
and	O
liver	O
enzyme	O
elevation	O
is	O
not	O
clear	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
(	O
2.1	O
,	O
5.3	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
such	O
as	O
flushing	B
and	O
dyspnea	B
have	O
been	O
observed	O
within	O
minutes	O
following	O
Vizamyl	O
administration	O
.	O
	
Observe	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
hypersensitivity	O
reactions	O
during	O
and	O
following	O
EOVIST	O
administration	O
.	O
	
Patients	O
who	O
demonstrate	O
hemodynamic	O
instability	O
on	O
alpha-blocker	O
therapy	O
alone	O
are	O
at	O
increased	O
risk	O
of	O
symptomatic	B
hypotension	I
with	O
concomitant	O
use	O
of	O
PDE5	O
inhibitors	O
.	O
	
Skin	O
biopsy	O
in	O
one	O
patient	O
demonstrated	O
deposition	B
of	I
anti-rhGAA	I
antibodies	I
in	O
the	O
lesion	O
.	O
	
Cases	O
of	O
chronic	B
leukemia	I
have	O
been	O
reported	O
in	O
association	O
with	O
post-marketing	O
TNF-blocker	O
use	O
in	O
RA	O
and	O
other	O
indications	O
.	O
	
Therefore	O
,	O
patients	O
should	O
be	O
monitored	O
for	O
decreased	O
efficacy	O
and	O
food	O
consumption	O
should	O
be	O
encouraged	O
while	O
taking	O
Coartem	O
Tablets	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.4	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
(	O
5.1,12.6	O
)	O
*	O
Halofantrine	O
and	O
Coartem	O
Tablets	O
should	O
not	O
be	O
administered	O
within	O
one	O
month	O
of	O
each	O
other	O
due	O
to	O
potential	O
additive	O
effects	O
on	O
the	O
QT	O
interval	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
20	O
%	O
)	O
were	O
nausea	B
,	O
fatigue	B
,	O
cough	B
,	O
diarrhea	B
,	O
and	O
headache	B
.	O
	
e	O
Includes	O
the	O
following	O
terms	O
:	O
brain	B
stem	I
hemorrhage	I
,	O
cerebral	B
hemorrhage	I
,	O
gastric	B
hemorrhage	I
,	O
epistaxis	B
,	O
gingival	B
hemorrhage	I
,	O
hematuria	B
,	O
vaginal	B
hemorrhage	I
,	O
hemorrhage	B
intracranial	I
,	O
eye	B
hemorrhage	I
,	O
and	O
vitreous	B
hemorrhage	I
.	O
	
6.2	O
Immunogenicity	O
In	O
the	O
KALBITOR	O
HAE	O
program	O
,	O
patients	O
developed	O
antibodies	O
to	O
KALBITOR	O
.	O
	
If	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
no	O
dose	O
modification	O
of	O
trametinib	O
is	O
required	O
for	O
patients	O
who	O
develop	O
non-cutaneous	O
malignancies	O
.	O
	
GI	B
bleed	I
includes	O
rectal	B
bleeding	I
.	O
	
Somnolence	B
led	O
to	O
withdrawal	O
in	O
<	O
1	O
%	O
of	O
patients	O
receiving	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
2	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
were	O
stomatitis	B
,	O
infections	B
,	O
rash	B
,	O
fatigue	B
,	O
diarrhea	B
,	O
and	O
decreased	B
appetite	I
.	O
	
Patients	O
may	O
present	O
with	O
fatigue	O
,	O
headache	O
,	O
mental	O
status	O
changes	O
,	O
abdominal	O
pain	O
,	O
unusual	O
bowel	O
habits	O
,	O
and	O
hypotension	O
,	O
or	O
nonspecific	O
symptoms	O
which	O
may	O
resemble	O
other	O
causes	O
such	O
as	O
brain	O
metastasis	O
or	O
underlying	O
disease	O
.	O
	
In	O
a	O
3-week	O
,	O
placebo-controlled	O
pediatric	O
trial	O
with	O
bipolar	O
I	O
disorder	O
,	O
the	O
mean	O
increases	B
(	I
at	I
Endpoint	I
)	I
in	I
prolactin	I
levels	I
were	O
3.2	O
ng/mL	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
2.1	O
ng/mL	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
6.4	O
ng/mL	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
compared	O
to	O
an	O
increase	O
of	O
2.5	O
ng/mL	O
for	O
placebo-treated	O
patients	O
.	O
	
(	O
2.3,5.3	O
)	O
*	O
Hepatic	B
toxicity	I
:	O
Fatal	B
hepatic	B
impairment	I
occurs	O
in	O
0.18	O
%	O
of	O
patients	O
.	O
	
5.4	O
Suicidal	O
Behavior	O
and	O
Ideation	O
HORIZANT	O
(	O
gabapentin	O
enacarbil	O
)	O
is	O
a	O
prodrug	O
of	O
gabapentin	O
,	O
an	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
.	O
	
All	O
9	O
patients	O
had	O
hypopituitarism	B
and	O
some	O
had	O
additional	O
concomitant	O
endocrinopathies	B
such	O
as	O
adrenal	B
insufficiency	I
,	O
hypogonadism	B
,	O
and	O
hypothyroidism	B
.	O
	
Recurrent	O
reactions	O
consisting	O
of	O
flu-like	B
illness	I
or	O
a	O
combination	O
of	O
events	O
such	O
as	O
pyrexia	B
,	O
chills	B
,	O
myalgia	B
,	O
arthralgia	B
,	O
pain	B
,	O
or	O
fatigue	B
occurring	O
after	O
completion	O
of	O
infusions	O
and	O
lasting	O
usually	O
for	O
1	O
-	O
3	O
days	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
alglucosidase	O
alfa	O
.	O
	
Several	O
patients	O
had	O
a	O
prior	O
history	O
of	O
pancreatitis	O
.	O
	
The	O
higher	O
risk	O
of	O
falls	B
for	O
patients	O
treated	O
with	O
INVOKANA	O
was	O
observed	O
within	O
the	O
first	O
few	O
weeks	O
of	O
treatment	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus	O
and	O
use	O
of	O
effective	O
contraception	O
.	O
	
Careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
patient	O
's	O
clinical	O
status	O
prior	O
to	O
administration	O
of	O
Vimizim	O
and	O
consider	O
delaying	O
the	O
Vimizim	O
infusion	O
(	O
5.2	O
)	O
.	O
	
5.6	O
Tumor	O
Lysis	O
Syndrome	O
Tumor	B
lysis	I
syndrome	I
has	O
been	O
reported	O
with	O
IMBRUVICA	O
therapy	O
.	O
	
Patients	O
experienced	O
relief	O
of	O
symptoms	O
upon	O
discontinuation	O
of	O
the	O
medication	O
.	O
	
The	O
safety	O
profile	O
for	O
patients	O
in	O
study	O
AS-1	O
treated	O
with	O
CIMZIA	O
was	O
similar	O
to	O
the	O
safety	O
profile	O
seen	O
in	O
patients	O
with	O
RA	O
.	O
	
Heart	O
Rate	O
Increase	O
and	O
Tachycardia	O
Related	O
Adverse	O
Reactions	O
.	O
	
All	O
were	O
serious	O
and	O
one	O
GI	B
fistula	I
was	O
fatal	B
(	O
<	O
1	O
%	O
)	O
.	O
	
These	O
hematomas	B
may	O
result	O
in	O
permanent	B
paralysis	I
(	O
5.3	O
)	O
.	O
	
Adverse	B
reactions	I
related	I
to	I
renal	I
function	I
can	O
occur	O
after	O
initiating	O
FARXIGA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
[	O
See	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
.	O
]	O
	
Rash	B
was	O
reported	O
more	O
frequently	O
in	O
female	O
subjects	O
than	O
in	O
male	O
subjects	O
(	O
rash	B
>	O
=	O
Grade	O
2	O
was	O
reported	O
in	O
13/64	O
[	O
20.3	O
%	O
]	O
females	O
versus	O
2/37	O
[	O
5.4	O
%	O
]	O
males	O
;	O
discontinuations	O
due	O
to	O
rash	B
were	O
reported	O
in	O
4/64	O
[	O
6.3	O
%	O
]	O
females	O
versus	O
0/37	O
[	O
0	O
%	O
]	O
males	O
)	O
.	O
	
AdreView	O
imaging	O
should	O
not	O
be	O
performed	O
if	O
discontinuation	O
of	O
these	O
medications	O
would	O
involve	O
risks	O
which	O
outweigh	O
the	O
value	O
of	O
AdreView	O
imaging	O
.	O
	
These	O
findings	O
were	O
generally	O
observed	O
within	O
the	O
first	O
12	O
weeks	O
of	O
treatment	O
and	O
were	O
reversible	O
with	O
dose	O
interruption	O
.	O
	
The	O
safety	O
of	O
ZYTIGA	O
in	O
patients	O
with	O
left	O
ventricular	O
ejection	O
fraction	O
<	O
50	O
%	O
or	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
Class	O
III	O
or	O
IV	O
heart	O
failure	O
(	O
in	O
Study	O
1	O
)	O
or	O
NYHA	O
Class	O
II	O
to	O
IV	O
heart	O
failure	O
(	O
in	O
Study	O
2	O
)	O
was	O
not	O
established	O
because	O
these	O
patients	O
were	O
excluded	O
from	O
these	O
randomized	O
clinical	O
trials	O
[	O
seeClinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
The	O
patient	O
demographics	O
were	O
similar	O
to	O
Studies	O
1	O
and	O
2	O
.	O
	
5.3	O
Immune-mediated	O
Dermatitis	O
In	O
Study	O
1	O
,	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
immune-mediated	B
dermatitis	I
(	O
eg	O
,	O
Stevens-Johnson	B
syndrome	I
,	O
toxic	B
epidermal	I
necrolysis	I
,	O
or	O
rash	B
complicated	O
by	O
full	O
thickness	O
dermal	B
ulceration	I
;	O
Grade	O
3-5	O
)	O
occurred	O
in	O
13	O
(	O
2.5	O
%	O
)	O
YERVOY-treated	O
patients	O
.	O
	
Hepatic	B
adenomas	I
are	O
associated	O
with	O
COC	O
use	O
.	O
	
Laboratory	O
abnormalities	O
considered	O
ADRs	O
are	O
included	O
in	O
Table	O
2	O
.	O
	
In	O
some	O
incidences	O
these	O
pneumonia	B
events	O
were	O
fatal	B
.	O
	
5.5	O
Gastrointestinal	O
Toxicity	O
Nausea	B
,	O
vomiting	B
and	O
diarrhea	B
occur	O
with	O
Beleodaq	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
and	O
may	O
require	O
the	O
use	O
of	O
antiemetic	O
and	O
antidiarrheal	O
medications	O
.	O
	
GRANIX	O
clinical	O
trials	O
safety	O
data	O
are	O
based	O
upon	O
the	O
results	O
of	O
three	O
randomized	O
clinical	O
trials	O
in	O
patients	O
receiving	O
myeloablative	O
chemotherapy	O
for	O
breast	O
cancer	O
(	O
N=348	O
)	O
,	O
lung	O
cancer	O
(	O
N=240	O
)	O
and	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
N=92	O
)	O
.	O
	
When	O
medically	O
feasible	O
,	O
stop	O
these	O
drugs	O
before	O
AdreView	O
administration	O
and	O
monitor	O
patients	O
for	O
the	O
occurrence	O
of	O
clinically	O
significant	O
withdrawal	O
symptoms	O
,	O
especially	O
patients	O
with	O
elevated	O
levels	O
of	O
circulating	O
catecholamines	O
and	O
their	O
metabolites	O
.	O
	
Neovascular	O
(	O
Wet	O
)	O
Age-Related	O
Macular	O
Degeneration	O
(	O
AMD	O
)	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
EYLEA	O
in	O
1824	O
patients	O
with	O
wet	O
AMD	O
,	O
including	O
1223	O
patients	O
treated	O
with	O
the	O
2-mg	O
dose	O
,	O
in	O
2	O
double-masked	O
,	O
active-controlled	O
clinical	O
studies	O
(	O
VIEW1	O
and	O
VIEW2	O
)	O
for	O
12	O
months	O
[	O
seeClinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
CIMZIA	O
should	O
be	O
discontinued	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
or	O
sepsis	O
.	O
	
5.2	O
Impairment	O
in	O
Renal	O
Function	O
FARXIGA	O
increases	B
serum	I
creatinine	I
and	O
decreases	B
eGFR	I
.	O
	
Adverse	O
reactions	O
which	O
occurred	O
in	O
>	O
=	O
25	O
%	O
of	O
COMETRIQ-treated	O
patients	O
occurring	O
more	O
frequently	O
in	O
the	O
COMETRIQ	O
arm	O
with	O
a	O
between-arm	O
difference	O
of	O
>	O
=	O
5	O
%	O
included	O
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
:	O
diarrhea	B
,	O
stomatitis	B
,	O
palmar-plantar	B
erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
,	O
decreased	B
weight	I
,	O
decreased	B
appetite	I
,	O
nausea	B
,	O
fatigue	B
,	O
oral	B
pain	I
,	O
hair	B
color	I
changes	I
,	O
dysgeusia	B
,	O
hypertension	B
,	O
abdominal	B
pain	I
,	O
and	O
constipation	B
.	O
	
Advise	O
women	O
of	O
potential	O
risk	O
to	O
a	O
fetus	O
.	O
	
The	O
most	O
common	O
non-hematologic	O
adverse	O
reactions	O
(	O
>	O
=30	O
%	O
)	O
were	O
nausea	B
(	O
75	O
%	O
)	O
,	O
fatigue	B
(	O
57	O
%	O
)	O
,	O
vomiting	B
(	O
40	O
%	O
)	O
,	O
diarrhea	B
(	O
37	O
%	O
)	O
and	O
pyrexia	B
(	O
34	O
%	O
)	O
.	O
	
If	O
abnormalities	O
are	O
detected	O
,	O
monitoring	O
of	O
these	O
parameters	O
should	O
be	O
continued	O
to	O
ensure	O
that	O
further	O
deterioration	O
does	O
not	O
occur	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reaction	O
is	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
:	O
*	O
Transaminase	B
Elevations	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
to	O
KALYDECO	O
(	O
occurring	O
in	O
>	O
=8	O
%	O
of	O
patients	O
with	O
CF	O
who	O
have	O
a	O
G551D	O
mutation	O
in	O
the	O
CFTR	O
gene	O
)	O
were	O
headache	B
,	O
oropharyngeal	B
pain	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
nasal	B
congestion	I
,	O
abdominal	B
pain	I
,	O
nasopharyngitis	B
,	O
diarrhea	B
,	O
rash	B
,	O
nausea	B
,	O
and	O
dizziness	B
.	O
	
Some	O
patients	O
required	O
hospitalization	O
and	O
discontinuation	O
of	O
APTIOM	O
.	O
	
If	O
a	O
serious	O
hypersensitivity	O
reaction	O
is	O
suspected	O
,	O
discontinue	O
NESINA	O
,	O
assess	O
for	O
other	O
potential	O
causes	O
for	O
the	O
event	O
and	O
institute	O
alternative	O
treatment	O
for	O
diabetes	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
in	O
Vimizim	O
patients	O
and	O
occurring	O
at	O
a	O
higher	O
incidence	O
than	O
placebo-treated	O
patients	O
)	O
were	O
pyrexia	B
,	O
vomiting	B
,	O
headache	B
,	O
nausea	B
,	O
abdominal	B
pain	I
,	O
chills	B
,	O
and	O
fatigue	B
(	O
6.1	O
)	O
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
adverse	O
events	O
was	O
4.2	O
%	O
and	O
0.8	O
%	O
for	O
the	O
placebo	O
and	O
Prolia	O
groups	O
,	O
respectively	O
.	O
	
Somnolence	O
and	O
Fatigue	O
APTIOM	O
causes	O
dose-dependent	O
increases	O
in	O
somnolence	B
and	O
fatigue-related	O
adverse	O
reactions	O
(	O
fatigue	B
,	O
asthenia	B
,	O
malaise	B
,	O
hypersomnia	B
,	O
sedation	B
,	O
and	O
lethargy	B
)	O
.	O
	
(	O
5.3	O
)	O
*	O
Tardive	B
Dyskinesia	I
:	O
Discontinue	O
if	O
clinically	O
appropriate	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Seizure	B
occurred	O
in	O
0.9	O
%	O
of	O
patients	O
receiving	O
XTANDI	O
who	O
previously	O
received	O
docetaxel	O
and	O
in	O
0.1	O
%	O
of	O
patients	O
who	O
were	O
chemotherapy-naive	O
.	O
	
2Includes	O
the	O
preferred	O
terms	O
oral	B
hypoesthesia	I
,	O
oral	B
paresthesia	I
,	O
and	O
oral	B
dysesthesia	I
.	O
	
Adverse	O
reactions	O
that	O
occurred	O
after	O
repeated	O
injections	O
in	O
2-3	O
%	O
of	O
the	O
population	O
included	O
bronchitis	B
,	O
influenza	B
,	O
pharyngolaryngeal	B
pain	I
,	O
cough	B
,	O
contact	B
dermatitis	I
,	O
injection	B
site	I
swelling	I
,	O
and	O
injection	B
site	I
discomfort	I
.	O
	
This	O
study	O
showed	O
a	O
statistically	O
significant	O
reduction	B
in	I
heart	I
rate	I
compared	O
to	O
baseline	O
,	O
averaging	O
about	O
three	O
beats	O
per	O
minute	O
,	O
observed	O
thirty	O
minutes	O
after	O
injection	O
.	O
	
5.2	O
Immune-Mediated	O
Reactions	O
Immune-mediated	B
cutaneous	I
reactions	I
have	O
been	O
reported	O
with	O
alglucosidase	O
alfa	O
including	O
necrotizing	B
skin	I
lesions	I
[	O
seeAdverse	O
Reactions	O
(	O
6.3	O
)	O
]	O
.	O
	
Inform	O
patients	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
,	O
hypersensitivity	O
reactions	O
,	O
and	O
immune-mediated	O
reactions	O
and	O
have	O
them	O
seek	O
immediate	O
medical	O
care	O
should	O
signs	O
and	O
symptoms	O
occur	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
)	O
]	O
.	O
	
*	O
If	O
you	O
take	O
too	O
much	O
DUAVEE	O
,	O
call	O
your	O
healthcare	O
provider	O
.	O
	
In	O
addition	O
to	O
the	O
hypersensitivity	B
reactions	I
reported	O
in	O
clinical	O
trials	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
,	O
the	O
following	O
hypersensitivity	B
reactions	I
have	O
been	O
reported	O
in	O
at	O
least	O
2	O
patients	O
and	O
included	O
:	O
anaphylactic	B
shock	I
,	O
respiratory	B
failure	I
,	O
respiratory	B
arrest	I
,	O
cardiac	B
arrest	I
,	O
hypoxia	B
,	O
dyspnea	B
,	O
wheezing	B
,	O
convulsions	B
,	O
peripheral	B
coldness	I
,	O
restlessness	B
,	O
nervousness	B
,	O
back	B
pain	I
,	O
stridor	B
,	O
pharyngeal	B
edema	I
,	O
abdominal	B
pain	I
,	O
apnea	B
,	O
muscle	B
spasm	I
,	O
and	O
conjunctivitis	B
.	O
	
Risk	O
factors	O
for	O
PML	O
include	O
treatment	O
with	O
immunosuppressant	O
therapies	O
and	O
impairment	O
of	O
immune	O
function	O
.	O
	
Angioedema	B
associated	O
with	O
upper	B
airway	I
swelling	I
may	O
be	O
life-threatening	O
.	O
	
Titration	O
was	O
used	O
over	O
the	O
first	O
5	O
days	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
Across	O
the	O
clinical	O
development	O
program	O
for	O
YERVOY	O
,	O
the	O
following	O
likely	O
immune-mediated	B
adverse	I
reactions	I
were	O
also	O
reported	O
with	O
less	O
than	O
1	O
%	O
incidence	O
:	O
myocarditis	B
,	O
angiopathy	B
,	O
temporal	B
arteritis	I
,	O
vasculitis	B
,	O
polymyalgia	B
rheumatica	I
,	O
conjunctivitis	B
,	O
blepharitis	B
,	O
episcleritis	B
,	O
scleritis	B
,	O
leukocytoclastic	B
vasculitis	I
,	O
erythema	B
multiforme	I
,	O
psoriasis	B
,	O
pancreatitis	B
,	O
arthritis	B
,	O
autoimmune	B
thyroiditis	I
,	O
sarcoidosis	B
,	O
neurosensory	B
hypoacusis	I
,	O
autoimmune	B
central	I
neuropathy	I
(	O
encephalitis	B
)	O
,	O
myositis	B
,	O
polymyositis	B
,	O
and	O
ocular	B
myositis	I
.	O
	
periodontal	O
and/or	O
other	O
pre-existing	O
dental	O
disease	O
,	O
anemia	O
,	O
coagulopathy	O
,	O
infection	O
,	O
ill-fitting	O
dentures	O
)	O
.	O
	
Prior	O
to	O
initiation	O
of	O
therapy	O
with	O
ILARIS	O
,	O
patients	O
should	O
receive	O
all	O
recommended	O
vaccinations	O
.	O
	
Drugs	O
that	O
affect	O
the	O
immune	O
system	O
by	O
blocking	O
TNF	O
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
new	O
tuberculosis	O
and	O
reactivation	O
of	O
latent	O
tuberculosis	O
(	O
TB	O
)	O
.	O
	
Gastrointestinal	O
Adverse	O
Reactions	O
In	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
,	O
gastrointestinal	B
complaints	I
occurred	O
more	O
frequently	O
among	O
patients	O
receiving	O
TANZEUM	O
(	O
39	O
%	O
)	O
than	O
patients	O
receiving	O
placebo	O
(	O
33	O
%	O
)	O
.	O
	
5.6	O
Potential	O
for	O
Tumor	O
Growth	O
Stimulatory	O
Effects	O
on	O
Malignant	O
Cells	O
The	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
receptor	O
through	O
which	O
GRANIX	O
acts	O
has	O
been	O
found	O
on	O
tumor	O
cell	O
lines	O
.	O
	
Because	O
CERDELGA	O
is	O
predicted	O
to	O
cause	O
increases	B
in	I
ECG	I
intervals	I
(	I
PR	I
)	O
at	O
substantially	O
elevated	O
eliglustat	O
plasma	O
concentrations	O
,	O
use	O
of	O
CERDELGA	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
pre-existing	O
cardiac	O
disease	O
(	O
congestive	O
heart	O
failure	O
,	O
recent	O
acute	O
myocardial	O
infarction	O
,	O
bradycardia	O
,	O
heart	O
block	O
,	O
ventricular	O
arrhythmia	O
)	O
,	O
long	O
QT	O
syndrome	O
,	O
and	O
in	O
combination	O
with	O
Class	O
IA	O
(	O
e.g.	O
,	O
quinidine	O
,	O
procainamide	O
)	O
and	O
Class	O
III	O
(	O
e.g.	O
,	O
amiodarone	O
,	O
sotalol	O
)	O
antiarrhythmic	O
medications	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Antibody	O
titers	O
were	O
determined	O
using	O
a	O
bridging	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
anti-glucarpidase	O
antibodies	O
.	O
	
The	O
incidence	O
of	O
urinary	B
tract	I
infections	I
in	O
female	O
patients	O
randomized	O
to	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
was	O
16.6	O
%	O
,	O
18.4	O
%	O
,	O
and	O
17.0	O
%	O
,	O
respectively	O
.	O
	
Delayed	O
reactions	O
can	O
occur	O
up	O
to	O
several	O
days	O
after	O
administration	O
.	O
	
Psychiatric	O
Disorders	O
:	O
psychotic	B
behavior	I
including	O
aggressive	B
thoughts	I
.	O
	
Increased	O
risk	O
of	O
thrombotic	B
events	I
after	O
premature	O
discontinuation	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
?	O
	
*	O
Immune	B
Reconstitution	I
Syndrome	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)	O
]	O
.	O
	
The	O
median	O
time	O
to	O
first	O
onset	O
of	O
any	O
grade	O
was	O
14	O
weeks	O
(	O
range	O
,	O
0.1-47	O
)	O
,	O
of	O
Grade	O
2	O
was	O
27	O
weeks	O
(	O
range	O
,	O
0.4-52	O
)	O
and	O
of	O
Grade	O
3	O
was	O
34	O
weeks	O
(	O
range	O
,	O
7-106	O
)	O
.	O
	
Prophylactic	O
therapy	O
(	O
i.e.	O
,	O
non-steroidal	O
anti-inflammatory	O
drug	O
[	O
NSAID	O
]	O
or	O
colchicine	O
upon	O
initiation	O
of	O
treatment	O
)	O
may	O
be	O
beneficial	O
for	O
up	O
to	O
six	O
months	O
.	O
	
Acute	B
cardiorespiratory	I
failure	I
has	O
been	O
observed	O
in	O
infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
underlying	O
cardiac	O
hypertrophy	O
,	O
possibly	O
associated	O
with	O
fluid	B
overload	I
with	O
intravenous	O
administration	O
of	O
alglucosidase	O
alfa	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Systemic	B
immune-mediated	I
reactions	I
,	O
including	O
possible	O
type	B
III	I
immune-mediated	I
reactions	I
have	O
been	O
observed	O
with	O
alglucosidase	O
alfa	O
.	O
	
In	O
some	O
patients	O
,	O
concomitant	O
use	O
of	O
these	O
two	O
drug	O
classes	O
can	O
lower	O
blood	O
pressure	O
significantly	O
leading	O
to	O
symptomatic	B
hypotension	I
(	O
e.g.	O
,	O
dizziness	B
,	O
lightheadedness	B
,	O
fainting	B
)	O
.	O
	
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
rhabdomyolysis	B
.	O
	
Most	O
studies	O
show	O
no	O
significant	O
increased	O
risk	O
associated	O
with	O
use	O
of	O
estrogens	O
for	O
less	O
than	O
1	O
year	O
.	O
	
Extravasation	O
into	O
tissues	O
during	O
Gadavist	O
administration	B
may	I
result	I
in	I
moderate	I
irritation	I
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.2	O
)	O
]	O
.	O
	
MULTAQ	O
offers	O
no	O
benefit	O
in	O
subjects	O
in	O
permanent	O
AF	O
.	O
	
Most	O
of	O
these	O
events	O
were	O
not	O
specific	O
to	O
the	O
injection	O
site	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Prophylaxis	O
for	O
Pneumocystis	O
jiroveci	O
is	O
recommended	O
after	O
transplantation	O
.	O
	
5.3	O
Hemorrhage	O
Hemorrhages	B
,	O
including	O
major	O
hemorrhages	B
defined	O
as	O
symptomatic	B
bleeding	I
in	O
a	O
critical	O
area	O
or	O
organ	O
,	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Includes	O
13	O
subjects	O
with	O
major	O
bleeding	B
events	O
that	O
occurred	O
before	O
the	O
first	O
dose	O
of	O
apixaban	O
(	O
administered	O
12	O
to	O
24	O
hours	O
post	O
surgery	O
)	O
.	O
	
Increased	O
incidence	O
of	O
seizures	B
has	O
been	O
observed	O
at	O
20	O
mg	O
twice	O
daily	O
in	O
controlled	O
clinical	O
studies	O
of	O
9-14	O
weeks	O
duration	O
with	O
dalfampridine	O
in	O
patients	O
with	O
MS	O
.	O
	
In	O
addition	O
to	O
the	O
examination	O
of	O
the	O
fundus	O
including	O
the	O
macula	O
prior	O
to	O
treatment	O
and	O
at	O
3-4	O
months	O
after	O
starting	O
treatment	O
,	O
MS	O
patients	O
with	O
diabetes	O
mellitus	O
or	O
a	O
history	O
of	O
uveitis	O
should	O
have	O
regular	O
follow-up	O
examinations	O
.	O
	
Treatment	O
discontinuations	O
due	O
to	O
adverse	O
drug	O
reactions	O
occurred	O
in	O
18	O
%	O
of	O
patients	O
who	O
received	O
JEVTANA	O
and	O
8	O
%	O
of	O
patients	O
who	O
received	O
mitoxantrone	O
.	O
	
In	O
a	O
limited	O
number	O
of	O
patients	O
,	O
hypophysitis	B
was	O
diagnosed	O
by	O
imaging	O
studies	O
through	O
enlargement	O
of	O
the	O
pituitary	O
gland	O
.	O
	
Clinical	O
trials	O
of	O
GILOTRIF	O
excluded	O
patients	O
with	O
an	O
abnormal	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
i.e.	O
,	O
below	O
the	O
institutional	O
lower	O
limit	O
of	O
normal	O
.	O
	
Reactions	O
already	O
listed	O
for	O
either	O
adults	O
or	O
pediatric	O
patients	O
in	O
other	O
parts	O
of	O
Adverse	O
Reactions	O
(	O
6	O
)	O
,	O
or	O
those	O
considered	O
in	O
Contraindications	O
(	O
4	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
or	O
Overdosage	O
(	O
10	O
)	O
are	O
not	O
included	O
.	O
	
Withhold	O
GILOTRIF	O
for	O
severe	O
and	O
prolonged	O
diarrhea	O
not	O
responsive	O
to	O
anti-diarrheal	O
agents	O
.	O
	
No	O
single	O
cause	O
of	O
death	B
predominated	O
.	O
	
(	O
5.1	O
)	O
.	O
	
Infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
compromised	O
cardiac	O
or	O
respiratory	O
function	O
may	O
be	O
at	O
risk	O
of	O
serious	O
acute	B
exacerbation	I
of	I
their	I
cardiac	I
or	I
respiratory	I
compromise	I
due	O
to	O
fluid	B
overload	I
,	O
and	O
require	O
additional	O
monitoring	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
While	O
subjects	O
aged	O
12	O
to	O
17	O
years	O
were	O
included	O
in	O
this	O
trial	O
,	O
BREO	O
ELLIPTA	O
is	O
not	O
approved	O
for	O
use	O
in	O
this	O
age-group	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
]	O
.	O
	
5.3	O
Acute	O
Kidney	O
Injury	O
In	O
patients	O
with	O
chronically	O
reduced	O
renal	O
function	O
,	O
acute	B
kidney	I
injury	I
requiring	O
dialysis	O
has	O
occurred	O
with	O
the	O
use	O
of	O
GBCAs	O
.	O
	
*	O
Classical	O
HL	O
post-auto-HSCT	O
consolidation	O
:	O
neutropenia	B
,	O
peripheral	B
sensory	I
neuropathy	I
,	O
thrombocytopenia	B
,	O
anemia	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
fatigue	B
,	O
peripheral	B
motor	I
neuropathy	I
,	O
nausea	B
,	O
cough	B
,	O
and	O
diarrhea	B
(	O
6.1	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
of	O
CIMZIA	O
were	O
tuberculosis	B
infections	I
(	O
0.5	O
%	O
)	O
;	O
and	O
pyrexia	B
,	O
urticaria	B
,	O
pneumonia	B
,	O
and	O
rash	B
(	O
0.3	O
%	O
)	O
.	O
	
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
venous	B
thromboembolic	I
events	I
were	O
reported	O
in	O
11/359	O
patients	O
(	O
3	O
%	O
)	O
receiving	O
INLYTA	O
and	O
2/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Table	O
10	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
2	O
%	O
or	O
More	O
of	O
Pediatric	O
Patients	O
(	O
Ages	O
10	O
to	O
17	O
Years	O
)	O
in	O
Any	O
SAPHRIS	O
Dose	O
Group	O
and	O
Which	O
Occurred	O
at	O
Greater	O
Incidence	O
Than	O
in	O
the	O
Placebo	O
Group	O
in	O
a	O
3-Week	O
Bipolar	O
Mania	O
Trial	O
1Includes	O
the	O
preferred	O
terms	O
tachycardia	B
and	O
heart	B
rate	I
increased	I
.	O
	
If	O
you	O
have	O
or	O
have	O
had	O
cancer	O
,	O
talk	O
with	O
your	O
healthcare	O
provider	O
about	O
whether	O
you	O
should	O
use	O
DUAVEE	O
.	O
	
The	O
clinical	O
significance	O
of	O
this	O
is	O
unknown	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
in	O
>	O
=13	O
%	O
of	O
patients	O
are	O
:	O
Infections	B
,	O
vomiting	B
,	O
abdominal	B
pain	I
,	O
pyrexia	B
,	O
tonsilitis	B
,	O
anemia	B
,	O
ear	B
infection	I
,	O
diarrhea	B
,	O
nasopharyngitis	B
,	O
and	O
headache	B
.	O
	
The	O
types	O
and	O
frequency	O
of	O
common	O
adverse	O
reactions	O
observed	O
in	O
the	O
pool	O
of	O
eight	O
clinical	O
trials	O
were	O
consistent	O
with	O
those	O
listed	O
in	O
Table	O
1	O
.	O
	
Adverse	O
reactions	O
reported	O
in	O
>	O
=	O
10	O
%	O
of	O
Prolia-treated	O
patients	O
receiving	O
ADT	O
for	O
prostate	O
cancer	O
or	O
adjuvant	O
AI	O
therapy	O
for	O
breast	O
cancer	O
,	O
and	O
more	O
frequently	O
than	O
in	O
the	O
placebo-treated	O
patients	O
were	O
:	O
arthralgia	B
(	O
13.0	O
%	O
placebo	O
vs.	O
14.3	O
%	O
Prolia	O
)	O
and	O
back	B
pain	I
(	O
10.5	O
%	O
placebo	O
vs.	O
11.5	O
%	O
Prolia	O
)	O
.	O
	
Increasing	O
the	O
daily	O
dosage	O
of	O
ARCAPTA	O
NEOHALER	O
beyond	O
the	O
recommended	O
dose	O
is	O
not	O
appropriate	O
in	O
this	O
situation	O
.	O
	
Across	O
clinical	O
trials	O
,	O
32	O
of	O
1560	O
patients	O
(	O
2.1	O
%	O
)	O
had	O
QTcF	B
(	I
corrected	I
QT	I
by	I
the	I
Fridericia	I
method	I
)	I
greater	I
than	I
or	I
equal	I
to	I
500	I
ms	I
and	O
76	O
of	O
1520	O
patients	O
(	O
5.0	O
%	O
)	O
had	O
an	O
increase	B
from	I
baseline	I
QTcF	I
greater	O
than	O
or	O
equal	O
to	O
60	O
ms	O
by	O
automated	O
machine-read	O
evaluation	O
of	O
ECG	O
.	O
	
Red	O
blood	O
cell	O
transfusions	O
were	O
administered	O
to	O
20	O
%	O
of	O
patients	O
receiving	O
TREANDA	O
compared	O
with	O
6	O
%	O
of	O
patients	O
receiving	O
chlorambucil	O
.	O
	
Serious	O
,	O
life-threatening	O
complications	O
were	O
reported	O
with	O
APTIOM-associated	O
hyponatremia	B
(	O
as	O
low	O
as	O
112	O
mEq/L	O
)	O
including	O
seizures	B
,	O
severe	O
nausea/vomiting	O
leading	O
to	O
dehydration	B
,	O
severe	O
gait	B
instability	I
,	O
and	O
injury	B
.	O
	
Non-Hodgkin	O
Lymphoma	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
TREANDA	O
in	O
176	O
patients	O
with	O
indolent	O
B-cell	O
NHL	O
treated	O
in	O
two	O
single-arm	O
studies	O
.	O
	
APTIOM	O
should	O
be	O
discontinued	O
in	O
patients	O
with	O
jaundice	O
or	O
other	O
evidence	O
of	O
significant	O
liver	O
injury	O
(	O
e.g.	O
,	O
laboratory	O
evidence	O
)	O
.	O
	
The	O
kidney	O
transplant	O
recipient	O
was	O
treated	O
with	O
the	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
,	O
mycophenolate	O
mofetil	O
(	O
MMF	O
)	O
,	O
and	O
corticosteroids	O
for	O
2	O
years	O
.	O
	
Investigators	O
graded	O
the	O
severity	O
of	O
gastrointestinal	B
adverse	I
reactions	I
occurring	O
on	O
0.75	O
mg	O
and	O
1.5	O
mg	O
of	O
TRULICITY	O
as	O
``	O
mild	O
''	O
in	B
58	O
%	O
and	O
48	O
%	O
of	O
cases	O
,	O
respectively	O
,	O
``	O
moderate	O
''	O
in	B
35	O
%	O
and	O
42	O
%	O
of	O
cases	O
,	O
respectively	O
,	O
or	O
``	O
severe	O
''	O
in	B
7	O
%	O
and	O
11	O
%	O
of	O
cases	O
,	O
respectively	O
.	O
	
The	O
population	O
exposed	O
to	O
COMETRIQ	O
was	O
70	O
%	O
male	O
,	O
90	O
%	O
white	O
,	O
and	O
had	O
a	O
median	O
age	O
of	O
55	O
years	O
.	O
	
The	O
most	O
frequently	O
reported	O
genital	B
mycotic	I
infections	I
were	O
vulvovaginal	B
mycotic	I
infections	I
in	O
females	O
and	O
balanitis	B
in	O
males	O
.	O
	
Elderly	O
patients	O
and	O
patients	O
with	O
impaired	O
renal	O
function	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
changes	O
.	O
	
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
PRADAXA	O
:	O
angioedema	B
,	O
thrombocytopenia	B
,	O
esophageal	B
ulcer	I
.	O
	
(	O
5.3	O
)	O
5.1	O
Hypertension	O
,	O
Hypokalemia	O
and	O
Fluid	O
Retention	O
Due	O
to	O
Mineralocorticoid	O
Excess	O
ZYTIGA	O
may	O
cause	O
hypertension	B
,	O
hypokalemia	B
,	O
and	O
fluid	B
retention	I
as	O
a	O
consequence	O
of	O
increased	B
mineralocorticoid	I
levels	I
resulting	O
from	O
CYP17	O
inhibition	O
[	O
seeClinical	O
Pharmacology	O
(	O
12.1	O
)	O
]	O
.	O
	
The	O
data	O
described	O
below	O
are	O
based	O
on	O
two	O
identical	O
,	O
pooled	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multi-center	O
trials	O
through	O
Day	O
365	O
in	O
patients	O
with	O
Peyronie	O
's	O
disease	O
(	O
Studies	O
1	O
and	O
2	O
)	O
.	O
	
(	O
5.2	O
)	O
*	O
AdreView	O
contains	O
benzyl	O
alcohol	O
(	O
10.3	O
mg/mL	O
)	O
which	O
may	O
cause	O
serious	O
reactions	O
in	O
premature	O
or	O
low	O
birth-weight	O
infants	O
.	O
	
COCs	O
also	O
increase	O
the	O
risk	O
for	O
stroke	B
in	O
women	O
with	O
other	O
underlying	O
risk	O
factors	O
.	O
	
Acute	O
or	O
chronic	O
disturbances	O
of	O
liver	O
function	O
may	O
necessitate	O
the	O
discontinuation	O
of	O
COC	O
use	O
until	O
markers	O
of	O
liver	O
function	O
return	O
to	O
normal	O
and	O
COC	O
causation	O
has	O
been	O
excluded	O
.	O
	
No	O
association	O
was	O
seen	O
between	O
antibody	O
development	O
and	O
the	O
development	O
of	O
adverse	O
events	O
.	O
	
A	O
pharmacokinetic	O
analysis	O
suggested	O
that	O
ZYKADIA	O
causes	O
concentration-dependent	O
increases	B
in	I
the	I
QTc	I
interval	I
.	O
	
[	O
See	O
Adverse	O
Reactions	O
(	O
6	O
)	O
.	O
]	O
	
Elevations	B
in	I
alanine	I
aminotransferase	I
(	O
ALT	O
)	O
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
occurred	O
in	O
27	O
%	O
of	O
255	O
patients	O
in	O
Study	O
1	O
.	O
	
The	O
incidence	O
of	O
serious	O
infections	B
during	O
the	O
controlled	O
clinical	O
studies	O
was	O
3	O
%	O
per	O
patient-year	O
for	O
CIMZIA-treated	O
patients	O
and	O
1	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
In	O
the	O
pool	O
of	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
the	O
types	O
and	O
frequency	O
of	O
common	O
adverse	O
reactions	O
,	O
excluding	O
hypoglycemia	B
,	O
were	O
similar	O
to	O
those	O
listed	O
in	O
Table	O
1	O
.	O
	
5.12	O
Monitoring	O
A	O
woman	O
who	O
is	O
taking	O
COCs	O
should	O
have	O
a	O
yearly	O
visit	O
with	O
her	O
healthcare	O
provider	O
for	O
a	O
blood	O
pressure	O
check	O
and	O
for	O
other	O
indicated	O
healthcare	O
.	O
	
Studies	O
also	O
do	O
not	O
suggest	O
a	O
teratogenic	B
effect	I
,	O
particularly	O
in	O
so	O
far	O
as	O
cardiac	B
anomalies	I
and	O
limb-reduction	B
defects	I
are	O
concerned	O
,	O
when	O
taken	O
inadvertently	O
during	O
early	O
pregnancy	O
.	O
	
(	O
5.1	O
)	O
*	O
The	O
rate	O
of	O
progression	O
of	O
retinal	O
abnormalities	O
and	O
their	O
reversibility	O
are	O
unknown	O
.	O
	
Common	O
Adverse	O
Reactions	O
(	O
>	O
=	O
2	O
%	O
)	O
:	O
headache	B
(	O
including	O
migraines	B
)	O
(	O
12.7	O
%	O
)	O
,	O
breast	B
pain	I
(	O
7.0	O
%	O
)	O
,	O
menstrual	B
disorders	I
(	O
metrorrhagia	B
,	O
menstruation	B
irregular	I
,	O
menorrhagia	B
,	O
vaginal	B
hemorrhage	I
,	O
dysfunctional	B
uterine	I
bleeding	I
,	O
genital	B
hemorrhage	I
,	O
abnormal	B
withdrawal	I
bleeding	I
,	O
uterine	B
hemorrhage	I
)	O
(	O
6.9	O
%	O
)	O
,	O
nausea	B
or	O
vomiting	B
(	O
6.0	O
%	O
)	O
,	O
acne	B
(	O
3.9	O
%	O
)	O
,	O
mood	B
changes	I
(	O
depression	B
,	O
mood	B
swings	I
,	O
depressed	B
mood	I
,	O
mood	B
altered	I
,	O
affect	B
lability	I
,	O
dysthymic	B
disorder	I
,	O
crying	B
)	O
(	O
3.0	O
%	O
)	O
and	O
increased	B
weight	I
(	O
2.9	O
%	O
)	O
.	O
	
Inform	O
patients	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
,	O
and	O
instruct	O
them	O
to	O
seek	O
immediate	O
medical	O
care	O
should	O
signs	O
and	O
symptoms	O
occur	O
.	O
	
(	O
5.9	O
)	O
*	O
Seizures	B
:	O
Use	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
conditions	O
that	O
lower	O
the	O
seizure	O
threshold	O
.	O
	
(	O
5.3	O
)	O
*	O
Bradycardia	B
:	O
XALKORI	O
can	O
cause	O
bradycardia	B
.	O
	
5.6	O
Embryofetal	O
Toxicity	O
There	O
are	O
no	O
adequate	O
and	O
well	O
controlled	O
studies	O
of	O
BOSULIF	O
in	O
pregnant	O
women	O
.	O
	
(	O
5.5	O
)	O
*	O
Embryofetal	B
Toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
In	O
the	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
these	O
events	O
were	O
reported	O
in	O
1	O
%	O
of	O
placebo	O
patients	O
,	O
4	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
800	O
mg/day	O
APTIOM	O
,	O
and	O
7	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
1200	O
mg/day	O
APTIOM	O
.	O
	
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.1	O
Anaphylaxis	O
and	O
Hypersensitivity	O
Reactions	O
Anaphylaxis	B
and	O
hypersensitivity	B
reactions	I
have	O
been	O
observed	O
in	O
patients	O
during	O
and	O
up	O
to	O
3	O
hours	O
after	O
alglucosidase	O
alfa	O
infusion	O
.	O
	
Grade	O
1-4	O
elevations	B
in	I
ALT	I
occurred	O
in	O
10	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
(	O
0.2	O
%	O
Grade	O
3-4	O
)	O
and	O
16	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
(	O
0.2	O
%	O
Grade	O
3-4	O
)	O
.	O
	
Estimated	O
creatinine	O
clearance	O
,	O
urine	O
glucose	O
and	O
urine	O
protein	O
should	O
be	O
documented	O
in	O
all	O
patients	O
prior	O
to	O
initiating	O
therapy	O
.	O
	
(	O
1.2	O
,	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
LABA	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
and	O
asthma-related	O
hospitalizations	O
.	O
	
Serious	O
adverse	O
drug	O
reactions	O
reported	O
in	O
2	O
%	O
or	O
more	O
of	O
patients	O
in	O
Study	O
1	O
were	O
convulsion	B
,	O
pneumonia	B
,	O
ILD/pneumonitis	O
,	O
dyspnea	B
,	O
dehydration	B
,	O
hyperglycemia	B
,	O
and	O
nausea	B
.	O
	
Some	O
patients	O
(	O
13	O
%	O
)	O
received	O
premedication	O
,	O
which	O
may	O
have	O
mitigated	O
or	O
masked	O
an	O
infusion	O
reaction	O
;	O
however	O
,	O
there	O
is	O
insufficient	O
evidence	O
to	O
determine	O
whether	O
premedication	O
diminishes	O
the	O
frequency	O
or	O
severity	O
of	O
infusion	O
reactions	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Patients	O
receiving	O
any	O
therapy	O
for	O
chronic	O
infection	O
should	O
not	O
begin	O
therapy	O
with	O
BENLYSTA	O
.	O
	
Acute	B
cardiorespiratory	I
failure	I
,	O
possibly	O
associated	O
with	O
fluid	B
overload	I
,	O
has	O
been	O
reported	O
in	O
infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
pre-existing	O
hypertrophic	O
cardiomyopathy	O
[	O
seeBoxed	O
WarningandWarning	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
ENTEREG	O
is	O
available	O
only	O
through	O
a	O
program	O
under	O
a	O
REMS	O
that	O
restricts	O
use	O
to	O
enrolled	O
hospitals	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
*	O
Discontinuation	B
Syndrome	I
:	O
Taper	O
dose	O
when	O
possible	O
and	O
monitor	O
for	O
discontinuation	O
symptoms	O
(	O
5.7	O
)	O
.	O
	
(	O
5.4	O
)	O
5.1	O
Serious	O
Infections	O
ILARIS	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	B
.	O
	
Phimosis	B
occurred	O
more	O
frequently	O
in	O
male	O
patients	O
treated	O
with	O
JARDIANCE	O
10	O
mg	O
(	O
less	O
than	O
0.1	O
%	O
)	O
and	O
JARDIANCE	O
25	O
mg	O
(	O
0.1	O
%	O
)	O
than	O
placebo	O
(	O
0	O
%	O
)	O
.	O
	
Because	O
they	O
are	O
reported	O
from	O
a	O
population	O
of	O
unknown	O
size	O
,	O
precise	O
estimates	O
of	O
frequency	O
can	O
not	O
be	O
made	O
.	O
	
history	O
of	O
hypoparathyroidism	O
,	O
thyroid	O
surgery	O
,	O
parathyroid	O
surgery	O
,	O
malabsorption	O
syndromes	O
,	O
excision	O
of	O
small	O
intestine	O
,	O
severe	O
renal	O
impairment	O
[	O
creatinine	O
clearance	O
<	O
30	O
mL/min	O
]	O
or	O
receiving	O
dialysis	O
)	O
,	O
clinical	O
monitoring	O
of	O
calcium	O
and	O
mineral	O
levels	O
(	O
phosphorus	O
and	O
magnesium	O
)	O
is	O
highly	O
recommended	O
within	O
14	O
days	O
of	O
Prolia	O
injection	O
.	O
	
In	O
total	O
,	O
11	O
%	O
of	O
the	O
patients	O
treated	O
with	O
ELIQUIS	O
2.5	O
mg	O
twice	O
daily	O
experienced	O
adverse	O
reactions	O
.	O
	
Adverse	B
reactions	I
of	I
the	I
hematologic	I
system	I
,	O
including	O
medically	O
significant	O
cytopenia	B
(	O
e.g.	O
,	O
leukopenia	B
,	O
pancytopenia	B
,	O
thrombocytopenia	B
)	O
have	O
been	O
infrequently	O
reported	O
with	O
CIMZIA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
For	O
patients	O
receiving	O
hemodialysis	O
,	O
physicians	O
may	O
consider	O
the	O
prompt	O
initiation	O
of	O
hemodialysis	O
following	O
the	O
administration	O
of	O
a	O
GBCA	O
in	O
order	O
to	O
enhance	O
the	O
contrast	O
agent	O
's	O
elimination	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
associated	O
with	O
infusion-related	B
reactions	I
were	O
nausea	B
(	O
4	O
%	O
)	O
,	O
chills	B
(	O
4	O
%	O
)	O
,	O
dyspnea	B
(	O
2	O
%	O
)	O
,	O
headache	B
(	O
2	O
%	O
)	O
,	O
pruritus	B
(	O
2	O
%	O
)	O
,	O
rash	B
(	O
2	O
%	O
)	O
,	O
back	B
pain	I
(	O
2	O
%	O
)	O
,	O
and	O
vomiting	B
(	O
2	O
%	O
)	O
.	O
	
5.5	O
Gallbladder	O
Disease	O
A	O
2-	O
to	O
4-fold	O
increase	O
in	O
the	O
risk	O
of	O
gallbladder	B
disease	I
requiring	O
surgery	O
in	O
postmenopausal	O
women	O
receiving	O
estrogens	O
has	O
been	O
reported	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
neutropenia	B
,	O
anemia	B
,	O
peripheral	B
sensory	I
neuropathy	I
,	O
fatigue	B
,	O
nausea	B
,	O
pyrexia	B
,	O
rash	B
,	O
diarrhea	B
,	O
and	O
pain	B
.	O
	
5.5	O
Interference	O
with	O
Laboratory	O
Tests	O
Serum	O
iron	O
determination	O
using	O
complexometric	O
methods	O
(	O
for	O
example	O
,	O
ferrocene	O
complexation	O
method	O
)	O
may	O
result	O
in	O
falsely	O
high	O
or	O
low	O
values	O
for	O
up	O
to	O
24	O
hours	O
after	O
the	O
examination	O
with	O
EOVIST	O
because	O
of	O
the	O
caloxetate	O
trisodium	O
excipients	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
some	O
instances	O
,	O
HBV	B
reactivation	I
occurring	O
in	O
conjunction	O
with	O
TNF	O
blocker	O
therapy	O
has	O
been	O
fatal	B
.	O
	
Table	O
4	O
Selected	O
Hematological	O
Parameters	O
Previously	O
Untreated	O
(	O
SPRINT-1	O
and	O
SPRINT-2	O
)	O
Previous	O
Treatment	O
Failures	O
(	O
RESPOND-2	O
)	O
Percentage	O
of	O
Subjects	O
Reporting	O
Selected	O
Hematological	O
Parameters	O
Percentage	O
of	O
Subjects	O
Reporting	O
Selected	O
Hematological	O
Parameters	O
Hematological	O
Parameters	O
VICTRELIS	O
+	O
PegIntron	O
+	O
REBETOL	O
(	O
n=1225	O
)	O
PegIntron	O
+	O
REBETOL	O
(	O
n=467	O
)	O
VICTRELIS	O
+	O
PegIntron	O
+	O
REBETOL	O
(	O
n=323	O
)	O
PegIntron	O
+	O
REBETOL	O
(	O
n=80	O
)	O
Hemoglobin	B
(	I
g/dL	I
)	I
6	O
3	O
10	O
1	O
Neutrophils	B
(	I
*	I
10	I
9	I
/L	I
)	I
8	O
4	O
7	O
4	O
Platelets	B
(	I
*	I
10	I
9	I
/L	I
)	I
<	O
1	O
0	O
0	O
0	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
No	O
serious	O
infusion	B
reactions	I
were	O
reported	O
.	O
	
f	O
Includes	O
the	O
following	O
terms	O
:	O
renal	B
failure	I
and	O
renal	B
failure	I
acute	I
.	O
	
Before	O
administering	O
Vizamyl	O
,	O
ask	O
patients	O
about	O
prior	O
reactions	O
to	O
drugs	O
,	O
especially	O
those	O
containing	O
polysorbate	O
80	O
.	O
	
Have	O
resuscitation	O
equipment	O
and	O
trained	O
personnel	O
immediately	O
available	O
at	O
the	O
time	O
of	O
Vizamyl	O
administration	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
During	O
adult	O
pre-marketing	O
clinical	O
trials	O
with	O
SAPHRIS	O
,	O
including	O
long-term	O
trials	O
without	O
comparison	O
to	O
placebo	O
,	O
somnolence	B
was	O
reported	O
in	O
18	O
%	O
(	O
358/1953	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
Vascular	O
Disorders	O
:	O
Hypertension	B
.	O
	
*	O
with	O
a	O
family	O
history	O
of	O
congenital	O
prolongation	O
of	O
the	O
QT	O
interval	O
or	O
sudden	O
death	O
.	O
	
Ovarian	O
Cancer	O
In	O
some	O
epidemiological	O
studies	O
,	O
the	O
use	O
of	O
estrogen-only	O
products	O
,	O
in	O
particular	O
for	O
5	O
or	O
more	O
years	O
,	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ovarian	B
cancer	I
.	O
	
Table	O
7	O
.	O
	
If	O
liver	O
injury	O
is	O
detected	O
,	O
promptly	O
interrupt	O
ULORIC	O
and	O
assess	O
patient	O
for	O
probable	O
cause	O
,	O
then	O
treat	O
cause	O
if	O
possible	O
,	O
to	O
resolution	O
or	O
stabilization	O
.	O
	
Adverse	O
reactions	O
that	O
led	O
to	O
dose	O
modifications	O
of	O
any	O
drug	O
(	O
primarily	O
PegIntron	O
and	O
REBETOL	O
)	O
occurred	O
in	O
39	O
%	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
24	O
%	O
of	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
Caution	O
is	O
advised	O
when	O
PDE5	O
inhibitors	O
are	O
co-administered	O
with	O
alpha-blockers	O
.	O
	
Bleeding	B
results	O
during	O
the	O
treatment	O
period	O
in	O
the	O
Phase	O
III	O
studies	O
are	O
shown	O
in	O
Table	O
3	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
call	O
877-377-3784	O
or	O
contact	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
SUICIDAL	B
THOUGHTS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Discontinue	O
GRANIX	O
in	O
patients	O
undergoing	O
a	O
sickle	O
cell	O
crisis	O
.	O
	
Take	O
the	O
next	O
dose	O
at	O
your	O
regular	O
time	O
.	O
	
Four	O
(	O
0.6	O
%	O
)	O
subjects	O
who	O
received	O
STRIBILD	O
developed	O
laboratory	O
findings	O
consistent	O
with	O
proximal	B
renal	I
tubular	I
dysfunction	I
leading	O
to	O
discontinuation	O
of	O
STRIBILD	O
during	O
the	O
first	O
48	O
weeks	O
of	O
treatment	O
.	O
	
Due	O
to	O
overlap	O
in	O
signs	O
and	O
symptoms	O
,	O
it	O
was	O
not	O
possible	O
to	O
distinguish	O
between	O
hypersensitivity	B
reactions	I
and	O
infusion	B
reactions	I
in	O
all	O
cases	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
most	O
serious	O
adverse	O
reactions	O
were	O
:	O
*	O
Serious	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Malignancies	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Heart	B
Failure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
and	O
controlled	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
,	O
and	O
may	O
not	O
predict	O
the	O
rates	O
observed	O
in	O
a	O
broader	O
patient	O
population	O
in	O
clinical	O
practice	O
.	O
	
Other	O
adverse	O
reactions	O
with	O
incidences	O
of	O
less	O
than	O
5	O
%	O
in	O
the	O
DYSPORT	O
(	O
r	O
)	O
500	O
Units	O
group	O
in	O
the	O
double-blind	O
phase	O
of	O
clinical	O
trials	O
included	O
dizziness	B
in	O
3.5	O
%	O
of	O
DYSPORT	O
(	O
r	O
)	O
-treated	O
patients	O
and	O
1	O
%	O
of	O
placebo-treated	O
patients	O
,	O
and	O
muscle	B
atrophy	I
in	O
1	O
%	O
of	O
DYSPORT	O
(	O
r	O
)	O
-treated	O
patients	O
and	O
in	O
none	O
of	O
the	O
placebo-treated	O
patients	O
.	O
	
Therapeutic	O
Infectious	O
Agents	O
Other	O
uses	O
of	O
therapeutic	O
infectious	O
agents	O
such	O
as	O
live	O
attenuated	O
bacteria	O
(	O
e.g.	O
,	O
BCG	O
bladder	O
instillation	O
for	O
the	O
treatment	O
of	O
cancer	O
)	O
could	O
result	O
in	O
clinical	O
infections	O
,	O
including	O
disseminated	O
infections	O
.	O
	
Table	O
1	O
shows	O
adverse	O
reactions	O
reported	O
in	O
Study	O
1	O
that	O
occurred	O
at	O
a	O
>	O
=	O
2	O
%	O
higher	O
frequency	O
in	O
the	O
XTANDI	O
arm	O
compared	O
to	O
the	O
placebo	O
arm	O
.	O
	
For	O
events	O
of	O
akathisia	B
,	O
incidences	O
were	O
2	O
%	O
,	O
2	O
%	O
,	O
and	O
1	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
,	O
as	O
compared	O
to	O
0	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Some	O
of	O
the	O
reactions	O
were	O
life-threatening	O
and	O
included	O
anaphylactic	B
shock	I
,	O
cardiac	B
arrest	I
,	O
respiratory	B
arrest	I
,	O
respiratory	B
distress	I
,	O
hypoxia	B
,	O
apnea	B
,	O
dyspnea	B
,	O
bradycardia	B
,	O
tachycardia	B
,	O
bronchospasm	B
,	O
throat	B
tightness	I
,	O
hypotension	B
,	O
angioedema	B
(	O
including	O
lip	B
swelling	I
,	O
periorbital	B
edema	I
,	O
and	O
face	B
edema	I
)	O
,	O
and	O
urticaria	B
.	O
	
Table	O
1	O
summarizes	O
adverse	O
reactions	O
occurring	O
in	O
2	O
or	O
more	O
patients	O
treated	O
with	O
Carbaglu	O
in	O
the	O
retrospective	O
case	O
series	O
.	O
	
The	O
three	O
factors	O
associated	O
with	O
the	O
largest	O
increase	O
in	O
volume	B
depletion-related	I
adverse	I
reactions	I
were	O
the	O
use	O
of	O
loop	O
diuretics	O
,	O
moderate	O
renal	O
impairment	O
(	O
eGFR	O
30	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
and	O
age	O
75	O
years	O
and	O
older	O
(	O
Table	O
2	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
and	O
8.6	O
)	O
]	O
.	O
	
Eye	B
events	I
were	O
serious	O
in	O
0.7	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0	O
placebo	O
patients	O
)	O
and	O
led	O
to	O
discontinuation	O
in	O
4	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0.2	O
%	O
of	O
placebo-treated	O
patients	O
)	O
.	O
	
The	O
use	O
of	O
ARCAPTA	O
NEOHALER	O
in	O
this	O
setting	O
is	O
inappropriate	O
.	O
	
Impaired	B
glucose	I
tolerance	I
.	O
	
New	O
Malignancies	O
The	O
overall	O
incidence	O
of	O
new	O
malignancies	B
was	O
4.3	O
%	O
in	O
the	O
placebo	O
and	O
4.8	O
%	O
in	O
the	O
Prolia	O
groups	O
.	O
	
5.2	O
Serious	O
Dermatologic	O
Reactions	O
Serious	O
dermatologic	B
reactions	I
including	O
Stevens-Johnson	B
Syndrome	I
(	O
SJS	B
)	O
have	O
been	O
reported	O
in	O
association	O
with	O
APTIOM	O
use	O
.	O
	
5.3	O
Drug	O
Reaction	O
with	O
Eosinophilia	O
and	O
Systemic	O
Symptoms	O
(	O
DRESS	O
)	O
/Multiorgan	O
Hypersensitivity	O
Drug	B
Reaction	I
with	I
Eosinophilia	I
and	I
Systemic	I
Symptoms	I
(	O
DRESS	B
)	O
,	O
also	O
known	O
as	O
Multiorgan	B
Hypersensitivity	I
,	O
has	O
been	O
reported	O
in	O
patients	O
taking	O
APTIOM	O
.	O
	
Abnormal	O
thyroid	O
function	O
tests	O
should	O
be	O
clinically	O
evaluated	O
.	O
	
Dizziness	B
and	O
disturbance	B
in	I
gait	I
were	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
Patients	O
receiving	O
Prolia	O
should	O
not	O
receive	O
Xgeva	O
.	O
	
Monitor	O
for	O
symptoms	O
(	O
5.4	O
)	O
*	O
Atypical	B
femoral	I
fractures	I
:	O
Have	O
been	O
reported	O
.	O
	
No	O
fatal	B
adverse	O
events	O
occurred	O
on	O
treatment	O
among	O
patients	O
in	O
remission	O
.	O
	
Activated	O
prothrombin	O
complex	O
concentrates	O
(	O
aPCCs	O
,	O
e.g.	O
,	O
FEIBA	O
)	O
,	O
or	O
recombinant	O
Factor	O
VIIa	O
,	O
or	O
concentrates	O
of	O
coagulation	O
factors	O
II	O
,	O
IX	O
or	O
X	O
may	O
be	O
considered	O
but	O
their	O
use	O
has	O
not	O
been	O
evaluated	O
in	O
clinical	O
trials	O
.	O
	
Promptly	O
evaluate	O
any	O
signs	O
or	O
symptoms	O
of	O
blood	O
loss	O
(	O
e.g.	O
,	O
a	O
drop	O
in	O
hemoglobin	O
and/or	O
hematocrit	O
or	O
hypotension	O
)	O
.	O
	
More	O
patients	O
receiving	O
TRULICITY	O
0.75	O
mg	O
(	O
1.3	O
%	O
)	O
and	O
TRULICITY	O
1.5	O
mg	O
(	O
3.5	O
%	O
)	O
discontinued	O
treatment	O
due	O
to	O
gastrointestinal	B
adverse	I
reactions	I
than	O
patients	O
receiving	O
placebo	O
(	O
0.2	O
%	O
)	O
.	O
	
Withhold	O
dose	O
for	O
moderate	O
immune-mediated	O
adverse	O
reactions	O
until	O
return	O
to	O
baseline	O
,	O
improvement	O
to	O
mild	O
severity	O
,	O
or	O
complete	O
resolution	O
,	O
and	O
patient	O
is	O
receiving	O
less	O
than	O
7.5	O
mg	O
prednisone	O
or	O
equivalent	O
per	O
day	O
.	O
	
(	O
5.7	O
)	O
*	O
Proteinuria	B
:	O
Monitor	O
urine	O
protein	O
.	O
	
Higher	O
proportions	O
of	O
patients	O
with	O
marked	O
laboratory	O
abnormalities	O
of	O
hyperphosphatemia	B
(	O
>	O
=5.6	O
mg/dL	O
for	O
age	O
17-65	O
years	O
or	O
>	O
=5.1	O
mg/dL	O
for	O
age	O
>	O
=66	O
years	O
)	O
were	O
reported	O
on	O
FARXIGA	O
at	O
Week	O
24	O
(	O
0.9	O
%	O
versus	O
1.7	O
%	O
for	O
placebo	O
and	O
FARXIGA	O
10	O
mg	O
,	O
respectively	O
)	O
.	O
	
5.3	O
Thrombotic	O
Events	O
COMETRIQ	O
treatment	O
results	O
in	O
an	O
increased	O
incidence	O
of	O
thrombotic	B
events	I
(	O
venous	B
thromboembolism	I
:	O
6	O
%	O
vs.	O
3	O
%	O
and	O
arterial	B
thromboembolism	I
:	O
2	O
%	O
vs.	O
0	O
%	O
in	O
COMETRIQ-treated	O
and	O
placebo-treated	O
patients	O
,	O
respectively	O
)	O
.	O
	
Advise	O
women	O
of	O
potential	O
harm	O
to	O
the	O
fetus	O
and	O
to	O
avoid	O
pregnancy	O
while	O
receiving	O
Beleodaq	O
.	O
	
Table	O
4	O
shows	O
the	O
incidence	O
of	O
adverse	O
reactions	O
that	O
were	O
reported	O
in	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
of	O
XIAFLEX-treated	O
patients	O
after	O
two	O
concurrent	O
injections	O
of	O
XIAFLEX	O
in	O
the	O
same	O
hand	O
through	O
Day	O
60	O
in	O
Study	O
3	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTS	O
,	O
and	O
(	O
B	O
)	O
EPIDURAL	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTS	O
:	O
Premature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
PRADAXA	O
,	O
increases	O
the	O
risk	O
of	O
thrombotic	O
events	O
.	O
	
Discontinue	O
Zydelig	O
for	O
recurrent	O
hepatotoxicity	O
.	O
	
This	O
includes	O
cases	O
of	O
Stevens-Johnson	B
syndrome	I
,	O
hypersensitivity	B
reaction	I
,	O
toxic	B
epidermal	I
necrolysis	I
and	O
erythema	B
multiforme	I
.	O
	
Generally	O
milder	O
withdrawal	O
symptoms	O
(	O
e.g.	O
,	O
dysphoria	O
,	O
anxiety	O
,	O
and	O
insomnia	O
)	O
have	O
been	O
reported	O
following	O
abrupt	O
discontinuance	O
of	O
benzodiazepines	O
taken	O
continuously	O
at	O
therapeutic	O
doses	O
for	O
several	O
months	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
See	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Monitor	O
blood	O
pressure	O
,	O
serum	O
potassium	O
and	O
symptoms	O
of	O
fluid	O
retention	O
at	O
least	O
monthly	O
.	O
	
Interrupt	O
or	O
discontinue	O
Zydelig	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
section	O
of	O
the	O
labeling	O
:	O
*	O
Endophthalmitis	B
and	O
retinal	B
detachments	I
*	O
Increased	B
intraocular	I
pressure	I
*	O
Thromboembolic	B
events	I
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
reported	O
in	O
patients	O
receiving	O
EYLEA	O
were	O
conjunctival	B
hemorrhage	I
,	O
eye	B
pain	I
,	O
cataract	B
,	O
vitreous	B
floaters	I
,	O
intraocular	B
pressure	I
increased	I
,	O
and	O
vitreous	B
detachment	I
.	O
	
The	O
underlying	O
pathology	O
was	O
not	O
ascertained	O
in	O
all	O
patients	O
but	O
in	O
some	O
instances	O
included	O
immune-mediated	B
hepatitis	I
.	O
	
Implement	O
a	O
plan	O
to	O
monitor	O
for	O
and	O
to	O
manage	O
agranulocytosis/neutropenia	O
prior	O
to	O
initiating	O
Ferriprox	O
treatment	O
.	O
	
Evaluate	O
for	O
retinal	O
vein	O
thrombosis	O
immediately	O
.	O
	
One	O
patient	O
(	O
0.4	O
%	O
)	O
required	O
permanent	O
discontinuation	O
due	O
to	O
elevated	B
transaminases	I
,	O
and	O
jaundice	B
.	O
	
RE-MEDY	O
was	O
an	O
active-controlled	O
study	O
(	O
warfarin	O
)	O
in	O
which	O
1430	O
patients	O
received	O
PRADAXA	O
150	O
mg	O
twice	O
daily	O
following	O
3	O
to	O
12	O
months	O
of	O
oral	O
anticoagulant	O
regimen	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Oral	O
contraceptive	O
use	O
should	O
be	O
discontinued	O
if	O
pregnancy	O
is	O
confirmed	O
.	O
	
If	O
PRADAXA	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
,	O
2.5	O
,	O
2.6	O
)	O
]	O
.	O
	
Increases	B
in	I
AST	I
of	O
Grade	O
3	O
or	O
4	O
were	O
limited	O
to	O
1	O
%	O
and	O
3	O
%	O
of	O
patients	O
,	O
respectively	O
.	O
	
Lenses	O
may	O
be	O
reinserted	O
after	O
10	O
minutes	O
following	O
administration	O
of	O
BEPREVE	O
.	O
	
DRESS	B
typically	O
,	O
although	O
not	O
exclusively	O
,	O
presents	O
with	O
fever	B
,	O
rash	B
,	O
and/or	O
lymphadenopathy	B
,	O
in	O
association	O
with	O
other	O
organ	O
system	O
involvement	O
,	O
such	O
as	O
hepatitis	B
,	O
nephritis	B
,	O
hematological	B
abnormalities	I
,	O
myocarditis	B
,	O
or	O
myositis	B
sometimes	O
resembling	O
an	O
acute	O
viral	O
infection	O
.	O
	
A	O
CBC	O
including	O
lymphocyte	O
count	O
should	O
also	O
be	O
obtained	O
after	O
6	O
months	O
of	O
treatment	O
,	O
every	O
6	O
to	O
12	O
months	O
thereafter	O
,	O
and	O
as	O
clinically	O
indicated	O
.	O
	
Fifty-eight	O
percent	O
(	O
58	O
%	O
)	O
of	O
the	O
population	O
was	O
male	O
and	O
73	O
%	O
were	O
Caucasian	O
,	O
16	O
%	O
were	O
Asian	O
,	O
and	O
4	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
In	O
the	O
pool	O
of	O
eight	O
clinical	O
trials	O
,	O
hypersensitivity-related	B
adverse	I
reactions	I
(	O
including	O
erythema	B
,	O
rash	B
,	O
pruritus	B
,	O
urticaria	B
,	O
and	O
angioedema	B
)	O
occurred	O
in	O
3.0	O
%	O
,	O
3.8	O
%	O
,	O
and	O
4.2	O
%	O
of	O
patients	O
receiving	O
comparator	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
(	O
5.4	O
)	O
*	O
Severe	O
Visual	B
Loss	I
:	O
Reported	O
in	O
0.2	O
%	O
of	O
patients	O
.	O
	
Somnolence	B
and	O
fatigue-related	B
events	I
were	O
serious	O
in	O
0.3	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0	O
placebo	O
patients	O
)	O
and	O
led	O
to	O
discontinuation	O
in	O
3	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0.7	O
%	O
of	O
placebo-treated	O
patients	O
)	O
.	O
	
Monitor	O
electrolytes	O
if	O
QT	O
prolongation	O
is	O
detected	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.4	O
)	O
]	O
.	O
	
5.2	O
Deterioration	O
of	O
Disease	O
and	O
Acute	O
Episodes	O
ARCAPTA	O
NEOHALER	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
with	O
acutely	O
deteriorating	O
COPD	O
,	O
which	O
may	O
be	O
a	O
life-threatening	O
condition	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
(	O
2.1	O
,	O
5.2	O
)	O
.	O
	
Prescribe	O
only	O
for	O
recommended	O
patient	O
populations	O
.	O
	
Serious	O
depression	B
was	O
reported	O
in	O
0.4	O
%	O
(	O
6/1,458	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
0.1	O
%	O
(	O
1/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Fatal	B
cardiac	B
failure	I
was	O
reported	O
in	O
2/359	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
1/355	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
(	O
5.6	O
)	O
*	O
accumulation	B
of	I
body	I
fat	I
:	O
Observed	O
in	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O
	
Severe	O
acute	B
exacerbations	I
of	I
hepatitis	I
B	I
have	O
been	O
reported	O
in	O
patients	O
coinfected	O
with	O
HIV-1	O
and	O
HBV	O
who	O
have	O
discontinued	O
EMTRIVA	O
or	O
VIREAD	O
,	O
two	O
of	O
the	O
components	O
of	O
STRIBILD	O
.	O
	
A	O
variety	O
of	O
CNS	B
anticholinergic	I
effects	I
have	O
been	O
reported	O
,	O
including	O
headache	B
,	O
dizziness	B
,	O
and	O
somnolence	B
.	O
	
*	O
Embryo-Fetal	B
Toxicity	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
.	O
	
5.3	O
Lack	O
of	O
Interchangeability	O
With	O
Gabapentin	O
HORIZANT	O
is	O
not	O
interchangeable	O
with	O
other	O
gabapentin	O
products	O
because	O
of	O
differing	O
pharmacokinetic	O
profiles	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
prolactin	B
elevations	I
>	O
=4	O
times	O
ULN	O
(	O
at	O
Endpoint	O
)	O
were	O
2.6	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
0.6	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Laboratory	O
Abnormalities	O
Treatment-naive	O
Subjects	O
:	O
Selected	O
laboratory	O
abnormalities	O
(	O
Grades	O
2	O
to	O
4	O
)	O
with	O
a	O
worsening	O
grade	O
from	O
baseline	O
and	O
representing	O
the	O
worst-grade	O
toxicity	O
in	O
at	O
least	O
2	O
%	O
of	O
subjects	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
VORAXAZE	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
All	O
patients	O
should	O
be	O
instructed	O
to	O
seek	O
medical	O
advice	O
if	O
signs	O
,	O
symptoms	O
,	O
or	O
high	O
risk	O
exposure	O
suggestive	O
of	O
tuberculosis	O
(	O
e.g.	O
,	O
persistent	O
cough	O
,	O
weight	O
loss	O
,	O
subfebrile	O
temperature	O
)	O
appear	O
during	O
or	O
after	O
ILARIS	O
therapy	O
.	O
	
The	O
changes	B
in	I
FEV1	I
appear	O
to	O
be	O
reversible	O
after	O
treatment	O
discontinuation	O
.	O
	
T3	B
resin	I
uptake	I
is	I
decreased	I
,	O
reflecting	O
the	O
elevated	B
TBG	I
.	O
	
The	O
range	O
of	O
time	O
to	O
diagnosis	O
of	O
basal	B
cell	I
carcinoma	I
was	O
28	O
to	O
249	O
days	O
in	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
was	O
197	O
days	O
for	O
the	O
patient	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
(	O
5.4	O
)	O
*	O
Cleviprex	O
gives	O
no	O
protection	O
against	O
the	O
effects	O
of	O
abrupt	O
beta-blocker	O
withdrawal	O
.	O
	
Symptoms	O
of	O
PRES	B
are	O
usually	O
reversible	O
but	O
may	O
evolve	O
into	O
ischemic	B
stroke	I
or	O
cerebral	B
hemorrhage	I
.	O
	
5.5	O
Hepatitis	O
B	O
Virus	O
Reactivation	O
Use	O
of	O
TNF	O
blockers	O
,	O
including	O
CIMZIA	O
,	O
has	O
been	O
associated	O
with	O
reactivation	B
of	I
hepatitis	I
B	I
virus	I
)	O
in	O
patients	O
who	O
are	O
chronic	O
carriers	O
of	O
this	O
virus	O
.	O
	
The	O
effect	O
of	O
treatment	O
with	O
DUAVEE	O
on	O
the	O
risk	O
of	O
ovarian	O
cancer	O
is	O
unknown	O
.	O
	
When	O
vasodilators	O
are	O
used	O
in	O
combination	O
,	O
an	O
additive	O
effect	O
on	O
blood	O
pressure	O
may	O
be	O
anticipated	O
.	O
	
Therefore	O
,	O
patients	O
receiving	O
alglucosidase	O
alfa	O
should	O
undergo	O
periodic	O
urinalysis	O
[	O
seeAdverse	O
Reactions	O
(	O
6.3	O
)	O
]	O
.	O
	
5.6	O
Visual	O
Abnormalities	O
Retinal	B
vascular	I
thrombosis	I
has	O
been	O
reported	O
in	O
patients	O
receiving	O
estrogens	O
.	O
	
The	O
usefulness	O
of	O
hemodialysis	O
in	O
the	O
prevention	O
of	O
NSF	O
is	O
unknown	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
Asthenia	B
.	O
	
The	O
malignancies	B
occurred	O
after	O
a	O
median	O
of	O
30	O
months	O
of	O
therapy	O
(	O
range	O
1	O
to	O
84	O
months	O
)	O
.	O
	
MULTAQ	O
doubles	O
the	O
risk	O
of	O
death	B
in	O
these	O
patients	O
(	O
4	O
,	O
5.1	O
,	O
14.3	O
)	O
.	O
	
Adverse	O
Reactions	O
(	O
>	O
=3	O
%	O
)	O
with	O
a	O
Higher	O
Incidence	O
for	O
PROMACTA	O
versus	O
Placebo	O
from	O
Two	O
Placebo-controlled	O
Trials	O
in	O
Pediatric	O
Patients	O
6	O
Years	O
and	O
Older	O
with	O
Chronic	O
Immune	O
(	O
Idiopathic	O
)	O
Thrombocytopenia	O
PROMACTA	O
Placebo	O
n	O
=	O
82	O
n	O
=	O
40	O
Adverse	O
Reaction	O
(	O
%	O
)	O
(	O
%	O
)	O
Upper	B
respiratory	I
tract	I
infection	I
16	O
5	O
Nasopharyngitis	B
12	O
5	O
Rhinitis	B
11	O
8	O
Abdominal	B
pain	I
9	O
5	O
Cough	B
9	O
0	O
Oropharyngeal	B
pain	I
9	O
3	O
Toothache	B
6	O
0	O
AST	B
increased	I
5	O
0	O
Diarrhea	B
5	O
3	O
Rash	B
5	O
3	O
ALT	B
increaseda	O
6	O
0	O
Vitamin	B
D	I
deficiency	I
4	O
0	O
*	O
a	O
Includes	O
adverse	O
reactions	O
or	O
laboratory	O
abnormalities	O
>	O
3	O
x	O
ULN	O
.	O
	
Hepatobiliary	O
Disorders	O
:	O
hepatic	B
failure	I
(	O
some	O
fatal	B
)	O
,	O
jaundice	B
,	O
serious	O
cases	O
of	O
abnormal	B
liver	I
function	I
test	O
results	O
,	O
liver	B
disorder	I
.	O
	
No	O
reports	O
involved	O
the	O
administration	O
of	O
methylene	O
blue	O
by	O
other	O
routes	O
(	O
such	O
as	O
oral	O
tablets	O
or	O
local	O
tissue	O
injection	O
)	O
or	O
at	O
lower	O
doses	O
.	O
	
Families	O
and	O
caregivers	O
of	O
patients	O
being	O
treated	O
with	O
antidepressants	O
for	O
major	O
depressive	O
disorder	O
or	O
other	O
indications	O
,	O
both	O
psychiatric	O
and	O
nonpsychiatric	O
,	O
should	O
be	O
alerted	O
about	O
the	O
need	O
to	O
monitor	O
patients	O
for	O
the	O
emergence	O
of	O
agitation	O
,	O
irritability	O
,	O
unusual	O
changes	O
in	O
behavior	O
,	O
and	O
the	O
other	O
symptoms	O
described	O
above	O
,	O
as	O
well	O
as	O
the	O
emergence	O
of	O
suicidality	O
,	O
and	O
to	O
report	O
such	O
symptoms	O
immediately	O
to	O
healthcare	O
providers	O
.	O
	
Do	O
not	O
restart	O
ULORIC	O
if	O
liver	O
injury	O
is	O
confirmed	O
and	O
no	O
alternate	O
etiology	O
can	O
be	O
found	O
.	O
	
5.4	O
Extravasation	O
and	O
Injection	B
Site	I
Reactions	I
.	O
	
5.9	O
Effects	O
on	O
Bleeding	O
The	O
safety	O
of	O
STENDRA	O
is	O
unknown	O
in	O
patients	O
with	O
bleeding	O
disorders	O
and	O
patients	O
with	O
active	O
peptic	O
ulceration	O
.	O
	
AST	B
greater	I
than	I
or	I
equal	I
to	I
3	I
x	I
ULN	I
was	O
reported	O
in	O
34	O
%	O
and	O
38	O
%	O
of	O
patients	O
for	O
PROMACTA	O
and	O
placebo	O
,	O
respectively	O
.	O
	
In	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
four	O
cases	O
of	O
non-cutaneous	B
malignancies	I
were	O
identified	O
:	O
KRAS	B
mutation-positive	I
pancreatic	I
adenocarcinoma	I
(	O
n	O
=	O
1	O
)	O
,	O
recurrent	B
NRAS	I
mutation-positive	I
colorectal	I
carcinoma	I
(	O
n	O
=	O
1	O
)	O
,	O
head	B
and	I
neck	I
carcinoma	I
(	O
n	O
=	O
1	O
)	O
,	O
and	O
glioblastoma	B
(	O
n	O
=	O
1	O
)	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Severe	O
or	O
Essential	O
Hypertension	O
Adverse	O
reactions	O
that	O
were	O
reported	O
in	O
<	O
1	O
%	O
of	O
patients	O
with	O
severe	O
or	O
essential	O
hypertension	O
included	O
:	O
Cardiac	O
:	O
myocardial	B
infarction	I
,	O
cardiac	B
arrestNervous	O
system	O
:	O
syncopeRespiratory	O
:	O
dyspnea	B
6.2	O
Post-Marketing	O
and	O
Other	O
Clinical	O
Experience	O
Because	O
adverse	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
estimate	O
reliably	O
their	O
frequency	O
or	O
to	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Monitor	O
heart	O
failure	O
patients	O
carefully	O
.	O
	
The	O
incidence	O
of	O
hypoglycemia	B
increased	O
when	O
JARDIANCE	O
was	O
administered	O
with	O
insulin	O
or	O
sulfonylurea	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
In	O
these	O
trials	O
,	O
93	O
%	O
of	O
patients	O
treated	O
with	O
BENLYSTA	O
reported	O
an	O
adverse	O
reaction	O
compared	O
with	O
92	O
%	O
treated	O
with	O
placebo	O
.	O
	
The	O
administration	O
of	O
antihistamines	O
,	O
steroids	O
,	O
bronchodilators	O
,	O
and/or	O
epinephrine	O
may	O
reduce	O
the	O
severity	O
of	O
the	O
reactions	O
.	O
	
Among	O
subjects	O
aged	O
12	O
to	O
17	O
years	O
,	O
asthma-related	O
hospitalizations	O
occurred	O
in	O
4	O
subjects	O
(	O
2.6	O
%	O
)	O
treated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
(	O
n	O
=	O
151	O
)	O
compared	O
with	O
0	O
subjects	O
treated	O
with	O
fluticasone	O
furoate	O
100	O
mcg	O
(	O
n	O
=	O
130	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Takeda	O
Pharmaceuticals	O
at	O
1-877-TAKEDA-7	O
(	O
1-877-825-3327	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Grade	O
3-4	O
renal	B
failure	I
occurred	O
in	O
six	O
patients	O
in	O
the	O
everolimus	O
arm	O
and	O
three	O
patients	O
in	O
the	O
placebo	O
arm	O
.	O
	
5.5	O
Central	O
Nervous	O
System	O
Effects	O
Toviaz	O
is	O
associated	O
with	O
anticholinergic	B
central	I
nervous	I
sytem	I
(	I
CNS	I
)	I
effects	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Across	O
the	O
3	O
studies	O
,	O
there	O
were	O
1493	O
patients	O
randomized	O
equally	O
to	O
placebo	O
,	O
OTEZLA	O
20	O
mg	O
twice	O
daily	O
or	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
.	O
	
In	O
short-term	O
placebo-controlled	O
trials	O
(	O
4-	O
to	O
6-weeks	O
)	O
,	O
there	O
were	O
1.0	O
%	O
(	O
13/1342	O
)	O
iloperidone-treated	O
patients	O
with	O
hematocrit	B
at	I
least	I
one	I
time	I
below	I
the	I
extended	I
normal	I
range	I
during	O
post-randomization	O
treatment	O
,	O
compared	O
to	O
0.3	O
%	O
(	O
2/585	O
)	O
on	O
placebo	O
.	O
	
5.3	O
New	O
Onset	O
or	O
Worsening	O
Renal	O
Impairment	O
Renal	B
impairment	I
,	O
including	O
cases	O
of	O
acute	B
renal	I
failure	I
and	O
Fanconi	B
syndrome	I
(	O
renal	B
tubular	I
injury	I
with	O
severe	O
hypophosphatemia	B
)	O
,	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
tenofovir	O
DF	O
,	O
a	O
component	O
of	O
STRIBILD	O
,	O
and	O
with	O
the	O
use	O
of	O
STRIBILD	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
*	O
ENTEREG	O
is	O
available	O
only	O
through	O
a	O
restricted	O
program	O
for	O
short-term	O
use	O
(	O
15	O
doses	O
)	O
called	O
the	O
ENTEREG	O
Access	O
Support	O
and	O
Education	O
(	O
E.A.S.E	O
.	O
	
There	O
were	O
no	O
new	O
clinically	O
relevant	O
AEs	O
that	O
emerged	O
in	O
the	O
later	O
treatment	O
cycles	O
.	O
	
The	O
Prolia	O
Postmarketing	O
Active	O
Safety	O
Surveillance	O
Program	O
is	O
available	O
to	O
collect	O
information	O
from	O
prescribers	O
on	O
specific	O
adverse	O
events	O
.	O
	
In	O
addition	O
,	O
patients	O
taking	O
Edarbi	O
who	O
had	O
moderate	O
to	O
severe	O
renal	O
impairment	O
at	O
baseline	O
or	O
who	O
were	O
>	O
75	O
years	O
of	O
age	O
were	O
more	O
likely	O
to	O
report	O
serum	B
creatinine	I
increases	I
.	O
	
Approximately	O
61	O
%	O
of	O
XEOMIN-treated	O
patients	O
had	O
previously	O
received	O
another	O
botulinum	O
toxin	O
type	O
A	O
product	O
.	O
	
The	O
relationship	O
to	O
GILENYA	O
remains	O
uncertain	O
.	O
	
In	O
the	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
these	O
events	O
were	O
reported	O
in	O
16	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
APTIOM	O
compared	O
to	O
6	O
%	O
of	O
placebo	O
patients	O
.	O
	
Epilepsy	O
and	O
many	O
other	O
illnesses	O
for	O
which	O
AEDs	O
are	O
prescribed	O
are	O
themselves	O
associated	O
with	O
morbidity	O
and	O
mortality	O
and	O
an	O
increased	O
risk	O
of	O
suicidal	O
thoughts	O
and	O
behavior	O
.	O
	
Increased	B
plasma	I
high-density	I
lipoprotein	I
,	O
reduced	B
low-density	I
lipoprotein	I
(	I
LDL	I
)	I
cholesterol	I
concentrations	I
,	O
increased	B
triglyceride	I
levels	I
.	O
	
In	O
a	O
placebo-controlled	O
clinical	O
trial	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
,	O
no	O
difference	O
was	O
detected	O
in	O
antibody	O
response	O
to	O
vaccine	O
between	O
CIMZIA	O
and	O
placebo	O
treatment	O
groups	O
when	O
the	O
pneumococcal	O
polysaccharide	O
vaccine	O
and	O
influenza	O
vaccine	O
were	O
administered	O
concurrently	O
with	O
CIMZIA	O
.	O
	
Other	O
important	O
serious	O
adverse	O
reactions	O
reported	O
in	O
clinical	O
trials	O
and/or	O
postmarketing	O
experience	O
were	O
acute	B
renal	I
failure	I
,	O
cardiac	B
failure	I
,	O
hypersensitivity	B
,	O
skin	B
reactions	I
,	O
pulmonary	B
fibrosis	I
,	O
and	O
myelodysplastic	B
syndrome	I
.	O
	
Due	O
to	O
the	O
potential	O
for	O
anaphylaxis	O
,	O
appropriate	O
medical	O
support	O
should	O
be	O
readily	O
available	O
when	O
Vimizim	O
is	O
administered	O
.	O
	
Consider	O
discontinuing	O
Prolia	O
if	O
severe	O
symptoms	O
develop	O
(	O
5.7	O
)	O
*	O
Severe	O
Muscle	B
Pain	I
may	O
occur	O
.	O
	
[	O
See	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
.	O
]	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
hypotension	O
after	O
initiating	O
therapy	O
.	O
	
(	O
5.5	O
)	O
*	O
Bladder	B
Cancer	I
:	O
An	O
imbalance	O
in	O
bladder	B
cancers	I
was	O
observed	O
in	O
clinical	O
trials	O
.	O
	
Severe	O
priapism	B
may	O
require	O
surgical	O
intervention	O
.	O
	
(	O
5.1	O
)	O
*	O
All	O
patients	O
taking	O
POTIGA	O
should	O
have	O
baseline	O
and	O
periodic	O
(	O
every	O
6	O
months	O
)	O
systematic	O
visual	O
monitoring	O
by	O
an	O
ophthalmic	O
professional	O
.	O
	
Twenty-nine	O
patients	O
(	O
85	O
%	O
)	O
with	O
Grade	O
3-5	O
enterocolitis	B
were	O
treated	O
with	O
high-dose	O
(	O
>	O
=40	O
mg	O
prednisone	O
equivalent	O
per	O
day	O
)	O
corticosteroids	O
,	O
with	O
a	O
median	O
dose	O
of	O
80	O
mg/day	O
of	O
prednisone	O
or	O
equivalent	O
;	O
the	O
median	O
duration	O
of	O
treatment	O
was	O
2.3	O
weeks	O
(	O
ranging	O
up	O
to	O
13.9	O
weeks	O
)	O
followed	O
by	O
corticosteroid	O
taper	O
.	O
	
The	O
population	O
in	O
these	O
studies	O
was	O
71	O
%	O
White	O
,	O
7	O
%	O
Black	O
or	O
African	O
American	O
,	O
11	O
%	O
Asian	O
;	O
32	O
%	O
were	O
of	O
Hispanic	O
or	O
Latino	O
ethnicity	O
.	O
	
Idelalisib	O
is	O
teratogenic	B
in	O
rats	O
,	O
at	O
systemic	O
exposures	O
12	O
times	O
those	O
reported	O
in	O
patients	O
at	O
the	O
recommended	O
dose	O
of	O
150	O
mg	O
twice	O
daily	O
.	O
	
All	O
patients	O
who	O
tested	O
positive	O
for	O
binding	O
antibodies	O
also	O
tested	O
positive	O
for	O
neutralizing	O
anti-blinatumomab	O
antibodies	O
.	O
	
Of	O
these	O
7	O
patients	O
,	O
6	O
had	O
complete	O
resolution	O
;	O
time	O
to	O
resolution	O
ranged	O
up	O
to	O
15.6	O
weeks	O
.	O
	
If	O
at	O
any	O
time	O
AST	O
or	O
ALT	O
rise	O
above	O
five	O
times	O
the	O
ULN	O
,	O
or	O
the	O
bilirubin	O
rises	O
above	O
three	O
times	O
the	O
ULN	O
,	O
interrupt	O
ZYTIGA	O
treatment	O
and	O
closely	O
monitor	O
liver	O
function	O
.	O
	
Stop	O
Natazia	O
if	O
there	O
is	O
unexplained	O
loss	O
of	O
vision	O
,	O
proptosis	O
,	O
diplopia	O
,	O
papilledema	O
,	O
or	O
retinal	O
vascular	O
lesions	O
.	O
	
These	O
patients	O
were	O
managed	O
without	O
surgical	O
intervention	O
,	O
but	O
the	O
long-term	O
consequences	O
are	O
unknown	O
.	O
	
Plasma	O
Zinc	O
Concentration	O
Decreased	B
plasma	I
zinc	I
concentrations	I
have	O
been	O
observed	O
on	O
Ferriprox	O
therapy	O
.	O
	
If	O
adequate	O
hyperglycemic	O
control	O
can	O
not	O
be	O
achieved	O
with	O
optimal	O
medical	O
management	O
,	O
permanently	O
discontinue	O
ZYKADIA	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
5.3	O
Laboratory	O
Tests	O
Serum	O
Liver	O
Enzyme	O
Activities	O
In	O
clinical	O
studies	O
,	O
7.5	O
%	O
of	O
642	O
subjects	O
treated	O
with	O
Ferriprox	O
developed	O
increased	B
ALT	I
values	I
.	O
	
In	O
cases	O
of	O
symptomatic	O
bradycardia	O
that	O
is	O
not	O
life-threatening	O
,	O
withhold	O
ZYKADIA	O
until	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
evaluate	O
the	O
use	O
of	O
concomitant	O
medications	O
,	O
and	O
adjust	O
the	O
dose	O
of	O
ZYKADIA	O
.	O
	
5.1	O
Risk	O
for	O
Image	O
Misinterpretation	O
and	O
Other	O
Errors	O
Errors	O
may	O
occur	O
in	O
the	O
Neuraceq	O
estimation	O
of	O
brain	O
neuritic	O
beta-amyloid	O
plaque	O
density	O
during	O
image	O
interpretation	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Table	O
5	O
:	O
Incidence	O
of	O
MajorMajor	O
episodes	O
of	O
hypoglycemia	B
were	O
defined	O
as	O
symptomatic	O
episodes	O
requiring	O
external	O
(	O
third	O
party	O
)	O
assistance	O
due	O
to	O
severe	O
impairment	B
in	I
consciousness	I
with	O
a	O
plasma	B
glucose	I
value	I
<	I
54	I
mg/dL	I
and	O
prompt	O
recovery	O
after	O
glucose	O
or	O
glucagon	O
administration	O
.	O
	
Overall	O
,	O
the	O
rate	O
of	O
PTLD	B
in	O
949	O
patients	O
treated	O
with	O
any	O
of	O
the	O
NULOJIX	O
regimens	O
was	O
9-fold	O
higher	O
in	O
those	O
who	O
were	O
EBV	O
seronegative	O
or	O
EBV	O
serostatus	O
unknown	O
(	O
8/139	O
)	O
compared	O
to	O
those	O
who	O
were	O
EBV	O
seropositive	O
(	O
5/810	O
patients	O
)	O
.	O
	
The	O
overall	O
percentage	O
of	O
patients	O
with	O
antibodies	O
to	O
certolizumab	O
pegol	O
detectable	O
on	O
at	O
least	O
one	O
occasion	O
was	O
7	O
%	O
(	O
105	O
of	O
1,509	O
)	O
in	O
the	O
rheumatoid	O
arthritis	O
placebo-controlled	O
trials	O
.	O
	
In	O
this	O
clinical	O
context	O
,	O
if	O
the	O
patient	O
is	O
found	O
to	O
have	O
clinically	O
significant	O
liver	O
enzyme	O
elevations	O
and	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
,	O
NESINA	O
should	O
be	O
interrupted	O
and	O
investigation	O
done	O
to	O
establish	O
the	O
probable	O
cause	O
.	O
	
Keep	O
bottle	O
tightly	O
closed	O
when	O
not	O
in	O
use	O
.	O
	
Patients	O
with	O
a	O
prior	O
anaphylactic-type	O
reaction	O
with	O
either	O
oxcarbazepine	O
or	O
APTIOM	O
should	O
not	O
be	O
treated	O
with	O
APTIOM	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
There	O
was	O
an	O
increased	O
risk	O
of	O
these	O
adverse	O
reactions	O
during	O
the	O
titration	O
period	O
(	O
compared	O
to	O
the	O
maintenance	O
period	O
)	O
and	O
there	O
also	O
may	O
be	O
an	O
increased	O
risk	O
of	O
these	O
adverse	O
reactions	O
in	O
patients	O
60	O
years	O
of	O
age	O
and	O
older	O
compared	O
to	O
younger	O
adults	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Pancreatitis	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
pancreatitis	I
in	O
patients	O
taking	O
NESINA	O
.	O
	
The	O
data	O
combined	O
eight	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
and	O
reflect	O
exposure	O
of	O
6177	O
patients	O
to	O
INVOKANA	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
discontinuation	O
of	O
XALKORI	O
were	O
ILD	B
(	O
1.7	O
%	O
)	O
,	O
AST	B
elevation	I
(	O
1.2	O
%	O
)	O
,	O
dyspnea	B
(	O
1.2	O
%	O
)	O
,	O
and	O
pulmonary	B
embolism	I
(	O
1.2	O
%	O
)	O
.	O
	
The	O
following	O
may	O
increase	O
the	O
risk	O
for	O
QT	B
prolongation	I
when	O
patients	O
are	O
receiving	O
SIRTURO	O
:	O
*	O
use	O
with	O
other	O
QT	O
prolonging	O
drugs	O
including	O
fluoroquinolones	O
and	O
macrolide	O
antibacterial	O
drugs	O
and	O
the	O
antimycobacterial	O
drug	O
,	O
clofazimine	O
*	O
a	O
history	O
of	O
Torsade	O
de	O
Pointes	O
*	O
a	O
history	O
of	O
congenital	O
long	O
QT	O
syndrome	O
*	O
a	O
history	O
of	O
or	O
ongoing	O
hypothyroidism	O
*	O
a	O
history	O
of	O
or	O
ongoing	O
bradyarrhythmias	O
*	O
a	O
history	O
of	O
uncompensated	O
heart	O
failure	O
*	O
serum	O
calcium	O
,	O
magnesium	O
,	O
or	O
potassium	O
levels	O
below	O
the	O
lower	O
limits	O
of	O
normal	O
If	O
necessary	O
,	O
bedaquiline	O
treatment	O
initiation	O
could	O
be	O
considered	O
in	O
these	O
patients	O
after	O
a	O
favorable	O
benefit	O
risk	O
assessment	O
and	O
with	O
frequent	O
ECG	O
monitoring	O
.	O
	
The	O
increased	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
AEDs	O
was	O
observed	O
as	O
early	O
as	O
1	O
week	O
after	O
starting	O
treatment	O
with	O
AEDs	O
and	O
persisted	O
for	O
the	O
duration	O
of	O
treatment	O
assessed	O
.	O
	
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
potential	O
for	O
immunogenicity	O
.	O
	
Cognitive	B
dysfunction-related	O
events	O
were	O
serious	O
in	O
0.2	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0.2	O
%	O
of	O
placebo	O
patients	O
)	O
and	O
led	O
to	O
discontinuation	O
in	O
1	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0.5	O
%	O
of	O
placebo-treated	O
patients	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
of	O
those	O
exposed	O
to	O
DUREZOL	O
occurring	O
in	O
5-10	O
%	O
of	O
subjects	O
included	O
blurred	B
vision	I
,	O
eye	B
irritation	I
,	O
eye	B
pain	I
,	O
headache	B
,	O
increased	B
IOP	I
,	O
iritis	B
,	O
conjunctival	B
hyperemia	I
,	O
punctate	B
keratitis	I
,	O
and	O
uveitis	B
.	O
	
The	O
incidence	O
of	O
serious	O
adverse	O
events	O
was	O
30.6	O
%	O
in	O
the	O
placebo	O
group	O
and	O
34.6	O
%	O
in	O
the	O
Prolia	O
group	O
.	O
	
More	O
than	O
half	O
(	O
55	O
%	O
)	O
of	O
the	O
population	O
was	O
male	O
;	O
46	O
%	O
were	O
White	O
,	O
50	O
%	O
were	O
Asian	O
,	O
and	O
3	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
The	O
QT	O
interval	O
should	O
be	O
monitored	O
when	O
POTIGA	O
is	O
prescribed	O
with	O
medicines	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
in	O
patients	O
with	O
known	O
prolonged	O
QT	O
interval	O
,	O
congestive	O
heart	O
failure	O
,	O
ventricular	O
hypertrophy	O
,	O
hypokalemia	O
,	O
or	O
hypomagnesemia	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
transaminase	B
elevations	I
>	O
=3	O
times	O
ULN	O
(	O
at	O
Endpoint	O
)	O
was	O
0.9	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
1.3	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Grade	O
3/4	O
hypertension	B
was	O
observed	O
in	O
56/359	O
patients	O
(	O
16	O
%	O
)	O
receiving	O
INLYTA	O
and	O
39/355	O
patients	O
(	O
11	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
*	O
Risk	O
of	O
Cardiac	B
Arrhythmia	I
and	O
Sudden	B
Cardiac	I
Death	I
during	O
General	O
Anesthesia	O
for	O
Central	O
Venous	O
Catheter	O
Placement	O
:	O
Caution	O
should	O
be	O
used	O
when	O
administering	O
general	O
anesthesia	O
for	O
the	O
placement	O
of	O
a	O
central	O
venous	O
catheter	O
intended	O
for	O
alglucosidase	O
alfa	O
infusion	O
(	O
5.4	O
)	O
.	O
	
The	O
common	O
adverse	O
events	O
occurring	O
at	O
a	O
rate	O
of	O
10	O
%	O
or	O
greater	O
with	O
Kyprolis	O
monotherapy	O
are	O
presented	O
in	O
Table	O
7	O
.	O
	
Additionally	O
,	O
serum	O
phosphorus	O
should	O
be	O
measured	O
in	O
patients	O
at	O
risk	O
for	O
renal	O
impairment	O
.	O
	
5.2	O
Hypotension	O
in	O
Volume-	O
or	O
Salt-Depleted	O
Patients	O
In	O
patients	O
with	O
an	O
activated	O
renin-angiotensin	O
system	O
,	O
such	O
as	O
volume-	O
and/or	O
salt-depleted	O
patients	O
(	O
e.g.	O
,	O
those	O
being	O
treated	O
with	O
high	O
doses	O
of	O
diuretics	O
)	O
,	O
symptomatic	B
hypotension	I
may	O
occur	O
after	O
initiation	O
of	O
treatment	O
with	O
Edarbi	O
.	O
	
Dizziness	B
led	O
to	O
withdrawal	O
in	O
1	O
%	O
of	O
patients	O
receiving	O
600	O
mg	O
of	O
HORIZANT	O
per	O
day	O
.	O
	
There	O
was	O
no	O
apparent	O
association	O
between	O
mean	O
or	O
peak	O
IgG	O
antibody	O
titers	O
and	O
the	O
occurrence	O
of	O
adverse	O
reactions	O
.	O
	
Do	O
not	O
use	O
BREO	O
ELLIPTA	O
for	O
patients	O
whose	O
asthma	O
is	O
adequately	O
controlled	O
on	O
low-	O
or	O
medium-dose	O
inhaled	O
corticosteroids	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
clinical	O
relevance	O
of	O
this	O
in	O
vitro	O
inhibition	O
is	O
not	O
fully	O
understood	O
.	O
	
When	O
dermatitis	O
is	O
controlled	O
,	O
corticosteroid	O
tapering	O
should	O
occur	O
over	O
a	O
period	O
of	O
at	O
least	O
1	O
month	O
.	O
	
Psychiatric	O
Disorders	O
:	O
Suicidal	B
ideation	I
.	O
	
Program	O
include	O
the	O
following	O
:	O
ENTEREG	O
is	O
available	O
only	O
for	O
short-term	O
(	O
15	O
doses	O
)	O
use	O
in	O
hospitalized	O
patients	O
.	O
	
There	O
were	O
484	O
subjects	O
included	O
in	O
the	O
efficacy	O
and	O
safety	O
analyses	O
.	O
	
Across	O
the	O
clinical	O
development	O
program	O
of	O
YERVOY	O
,	O
myasthenia	B
gravis	I
and	O
additional	O
cases	O
of	O
Guillain-Barre	B
syndrome	I
have	O
been	O
reported	O
.	O
	
In	O
many	O
cases	O
,	O
the	O
occurrence	O
of	O
these	O
adverse	O
reactions	O
led	O
to	O
discontinuation	O
of	O
therapy	O
.	O
	
There	O
were	O
many	O
adverse	O
events	O
associated	O
with	O
the	O
operative	O
procedure	O
in	O
the	O
clinical	O
studies	O
of	O
Cleviprex	O
and	O
relatively	O
few	O
plausibly	O
related	O
to	O
the	O
drugs	O
used	O
to	O
lower	O
blood	O
pressure	O
.	O
	
5.9	O
Drug-drug	O
Interactions	O
Due	O
to	O
significant	O
increases	O
in	O
exposure	O
of	O
everolimus	O
,	O
co-administration	O
with	O
strong	O
CYP3A4/PgP	O
inhibitors	O
should	O
be	O
avoided	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
,	O
2.5	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Refer	O
to	O
Table	O
2	O
for	O
recommended	O
dose	O
modifications	O
for	O
adverse	O
reactions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Do	O
not	O
discontinue	O
therapy	O
with	O
leucovorin	O
based	O
on	O
the	O
determination	O
of	O
a	O
single	O
methotrexate	O
concentration	O
below	O
the	O
leucovorin	O
treatment	O
threshold	O
.	O
	
In	O
the	O
pool	O
of	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
the	O
types	O
and	O
frequency	O
of	O
common	O
adverse	O
reactions	O
excluding	O
hypoglycemia	B
were	O
similar	O
to	O
those	O
listed	O
in	O
Table	O
1	O
.	O
	
For	O
patients	O
who	O
test	O
positive	O
for	O
HBV	O
infection	O
,	O
consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
hepatitis	O
B	O
is	O
recommended	O
.	O
	
Venous	O
Thromboembolism	O
(	O
VTE	O
)	O
In	O
the	O
WHI	O
estrogen-alone	O
substudy	O
,	O
the	O
risk	O
of	O
VTE	B
[	O
DVT	B
and	O
pulmonary	B
embolism	I
(	O
PE	B
)	O
]	O
was	O
increased	O
for	O
women	O
receiving	O
daily	O
conjugated	O
estrogens	O
(	O
0.625	O
mg	O
)	O
-alone	O
compared	O
to	O
placebo	O
(	O
30	O
versus	O
22	O
per	O
10,000	O
women-years	O
)	O
,	O
although	O
only	O
the	O
increased	O
risk	O
of	O
DVT	B
reached	O
statistical	O
significance	O
(	O
23	O
versus	O
15	O
per	O
10,000	O
women-years	O
)	O
.	O
	
Testing	O
for	O
IgG	O
titers	O
may	O
also	O
be	O
considered	O
if	O
patients	O
develop	O
hypersensitivity	O
reactions	O
,	O
other	O
immune-mediated	O
reactions	O
,	O
or	O
lose	O
clinical	O
response	O
.	O
	
(	O
5.1	O
)	O
*	O
Anemia	B
-	O
The	O
addition	O
of	O
VICTRELIS	O
to	O
peginterferon	O
alfa	O
and	O
ribavirin	O
is	O
associated	O
with	O
an	O
additional	O
decrease	B
in	I
hemoglobin	I
concentrations	I
compared	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
alone	O
.	O
	
Advise	O
female	O
patients	O
of	O
reproductive	O
potential	O
to	O
avoid	O
becoming	O
pregnant	O
and	O
to	O
use	O
highly	O
effective	O
contraception	O
while	O
using	O
AFINITOR	O
and	O
for	O
up	O
to	O
8	O
weeks	O
after	O
ending	O
treatment	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Patients	O
should	O
be	O
monitored	O
for	O
IgG	O
antibody	O
formation	O
every	O
3	O
months	O
for	O
2	O
years	O
and	O
then	O
annually	O
thereafter	O
.	O
	
These	O
cases	O
were	O
reported	O
post-marketing	O
and	O
are	O
derived	O
from	O
a	O
variety	O
of	O
sources	O
including	O
registries	O
and	O
spontaneous	O
post-marketing	O
reports	O
.	O
	
Reduction	O
of	O
Risk	O
of	O
Stroke	O
and	O
Systemic	O
Embolism	O
in	O
Patients	O
with	O
Nonvalvular	O
Atrial	O
Fibrillation	O
The	O
safety	O
of	O
ELIQUIS	O
was	O
evaluated	O
in	O
the	O
ARISTOTLE	O
and	O
AVERROES	O
studies	O
[	O
seeClinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
including	O
11,284	O
patients	O
exposed	O
to	O
ELIQUIS	O
5	O
mg	O
twice	O
daily	O
and	O
602	O
patients	O
exposed	O
to	O
ELIQUIS	O
2.5	O
mg	O
twice	O
daily	O
.	O
	
TAFINLAR	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
results	O
in	O
an	O
increased	O
incidence	O
of	O
basal	B
cell	I
carcinoma	I
.	O
	
Rare	O
cases	O
of	O
neurological	B
disorders	I
,	O
including	O
seizure	B
disorder	I
,	O
optic	B
neuritis	I
,	O
and	O
peripheral	B
neuropathy	I
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
CIMZIA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
incidence	O
of	O
antibody	O
development	O
in	O
patients	O
receiving	O
GRANIX	O
has	O
not	O
been	O
adequately	O
determined	O
.	O
	
A	O
negative	O
image	O
does	O
not	O
rule	O
out	O
the	O
presence	O
of	O
recurrent	O
prostate	O
cancer	O
and	O
a	O
positive	O
image	O
does	O
not	O
confirm	O
the	O
presence	O
of	O
recurrent	O
cancer	O
.	O
	
The	O
conditions	O
and	O
duration	O
of	O
exposure	O
varied	O
greatly	O
and	O
included	O
single-	O
and	O
multiple-dose	O
clinical	O
pharmacology	O
studies	O
in	O
healthy	O
volunteers	O
and	O
two	O
double-blind	O
studies	O
in	O
patients	O
with	O
LGS	O
(	O
Study	O
1	O
and	O
2	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
PML	O
is	O
usually	O
diagnosed	O
by	O
brain	O
imaging	O
,	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
testing	O
for	O
JC	O
viral	O
DNA	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
and/or	O
brain	O
biopsy	O
.	O
	
A	O
reduction	O
of	O
the	O
AFINITOR	O
dose	O
is	O
recommended	O
when	O
co-administered	O
with	O
a	O
moderate	O
CYP3A4/PgP	O
inhibitor	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
,	O
2.5	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
5.10	O
Immune	O
System	O
Effects	O
Following	O
GILENYA	O
Discontinuation	O
Fingolimod	O
remains	O
in	O
the	O
blood	O
and	O
has	O
pharmacodynamic	O
effects	O
,	O
including	O
decreased	B
lymphocyte	I
counts	I
,	O
for	O
up	O
to	O
2	O
months	O
following	O
the	O
last	O
dose	O
of	O
GILENYA	O
.	O
	
(	O
5.1	O
,	O
6	O
)	O
*	O
Use	O
with	O
CYP3A	O
inducers	O
:	O
Concomitant	O
use	O
with	O
strong	O
CYP3A	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
St.	O
John	O
's	O
wort	O
)	O
substantially	O
decreases	O
exposure	O
of	O
ivacaftor	O
,	O
which	O
may	O
diminish	O
effectiveness	O
.	O
	
*	O
Application	B
site	I
reactions	I
,	O
have	O
been	O
reported	O
.	O
	
It	O
is	O
important	O
to	O
emphasize	O
that	O
,	O
although	O
the	O
reactions	O
reported	O
occurred	O
during	O
treatment	O
with	O
FANAPT	O
,	O
they	O
were	O
not	O
necessarily	O
caused	O
by	O
it	O
.	O
	
Non-acute	O
hypersensitivity	B
reactions	I
including	O
rash	B
,	O
nausea	B
,	O
fatigue	B
,	O
myalgia	B
,	O
headache	B
,	O
and	O
facial	B
edema	I
,	O
have	O
been	O
reported	O
and	O
typically	O
occurred	O
up	O
to	O
a	O
week	O
following	O
the	O
most	O
recent	O
infusion	O
.	O
	
The	O
incidence	O
of	O
these	O
adverse	O
reactions	O
was	O
greater	O
in	O
the	O
patients	O
receiving	O
1,200	O
mg	O
per	O
day	O
.	O
	
Reduction	O
in	O
Heart	O
Rate	O
After	O
the	O
first	O
dose	O
of	O
GILENYA	O
,	O
the	O
heart	B
rate	I
decrease	I
starts	O
within	O
an	O
hour	O
.	O
	
In	O
patients	O
treated	O
with	O
Kyprolis	O
,	O
the	O
incidence	O
of	O
serious	O
adverse	O
events	O
was	O
higher	O
in	O
those	O
>	O
=	O
65	O
years	O
old	O
and	O
in	O
those	O
>	O
=	O
75	O
years	O
old	O
[	O
see	O
Geriatric	O
Use	O
(	O
8.5	O
)	O
]	O
.	O
	
In	O
short-term	O
placebo-controlled	O
bipolar	O
mania	O
adult	O
trials	O
,	O
the	O
incidence	O
of	O
EPS-related	B
events	I
,	O
excluding	O
events	O
related	O
to	O
akathisia	B
,	O
for	O
SAPHRIS-treated	O
patients	O
was	O
7	O
%	O
versus	O
2	O
%	O
for	O
placebo	O
;	O
and	O
the	O
incidence	O
of	O
akathisia-related	O
events	O
for	O
SAPHRIS-treated	O
patients	O
was	O
4	O
%	O
versus	O
2	O
%	O
for	O
placebo	O
.	O
	
Table	O
7	O
:	O
Most	O
Commonly	O
Reported	O
Adverse	O
Events	O
(	O
>	O
=	O
10	O
%	O
)	O
with	O
Kyprolis	O
Monotherapy	O
a	O
Pneumonia	B
includes	O
the	O
preferred	O
terms	O
of	O
pneumonia	B
,	O
bronchopneumonia	B
.	O
	
One	O
patient	O
with	O
urticaria	B
had	O
recurrence	O
when	O
INVOKANA	O
was	O
re-initiated	O
.	O
	
6.2	O
Endogenous	O
Anterior	O
Uveitis	O
A	O
total	O
of	O
200	O
subjects	O
participated	O
in	O
the	O
clinical	O
trials	O
for	O
endogenous	O
anterior	O
uveitis	O
,	O
of	O
which	O
106	O
were	O
exposed	O
to	O
DUREZOL	O
.	O
	
Cognitive	B
dysfunction	I
events	O
were	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
The	O
QT-prolonging	B
effect	O
occurred	O
within	O
3	O
hours	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
INCREASED	B
MORTALITY	I
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
WARNING	O
:	O
INCREASED	B
MORTALITY	I
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
.	O
	
*	O
Embryo-Fetal	B
Toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
[	O
See	O
Clinical	O
Studies	O
(	O
14.1	O
,	O
14.2	O
.	O
)	O
]	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
Heart	O
Failure	O
In	O
placebo-controlled	O
and	O
open-label	O
rheumatoid	O
arthritis	O
studies	O
,	O
cases	O
of	O
worsening	B
heart	I
failure	I
have	O
been	O
reported	O
for	O
CIMZIA-treated	O
patients	O
.	O
	
Adverse	O
Reactions	O
With	O
>	O
=	O
10	O
%	O
Incidence	O
for	O
Any	O
Grade	O
or	O
>	O
=	O
5	O
%	O
Incidence	O
for	O
Grade	O
3	O
or	O
Higher	O
(	O
N	O
=	O
212	O
)	O
Adverse	O
Reaction	O
Any	O
GradeGrading	O
based	O
on	O
NCI	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
(	O
CTCAE	O
)	O
version	O
4.0	O
(	O
%	O
)	O
Grade	O
3	O
or	O
Higher	O
(	O
%	O
)	O
Blood	O
and	O
lymphatic	O
system	O
disorders	O
Febrile	B
neutropenia	I
Anemia	B
Neutropenia	B
Thrombocytopenia	B
Leukopenia	B
251816119	O
23131588	O
Gastrointestinal	O
disorders	O
Nausea	B
Constipation	B
DiarrheaDiarrhea	O
includes	O
the	O
following	O
terms	O
:	O
colitis	B
,	O
diarrhea	B
,	O
enteritis	B
,	O
and	O
neutropenic	B
colitis	I
.	O
	
The	O
incidence	O
of	O
XIAFLEX-associated	O
pruritus	B
was	O
similar	O
after	O
each	O
injection	O
regardless	O
of	O
the	O
number	O
of	O
injections	O
administered	O
.	O
	
Studies	O
1	O
and	O
2	O
were	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
in	O
newly	O
diagnosed	O
patients	O
with	O
pulmonary	O
MDR-TB	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
=25	O
%	O
)	O
are	O
increased	B
AST	I
,	O
increased	B
ALT	I
,	O
lymphopenia	B
,	O
increased	B
alkaline	I
phosphatase	I
,	O
hypocalcemia	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
hypophosphatemia	B
,	O
and	O
hyperbilirubinemia	B
.	O
	
Permanently	O
discontinue	O
ZYKADIA	O
for	O
life-threatening	O
bradycardia	O
if	O
no	O
contributing	O
concomitant	O
medication	O
is	O
identified	O
;	O
however	O
,	O
if	O
associated	O
with	O
a	O
concomitant	O
medication	O
known	O
to	O
cause	O
bradycardia	O
or	O
hypotension	O
,	O
withhold	O
ZYKADIA	O
until	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
and	O
if	O
the	O
concomitant	O
medication	O
can	O
be	O
adjusted	O
or	O
discontinued	O
,	O
resume	O
ZYKADIA	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
upon	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
with	O
frequent	O
monitoring	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Women	O
of	O
reproductive	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
pregnancy	O
when	O
taking	O
Ferriprox	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
and	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
Studies	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
developing	O
hepatocellular	B
carcinoma	I
in	O
long-term	O
(	O
>	O
8	O
years	O
)	O
COC	O
users	O
.	O
	
Four	O
(	O
0.62	O
%	O
)	O
Ferriprox-treated	O
subjects	O
discontinued	O
the	O
drug	O
due	O
to	O
increased	B
serum	I
ALT	I
levels	O
and	O
1	O
(	O
0.16	O
%	O
)	O
due	O
to	O
an	O
increase	B
in	I
both	I
ALT	I
.	O
	
5.8	O
Bleeding	O
Irregularities	O
Breakthrough	B
bleeding	I
and	O
spotting	B
sometimes	O
occur	O
in	O
patients	O
on	O
COCs	O
,	O
especially	O
during	O
the	O
first	O
three	O
months	O
of	O
use	O
.	O
	
Oral	O
contraceptive-related	O
cholestasis	B
may	O
occur	O
in	O
women	O
with	O
a	O
history	O
of	O
pregnancy-related	O
cholestasis	O
.	O
	
AdreView	O
safety	O
and	O
effectiveness	O
have	O
not	O
been	O
established	O
in	O
neonates	O
(	O
pediatric	O
patients	O
below	O
the	O
age	O
of	O
1	O
month	O
)	O
.	O
	
Forty-four	O
(	O
70	O
%	O
)	O
patients	O
with	O
moderate	O
dermatitis	B
were	O
reported	O
to	O
have	O
complete	O
resolution	O
,	O
7	O
(	O
11	O
%	O
)	O
improved	O
to	O
mild	O
(	O
Grade	O
1	O
)	O
severity	O
,	O
and	O
12	O
(	O
19	O
%	O
)	O
had	O
no	O
reported	O
improvement	O
.	O
	
Study	O
3	O
was	O
an	O
open-label	O
,	O
noncomparative	O
study	O
with	O
SIRTURO	O
administered	O
as	O
part	O
of	O
an	O
individualized	O
pulmonary	O
MDR-TB	O
treatment	O
regimen	O
in	O
previously	O
treated	O
patients	O
.	O
	
Adverse	O
Reactions	O
Incidence	O
in	O
Placebo-Controlled	O
Adjunctive	O
Trials	O
in	O
Adult	O
Patients	O
with	O
Partial-Onset	O
Seizures	O
(	O
Adverse	O
reactions	O
in	O
at	O
least	O
2	O
%	O
of	O
patients	O
treated	O
with	O
POTIGA	O
in	O
any	O
treatment	O
group	O
and	O
numerically	O
more	O
frequent	O
than	O
in	O
the	O
placebo	O
group	O
.	O
)	O
	
Across	O
all	O
YERVOY-treated	O
patients	O
(	O
n=511	O
)	O
,	O
5	O
(	O
1	O
%	O
)	O
patients	O
developed	O
intestinal	B
perforation	I
,	O
4	O
(	O
0.8	O
%	O
)	O
patients	O
died	B
as	O
a	O
result	O
of	O
complications	O
,	O
and	O
26	O
(	O
5	O
%	O
)	O
patients	O
were	O
hospitalized	O
for	O
severe	O
enterocolitis	B
.	O
	
5.11	O
Interference	O
with	O
Laboratory	O
Tests	O
The	O
use	O
of	O
COCs	O
may	O
change	O
the	O
results	O
of	O
some	O
laboratory	O
tests	O
,	O
such	O
as	O
coagulation	O
factors	O
,	O
lipids	O
,	O
glucose	O
tolerance	O
,	O
and	O
binding	O
proteins	O
.	O
	
(	O
5.6	O
)	O
*	O
Macrovascular	O
outcomes	O
:	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
FARXIGA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Malignancies	O
In	O
clinical	O
studies	O
of	O
CIMZIA	O
,	O
the	O
overall	O
incidence	O
rate	O
of	O
malignancies	B
was	O
similar	O
for	O
CIMZIA-treated	O
and	O
control	O
patients	O
.	O
	
(	O
5.5	O
)	O
*	O
Macrovascular	O
outcomes	O
:	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
NESINA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Adverse	O
reactions	O
reported	O
as	O
reasons	O
for	O
discontinuation	O
of	O
treatment	O
In	O
the	O
pre-marketing	O
pooled	O
8-week	O
placebo-controlled	O
studies	O
in	O
patients	O
with	O
MDD	O
,	O
1,834	O
patients	O
were	O
exposed	O
to	O
PRISTIQ	O
(	O
50	O
to	O
400	O
mg	O
)	O
.	O
	
5.4	O
Anaphylactic	O
Reactions	O
and	O
Angioedema	O
Rare	O
cases	O
of	O
anaphylaxis	B
and	O
angioedema	B
have	O
been	O
reported	O
in	O
patients	O
taking	O
APTIOM	O
.	O
	
Across	O
clinical	O
trials	O
,	O
bradycardia	B
occurred	O
in	O
205	O
(	O
12.3	O
%	O
)	O
of	O
1669	O
patients	O
treated	O
with	O
XALKORI	O
.	O
	
Measure	O
liver	O
tests	O
promptly	O
in	O
patients	O
who	O
report	O
symptoms	O
that	O
may	O
indicate	O
liver	O
injury	O
,	O
including	O
fatigue	O
,	O
anorexia	O
,	O
right	O
upper	O
abdominal	O
discomfort	O
,	O
dark	O
urine	O
or	O
jaundice	O
.	O
	
Risk	O
factors	O
for	O
development	O
of	O
serious	O
dermatologic	B
reactions	I
with	O
APTIOM	O
use	O
have	O
not	O
been	O
identified	O
.	O
	
5.4	O
Flushing	O
TECFIDERA	O
may	O
cause	O
flushing	B
(	O
e.g.	O
,	O
warmth	B
,	O
redness	B
,	O
itching	B
,	O
and/or	O
burning	B
sensation	I
)	O
.	O
	
Before	O
initiating	O
treatment	O
with	O
TECFIDERA	O
,	O
a	O
CBC	O
including	O
lymphocyte	O
count	O
should	O
be	O
obtained	O
.	O
	
Reduction	O
of	O
Risk	O
of	O
Stroke	O
and	O
Systemic	O
Embolism	O
in	O
Non-valvular	O
Atrial	O
Fibrillation	O
The	O
RE-LY	O
(	O
Randomized	O
Evaluation	O
of	O
Long-term	O
Anticoagulant	O
Therapy	O
)	O
study	O
provided	O
safety	O
information	O
on	O
the	O
use	O
of	O
two	O
doses	O
of	O
PRADAXA	O
and	O
warfarin	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
known	O
cardiovascular	O
or	O
cerebrovascular	O
disease	O
,	O
and	O
in	O
antipsychotic-naive	O
patients	O
.	O
	
These	O
application	B
site	I
reactions	I
.	O
	
SAPHRIS	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
[	O
seeBoxed	O
Warningand	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
The	O
mean	O
change	O
from	O
baseline	O
for	O
the	O
all-SAPHRIS	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
treated	O
group	O
was	O
comparable	O
to	O
placebo	O
in	O
each	O
of	O
the	O
rating	O
scale	O
scores	O
.	O
	
Other	O
accompanying	O
reactions	O
included	O
chest	B
discomfort	I
,	O
wheezing	B
,	O
tachypnea	B
,	O
cyanosis	B
,	O
decreased	B
oxygen	I
saturation	I
,	O
convulsions	B
,	O
pruritus	B
,	O
rash	B
,	O
hyperhidrosis	B
,	O
nausea	B
,	O
dizziness	B
,	O
hypertension/increased	O
blood	B
pressure	I
,	O
flushing/feeling	O
hot	B
,	O
erythema	B
,	O
pyrexia	B
,	O
pallor	B
,	O
peripheral	B
coldness	I
,	O
restlessness	B
,	O
nervousness	B
,	O
headache	B
,	O
back	B
pain	I
,	O
and	O
paresthesia	B
.	O
	
The	O
most	O
common	O
cause	O
of	O
discontinuation	O
due	O
to	O
an	O
adverse	O
event	O
was	O
acute	B
renal	I
failure	I
(	O
2	O
%	O
)	O
.	O
	
There	O
were	O
808	O
subjects	O
included	O
in	O
the	O
efficacy	O
and	O
safety	O
analyses	O
.	O
	
System	O
Organ	O
Class/Preferred	O
Term	O
Placebo	O
N=166	O
%	O
SAPHRIS	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily*	O
N=158	O
%	O
Gastrointestinal	O
disorders	O
Dyspepsia	B
2	O
3	O
Oral	B
hypoesthesia	I
0	O
5	O
General	O
disorders	O
Fatigue	B
2	O
4	O
Edema	B
peripheral	I
<	O
1	O
3	O
Investigations	O
Increased	B
weight	I
0	O
3	O
Nervous	O
system	O
disorders	O
Dizziness	B
2	O
4	O
Other	O
extrapyramidal	B
symptoms	I
(	O
excluding	O
akathisia	B
)	O
5	O
6	O
Somnolence	B
?	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
This	O
finding	O
with	O
salmeterol	O
is	O
considered	O
a	O
class	O
effect	O
of	O
LABA	O
.	O
	
5.5	O
Infusion	O
Reactions	O
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
adverse	B
events	I
associated	I
with	I
the	I
infusion	I
(	O
occurring	O
on	O
the	O
same	O
day	O
of	O
the	O
infusion	O
)	O
were	O
reported	O
in	O
17	O
%	O
(	O
251/1,458	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
15	O
%	O
(	O
99/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Patients	O
should	O
be	O
monitored	O
for	O
signs	O
of	O
anticholinergic	O
CNS	O
effects	O
,	O
particularly	O
after	O
beginning	O
treatment	O
or	O
increasing	O
the	O
dose	O
.	O
	
Treatment-experienced	O
,	O
Integrase	O
Strand	O
Transfer	O
Inhibitor-naive	O
Subjects	O
:	O
In	O
an	O
international	O
,	O
multicenter	O
,	O
double-blind	O
trial	O
(	O
ING111762	O
,	O
SAILING	O
)	O
,	O
719	O
HIV-1-infected	O
,	O
antiretroviral	O
treatment-experienced	O
adults	O
were	O
randomized	O
and	O
received	O
either	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
or	O
raltegravir	O
400	O
mg	O
twice	O
daily	O
with	O
investigator-selected	O
background	O
regimen	O
consisting	O
of	O
up	O
to	O
2	O
agents	O
,	O
including	O
at	O
least	O
one	O
fully	O
active	O
agent	O
.	O
	
(	O
5.2	O
,	O
7.2	O
,	O
12.3	O
)	O
*	O
Cataracts	B
:	O
Non-congenital	B
lens	I
opacities	I
have	O
been	O
reported	O
in	O
pediatric	O
patients	O
treated	O
with	O
KALYDECO	O
.	O
	
Institute	O
medical	O
intervention	O
as	O
appropriate	O
for	O
management	O
of	O
severe	O
neuropathy	O
.	O
	
ENTEREG	O
REMS	O
Program	O
ENTEREG	O
is	O
available	O
only	O
through	O
a	O
program	O
called	O
the	O
ENTEREG	O
Access	O
Support	O
and	O
Education	O
(	O
E.A.S.E	O
.	O
)	O
	
Advise	O
females	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
and	O
to	O
use	O
highly	O
effective	O
contraception	O
.	O
	
Patient	O
monitoring	O
may	O
help	O
detect	O
patients	O
at	O
risk	O
for	O
PVAN	O
.	O
	
Obtain	O
frequent	O
blood	O
counts	O
to	O
monitor	O
for	O
neutropenia	O
.	O
	
In	O
clinical	O
trials	O
,	O
GILENYA	O
was	O
discontinued	O
if	O
the	O
elevation	O
exceeded	O
5	O
times	O
the	O
ULN	O
.	O
	
As	O
PML	O
has	O
been	O
associated	O
with	O
high	O
levels	O
of	O
overall	O
immunosuppression	O
,	O
the	O
recommended	O
doses	O
and	O
frequency	O
of	O
NULOJIX	O
and	O
concomitant	O
immunosuppressives	O
,	O
including	O
MMF	O
,	O
should	O
not	O
be	O
exceeded	O
.	O
	
Patients	O
were	O
permitted	O
to	O
participate	O
sequentially	O
in	O
both	O
placebo-controlled	O
trials	O
;	O
safety	O
data	O
collected	O
during	O
exposure	O
to	O
KALBITOR	O
was	O
attributed	O
to	O
treatment	O
with	O
KALBITOR	O
,	O
and	O
safety	O
data	O
collected	O
during	O
exposure	O
to	O
placebo	O
was	O
attributed	O
to	O
treatment	O
with	O
placebo	O
.	O
	
Healthcare	O
providers	O
should	O
follow	O
current	O
CDC	O
guidelines	O
both	O
to	O
evaluate	O
for	O
and	O
to	O
treat	O
possible	O
latent	O
tuberculosis	O
infections	O
before	O
initiating	O
therapy	O
with	O
ILARIS	O
.	O
	
Discontinuation	O
from	O
study	O
due	O
to	O
genital	B
infection	I
occurred	O
in	O
0	O
%	O
of	O
placebo-treated	O
patients	O
and	O
0.2	O
%	O
of	O
patients	O
treated	O
with	O
either	O
JARDIANCE	O
10	O
or	O
25	O
mg	O
.	O
	
5.5	O
Atypical	O
Subtrochanteric	O
and	O
Diaphyseal	O
Femoral	B
Fractures	I
have	O
been	O
reported	O
in	O
patients	O
receiving	O
Prolia	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.6	O
Neurologic	O
Reactions	O
Use	O
of	O
TNF	O
blockers	O
,	O
of	O
which	O
CIMZIA	O
is	O
a	O
member	O
,	O
has	O
been	O
associated	O
with	O
rare	O
cases	O
of	O
new	O
onset	O
or	O
exacerbation	O
of	O
clinical	O
symptoms	O
and/or	O
radiographic	O
evidence	O
of	O
central	B
nervous	I
system	I
demyelinating	I
disease	I
,	O
including	O
multiple	B
sclerosis	I
,	O
and	O
with	O
peripheral	B
demyelinating	I
disease	I
,	O
including	O
Guillain-Barre	B
syndrome	I
.	O
	
Adverse	O
reactions	O
leading	O
to	O
permanent	O
treatment	O
discontinuation	O
occurred	O
in	O
33	O
%	O
of	O
patients	O
>	O
=	O
65	O
years	O
of	O
age	O
compared	O
to	O
17	O
%	O
in	O
patients	O
<	O
65	O
years	O
of	O
age	O
.	O
	
For	O
women	O
with	O
a	O
history	O
of	O
cholestatic	O
jaundice	O
associated	O
with	O
past	O
estrogen	O
use	O
or	O
with	O
pregnancy	O
,	O
caution	O
should	O
be	O
exercised	O
;	O
and	O
in	O
the	O
case	O
of	O
recurrence	O
,	O
DUAVEE	O
should	O
be	O
discontinued	O
.	O
	
Malignancies	O
One	O
case	O
of	O
malignancy	B
other	O
than	O
lymphoma	B
and	O
NMSC	B
with	O
SIMPONI	O
ARIA	O
was	O
reported	O
through	O
Week	O
24	O
during	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
.	O
	
Most	O
patients	O
responded	O
to	O
corticosteroids	O
.	O
	
Discontinuation	O
of	O
Coartem	O
Tablets	O
due	O
to	O
adverse	O
drug	O
reactions	O
occurred	O
in	O
1.1	O
%	O
of	O
patients	O
treated	O
with	O
the	O
6-dose	O
regimen	O
overall	O
:	O
0.2	O
%	O
(	O
1/647	O
)	O
in	O
adults	O
and	O
1.6	O
%	O
(	O
21/1,332	O
)	O
in	O
children	O
.	O
	
Approximately	O
half	O
the	O
cases	O
were	O
lymphomas	B
,	O
including	O
non-Hodgkin	B
's	I
lymphoma	I
.	O
	
During	O
randomized	O
controlled	O
studies	O
,	O
transaminase	B
elevations	I
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
were	O
observed	O
(	O
AST	O
:	O
2	O
%	O
,	O
2	O
%	O
,	O
and	O
ALT	O
:	O
3	O
%	O
,	O
2	O
%	O
in	O
ULORIC	O
and	O
allopurinol-treated	O
patients	O
,	O
respectively	O
)	O
.	O
	
Neutrophils	O
and	O
Platelets	O
The	O
proportion	O
of	O
subjects	O
with	O
decreased	B
neutrophil	I
and	I
platelet	I
counts	I
was	O
higher	O
in	O
subjects	O
treated	O
with	O
VICTRELIS	O
in	O
combination	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
Advise	O
patients	O
treated	O
with	O
MULTAQ	O
to	O
report	O
immediately	O
symptoms	O
suggesting	O
hepatic	O
injury	O
(	O
such	O
as	O
anorexia	O
,	O
nausea	O
,	O
vomiting	O
,	O
fever	O
,	O
malaise	O
,	O
fatigue	O
,	O
right	O
upper	O
quadrant	O
pain	O
,	O
jaundice	O
,	O
dark	O
urine	O
,	O
or	O
itching	O
)	O
.	O
	
In	O
the	O
controlled	O
portions	O
of	O
clinical	O
trials	O
of	O
all	O
the	O
TNF	O
blockers	O
,	O
more	O
cases	O
of	O
lymphoma	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF	O
blockers	O
compared	O
to	O
control	O
patients	O
.	O
	
An	O
observational	O
study	O
evaluated	O
whether	O
recent	O
use	O
of	O
PDE5	O
inhibitors	O
,	O
as	O
a	O
class	O
,	O
was	O
associated	O
with	O
acute	O
onset	O
of	O
NAION	B
.	O
	
For	O
patients	O
with	O
lesser	O
elevations	O
of	O
serum	O
ALT	O
or	O
bilirubin	O
and	O
with	O
an	O
alternate	O
probable	O
cause	O
,	O
treatment	O
with	O
ULORIC	O
can	O
be	O
used	O
with	O
caution	O
.	O
	
If	O
CDAD	O
is	O
suspected	O
or	O
confirmed	O
,	O
antibacterials	O
not	O
directed	O
against	O
C.	O
difficile	O
should	O
be	O
discontinued	O
,	O
if	O
possible	O
.	O
	
The	O
effect	O
of	O
antibody	O
development	O
on	O
the	O
long	O
term	O
efficacy	O
of	O
alglucosidase	O
alfa	O
is	O
not	O
fully	O
understood	O
.	O
	
(	O
5.1	O
)	O
*	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
with	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
Teflaro	O
.	O
	
Neoplasms	O
Benign	O
,	O
Malignant	O
,	O
and	O
Unspecified	O
(	O
including	O
cysts	O
and	O
polyps	O
)	O
:	O
Skin	B
papilloma	I
.	O
	
No	O
dose-effect	O
relationship	O
for	O
these	O
transaminase	O
elevations	O
was	O
noted	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
In	O
the	O
controlled	O
and	O
uncontrolled	O
portions	O
of	O
Trial	O
1	O
,	O
in	O
SIMPONI	O
ARIA	O
treated	O
patients	O
,	O
the	O
incidence	O
of	O
active	B
TB	I
per	O
100	O
patient-years	O
was	O
0.31	O
(	O
95	O
%	O
CI	O
:	O
0.06	O
;	O
0.92	O
)	O
and	O
the	O
incidence	O
of	O
other	O
opportunistic	B
infections	I
per	O
100	O
patient-years	O
was	O
0.42	O
(	O
95	O
%	O
CI	O
:	O
0.11	O
,	O
1.07	O
)	O
.	O
	
Counseling	O
patients	O
about	O
the	O
protective	O
measures	O
necessary	O
to	O
guard	O
against	O
sexually	O
transmitted	O
diseases	O
,	O
including	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
)	O
,	O
should	O
be	O
considered	O
.	O
	
5.7	O
Geriatric	O
Patients	O
In	O
the	O
randomized	O
advanced	O
hormone	O
receptor-positive	O
,	O
HER2-negative	O
breast	O
cancer	O
study	O
,	O
the	O
incidence	O
of	O
deaths	B
due	O
to	O
any	O
cause	O
within	O
28	O
days	O
of	O
the	O
last	O
AFINITOR	O
dose	O
was	O
6	O
%	O
in	O
patients	O
>	O
=	O
65	O
years	O
of	O
age	O
compared	O
to	O
2	O
%	O
in	O
patients	O
<	O
65	O
years	O
of	O
age	O
.	O
	
Transient	O
decreases	B
in	I
absolute	I
neutrophil	I
count	I
)	O
to	O
less	O
than	O
1x10	O
9	O
/L	O
were	O
reported	O
in	O
3	O
patients	O
(	O
6.0	O
%	O
)	O
in	O
the	O
ILARIS	O
group	O
compared	O
to1	O
patient	O
(	O
2.0	O
%	O
)	O
in	O
the	O
placebo	O
group	O
.	O
	
Hypoglycemia	B
was	O
more	O
frequent	O
when	O
TANZEUM	O
was	O
added	O
to	O
sulfonylurea	O
or	O
insulin	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Patients	O
were	O
treated	O
with	O
KALBITOR	O
30	O
mg	O
subcutaneous	O
or	O
placebo	O
.	O
	
Physicians	O
should	O
consider	O
PML	O
in	O
the	O
differential	O
diagnosis	O
in	O
patients	O
with	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
or	O
symptoms	O
.	O
	
Most	O
Common	O
Adverse	O
Reactions	O
in	O
an	O
LGS	O
Placebo	O
Controlled	O
Clinical	O
Trial	O
(	O
Study	O
1	O
)	O
Table	O
3	O
lists	O
the	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=5	O
%	O
of	O
ONFI	O
treated	O
patients	O
(	O
at	O
any	O
dose	O
)	O
,	O
and	O
at	O
a	O
rate	O
greater	O
than	O
placebo	O
treated	O
patients	O
,	O
in	O
the	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
clinical	O
study	O
of	O
adjunctive	O
AED	O
therapy	O
for	O
15	O
weeks	O
(	O
Study	O
1	O
)	O
.	O
	
Serum	O
transaminase	O
levels	O
returned	O
to	O
normal	O
within	O
approximately	O
2	O
months	O
after	O
discontinuation	O
of	O
GILENYA	O
.	O
	
5.4	O
Use	O
in	O
Patients	O
with	O
Sickle	O
Cell	O
Disease	O
Severe	O
and	O
sometimes	O
fatal	B
sickle	B
cell	I
crises	I
can	O
occur	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
receiving	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
.	O
	
Antibody	O
titers	O
for	O
cellular	O
uptake	O
inhibition	O
were	O
present	O
in	O
18	O
of	O
59	O
(	O
31	O
%	O
)	O
patients	O
by	O
Week	O
78	O
.	O
	
(	O
6.1	O
)	O
*	O
Most	O
common	O
non-hematologic	O
adverse	O
reactions	O
for	O
NHL	O
(	O
frequency	O
>	O
=	O
15	O
%	O
)	O
are	O
nausea	B
,	O
fatigue	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
pyrexia	B
,	O
constipation	B
,	O
anorexia	B
,	O
cough	B
,	O
headache	B
,	O
weight	B
decreased	I
,	O
dyspnea	B
,	O
rash	B
,	O
and	O
stomatitis	B
.	O
	
In	O
the	O
remaining	O
patients	O
,	O
symptoms	O
resolved	O
within	O
3	O
to	O
4	O
weeks	O
.	O
	
In	O
Study	O
2	O
,	O
1	O
patient	O
in	O
each	O
treatment	O
group	O
(	O
0.1	O
%	O
)	O
had	O
an	O
infection	B
resulting	O
in	O
death	B
.	O
	
(	O
5.3	O
)	O
5.1	O
Fetal	O
Toxicity	O
Use	O
of	O
drugs	O
that	O
act	O
on	O
the	O
renin-angiotensin	O
system	O
during	O
the	O
second	O
and	O
third	O
trimesters	O
of	O
pregnancy	O
reduces	B
fetal	I
renal	I
function	I
and	O
increases	O
neonatal	B
morbidity	I
.	O
	
(	O
5.4	O
)	O
*	O
Posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
:	O
If	O
suspected	O
,	O
discontinue	O
GILENYA	O
.	O
	
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
DaTscan	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Some	O
of	O
these	O
reactions	O
were	O
IgE-mediated	O
.	O
	
The	O
rates	O
of	O
adverse	O
reactions	O
were	O
higher	O
in	O
the	O
combined	O
controlled	O
and	O
open-label	O
experience	O
than	O
in	O
the	O
placebo-controlled	O
trials	O
.	O
	
5.3	O
Hepatotoxicity	O
More	O
hepatic-related	B
adverse	I
reactions	I
were	O
reported	O
with	O
the	O
use	O
of	O
SIRTURO	O
plus	O
other	O
drugs	O
used	O
to	O
treat	O
tuberculosis	O
compared	O
to	O
other	O
drugs	O
used	O
to	O
treat	O
tuberculosis	O
without	O
the	O
addition	O
of	O
SIRTURO	O
.	O
	
A	O
total	O
of	O
725	O
men	O
were	O
exposed	O
to	O
placebo	O
and	O
731	O
men	O
were	O
exposed	O
to	O
Prolia	O
administered	O
once	O
every	O
6	O
months	O
as	O
a	O
single	O
60	O
mg	O
subcutaneous	O
dose	O
.	O
	
In	O
clinical	O
trials	O
,	O
SCC	O
was	O
observed	O
both	O
in	O
patients	O
receiving	O
Vimizim	O
and	O
patients	O
receiving	O
placebo	O
.	O
	
Grade	O
3	O
or	O
greater	O
infections	B
occurred	O
in	O
14	O
%	O
to	O
26	O
%	O
of	O
patients	O
.	O
	
Temporarily	O
suspend	O
,	O
dose	O
reduce	O
,	O
or	O
permanently	O
discontinue	O
XALKORI	O
as	O
described	O
in	O
Table	O
2	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
In	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
these	O
events	O
were	O
reported	O
in	O
26	O
%	O
and	O
38	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
APTIOM	O
at	O
doses	O
of	O
800	O
mg	O
and	O
1200	O
mg/day	O
,	O
respectively	O
,	O
compared	O
to	O
12	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
5.6	O
Osteonecrosis	O
of	O
the	O
Jaw	O
Osteonecrosis	B
of	I
the	I
jaw	I
(	O
ONJ	B
)	O
occurred	O
in	O
1	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
c	O
Includes	O
abdominal	B
discomfort	I
,	O
abdominal	B
pain	I
,	O
abdominal	B
pain	I
lower	I
,	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
tenderness	I
,	O
gastrointestinal	B
pain	I
.	O
	
Because	O
XIAFLEX	O
contains	O
foreign	O
proteins	O
,	O
severe	O
allergic	B
reactions	I
to	O
XIAFLEX	O
can	O
occur	O
.	O
	
5.10	O
Depression	O
Women	O
with	O
a	O
history	O
of	O
depression	O
should	O
be	O
carefully	O
observed	O
and	O
Natazia	O
discontinued	O
if	O
depression	O
recurs	O
to	O
a	O
serious	O
degree	O
.	O
	
Among	O
401	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
treated	O
with	O
the	O
recommended	O
regimen	O
of	O
NULOJIX	O
and	O
the	O
71	O
patients	O
in	O
Study	O
3	O
treated	O
with	O
a	O
very	O
similar	O
(	O
but	O
non-identical	O
)	O
NULOJIX	O
regimen	O
,	O
there	O
were	O
5	O
cases	O
of	O
PTLD	B
:	O
3	O
in	O
EBV	O
seropositive	O
patients	O
and	O
2	O
in	O
EBV	O
seronegative	O
patients	O
.	O
	
5.14	O
Potential	O
for	O
Cognitive	O
and	O
Motor	O
Impairment	O
FANAPT	O
,	O
like	O
other	O
antipsychotics	O
,	O
has	O
the	O
potential	O
to	O
impair	B
judgment	I
.	O
	
FARXIGA	O
should	O
not	O
be	O
used	O
in	O
patients	O
with	O
active	O
bladder	O
cancer	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
bladder	O
cancer	O
.	O
	
If	O
formation	O
of	O
anti-blinatumomab	O
antibodies	O
with	O
a	O
clinically	O
significant	O
effect	O
is	O
suspected	O
,	O
contact	O
Amgen	O
at	O
1-800-77-AMGEN	O
(	O
1-800-772-6436	O
)	O
to	O
discuss	O
antibody	O
testing	O
.	O
	
In	O
both	O
treatment	O
arms	O
,	O
patients	O
received	O
SIRTURO	O
or	O
placebo	O
in	O
combination	O
with	O
other	O
drugs	O
used	O
to	O
treat	O
MDR-TB	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
1670	O
patients	O
to	O
TRULICITY	O
and	O
a	O
mean	O
duration	O
of	O
exposure	O
to	O
TRULICITY	O
of	O
23.8	O
weeks	O
.	O
	
Neuraceq	O
,	O
like	O
all	O
radiopharmaceuticals	O
,	O
contributes	O
to	O
a	O
patient	O
's	O
long-term	B
cumulative	I
radiation	I
exposure	I
.	O
	
Elevations	O
of	O
AST	O
,	O
ALT	O
,	O
or	O
bilirubin	O
from	O
the	O
patient	O
's	O
baseline	O
should	O
prompt	O
more	O
frequent	O
monitoring	O
.	O
	
(	O
5.15	O
)	O
*	O
Be	O
alert	O
to	O
hypokalemia	O
and	O
hyperglycemia	O
.	O
	
No	O
new	O
safety	O
signals	O
were	O
identified	O
among	O
subjects	O
who	O
were	O
retreated	O
with	O
XIAFLEX	O
.	O
	
CTCAE	O
Grade	O
3	O
or	O
4	O
ILD/pneumonitis	O
was	O
reported	O
in	O
3	O
%	O
of	O
patients	O
,	O
and	O
fatal	B
ILD/pneumonitis	O
was	O
reported	O
in	O
1	O
patient	O
(	O
0.4	O
%	O
)	O
in	O
Study	O
1	O
.	O
	
No	O
deaths	B
clearly	O
related	O
to	O
ZYTIGA	O
were	O
reported	O
due	O
to	O
hepatotoxicity	B
events	O
.	O
	
5.7	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
FARXIGA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Gastrointestinal	O
Adverse	O
Reactions	O
In	O
the	O
four	O
pivotal	O
studies	O
,	O
patients	O
on	O
PRADAXA	O
150	O
mg	O
had	O
a	O
similar	O
incidence	O
of	O
gastrointestinal	B
adverse	I
reactions	I
(	O
24.7	O
%	O
vs.	O
22.7	O
%	O
on	O
warfarin	O
)	O
.	O
	
(	O
5.7	O
)	O
*	O
Embryo-fetal	B
toxicity	I
:	O
may	O
cause	O
fetal	B
harm	I
.	O
	
The	O
period	O
of	O
time	O
necessary	O
to	O
discontinue	O
any	O
specific	O
medication	O
prior	O
to	O
AdreView	O
dosing	O
has	O
not	O
been	O
established	O
[	O
see	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
5.5	O
Hyperglycemia	O
Hyperglycemia	B
can	O
occur	O
in	O
patients	O
receiving	O
ZYKADIA	O
.	O
	
The	O
frequency	O
,	O
type	O
and	O
severity	O
of	O
adverse	O
drug	O
reactions	O
in	O
pediatric	O
subjects	O
were	O
comparable	O
to	O
those	O
observed	O
in	O
adult	O
subjects	O
,	O
except	O
for	O
rash	B
which	O
was	O
observed	O
more	O
frequently	O
in	O
pediatric	O
subjects	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTS	O
,	O
(	O
B	O
)	O
EPIDURAL	B
HEMATOMA	I
WARNING	O
:	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTS	O
,	O
(	O
B	O
)	O
EPIDURAL	B
HEMATOMA	I
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTSPremature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
PRADAXA	O
,	O
increases	O
the	O
risk	O
of	O
thrombotic	O
events	O
.	O
	
Injection	O
of	O
XIAFLEX	O
into	O
corpora	B
cavernosa	I
of	I
the	I
penis	I
may	I
result	I
in	I
damage	I
to	O
those	O
structures	O
and	O
possible	O
injury	O
such	O
as	O
corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
were	O
injection	B
site	I
reactions	I
,	O
which	O
occurred	O
in	O
almost	O
all	O
patients	O
(	O
97	O
%	O
)	O
in	O
clinical	O
trials	O
.	O
	
Tissue	O
culture	O
experiments	O
indicate	O
that	O
approximately	O
one-third	O
of	O
human	O
breast	O
cancers	O
are	O
prolactin-dependent	O
in	O
vitro	O
,	O
a	O
factor	O
of	O
potential	O
importance	O
if	O
the	O
prescription	O
of	O
these	O
drugs	O
is	O
contemplated	O
in	O
a	O
patient	O
with	O
previously	O
detected	O
breast	O
cancer	O
.	O
	
The	O
Study	O
1	O
population	O
included	O
patients	O
with	O
a	O
median	O
age	O
of	O
11	O
years	O
(	O
2	O
to	O
18	O
years	O
)	O
;	O
59	O
%	O
were	O
male	O
,	O
78	O
%	O
were	O
White	O
,	O
10	O
%	O
were	O
Black/African	O
American	O
,	O
5	O
%	O
were	O
Asian	O
,	O
and	O
7	O
%	O
were	O
other	O
or	O
unknown	O
.	O
	
Among	O
the	O
477	O
patients	O
in	O
Studies	O
1	O
,	O
2	O
,	O
and	O
3	O
treated	O
with	O
the	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
,	O
there	O
were	O
8	O
cases	O
of	O
PTLD	B
:	O
2	O
in	O
EBV	O
seropositive	O
patients	O
and	O
6	O
in	O
EBV	O
seronegative	O
or	O
serostatus	O
unknown	O
patients	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Janssen	O
Therapeutics	O
,	O
Division	O
of	O
Janssen	O
Products	O
,	O
LP	O
at	O
1-800-JANSSEN	O
(	O
1-800-526-7736	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Patients	O
with	O
severe	O
neutropenia	O
(	O
absolute	O
neutrophil	O
count	O
<	O
1000/mm	O
3	O
)	O
should	O
discontinue	O
FANAPT	O
and	O
have	O
their	O
WBC	O
followed	O
until	O
recovery	O
.	O
	
These	O
patients	O
received	O
TREANDA	O
at	O
a	O
dose	O
of	O
120	O
mg/m	O
2	O
intravenously	O
on	O
Days	O
1	O
and	O
2	O
for	O
up	O
to	O
eight	O
21-day	O
cycles	O
.	O
	
In	O
the	O
majority	O
of	O
patients	O
who	O
experienced	O
flushing	B
,	O
it	O
was	O
mild	O
or	O
moderate	O
in	O
severity	O
.	O
	
high	O
tumor	O
burden	O
)	O
(	O
5.6	O
)	O
.	O
	
Depending	O
on	O
the	O
severity	O
of	O
hyponatremia	O
,	O
the	O
dose	O
of	O
APTIOM	O
may	O
need	O
to	O
be	O
reduced	O
or	O
discontinued	O
.	O
	
In	O
the	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
4/415	O
patients	O
(	O
1.0	O
%	O
)	O
treated	O
with	O
800	O
mg	O
and	O
6/410	O
(	O
1.5	O
%	O
)	O
patients	O
treated	O
with	O
1200	O
mg	O
of	O
APTIOM	O
had	O
at	O
least	O
one	O
serum	O
sodium	O
value	O
less	O
than	O
125	O
mEq/L	O
,	O
compared	O
to	O
none	O
of	O
the	O
patients	O
assigned	O
to	O
placebo	O
.	O
	
Adverse	O
Reaction	O
PlaceboN=646	O
INVOKANA	O
100	O
mgN=833	O
INVOKANA	O
300	O
mgN=834	O
Female	B
genital	I
mycotic	I
infections	I
3.2	O
%	O
10.4	O
%	O
11.4	O
%	O
Urinary	B
tract	I
infections	I
4.0	O
%	O
5.9	O
%	O
4.3	O
%	O
Increased	B
urination	I
0.8	O
%	O
5.3	O
%	O
4.6	O
%	O
Male	B
genital	I
mycotic	I
infections	I
0.6	O
%	O
4.2	O
%	O
3.7	O
%	O
Vulvovaginal	B
pruritus	I
0.0	O
%	O
1.6	O
%	O
3.0	O
%	O
Thirst	B
0.2	O
%	O
2.8	O
%	O
2.3	O
%	O
Constipation	B
0.9	O
%	O
1.8	O
%	O
2.3	O
%	O
Nausea	B
1.5	O
%	O
2.2	O
%	O
2.3	O
%	O
Abdominal	B
pain	I
was	O
also	O
more	O
commonly	O
reported	O
in	O
patients	O
taking	O
INVOKANA	O
100	O
mg	O
(	O
1.8	O
%	O
)	O
,	O
300	O
mg	O
(	O
1.7	O
%	O
)	O
than	O
in	O
patients	O
taking	O
placebo	O
(	O
0.8	O
%	O
)	O
.	O
	
The	O
majority	O
(	O
95	O
%	O
)	O
of	O
these	O
patients	O
had	O
Grade	O
1	O
visual	B
adverse	I
reactions	I
.	O
	
In	O
patients	O
with	O
transaminase	O
elevations	O
,	O
monitor	O
liver	O
enzymes	O
more	O
frequently	O
.	O
	
Inhalation	O
of	O
high	O
doses	O
of	O
beta2-adrenergic	O
agonists	O
may	O
produce	O
increases	B
in	I
plasma	I
glucose	I
.	O
	
Advise	O
the	O
patient	O
to	O
rinse	O
his/her	O
mouth	O
with	O
water	O
without	O
swallowing	O
after	O
inhalation	O
to	O
help	O
reduce	O
the	O
risk	O
.	O
	
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
in	O
All	O
Controlled	O
Clinical	O
Studies	O
In	O
the	O
3	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
studies	O
,	O
199	O
of	O
813	O
patients	O
(	O
25	O
%	O
)	O
receiving	O
POTIGA	O
and	O
45	O
of	O
427	O
patients	O
(	O
11	O
%	O
)	O
receiving	O
placebo	O
discontinued	O
treatment	O
because	O
of	O
adverse	O
reactions	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
eye	B
swelling	I
,	O
eyelid	B
edema	I
,	O
dysphagia	B
,	O
nausea	B
,	O
flu-like	B
symptoms	I
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
reaction	I
,	O
allergic	B
dermatitis	I
,	O
localized	B
allergic	I
reactions	I
,	O
herpes	B
zoster	I
,	O
muscular	B
weakness	I
,	O
muscle	B
spasm	I
,	O
dysarthria	B
,	O
myalgia	B
and	O
hypersensitivity	B
.	O
	
*	O
When	O
pregnancy	O
is	O
detected	O
,	O
discontinue	O
Edarbi	O
as	O
soon	O
as	O
possible	O
.	O
	
Monitor	O
for	O
symptoms	O
of	O
gastrointestinal	O
perforation	O
or	O
fistula	O
periodically	O
throughout	O
treatment	O
with	O
INLYTA	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
transaminase	B
elevations	I
>	O
=3	O
times	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
(	O
at	O
Endpoint	O
)	O
was	O
2.5	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
0.6	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
In	O
patients	O
with	O
PHN	O
receiving	O
HORIZANT	O
twice	O
daily	O
,	O
the	O
dose	O
should	O
be	O
reduced	O
to	O
once	O
daily	O
for	O
1	O
week	O
prior	O
to	O
discontinuation	O
to	O
minimize	O
the	O
potential	O
of	O
withdrawal	O
seizure	O
,	O
see	O
Table	O
2	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
(	O
6.2	O
)	O
In	O
clinical	O
trials	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
,	O
headache	B
,	O
nausea	B
,	O
vertigo	B
,	O
dry	B
mouth	I
or	O
dizziness	B
occurred	O
in	O
<	O
1	O
%	O
of	O
subjects	O
.	O
	
Since	O
patients	O
who	O
develop	O
IgE	O
antibodies	O
to	O
alglucosidase	O
alfa	O
appear	O
to	O
be	O
at	O
a	O
higher	O
risk	O
for	O
developing	O
anaphylaxis	O
and	O
hypersensitivity	O
reactions	O
,	O
these	O
patients	O
should	O
be	O
monitored	O
more	O
closely	O
during	O
administration	O
of	O
alglucosidase	O
alfa	O
.	O
	
The	O
incidence	O
of	O
constipation	B
was	O
2	O
%	O
in	O
those	O
taking	O
placebo	O
,	O
4	O
%	O
in	O
those	O
taking	O
4	O
mg/day	O
,	O
and	O
6	O
%	O
in	O
those	O
taking	O
8	O
mg/day	O
.	O
	
In	O
the	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
in	O
late-onset	O
patients	O
,	O
all	O
alglucosidase	O
alfa-treated	O
patients	O
with	O
available	O
samples	O
(	O
N=59	O
,	O
100	O
%	O
)	O
developed	O
IgG	O
antibodies	O
to	O
alglucosidase	O
alfa	O
.	O
	
However	O
,	O
there	O
is	O
substantial	O
evidence	O
from	O
placebo-controlled	O
maintenance	O
studies	O
in	O
adults	O
with	O
depression	O
that	O
the	O
use	O
of	O
antidepressants	O
can	O
delay	O
the	O
recurrence	O
of	O
depression	O
.	O
	
The	O
data	O
obtained	O
in	O
an	O
assay	O
are	O
highly	O
dependent	O
on	O
several	O
factors	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
underlying	O
disease	O
,	O
and	O
the	O
number	O
of	O
patients	O
tested	O
.	O
	
Pool	O
of	O
Placebo-	O
and	O
Active-controlled	O
Trials	O
The	O
occurrence	O
of	O
adverse	O
reactions	O
was	O
also	O
evaluated	O
in	O
a	O
larger	O
pool	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
participating	O
in	O
7	O
placebo-	O
and	O
active-controlled	O
trials	O
.	O
	
tooth	O
extraction	O
,	O
dental	O
implants	O
,	O
oral	O
surgery	O
)	O
,	O
diagnosis	O
of	O
cancer	O
,	O
concomitant	O
therapies	O
(	O
e.g	O
.	O
	
5.1	O
Suicidal	O
Thoughts	O
and	O
Behaviors	O
in	O
Children	O
,	O
Adolescents	O
and	O
Young	O
Adults	O
Patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
,	O
both	O
adult	O
and	O
pediatric	O
,	O
may	O
experience	O
worsening	O
of	O
their	O
depression	O
and/or	O
the	O
emergence	O
of	O
suicidal	O
ideation	O
and	O
behavior	O
(	O
suicidality	O
)	O
or	O
unusual	O
changes	O
in	O
behavior	O
,	O
whether	O
or	O
not	O
they	O
are	O
taking	O
antidepressant	O
medications	O
,	O
and	O
this	O
risk	O
may	O
persist	O
until	O
significant	O
remission	O
occurs	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Auxilium	O
Pharmaceuticals	O
,	O
Inc.	O
at	O
1-877-663-0412	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Patients	O
with	O
preexisting	O
liver	O
disease	O
may	O
be	O
at	O
increased	O
risk	O
of	O
developing	O
elevated	B
liver	I
enzymes	I
when	O
taking	O
GILENYA	O
.	O
	
In	O
Trial	O
2	O
,	O
the	O
incidence	O
of	O
fever	B
(	O
serious	O
and	O
non-serious	O
)	O
was	O
71	O
%	O
(	O
39/55	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
26	O
%	O
(	O
14/53	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
If	O
feasible	O
,	O
DUAVEE	O
should	O
be	O
discontinued	O
at	O
least	O
4	O
to	O
6	O
weeks	O
before	O
surgery	O
of	O
the	O
type	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
thromboembolism	O
,	O
or	O
during	O
periods	O
of	O
prolonged	O
immobilization	O
.	O
	
There	O
were	O
no	O
Grade	O
3	O
or	O
4	O
infusion-related	B
reactions	I
reported	O
in	O
Studies	O
1	O
and	O
2	O
;	O
however	O
,	O
Grade	O
1	O
or	O
2	O
infusion-related	B
reactions	I
were	O
reported	O
for	O
19	O
patients	O
(	O
12	O
%	O
)	O
.	O
	
Stepwise	O
increase	O
in	O
alpha-blocker	O
dose	O
may	O
be	O
associated	O
with	O
further	O
lowering	O
of	O
blood	O
pressure	O
when	O
taking	O
a	O
PDE5	O
inhibitor	O
.	O
	
5.9	O
Hepatic	O
Impairment	O
and	O
Past	O
History	O
of	O
Cholestatic	O
Jaundice	O
DUAVEE	O
has	O
not	O
been	O
studied	O
in	O
women	O
with	O
impaired	O
liver	O
function	O
or	O
past	O
history	O
of	O
cholestatic	O
jaundice	O
.	O
	
Infusion	O
reactions	O
Two	O
cases	O
of	O
anaphylaxis	B
were	O
reported	O
in	O
the	O
dose-finding	O
trials	O
.	O
	
Eight	O
patients	O
had	O
a	O
new	O
cytogenetic	B
abnormality	I
reported	O
on	O
therapy	O
,	O
including	O
5	O
patients	O
who	O
had	O
complex	O
changes	B
in	I
chromosome	I
7	I
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
are	O
nausea	B
(	O
11	O
%	O
)	O
,	O
vomiting	B
(	O
7	O
%	O
)	O
,	O
abdominal	B
pain	I
(	O
6	O
%	O
)	O
,	O
gastrointestinal	B
hemorrhage	I
(	O
4	O
%	O
)	O
,	O
anemia	B
(	O
2	O
%	O
)	O
,	O
and	O
neutropenia	B
(	O
2	O
%	O
)	O
(	O
6	O
)	O
.	O
	
Because	O
immobilization	O
increases	O
the	O
risk	O
for	O
venous	O
thromboembolic	O
events	O
independent	O
of	O
therapy	O
,	O
DUAVEE	O
should	O
be	O
discontinued	O
prior	O
to	O
and	O
during	O
prolonged	O
immobilization	O
(	O
e.g.	O
,	O
post-surgical	O
recovery	O
,	O
prolonged	O
bed	O
rest	O
)	O
and	O
DUAVEE	O
therapy	O
should	O
be	O
resumed	O
only	O
after	O
the	O
patient	O
is	O
fully	O
ambulatory	O
.	O
	
Treatment	O
with	O
antibacterial	O
agents	O
alters	O
the	O
normal	O
flora	O
of	O
the	O
colon	O
and	O
may	O
permit	O
overgrowth	O
of	O
C.	O
difficile	O
.	O
	
Patients	O
with	O
RA	O
,	O
particularly	O
those	O
with	O
highly	O
active	O
disease	O
,	O
are	O
at	O
a	O
higher	O
risk	O
for	O
the	O
development	O
of	O
lymphoma	O
.	O
	
(	O
5.3	O
)	O
*	O
Hypersensitivity	B
-	O
Serious	O
acute	B
hypersensitivity	I
reactions	I
(	O
e.g.	O
,	O
urticaria	B
,	O
angioedema	B
)	O
have	O
been	O
observed	O
during	O
combination	O
therapy	O
with	O
VICTRELIS	O
,	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
In	O
adults	O
,	O
the	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
were	O
headache	B
,	O
anorexia	B
,	O
dizziness	B
,	O
and	O
asthenia	B
.	O
	
Inhibitors	O
of	O
CYP3A4	O
may	O
reduce	O
STENDRA	O
clearance	O
and	O
increase	O
plasma	O
concentrations	O
of	O
avanafil	O
.	O
	
ESCAPE-1	O
ESCAPE-2	O
CLVN=53	O
(	O
%	O
)	O
PBON=51	O
(	O
%	O
)	O
CLVN=61	O
(	O
%	O
)	O
PBON=49	O
(	O
%	O
)	O
Any	O
common	O
adverse	O
event	O
27	O
(	O
51	O
%	O
)	O
21	O
(	O
41	O
%	O
)	O
32	O
(	O
53	O
%	O
)	O
24	O
(	O
49	O
%	O
)	O
Acute	B
renal	I
failure	I
5	O
(	O
9	O
%	O
)	O
1	O
(	O
2	O
%	O
)	O
--	O
--	O
Atrial	B
fibrillation	I
--	O
--	O
13	O
(	O
21	O
%	O
)	O
6	O
(	O
12	O
%	O
)	O
Nausea	B
--	O
--	O
13	O
(	O
21	O
%	O
)	O
6	O
(	O
12	O
%	O
)	O
Three	O
randomized	O
,	O
parallel	O
,	O
open-label	O
studies	O
called	O
ECLIPSE	O
,	O
with	O
longer	O
exposure	O
in	O
cardiac	O
surgery	O
patients	O
define	O
the	O
adverse	O
reactions	O
for	O
patients	O
with	O
perioperative	O
hypertension	O
.	O
	
In	O
patients	O
with	O
mild	O
renal	O
impairment	O
(	O
CrCl	O
51-80	O
mL/min	O
)	O
,	O
AMPYRA	O
plasma	O
levels	O
may	O
approach	O
those	O
seen	O
at	O
a	O
dose	O
of	O
15	O
mg	O
twice	O
daily	O
,	O
a	O
dose	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
seizures	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
5.5	O
Urinary	O
Tract	O
Infections	O
Urinary	B
tract	I
infections	I
(	O
UTIs	B
)	O
were	O
reported	O
more	O
frequently	O
as	O
adverse	O
reactions	O
in	O
controlled	O
studies	O
in	O
patients	O
receiving	O
AMPYRA	O
10	O
mg	O
twice	O
daily	O
(	O
12	O
%	O
)	O
as	O
compared	O
to	O
placebo	O
(	O
8	O
%	O
)	O
.	O
	
The	O
CAPS	O
clinical	O
studies	O
employed	O
the	O
biosensor	O
binding	O
assay	O
,	O
and	O
most	O
of	O
the	O
SJIA	O
clinical	O
studies	O
employed	O
the	O
bridging	O
assay	O
.	O
	
Patients	O
should	O
be	O
advised	O
not	O
to	O
drive	O
a	O
car	O
or	O
operate	O
other	O
complex	O
machinery	O
until	O
they	O
have	O
gained	O
sufficient	O
experience	O
on	O
HORIZANT	O
to	O
assess	O
whether	O
HORIZANT	O
impairs	O
their	O
ability	O
to	O
perform	O
these	O
tasks	O
.	O
	
For	O
patients	O
with	O
a	O
history	O
of	O
transaminase	O
elevations	O
,	O
more	O
frequent	O
monitoring	O
of	O
liver	O
function	O
tests	O
should	O
be	O
considered	O
.	O
	
STRIBILD	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
chronic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
and	O
the	O
safety	O
and	O
efficacy	O
of	O
STRIBILD	O
have	O
not	O
been	O
established	O
in	O
patients	O
coinfected	O
with	O
HBV	O
and	O
HIV-1	O
.	O
	
The	O
rate	O
of	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
was	O
4	O
%	O
of	O
subjects	O
at	O
Week	O
48	O
.	O
	
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
malignancies	B
,	O
excluding	O
non-melanoma	O
skin	O
cancers	O
,	O
were	O
observed	O
in	O
0.2	O
%	O
(	O
3/1,458	O
)	O
and	O
0.3	O
%	O
(	O
2/675	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
placebo	O
,	O
respectively	O
.	O
	
(	O
2.3,5.2	O
)	O
*	O
Interstitial	B
lung	I
disease	I
(	O
ILD	B
)	O
:	O
Occurs	O
in	O
1.5	O
%	O
of	O
patients	O
.	O
	
The	O
median	O
age	O
of	O
these	O
patients	O
was	O
64	O
years	O
(	O
range	O
32-87	O
)	O
.	O
	
WARNING	O
:	O
FETAL	B
TOXICITY	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
5.6	O
Use	O
with	O
Anakinra	O
Concurrent	O
administration	O
of	O
anakinra	O
(	O
an	O
interleukin-1	O
antagonist	O
)	O
and	O
another	O
TNF-blocker	O
,	O
was	O
associated	O
with	O
a	O
greater	O
portion	O
of	O
serious	O
infections	O
and	O
neutropenia	O
and	O
no	O
additional	O
benefits	O
compared	O
with	O
the	O
TNF-blocker	O
alone	O
.	O
	
In	O
patients	O
whose	O
renal	O
function	O
may	O
depend	O
on	O
the	O
activity	O
of	O
the	O
renin-angiotensin	O
system	O
(	O
e.g.	O
,	O
patients	O
with	O
severe	O
congestive	O
heart	O
failure	O
,	O
renal	O
artery	O
stenosis	O
,	O
or	O
volume	O
depletion	O
)	O
,	O
treatment	O
with	O
angiotensin-converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	O
receptor	O
blockers	O
has	O
been	O
associated	O
with	O
oliguria	B
or	O
progressive	B
azotemia	I
and	O
rarely	O
with	O
acute	B
renal	I
failure	I
and	O
death	B
.	O
	
Grade	O
3-4	O
adverse	O
reactions	O
were	O
reported	O
in	O
44	O
%	O
of	O
XTANDI-treated	O
patients	O
and	O
37	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
Table	O
3	O
shows	O
absolute	O
and	O
relative	O
risk	O
by	O
indication	O
for	O
all	O
evaluated	O
AEDs	O
.	O
	
Additionally	O
in	O
Prolia-treated	O
men	O
with	O
nonmetastatic	O
prostate	O
cancer	O
receiving	O
ADT	O
,	O
a	O
greater	O
incidence	O
of	O
cataracts	B
was	O
observed	O
(	O
1.2	O
%	O
placebo	O
vs.	O
4.7	O
%	O
Prolia	O
)	O
.	O
	
One	O
death	B
occurred	O
during	O
the	O
24	O
weeks	O
of	O
administration	O
of	O
SIRTURO	O
.	O
	
*	O
Tumor	B
Lysis	I
Syndrome	I
(	O
TLS	B
)	O
:	O
Monitor	O
patients	O
at	O
risk	O
for	O
TLS	O
(	O
e.g	O
.	O
	
If	O
super-infection	O
occurs	O
,	O
discontinue	O
use	O
and	O
institute	O
alternative	O
therapy	O
.	O
	
(	O
24	O
weeks	O
)	O
N=197	O
N=212	O
N=196	O
Major	O
[	O
n	O
(	O
%	O
)	O
]	O
1	O
(	O
0.5	O
)	O
1	O
(	O
0.5	O
)	O
1	O
(	O
0.5	O
)	O
Minor	O
[	O
n	O
(	O
%	O
)	O
]	O
67	O
(	O
34.0	O
)	O
92	O
(	O
43.4	O
)	O
79	O
(	O
40.3	O
)	O
Genital	O
Mycotic	O
Infections	O
Genital	B
mycotic	I
infections	I
were	O
more	O
frequent	O
with	O
FARXIGA	O
treatment	O
.	O
	
5.9	O
Hyperprolactinemia	O
As	O
with	O
other	O
drugs	O
that	O
antagonize	O
dopamine	O
D2	O
receptors	O
,	O
FANAPT	O
elevates	B
prolactin	I
levels	I
.	O
	
Upon	O
improvement	O
to	O
Grade	O
1	O
or	O
less	O
,	O
initiate	O
corticosteroid	O
taper	O
and	O
continue	O
to	O
taper	O
over	O
at	O
least	O
1	O
month	O
.	O
	
Monitor	O
blood	O
pressure	O
prior	O
to	O
initiation	O
and	O
regularly	O
during	O
COMETRIQ	O
treatment	O
.	O
	
In	O
these	O
trials	O
,	O
which	O
had	O
a	O
median	O
treatment	O
duration	O
of	O
12	O
weeks	O
,	O
the	O
estimated	O
incidence	O
rate	O
of	O
suicidal	B
behavior	I
among	O
27,863	O
AED	O
treated	O
patients	O
was	O
0.43	O
%	O
,	O
compared	O
to	O
0.24	O
%	O
among	O
16,029	O
placebo	O
treated	O
patients	O
,	O
representing	O
an	O
increase	O
of	O
approximately	O
one	O
case	O
of	O
suicidal	B
thinking	I
for	O
every	O
530	O
patients	O
treated	O
.	O
	
Rash	B
was	O
self-limiting	O
and	O
generally	O
resolved	O
within	O
1	O
week	O
on	O
continued	O
therapy	O
.	O
	
Treatment	O
of	O
hyperammonemia	O
may	O
require	O
dialysis	O
,	O
preferably	O
hemodialysis	O
,	O
to	O
remove	O
a	O
large	O
burden	O
of	O
ammonia	O
.	O
	
ONFI	O
should	O
be	O
tapered	O
by	O
decreasing	O
the	O
dose	O
every	O
week	O
by	O
5-10	O
mg/day	O
until	O
discontinuation	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
CTCAE	O
Grade	O
3-4	O
elevations	B
of	I
lipase	I
occurred	O
in	O
15	O
%	O
of	O
patients	O
receiving	O
ZYKADIA	O
in	O
Study	O
1	O
.	O
	
In	O
animal	O
studies	O
,	O
administration	O
of	O
deferiprone	O
during	O
the	O
period	O
of	O
organogenesis	O
resulted	O
in	O
embryofetal	B
death	I
at	O
doses	O
lower	O
than	O
equivalent	O
human	O
clinical	O
doses	O
.	O
	
Avoid	O
concurrent	O
use	O
of	O
Zydelig	O
and	O
other	O
drugs	O
that	O
cause	O
diarrhea	O
.	O
	
Errors	O
may	O
also	O
occur	O
in	O
cases	O
with	O
severe	O
brain	O
atrophy	O
that	O
limits	O
the	O
ability	O
to	O
distinguish	O
gray	O
and	O
white	O
matter	O
on	O
the	O
Neuraceq	O
scan	O
.	O
	
Neuraceq	O
scan	O
results	O
are	O
indicative	O
of	O
the	O
presence	O
of	O
brain	O
neuritic	O
beta-amyloid	O
plaques	O
only	O
at	O
the	O
time	O
of	O
image	O
acquisition	O
and	O
a	O
negative	O
scan	O
result	O
does	O
not	O
preclude	O
the	O
development	O
of	O
brain	O
neuritic	O
beta-amyloid	O
plaques	O
in	O
the	O
future	O
.	O
	
Table	O
1	O
:	O
Treatment-Emergent	O
Adverse	O
ReactionsIncludes	O
adverse	O
reactions	O
at	O
least	O
possibly	O
,	O
probably	O
,	O
or	O
very	O
likely	O
related	O
to	O
the	O
drug	O
.	O
	
5.3	O
Hepatotoxicity	O
In	O
the	O
two	O
randomized	O
clinical	O
trials	O
,	O
grade	O
3	O
or	O
4	O
AST	B
increases	I
(	O
at	O
least	O
5*	O
ULN	O
)	O
were	O
reported	O
in	O
4	O
%	O
of	O
patients	O
who	O
received	O
ZYTIGA	O
,	O
typically	O
during	O
the	O
first	O
3	O
months	O
after	O
starting	O
treatment	O
.	O
	
Median	O
time	O
to	O
resolution	O
ranged	O
between	O
1	O
week	O
and	O
1	O
month	O
across	O
trials	O
,	O
following	O
interruption	O
of	O
Zydelig	O
therapy	O
and	O
in	O
some	O
instances	O
,	O
use	O
of	O
corticosteroids	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
The	O
adverse	O
reaction	O
profile	O
was	O
similar	O
for	O
each	O
injection	O
,	O
regardless	O
of	O
the	O
number	O
of	O
injections	O
administered	O
.	O
	
Besivance	O
is	O
for	O
topical	O
ophthalmic	O
use	O
only	O
,	O
and	O
should	O
not	O
be	O
injected	O
subconjunctivally	O
,	O
nor	O
should	O
it	O
be	O
introduced	O
directly	O
into	O
the	O
anterior	O
chamber	O
of	O
the	O
eye	O
.	O
	
Lenses	O
may	O
be	O
reinserted	O
after	O
10	O
minutes	O
following	O
administration	O
of	O
DUREZOL	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling	O
:	O
*	O
Increased	B
mortality	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
QT	B
Prolongation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Drug	O
Interactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
in	O
10	O
%	O
or	O
more	O
of	O
patients	O
treated	O
with	O
SIRTURO	O
were	O
nausea	B
,	O
arthralgia	B
,	O
headache	B
,	O
hemoptysis	B
and	O
chest	B
pain	I
.	O
	
In	O
symptomatic	O
patients	O
,	O
rule	O
out	O
infectious	O
etiologies	O
and	O
consider	O
endoscopic	O
evaluation	O
for	O
persistent	O
or	O
severe	O
symptoms	O
.	O
	
Six	O
percent	O
(	O
6	O
%	O
)	O
of	O
TECFIDERA	O
patients	O
and	O
<	O
1	O
%	O
of	O
placebo	O
patients	O
experienced	O
lymphocyte	B
counts	I
<	I
0.5x10	I
9	I
/L	I
(	O
lower	O
limit	O
of	O
normal	O
0.91x10	O
9	O
/L	O
)	O
.	O
	
Flushing	B
symptoms	O
generally	O
began	O
soon	O
after	O
initiating	O
TECFIDERA	O
and	O
usually	O
improved	O
or	O
resolved	O
over	O
time	O
.	O
	
Therefore	O
,	O
obtaining	O
a	O
liver	O
test	O
panel	O
and	O
assessing	O
the	O
patient	O
before	O
initiating	O
NESINA	O
therapy	O
is	O
recommended	O
.	O
	
Approximately	O
half	O
of	O
the	O
patients	O
(	O
49	O
%	O
)	O
were	O
male	O
.	O
	
6.1	O
Ocular	O
Surgery	O
Ocular	B
adverse	I
reactions	I
occurring	O
in	O
5-15	O
%	O
of	O
subjects	O
in	O
clinical	O
studies	O
with	O
DUREZOL	O
included	O
corneal	B
edema	I
,	O
conjunctival	B
hyperemia	I
,	O
eye	B
pain	I
,	O
photophobia	B
,	O
posterior	B
capsule	I
opacification	I
,	O
anterior	B
chamber	I
cells	I
,	O
anterior	B
chamber	I
flare	I
,	O
conjunctival	B
edema	I
,	O
and	O
blepharitis	B
.	O
	
The	O
decrease	B
in	I
serum	I
potassium	I
is	O
usually	O
transient	O
,	O
not	O
requiring	O
supplementation	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
15	O
%	O
)	O
are	O
gastritis-like	O
symptoms	O
and	O
bleeding	B
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Boehringer	O
Ingelheim	O
Pharmaceuticals	O
,	O
Inc.	O
at	O
(	O
800	O
)	O
542-6257	O
or	O
(	O
800	O
)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Heart	B
rates	I
below	I
40	I
beats	I
per	I
minute	I
were	O
rarely	O
observed	O
.	O
	
A	O
total	O
of	O
801	O
patients	O
were	O
treated	O
for	O
at	O
least	O
6	O
months	O
,	O
585	O
patients	O
were	O
treated	O
for	O
1	O
year	O
or	O
longer	O
,	O
and	O
311	O
patients	O
were	O
treated	O
for	O
at	O
least	O
2	O
years	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Hypersensitivity	B
and	O
injection	B
site	I
reactions	I
have	O
been	O
reported	O
following	O
DaTscan	O
administration	O
.	O
	
If	O
INLYTA	O
is	O
interrupted	O
,	O
patients	O
receiving	O
antihypertensive	O
medications	O
should	O
be	O
monitored	O
for	O
hypotension	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
The	O
risks	O
and	O
benefits	O
of	O
re-administering	O
alglucosidase	O
alfa	O
following	O
an	O
anaphylactic	O
or	O
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
.	O
	
In	O
these	O
trials	O
,	O
which	O
had	O
a	O
median	O
treatment	O
duration	O
of	O
12	O
weeks	O
,	O
the	O
estimated	O
incidence	O
rate	O
of	O
suicidal	B
behavior	I
among	O
27,863	O
AED-treated	O
patients	O
was	O
0.43	O
%	O
,	O
compared	O
with	O
0.24	O
%	O
among	O
16,029	O
placebo-treated	O
patients	O
,	O
representing	O
an	O
increase	O
of	O
approximately	O
1	O
case	O
of	O
suicidal	B
thinking	I
for	O
every	O
530	O
patients	O
treated	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
50	O
%	O
)	O
were	O
decreased	B
hemoglobin	I
,	O
hyperglycemia	B
,	O
alkaline	B
phosphatase	I
increased	I
,	O
hypercholesterolemia	B
,	O
bicarbonate	B
decreased	I
,	O
and	O
increased	B
aspartate	I
transaminase	I
)	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
cytochrome	O
P450	O
enzyme	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
phenobarbital	O
,	O
carbamazepine	O
,	O
phenytoin	O
)	O
with	O
OTEZLA	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
In	O
addition	O
to	O
the	O
reactions	O
shown	O
in	O
Tables	O
2	O
and	O
3	O
,	O
adverse	O
reactions	O
occurring	O
in	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
of	O
the	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
or	O
BREO	O
ELLIPTA	O
200/25	O
for	O
12	O
months	O
included	O
pyrexia	B
,	O
back	B
pain	I
,	O
extrasystoles	B
,	O
upper	B
abdominal	I
pain	I
,	O
respiratory	B
tract	I
infection	I
,	O
allergic	B
rhinitis	I
,	O
pharyngitis	B
,	O
rhinitis	B
,	O
arthralgia	B
,	O
supraventricular	B
extrasystoles	I
,	O
ventricular	B
extrasystoles	I
,	O
acute	B
sinusitis	I
,	O
and	O
pneumonia	B
.	O
	
A	O
reaction	O
was	O
considered	O
treatment-emergent	O
if	O
it	O
occurred	O
for	O
the	O
first	O
time	O
or	O
worsened	O
while	O
receiving	O
therapy	O
following	O
baseline	O
evaluation	O
.	O
	
Immune	O
System	O
Disorders	O
Hypersensitivity	B
reactions	I
,	O
including	O
anaphylaxis	B
,	O
angioedema	B
,	O
rash	B
,	O
and	O
urticaria	B
.	O
	
Table	O
1	O
lists	O
adverse	O
events	O
,	O
regardless	O
of	O
causality	O
,	O
that	O
were	O
reported	O
in	O
the	O
combined	O
Phase	O
3	O
,	O
randomized	O
,	O
placebo-controlled	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
and	O
in	O
1	O
%	O
or	O
more	O
of	O
patients	O
treated	O
with	O
Toviaz	O
4	O
or	O
8	O
mg	O
once	O
daily	O
for	O
up	O
to	O
12	O
weeks	O
.	O
	
Some	O
patients	O
who	O
tested	O
positive	O
for	O
alglucosidase	O
alfa-specific	O
IgE	O
antibodies	O
and	O
experienced	O
hypersensitivity	B
reactions	I
were	O
able	O
to	O
be	O
rechallenged	O
with	O
alglucosidase	O
alfa	O
using	O
a	O
slower	O
infusion	O
rate	O
at	O
lower	O
starting	O
doses	O
and	O
have	O
continued	O
to	O
receive	O
treatment	O
under	O
close	O
clinical	O
supervision	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Includes	O
5	O
subjects	O
with	O
major	O
bleeding	B
events	O
that	O
occurred	O
before	O
the	O
first	O
dose	O
of	O
apixaban	O
(	O
administered	O
12	O
to	O
24	O
hours	O
post	O
surgery	O
)	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
canakinumab	O
between	O
the	O
CAPS	O
and	O
SJIA	O
clinical	O
studies	O
or	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Because	O
it	O
takes	O
approximately	O
2	O
months	O
to	O
eliminate	O
GILENYA	O
from	O
the	O
body	O
,	O
women	O
of	O
childbearing	O
potential	O
should	O
use	O
effective	O
contraception	O
to	O
avoid	O
pregnancy	O
during	O
and	O
for	O
2	O
months	O
after	O
stopping	O
GILENYA	O
treatment	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Astellas	O
Pharma	O
US	O
,	O
Inc.	O
at	O
1-800-727-7003	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
If	O
concomitant	O
use	O
of	O
PRISTIQ	O
with	O
other	O
serotonergic	O
drugs	O
is	O
clinically	O
warranted	O
,	O
patients	O
should	O
be	O
made	O
aware	O
of	O
a	O
potential	O
increased	O
risk	O
for	O
serotonin	O
syndrome	O
,	O
particularly	O
during	O
treatment	O
initiation	O
and	O
dose	O
increases	O
(	O
5.2	O
)	O
.	O
	
5.3	O
Malignant	O
Neoplasms	O
Endometrial	O
Cancer	O
An	O
increased	O
risk	O
of	O
endometrial	B
cancer	I
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
unopposed	O
estrogen	O
therapy	O
in	O
women	O
with	O
a	O
uterus	O
.	O
	
Standard	O
international	O
guidelines	O
were	O
followed	O
for	O
infection	O
prophylaxis	O
for	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
,	O
varicella-zoster	O
virus	O
(	O
VZV	O
)	O
,	O
and	O
Pneumocystis	O
jiroveci	O
pneumonia	O
(	O
PCP	O
)	O
post-auto-HSCT	O
.	O
	
5.15	O
Dysphagia	O
Esophageal	B
dysmotility	I
and	O
aspiration	B
have	O
been	O
associated	O
with	O
antipsychotic	O
drug	O
use	O
.	O
	
For	O
patients	O
taking	O
concomitant	O
moderate	O
CYP3A4	O
inhibitors	O
(	O
including	O
erythromycin	O
,	O
amprenavir	O
,	O
aprepitant	O
,	O
diltiazem	O
,	O
fluconazole	O
,	O
fosamprenavir	O
,	O
and	O
verapamil	O
)	O
,	O
the	O
maximum	O
recommended	O
dose	O
of	O
STENDRA	O
is	O
50	O
mg	O
,	O
not	O
to	O
exceed	O
once	O
every	O
24	O
hours	O
[	O
seeDrug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
myocardial	O
infarction	O
(	O
MI	O
)	O
and	O
stroke	O
.	O
	
Contact	O
your	O
local	O
Genzyme	O
representative	O
or	O
Genzyme	O
Corporation	O
at	O
1-800-745-4447	O
for	O
information	O
on	O
testing	O
and	O
to	O
obtain	O
a	O
sample	O
collection	O
box	O
.	O
	
5.3	O
Prolonged	O
Erection	O
Prolonged	B
erection	I
greater	O
than	O
4	O
hours	O
and	O
priapism	B
(	O
painful	B
erections	I
greater	O
than	O
6	O
hours	O
in	O
duration	O
)	O
have	O
been	O
reported	O
with	O
other	O
PDE5	O
inhibitors	O
.	O
	
(	O
5.5	O
)	O
5.1	O
Embryofetal	O
Toxicity	O
(	O
Use	O
with	O
Ribavirin	O
and	O
Peginterferon	O
Alfa	O
)	O
Ribavirin	O
may	O
cause	O
birth	B
defects	I
and/or	O
death	B
of	I
the	I
exposed	I
fetus	I
.	O
	
5.3	O
Hepatic	O
Effects	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
fatal	B
and	O
non-fatal	O
hepatic	B
failure	I
in	O
patients	O
taking	O
ULORIC	O
,	O
although	O
the	O
reports	O
contain	O
insufficient	O
information	O
necessary	O
to	O
establish	O
the	O
probable	O
cause	O
.	O
	
Laboratory	O
Values	O
Changes	O
in	O
selected	O
hematological	O
parameters	O
during	O
treatment	O
of	O
adult	O
subjects	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron	O
and	O
REBETOL	O
are	O
described	O
in	O
Table	O
4	O
.	O
	
5.5	O
Sudden	O
Hearing	O
Loss	O
Use	O
of	O
PDE5	O
inhibitors	O
has	O
been	O
associated	O
with	O
loss	B
of	I
hearing	I
,	O
which	O
may	O
be	O
accompanied	O
by	O
tinnitus	B
or	O
dizziness	B
.	O
	
A	O
number	O
of	O
reports	O
note	O
that	O
patients	O
were	O
also	O
receiving	O
treatment	O
with	O
glucocorticoids	O
(	O
e.g	O
.	O
	
5.4	O
Anaphylaxis	O
AMPYRA	O
can	O
cause	O
anaphylaxis	B
and	O
severe	O
allergic	B
reactions	I
.	O
	
5.12	O
Hypocalcemia	O
Estrogen	O
therapy	O
should	O
be	O
used	O
with	O
caution	O
in	O
women	O
with	O
hypoparathyroidism	O
as	O
estrogen-induced	O
hypocalcemia	O
may	O
occur	O
.	O
	
The	O
most	O
common	O
(	O
>	O
=	O
5	O
%	O
)	O
grade	O
3-4	O
adverse	O
reactions	O
in	O
patients	O
who	O
received	O
JEVTANA	O
were	O
neutropenia	B
,	O
leukopenia	B
,	O
anemia	B
,	O
febrile	B
neutropenia	I
,	O
diarrhea	B
,	O
fatigue	B
,	O
and	O
asthenia	B
.	O
	
Because	O
of	O
the	O
nature	O
of	O
the	O
adverse	O
events	O
seen	O
with	O
this	O
combination	O
therapy	O
,	O
similar	O
toxicities	O
may	O
also	O
result	O
from	O
the	O
use	O
of	O
CIMZIA	O
in	O
this	O
combination	O
.	O
	
However	O
,	O
prescribers	O
and	O
patients	O
should	O
be	O
aware	O
that	O
patients	O
'	O
ability	O
to	O
assess	O
their	O
own	O
driving	O
competence	O
,	O
as	O
well	O
as	O
their	O
ability	O
to	O
assess	O
the	O
degree	O
of	O
somnolence	O
caused	O
by	O
HORIZANT	O
,	O
can	O
be	O
imperfect	O
.	O
	
In	O
the	O
event	O
of	O
a	O
serious	O
reaction	O
,	O
administration	O
of	O
BENLYSTA	O
must	O
be	O
discontinued	O
immediately	O
and	O
appropriate	O
medical	O
therapy	O
administered	O
.	O
	
In	O
those	O
patients	O
treated	O
with	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
who	O
reported	O
somnolence	B
(	O
10	O
%	O
)	O
,	O
the	O
somnolence	B
persisted	O
during	O
treatment	O
in	O
about	O
27	O
%	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
were	O
hyperglycemia	B
,	O
lymphopenia	B
,	O
decreased	B
hemoglobin	I
,	O
hypophosphatemia	B
,	O
increased	B
alkaline	I
phosphatase	I
,	O
neutropenia	B
,	O
increased	B
aspartate	I
transaminase	I
)	O
,	O
potassium	B
decreased	I
,	O
and	O
thrombocytopenia	B
.	O
	
Exacerbation	O
Trial	O
In	O
a	O
24-	O
to	O
76-week	O
trial	O
,	O
subjects	O
received	O
BREO	O
ELLIPTA	O
100/25	O
(	O
n	O
=	O
1,009	O
)	O
or	O
fluticasone	O
furoate	O
100	O
mcg	O
(	O
n	O
=	O
1,010	O
)	O
(	O
Trial	O
5	O
)	O
.	O
	
(	O
5.6	O
)	O
*	O
Not	O
recommended	O
in	O
pancreatic	O
or	O
gastric	O
anastomosis	O
.	O
	
Pooled	O
analyses	O
of	O
199	O
placebo-controlled	O
clinical	O
trials	O
(	O
monotherapy	O
and	O
adjunctive	O
therapy	O
)	O
of	O
11	O
different	O
AEDs	O
showed	O
that	O
patients	O
randomized	O
to	O
1	O
of	O
the	O
AEDs	O
had	O
approximately	O
twice	O
the	O
risk	O
[	O
adjusted	O
relative	O
risk	O
1.8	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.2	O
,	O
2.7	O
]	O
of	O
suicidal	B
thinking	I
compared	O
with	O
patients	O
randomized	O
to	O
placebo	O
.	O
	
Creatine	O
Kinase	O
(	O
CK	O
)	O
:	O
The	O
proportion	O
of	O
adult	O
patients	O
with	O
CK	B
elevations	I
>	O
3	O
times	O
ULN	O
at	O
any	O
time	O
were	O
6.4	O
%	O
and	O
11.1	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
,	O
as	O
compared	O
to	O
6.7	O
%	O
for	O
placebo-treated	O
patients	O
in	O
short-term	O
,	O
fixed-dose	O
trials	O
in	O
schizophrenia	O
and	O
bipolar	O
mania	O
.	O
	
Extrapyramidal	O
Symptoms	O
:	O
In	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
adult	O
trials	O
,	O
data	O
was	O
objectively	O
collected	O
on	O
the	O
Simpson	O
Angus	O
Rating	O
Scale	O
for	O
extrapyramidal	B
symptoms	I
(	O
EPS	B
)	O
,	O
the	O
Barnes	O
Akathisia	O
Scale	O
(	O
for	O
akathisia	B
)	O
and	O
the	O
Assessments	O
of	O
Involuntary	O
Movement	O
Scales	O
(	O
for	O
dyskinesias	B
)	O
.	O
	
5.2	O
Arterial	O
Thromboembolic	O
Events	O
In	O
clinical	O
trials	O
,	O
arterial	B
thromboembolic	I
events	I
have	O
been	O
reported	O
,	O
including	O
deaths	B
.	O
	
The	O
patients	O
received	O
a	O
median	O
of	O
5	O
(	O
range	O
1-20	O
)	O
prior	O
regimens	O
.	O
	
What	O
should	O
I	O
tell	O
my	O
healthcare	O
provider	O
before	O
taking	O
DUAVEE	O
?	O
	
The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O
	
Table	O
2	O
includes	O
adverse	O
reactions	O
reported	O
in	O
Study	O
2	O
that	O
occurred	O
at	O
a	O
>	O
=	O
2	O
%	O
higher	O
frequency	O
in	O
the	O
XTANDI	O
arm	O
compared	O
to	O
the	O
placebo	O
arm	O
.	O
	
5.4	O
Avoid	O
Use	O
with	O
Other	O
Antiretroviral	O
Products	O
STRIBILD	O
is	O
indicated	O
for	O
use	O
as	O
a	O
complete	O
regimen	O
for	O
the	O
treatment	O
of	O
HIV-1	O
infection	O
and	O
coadministration	O
with	O
other	O
antiretroviral	O
products	O
is	O
not	O
recommended	O
.	O
	
5.8	O
Hematologic	O
Cytopenias	O
There	O
have	O
been	O
post-marketing	O
reports	O
of	O
pancytopenia	B
,	O
leukopenia	B
,	O
neutropenia	B
,	O
aplastic	B
anemia	I
,	O
and	O
thrombocytopenia	B
in	O
patients	O
receiving	O
TNF-blockers	O
.	O
	
Medical	O
history	O
of	O
hypertension	O
was	O
balanced	O
between	O
arms	O
.	O
	
5.6	O
Cardiovascular	O
Effects	O
ARCAPTA	O
NEOHALER	O
,	O
like	O
other	O
beta2-agonists	O
,	O
can	O
produce	O
a	O
clinically	O
significant	O
cardiovascular	B
effect	I
in	O
some	O
patients	O
as	O
measured	O
by	O
increases	B
in	I
pulse	I
rate	I
,	O
or	O
symptoms	O
.	O
	
5.3	O
Excessive	O
Use	O
of	O
ARCAPTA	O
NEOHALER	O
and	O
Use	O
with	O
Other	O
Long-Acting	O
Beta2-Agonists	O
As	O
with	O
other	O
inhaled	O
beta2-adrenergic	O
drugs	O
,	O
ARCAPTA	O
NEOHALER	O
should	O
not	O
be	O
used	O
more	O
often	O
,	O
at	O
higher	O
doses	O
than	O
recommended	O
,	O
or	O
in	O
conjunction	O
with	O
other	O
medications	O
containing	O
long-acting	O
beta2-agonists	O
,	O
as	O
an	O
overdose	O
may	O
result	O
.	O
	
Table	O
1	O
contains	O
the	O
treatment	O
emergent	O
adverse	O
reactions	O
,	O
regardless	O
of	O
attribution	O
,	O
that	O
were	O
reported	O
in	O
>	O
=	O
5	O
%	O
of	O
patients	O
in	O
either	O
treatment	O
group	O
in	O
the	O
randomized	O
CLL	O
clinical	O
study	O
.	O
	
5.2	O
Risk	O
of	O
Acute	O
Respiratory	O
Complications	O
Patients	O
with	O
acute	O
febrile	O
or	O
respiratory	O
illness	O
at	O
the	O
time	O
of	O
Vimizim	O
infusion	O
may	O
be	O
at	O
higher	O
risk	O
of	O
life-threatening	O
complications	O
from	O
hypersensitivity	B
reactions	I
.	O
	
Permanently	O
discontinue	O
YERVOY	O
in	O
patients	O
with	O
severe	O
enterocolitis	O
and	O
initiate	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
of	O
prednisone	O
or	O
equivalent	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
a	O
median	O
exposure	O
to	O
COMETRIQ	O
for	O
204	O
days	O
.	O
	
Should	O
the	O
physician	O
decide	O
to	O
administer	O
anticoagulation	O
in	O
the	O
context	O
of	O
epidural	O
or	O
spinal	O
anesthesia/analgesia	O
or	O
lumbar	O
puncture	O
,	O
monitor	O
frequently	O
to	O
detect	O
any	O
signs	O
or	O
symptoms	O
of	O
neurological	O
impairment	O
,	O
such	O
as	O
midline	O
back	O
pain	O
,	O
sensory	O
and	O
motor	O
deficits	O
(	O
numbness	O
,	O
tingling	O
,	O
or	O
weakness	O
in	O
lower	O
limbs	O
)	O
,	O
bowel	O
and/or	O
bladder	O
dysfunction	O
.	O
	
Use	O
caution	O
when	O
treating	O
patients	O
whose	O
underlying	O
medical	O
conditions	O
might	O
be	O
compromised	O
by	O
increases	O
in	O
blood	O
pressure	O
,	O
hypokalemia	O
or	O
fluid	O
retention	O
,	O
e.g.	O
,	O
those	O
with	O
heart	O
failure	O
,	O
recent	O
myocardial	O
infarction	O
or	O
ventricular	O
arrhythmia	O
.	O
	
Approximately	O
81	O
%	O
of	O
these	O
local	O
reactions	O
resolved	O
without	O
intervention	O
within	O
4	O
weeks	O
of	O
XIAFLEX	O
injections	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
signs	O
of	O
peripheral	O
motor	O
and	O
sensory	O
neuropathy	O
.	O
	
Interrupt	O
Ferriprox	O
therapy	O
if	O
neutropenia	O
develops	O
(	O
ANC	O
<	O
1.5	O
x	O
10	O
9	O
/L	O
)	O
.	O
	
These	O
include	O
cases	O
of	O
Stevens-Johnson	B
syndrome	I
,	O
toxic	B
epidermal	I
necrolysis	I
and	O
erythema	B
multiforme	I
.	O
	
Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
from	O
first	O
drug	O
intake	O
to	O
event	O
date	O
,	O
date	O
of	O
last	O
drug	O
intake	O
+	O
2	O
,	O
death	O
date	O
(	O
whatever	O
occurred	O
first	O
)	O
across	O
all	O
treated	O
subjects	O
divided	O
by	O
365.25	O
.	O
	
Anyone	O
considering	O
prescribing	O
ONFI	O
or	O
any	O
other	O
AED	O
must	O
balance	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
or	O
behavior	O
with	O
the	O
risk	O
of	O
untreated	O
illness	O
.	O
	
These	O
were	O
commonly	O
dyspepsia	B
(	O
including	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
pain	I
,	O
abdominal	B
discomfort	I
,	O
and	O
epigastric	B
discomfort	I
)	O
and	O
gastritis-like	O
symptoms	O
(	O
including	O
GERD	B
,	O
esophagitis	B
,	O
erosive	B
gastritis	I
,	O
gastric	B
hemorrhage	I
,	O
hemorrhagic	B
gastritis	I
,	O
hemorrhagic	B
erosive	I
gastritis	I
,	O
and	O
gastrointestinal	B
ulcer	I
)	O
.	O
	
Based	O
on	O
the	O
severity	O
of	O
the	O
adverse	O
drug	O
reaction	O
,	O
withhold	O
ZYKADIA	O
with	O
resumption	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Patients	O
with	O
alanine	O
aminotransferase	O
or	O
aspartate	O
aminotransferase	O
>	O
3	O
*	O
ULN	O
(	O
upper	O
limit	O
of	O
normal	O
)	O
experienced	O
a	O
higher	O
incidence	O
of	O
Grade	O
4	O
neutropenia	B
and	O
febrile	B
neutropenia	I
than	O
patients	O
with	O
normal	O
aminotransferase	O
levels	O
.	O
	
Among	O
patients	O
in	O
Study	O
3	O
who	O
reported	O
no	O
prior	O
exposure	O
to	O
XIAFLEX	O
,	O
97	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-I	O
and	O
AUX-II	O
after	O
two	O
concurrent	O
doses	O
of	O
XIAFLEX	O
0.58	O
mg	O
(	O
total	O
dose	O
of	O
1.16	O
mg	O
)	O
in	O
the	O
same	O
hand	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
20	O
%	O
)	O
reported	O
in	O
the	O
two	O
randomized	O
clinical	O
trials	O
that	O
occurred	O
more	O
commonly	O
(	O
>	O
=2	O
%	O
)	O
in	O
the	O
abiraterone	O
acetate	O
arm	O
were	O
anemia	B
,	O
elevated	B
alkaline	I
phosphatase	I
,	O
hypertriglyceridemia	B
,	O
lymphopenia	B
,	O
hypercholesterolemia	B
,	O
hyperglycemia	B
,	O
elevated	B
AST	I
,	O
hypophosphatemia	B
,	O
elevated	B
ALT	I
and	O
hypokalemia	B
.	O
	
Controlled	O
Studies	O
with	O
Rheumatoid	O
Arthritis	O
CIMZIA	O
was	O
studied	O
primarily	O
in	O
placebo-controlled	O
trials	O
and	O
in	O
long-term	O
follow-up	O
studies	O
.	O
	
Table	O
1	O
:	O
Change	O
in	O
Fasting	O
Glucose	O
FANAPT	O
Placebo	O
24	O
mg/day	O
Mean	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
n=114	O
n=228	O
Serum	O
Glucose	O
Change	O
from	O
Baseline	O
-0.5	O
6.6	O
Proportion	O
of	O
Patients	O
with	O
Shifts	O
Serum	O
Glucose	O
Normal	O
to	O
High	O
2.5	O
%	O
10.7	O
%	O
(	O
<	O
100	O
mg/dL	O
to	O
>	O
=126	O
mg/dL	O
)	O
(	O
2/80	O
)	O
(	O
18/169	O
)	O
Pooled	O
analyses	O
of	O
glucose	O
data	O
from	O
clinical	O
studies	O
including	O
longer	O
term	O
trials	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
*	O
Palmar-plantar	B
Erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
:	O
Interrupt	O
COMETRIQ	O
,	O
decrease	O
dose	O
.	O
	
Abrupt	O
discontinuation	O
or	O
dose	O
reduction	O
has	O
been	O
associated	O
with	O
the	O
appearance	O
of	O
new	O
symptoms	O
that	O
include	O
dizziness	B
,	O
nausea	B
,	O
headache	B
,	O
irritability	B
,	O
insomnia	B
,	O
diarrhea	B
,	O
anxiety	B
,	O
fatigue	B
,	O
abnormal	B
dreams	I
,	O
and	O
hyperhidrosis	B
.	O
	
(	O
5.4	O
)	O
item	O
{	O
Viral	O
infections-	O
Employment	O
of	O
a	O
corticosteroid	O
medication	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
a	O
history	O
of	O
herpes	O
simplex	O
requires	O
great	O
caution	O
.	O
	
Caution	O
should	O
be	O
exercised	O
in	O
treating	O
patients	O
with	O
pre-existing	O
hypertension	O
,	O
cardiovascular	O
,	O
or	O
cerebrovascular	O
conditions	O
that	O
might	O
be	O
compromised	O
by	O
increases	O
in	O
blood	O
pressure	O
.	O
	
5.14	O
Glaucoma	O
and	O
Cataracts	O
Glaucoma	B
,	O
increased	B
intraocular	I
pressure	I
,	O
and	O
cataracts	B
have	O
been	O
reported	O
in	O
patients	O
with	O
COPD	O
or	O
asthma	O
following	O
the	O
long-term	O
administration	O
of	O
inhaled	O
corticosteroids	O
.	O
	
Advise	O
patients	O
with	O
myelosuppression	O
following	O
TREANDA	O
treatment	O
to	O
contact	O
a	O
physician	O
if	O
they	O
have	O
symptoms	O
or	O
signs	O
of	O
infection	O
.	O
	
(	O
6.1	O
)	O
*	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
for	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
are	O
pyrexia	B
,	O
chills	B
,	O
fatigue	B
,	O
rash	B
,	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
abdominal	B
pain	I
,	O
peripheral	B
edema	I
,	O
cough	B
,	O
headache	B
,	O
arthralgia	B
,	O
night	B
sweats	I
,	O
decreased	B
appetite	I
,	O
constipation	B
,	O
and	O
myalgia	B
.	O
	
In	O
the	O
clinical	O
trials	O
,	O
blood	O
counts	O
were	O
monitored	O
every	O
week	O
initially	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Valeant	O
Pharmaceuticals	O
North	O
America	O
LLC	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Patients	O
were	O
randomized	O
to	O
three	O
treatment	O
groups	O
:	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
(	O
n=58	O
)	O
,	O
Vimizim	O
2	O
mg/kg	O
once	O
every	O
other	O
week	O
(	O
n=59	O
)	O
,	O
or	O
placebo	O
(	O
n=59	O
)	O
.	O
	
Approximately	O
50	O
%	O
of	O
the	O
subjects	O
were	O
male	O
and	O
the	O
ethnic	O
distribution	O
was	O
60	O
%	O
Caucasian	O
,	O
30	O
%	O
Asian	O
,	O
6	O
%	O
Hispanic	O
,	O
2	O
%	O
Black	O
,	O
and	O
3	O
%	O
patients	O
of	O
other	O
ethnic	O
groups	O
.	O
	
This	O
finding	O
with	O
salmeterol	O
is	O
considered	O
a	O
class	O
effect	O
of	O
LABA	O
,	O
including	O
indacaterol	O
,	O
the	O
active	O
ingredient	O
in	O
ARCAPTA	O
NEOHALER	O
.	O
	
(	O
2.4	O
,	O
5.10	O
)	O
*	O
Hepatic	B
Toxicity	I
and	O
Hepatic	B
Failure	I
:	O
Monitor	O
liver	O
enzymes	O
.	O
	
(	O
5.9	O
)	O
*	O
Monitor	O
for	O
proteinuria	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
.	O
	
Because	O
of	O
the	O
risk	O
of	O
seizure	O
associated	O
with	O
XTANDI	O
use	O
,	O
patients	O
should	O
be	O
advised	O
of	O
the	O
risk	O
of	O
engaging	O
in	O
any	O
activity	O
where	O
sudden	O
loss	O
of	O
consciousness	O
could	O
cause	O
serious	O
harm	O
to	O
themselves	O
or	O
others	O
.	O
	
The	O
symptoms	O
are	O
consistent	O
with	O
the	O
mechanism	O
of	O
action	O
of	O
botulinum	O
toxin	O
and	O
may	O
include	O
asthenia	B
,	O
generalized	B
muscle	I
weakness	I
,	O
diplopia	B
,	O
blurred	B
vision	I
,	O
ptosis	B
,	O
dysphagia	B
,	O
dysphonia	B
,	O
dysarthria	B
,	O
urinary	B
incontinence	I
,	O
and	O
breathing	B
difficulties	I
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
age	O
>	O
60	O
years	O
,	O
hypertension	O
or	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
has	O
occurred	O
in	O
patients	O
with	O
impaired	O
elimination	O
of	O
GBCAs	O
.	O
	
Of	O
the	O
14	O
patients	O
receiving	O
GILENYA	O
,	O
7	O
patients	O
had	O
2:1	B
AV	I
block	I
(	O
5	O
patients	O
within	O
the	O
first	O
6	O
hours	O
postdose	O
and	O
2	O
patients	O
after	O
6	O
hours	O
postdose	O
)	O
.	O
	
In	O
Study	O
2	O
,	O
1	O
of	O
871	O
(	O
0.1	O
%	O
)	O
chemotherapy-naive	O
patients	O
treated	O
with	O
XTANDI	O
and	O
1	O
of	O
844	O
(	O
0.1	O
%	O
)	O
patients	O
treated	O
with	O
placebo	O
experienced	O
a	O
seizure	B
.	O
	
5.3	O
Congestive	O
Heart	O
Failure	O
Cases	O
of	O
worsening	B
congestive	I
heart	I
failure	I
)	O
and	O
new	B
onset	I
CHF	I
have	O
been	O
reported	O
with	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
.	O
	
Adverse	O
events	O
that	O
led	O
to	O
treatment	O
discontinuation	O
and	O
occurred	O
in	O
more	O
than	O
1	O
%	O
of	O
patients	O
taking	O
GILENYA	O
0.5	O
mg	O
were	O
serum	B
transaminase	I
elevations	I
(	O
4.7	O
%	O
compared	O
to	O
1	O
%	O
on	O
placebo	O
)	O
and	O
basal	B
cell	I
carcinoma	I
(	O
1	O
%	O
compared	O
to	O
0.5	O
%	O
on	O
placebo	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
3	O
%	O
;	O
2	O
or	O
more	O
patients	O
)	O
observed	O
in	O
alglucosidase	O
alfa-treated	O
patients	O
were	O
hypersensitivity	B
reactions	I
and	O
included	O
anaphylaxis	B
,	O
headache	B
,	O
nausea	B
,	O
urticaria	B
,	O
dizziness	B
,	O
chest	B
discomfort	I
,	O
vomiting	B
,	O
hyperhidrosis	B
,	O
flushing/feeling	O
hot	B
,	O
increased	B
blood	I
pressure	I
,	O
paresthesia	B
,	O
pyrexia	B
,	O
local	B
swelling	I
,	O
diarrhea	B
,	O
pruritus	B
,	O
rash	B
,	O
and	O
throat	B
tightness	I
.	O
	
Evaluate	O
dyspnea	O
to	O
exclude	O
cardiopulmonary	O
conditions	O
including	O
cardiac	O
failure	O
and	O
pulmonary	O
syndromes	O
.	O
	
In	O
some	O
cases	O
of	O
anaphylactic	B
reactions	I
,	O
epinephrine	O
was	O
administered	O
.	O
	
b	O
Includes	O
diarrhea	B
,	O
enteritis	B
,	O
enterocolitis	B
,	O
colitis	B
,	O
defecation	B
urgency	I
,	O
and	O
steatorrhea	B
.	O
	
5.5	O
Keratitis	O
Keratitis	B
,	O
characterized	O
as	O
worsening	B
eye	I
inflammation	I
,	O
lacrimation	B
,	O
light	B
sensitivity	I
,	O
blurred	B
vision	I
,	O
eye	B
pain	I
,	O
and/or	O
red	B
eye	I
occurred	O
in	O
0.8	O
%	O
of	O
patients	O
treated	O
with	O
GILOTRIF	O
among	O
3865	O
patients	O
across	O
clinical	O
trials	O
.	O
	
No	O
cases	O
of	O
transmission	O
of	O
viral	O
diseases	O
or	O
CJD	O
have	O
ever	O
been	O
reported	O
for	O
albumin	O
.	O
	
(	O
2.1	O
,	O
5.7	O
,	O
14.1	O
)	O
*	O
Immunizations	O
:	O
avoid	O
use	O
of	O
live	O
vaccines	O
during	O
treatment	O
.	O
	
If	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
do	O
not	O
modify	O
the	O
dose	O
of	O
TAFINLAR	O
.	O
	
Avoid	O
use	O
of	O
PRADAXA	O
and	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
(	O
CrCl	O
15-30	O
mL/min	O
)	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Symptomatic	O
treatment	O
employed	O
in	O
clinical	O
trials	O
included	O
steroid	O
and	O
mydriatic	O
ophthalmic	O
drops	O
.	O
	
In	O
Study	O
1	O
,	O
VORAXAZE-related	O
adverse	O
reactions	O
were	O
collected	O
on	O
a	O
flow	O
sheet	O
with	O
a	O
daily	O
log	O
of	O
adverse	O
reactions	O
characterized	O
as	O
``	O
glucarpidase	O
toxicity	O
.	O
''	O
	
(	O
5.6	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Post-Transplant	B
Lymphoproliferative	I
Disorder	I
(	O
PTLD	B
)	O
:	O
increased	O
risk	O
,	O
predominantly	O
involving	O
the	O
CNS	O
;	O
monitor	O
for	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
and	O
symptoms	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
Clinical	O
Trials	O
of	O
Vizamyl	O
(	O
N	O
=	O
761	O
subjects	O
)	O
Adverse	O
Reaction	O
N	O
(	O
percent	O
of	O
patients	O
)	O
Flushing	B
16	O
(	O
2	O
%	O
)	O
Increased	B
blood	I
pressure	I
13	O
(	O
2	O
%	O
)	O
Headache	B
10	O
(	O
1	O
%	O
)	O
Nausea	B
8	O
(	O
1	O
%	O
)	O
Dizziness	B
8	O
(	O
1	O
%	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
reactions	I
:	O
Ask	O
patients	O
about	O
prior	O
reactions	O
to	O
Vizamyl	O
.	O
	
These	O
two	O
trials	O
also	O
included	O
a	O
total	O
of	O
403	O
patients	O
treated	O
with	O
a	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Hepatic	O
Decompensation	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	O
C	O
In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
PROMACTA	O
in	O
combination	O
with	O
interferon	O
and	O
ribavirin	O
may	O
increase	O
the	O
risk	O
of	O
hepatic	B
decompensation	I
.	O
	
In	O
patients	O
with	O
a	O
pre-existing	O
low	O
WBC/ANC	O
or	O
drug-induced	O
leukopenia/neutropenia	O
,	O
perform	O
a	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
.	O
	
SPRINT-2	O
(	O
subjects	O
who	O
were	O
previously	O
untreated	O
)	O
and	O
RESPOND-2	O
(	O
subjects	O
who	O
had	O
failed	O
previous	O
therapy	O
)	O
evaluated	O
the	O
use	O
of	O
VICTRELIS	O
800	O
mg	O
three	O
times	O
daily	O
in	O
combination	O
with	O
PegIntron/REBETOL	O
with	O
a	O
four-week	O
lead-in	O
period	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
PegIntron/REBETOL	O
alone	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
5.2	O
Acute	O
Pancreatitis	O
In	O
clinical	O
trials	O
,	O
acute	B
pancreatitis	I
has	O
been	O
reported	O
in	O
association	O
with	O
TANZEUM	O
.	O
	
(	O
N=134	O
)	O
40	O
mg	O
daily	O
(	O
N=757	O
)	O
80	O
mg	O
daily	O
(	O
N=1279	O
)	O
(	O
N=1277	O
)	O
Liver	B
Function	I
Abnormalities	I
0.7	O
%	O
6.6	O
%	O
4.6	O
%	O
4.2	O
%	O
Nausea	B
0.7	O
%	O
1.1	O
%	O
1.3	O
%	O
0.8	O
%	O
Arthralgia	B
0	O
%	O
1.1	O
%	O
0.7	O
%	O
0.7	O
%	O
Rash	B
0.7	O
%	O
0.5	O
%	O
1.6	O
%	O
1.6	O
%	O
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
discontinuation	O
from	O
therapy	O
was	O
liver	B
function	I
abnormalities	I
in	O
1.8	O
%	O
of	O
ULORIC	O
40	O
mg	O
,	O
1.2	O
%	O
of	O
ULORIC	O
80	O
mg	O
,	O
and	O
in	O
0.9	O
%	O
of	O
allopurinol-treated	O
subjects	O
.	O
	
You	O
can	O
ask	O
your	O
pharmacist	O
or	O
healthcare	O
provider	O
for	O
information	O
about	O
DUAVEE	O
that	O
is	O
written	O
for	O
health	O
professionals	O
.	O
	
Do	O
not	O
restart	O
if	O
confirmed	O
.	O
	
If	O
anemia	O
develops	O
during	O
or	O
after	O
treatment	O
with	O
Teflaro	O
,	O
drug-induced	O
hemolytic	O
anemia	O
should	O
be	O
considered	O
.	O
	
The	O
most	O
serious	O
adverse	O
reactions	O
reported	O
with	O
alglucosidase	O
alfa	O
treatment	O
included	O
anaphylaxis	B
and	O
acute	B
cardiorespiratory	I
failure	I
.	O
	
Renal	O
and	O
Urinary	O
Disorders	O
:	O
Interstitial	B
nephritis	I
.	O
	
Hepatotoxicity	B
may	O
reoccur	O
if	O
PROMACTA	O
is	O
reinitiated	O
.	O
	
Risk	O
factors	O
for	O
arterial	O
vascular	O
disease	O
(	O
for	O
example	O
,	O
hypertension	O
,	O
diabetes	O
mellitus	O
,	O
tobacco	O
use	O
,	O
hypercholesterolemia	O
,	O
and	O
obesity	O
)	O
and/or	O
VTE	O
(	O
for	O
example	O
,	O
personal	O
history	O
or	O
family	O
history	O
of	O
VTE	O
,	O
obesity	O
,	O
and	O
systemic	O
lupus	O
erythematosus	O
)	O
should	O
be	O
managed	O
appropriately	O
.	O
	
If	O
the	O
potential	O
benefit	O
for	O
reinitiating	O
treatment	O
with	O
PROMACTA	O
is	O
considered	O
to	O
outweigh	O
the	O
risk	O
for	O
hepatotoxicity	O
,	O
then	O
consider	O
cautiously	O
reintroducing	O
PROMACTA	O
and	O
measure	O
serum	O
liver	O
tests	O
weekly	O
during	O
the	O
dose	O
adjustment	O
phase	O
.	O
	
BRAF	O
V600E	O
or	O
V600K	O
Unresectable	O
or	O
Metastatic	O
Melanoma	O
:	O
The	O
safety	O
of	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
was	O
evaluated	O
in	O
Trial	O
2	O
and	O
other	O
trials	O
consisting	O
of	O
a	O
total	O
of	O
202	O
patients	O
with	O
BRAF	O
V600	O
mutation-positive	O
unresectable	O
or	O
metastatic	O
melanoma	O
who	O
received	O
TAFINLAR	O
150	O
mg	O
orally	O
twice	O
daily	O
in	O
combination	O
with	O
trametinib	O
2	O
mg	O
orally	O
once	O
daily	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
Diagnostic	O
studies	O
including	O
a	O
direct	O
Coombs	O
'	O
test	O
,	O
should	O
be	O
performed	O
.	O
	
Because	O
these	O
reactions	O
may	O
worsen	O
renal	O
function	O
,	O
use	O
caution	O
when	O
initiating	O
or	O
escalating	O
doses	O
of	O
TANZEUM	O
in	O
patients	O
with	O
renal	O
impairment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
A	O
causal	O
relationship	O
to	O
STENDRA	O
is	O
uncertain	O
.	O
	
Ask	O
your	O
healthcare	O
provider	O
for	O
ways	O
to	O
lower	O
your	O
chances	O
of	O
getting	O
heart	O
disease	O
.	O
	
These	O
hypersensitivity	B
reactions	I
included	O
:	O
anaphylaxis	B
,	O
angioedema	B
,	O
hypotension	B
,	O
tachycardia	B
,	O
swollen	B
tongue	I
,	O
dyspnea	B
,	O
wheezing	B
and	O
rash	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
,	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
medical	O
practice	O
.	O
	
*	O
Invasive	B
fungal	I
infections	I
-	O
For	O
patients	O
who	O
develop	O
a	O
systemic	O
illness	O
on	O
SIMPONI	O
ARIA	O
,	O
consider	O
empiric	O
antifungal	O
therapy	O
for	O
those	O
who	O
reside	O
in	O
or	O
travel	O
to	O
regions	O
where	O
mycoses	O
are	O
endemic	O
(	O
5.1	O
)	O
.	O
	
Consider	O
tuberculosis	O
in	O
the	O
differential	O
diagnosis	O
in	O
patients	O
who	O
develop	O
a	O
new	O
infection	O
during	O
SIMPONI	O
ARIA	O
treatment	O
,	O
especially	O
in	O
patients	O
who	O
have	O
previously	O
or	O
recently	O
traveled	O
to	O
countries	O
with	O
a	O
high	O
prevalence	O
of	O
tuberculosis	O
,	O
or	O
who	O
have	O
had	O
close	O
contact	O
with	O
a	O
person	O
with	O
active	O
tuberculosis	O
.	O
	
For	O
these	O
reasons	O
,	O
the	O
incidence	O
of	O
antibodies	O
to	O
albiglutide	O
can	O
not	O
be	O
directly	O
compared	O
with	O
the	O
incidence	O
of	O
antibodies	O
of	O
other	O
products	O
.	O
	
Doses	O
ranged	O
from	O
6	O
to	O
189	O
Units/kg	O
,	O
with	O
a	O
median	O
dose	O
of	O
50	O
Units/kg	O
.	O
	
Treatment	O
and	O
Reduction	O
in	O
the	O
Risk	O
of	O
Recurrence	O
of	O
Deep	O
Venous	O
Thrombosis	O
and	O
Pulmonary	O
Embolism	O
Avoid	O
use	O
of	O
PRADAXA	O
and	O
concomitant	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
CrCl	O
<	O
50	O
mL/min	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Perform	O
ophthalmological	O
evaluation	O
at	O
any	O
time	O
a	O
patient	O
reports	O
visual	O
disturbances	O
and	O
compare	O
with	O
baseline	O
,	O
if	O
available	O
.	O
	
A	O
theoretical	O
risk	O
for	O
transmission	O
of	O
Creutzfeldt-Jakob	B
disease	I
(	O
CJD	B
)	O
is	O
also	O
considered	O
extremely	O
remote	O
.	O
	
The	O
most	O
common	O
medical	O
interventions	O
required	O
during	O
AFINITOR	O
treatment	O
were	O
for	O
infections	B
,	O
anemia	B
,	O
and	O
stomatitis	B
.	O
	
Caution	O
is	O
warranted	O
when	O
prescribing	O
FANAPT	O
with	O
drugs	O
that	O
inhibit	O
FANAPT	O
metabolism	O
[	O
see	O
Drug	O
Interaction	O
s	O
(	O
7.1	O
)	O
]	O
,	O
and	O
in	O
patients	O
with	O
reduced	O
activity	O
of	O
CYP2D6	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
(	O
5.12	O
)	O
*	O
Priapism	B
:	O
Cases	O
have	O
been	O
reported	O
in	O
association	O
with	O
FANAPT	O
treatment	O
.	O
	
In	O
patients	O
who	O
develop	O
severe	O
hepatic	O
impairment	O
while	O
taking	O
GILOTRIF	O
,	O
treatment	O
should	O
be	O
discontinued	O
.	O
	
c	O
Includes	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
pulmonary	B
fibrosis	I
and	O
restrictive	B
pulmonary	I
disease	I
.	O
	
Posterior	O
reversible	O
encephalopathy	O
syndrome	O
(	O
PRES	O
)	O
,	O
formerly	O
termed	O
Reversible	O
Posterior	O
Leukoencephalopathy	O
Syndrome	O
(	O
RPLS	O
)	O
,	O
is	O
a	O
neurological	O
disorder	O
which	O
can	O
present	O
with	O
seizure	O
,	O
headache	O
,	O
lethargy	O
,	O
confusion	O
,	O
blindness	O
,	O
altered	O
consciousness	O
,	O
and	O
other	O
visual	O
and	O
neurological	O
disturbances	O
,	O
along	O
with	O
hypertension	O
,	O
and	O
the	O
diagnosis	O
is	O
confirmed	O
by	O
neuro-radiological	O
imaging	O
(	O
MRI	O
)	O
.	O
	
No	O
association	O
between	O
anti-icatibant	O
antibodies	O
and	O
efficacy	O
was	O
observed	O
.	O
	
ARCAPTA	O
NEOHALER	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
asthma	O
[	O
See	O
B	O
oxed	O
Warning	O
and	O
W	O
arning	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
observed	O
in	O
the	O
other	O
trials	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
confirmatory	O
trials	O
.	O
	
Before	O
initiating	O
therapy	O
with	O
ZERBAXA	O
,	O
make	O
careful	O
inquiry	O
about	O
previous	O
hypersensitivity	O
reactions	O
to	O
other	O
cephalosporins	O
,	O
penicillins	O
,	O
or	O
other	O
beta-lactams	O
.	O
	
Patients	O
experiencing	O
seizure	B
were	O
permanently	O
discontinued	O
from	O
therapy	O
and	O
all	O
seizure	O
events	O
resolved	O
.	O
	
System	O
Organ	O
Class/Preferred	O
Term	O
Placebo	O
N=203	O
%	O
SAPHRIS	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily*	O
N=379	O
%	O
Gastrointestinal	O
disorders	O
Dry	B
mouth	I
1	O
3	O
Dyspepsia	B
2	O
4	O
Oral	B
hypoesthesia	I
<	O
1	O
4	O
Toothache	B
2	O
3	O
General	O
disorders	O
Fatigue	B
2	O
4	O
Investigations	O
Increased	B
weight	I
<	O
1	O
5	O
Metabolism	O
disorders	O
Increased	B
appetite	I
1	O
4	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Arthralgia	B
1	O
3	O
Pain	B
in	I
extremity	I
<	O
1	O
2	O
Nervous	O
system	O
disorders	O
Akathisia	B
2	O
4	O
Dizziness	B
3	O
11	O
Dysgeusia	B
<	O
1	O
3	O
Headache	B
11	O
12	O
Other	O
extrapyramidal	B
symptoms	I
(	O
excluding	O
akathisia	B
)	O
2	O
7	O
Somnolence	B
?	O
	
In	O
placebo-controlled	O
trials	O
,	O
the	O
most	O
frequent	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=10	O
%	O
and	O
>	O
placebo	O
)	O
for	O
GILENYA	O
0.5	O
mg	O
were	O
headache	B
,	O
liver	B
transaminase	I
elevation	I
,	O
diarrhea	B
,	O
cough	B
,	O
influenza	B
,	O
sinusitis	B
,	O
back	B
pain	I
,	O
abdominal	B
pain	I
,	O
and	O
pain	B
in	I
extremity	I
.	O
	
(	O
2.1	O
)	O
Monitor	O
for	O
TLS	O
,	O
including	O
uric	O
acid	O
levels	O
and	O
treat	O
promptly	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
a	O
6-dose	O
regimen	O
of	O
Coartem	O
Tablets	O
in	O
1,979	O
patients	O
including	O
647	O
adults	O
(	O
older	O
than	O
16	O
years	O
)	O
and	O
1,332	O
children	O
(	O
16	O
years	O
and	O
younger	O
)	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Gastrointestinal	O
Toxicity	O
Diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
and	O
abdominal	B
pain	I
occur	O
with	O
BOSULIF	O
treatment	O
.	O
	
Data	O
from	O
a	O
large	O
placebo-controlled	O
US	O
study	O
that	O
compared	O
the	O
safety	O
of	O
another	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonist	O
(	O
salmeterol	O
)	O
or	O
placebo	O
added	O
to	O
usual	O
asthma	O
therapy	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
patients	O
receiving	O
salmeterol	O
.	O
	
Table	O
4	O
identifies	O
the	O
clinically	O
relevant	O
or	O
severe	O
Grade	O
3/4	O
laboratory	O
test	O
abnormalities	O
for	O
the	O
Phase	O
1/2	O
CML	O
safety	O
population	O
.	O
	
All	O
patients	O
were	O
treated	O
with	O
antihistamines	O
prior	O
to	O
each	O
infusion	O
.	O
	
Patients	O
with	O
hypovolemia	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
changes	O
.	O
	
The	O
data	O
described	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
reflect	O
exposure	O
to	O
INLYTA	O
in	O
359	O
patients	O
with	O
advanced	O
RCC	O
who	O
participated	O
in	O
a	O
randomized	O
clinical	O
study	O
versus	O
sorafenib	O
[	O
seeClinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
In	O
the	O
event	O
of	O
treatment-related	O
myelosuppression	O
,	O
monitor	O
leukocytes	O
,	O
platelets	O
,	O
hemoglobin	O
(	O
Hgb	O
)	O
,	O
and	O
neutrophils	O
frequently	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
in	O
patients	O
with	O
B-cell	O
malignancies	O
(	O
MCL	O
,	O
CLL	O
,	O
WM	O
)	O
were	O
thrombocytopenia	B
,	O
neutropenia	B
,	O
diarrhea	B
,	O
anemia	B
,	O
fatigue	B
,	O
musculoskeletal	B
pain	I
,	O
bruising	B
,	O
nausea	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
and	O
rash	B
.	O
	
*	O
Dulaglutide	O
causes	O
thyroid	B
C-cell	I
tumors	I
in	O
rats	O
.	O
	
5.7	O
Discontinuation	O
Syndrome	O
Discontinuation	O
symptoms	O
have	O
been	O
systematically	O
and	O
prospectively	O
evaluated	O
in	O
patients	O
treated	O
with	O
PRISTIQ	O
during	O
clinical	O
studies	O
in	O
Major	O
Depressive	O
Disorder	O
.	O
	
Vascular	O
disorders	O
:	O
Thrombophlebitis	B
,	O
vasculitis	B
.	O
	
Trial	O
1	O
included	O
197	O
control-treated	O
patients	O
and	O
463	O
SIMPONI	O
ARIA-treated	O
patients	O
(	O
which	O
includes	O
control-treated	O
patients	O
who	O
switched	O
to	O
SIMPONI	O
ARIA	O
at	O
Week	O
16	O
)	O
.	O
	
Study	O
1	O
:	O
Metastatic	O
CRPC	O
Following	O
Chemotherapy	O
Study	O
1	O
enrolled	O
1195	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
received	O
prior	O
docetaxel	O
chemotherapy	O
.	O
	
Patients	O
with	O
bilirubin	O
>	O
1.5	O
*	O
ULN	O
also	O
had	O
a	O
higher	O
incidence	O
of	O
Grade	O
4	O
neutropenia	B
and	O
febrile	B
neutropenia	I
.	O
	
Monitor	O
and	O
manage	O
patients	O
using	O
standards	O
of	O
care	O
,	O
including	O
anti-diarrheals	O
,	O
anti-emetics	O
,	O
or	O
fluid	O
replacement	O
,	O
as	O
indicated	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
2338	O
patients	O
to	O
FARXIGA	O
with	O
a	O
mean	O
exposure	O
duration	O
of	O
21	O
weeks	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
patients	O
treated	O
with	O
AMPYRA	O
10	O
mg	O
twice	O
daily	O
,	O
and	O
more	O
frequently	O
than	O
in	O
placebo-treated	O
patients	O
,	O
in	O
controlled	O
clinical	O
trials	O
.	O
	
bAnnual	O
event	O
rate	O
per	O
100	O
pt-years	O
=	O
100	O
*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O
.	O
	
5.3	O
Hematologic	O
Toxicities	O
Prolonged	O
(	O
>	O
=1	O
week	O
)	O
severe	O
neutropenia	B
and	O
Grade	O
3	O
or	O
Grade	O
4	O
thrombocytopenia	B
or	O
anemia	B
can	O
occur	O
with	O
ADCETRIS	O
.	O
	
Blood	O
and	O
lymphatic	O
system	O
disorders	O
:	O
thrombocytosis	B
,	O
pancytopenia	B
.	O
	
Complete	O
blood	O
counts	O
should	O
be	O
monitored	O
prior	O
to	O
each	O
dose	O
of	O
ADCETRIS	O
and	O
more	O
frequent	O
monitoring	O
should	O
be	O
considered	O
for	O
patients	O
with	O
Grade	O
3	O
or	O
4	O
neutropenia	O
.	O
	
5.3	O
Radiation	O
Risks	O
Choline	O
C	O
11	O
Injection	O
contributes	O
to	O
a	O
patient	O
's	O
overall	O
long-term	O
cumulative	O
radiation	O
exposure	O
.	O
	
Dose	O
reduction	O
due	O
to	O
neutropenia	B
was	O
required	O
in	O
12	O
%	O
(	O
62/503	O
)	O
of	O
patients	O
and	O
discontinuation	O
was	O
required	O
in	O
<	O
1	O
%	O
of	O
patients	O
.	O
	
(	O
5.1	O
,	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
ApoPharma	O
Inc.	O
at	O
:	O
Telephone	O
:	O
1-866-949-0995	O
Email	O
:	O
medicalsafety	O
@	O
apopharma.com	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
}	O
}	O
6.1	O
Clinical	O
Trial	O
Experience	O
The	O
following	O
adverse	O
reactions	O
are	O
also	O
discussed	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
Agranulocytosis/Neutropenia	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Avoid	O
in	O
patients	O
with	O
congenital	O
long	O
QT	O
syndrome	O
(	O
5.4	O
)	O
5.1	O
Neutropenia	O
Severe	O
neutropenia	B
(	O
ANC	O
<	O
500/mm	O
3	O
)	O
lasting	O
more	O
than	O
one	O
week	O
occurred	O
in	O
12	O
%	O
(	O
62/503	O
)	O
of	O
patients	O
in	O
Study	O
1	O
,	O
leading	O
to	O
discontinuation	O
in	O
<	O
1	O
%	O
of	O
patients	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
More	O
rapid	O
titration	O
would	O
be	O
expected	O
to	O
increase	O
the	O
rate	O
of	O
orthostatic	O
hypotension	O
and	O
syncope	O
.	O
	
Median	O
exposure	O
in	O
days	O
for	O
pooled	O
studies	O
:	O
1203	O
for	O
NULOJIX	O
recommended	O
regimen	O
and	O
1163	O
for	O
cyclosporine	O
in	O
Studies	O
1	O
and	O
2.	O
?	O
	
Immune-mediated	B
endocrinopathies	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Gilead	O
Sciences	O
,	O
Inc.	O
at	O
1-800-GILEAD-5	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
The	O
protocol	O
included	O
provisions	O
for	O
patients	O
taking	O
placebo	O
to	O
receive	O
treatment	O
with	O
SIMPONI	O
ARIA	O
at	O
Week	O
16	O
or	O
Week	O
24	O
either	O
by	O
patient	O
response	O
(	O
based	O
on	O
uncontrolled	O
disease	O
activity	O
)	O
or	O
by	O
design	O
,	O
so	O
that	O
adverse	O
events	O
can	O
not	O
always	O
be	O
unambiguously	O
attributed	O
to	O
a	O
given	O
treatment	O
.	O
	
Two	O
patients	O
continued	O
treatment	O
with	O
POTIGA	O
and	O
were	O
able	O
to	O
void	O
spontaneously	O
after	O
catheter	O
removal	O
.	O
	
Table	O
2	O
:	O
Change	O
in	O
Glucose	O
Mean	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
3-6	O
months	O
6-12	O
months	O
>	O
12	O
months	O
FANAPT	O
10-16	O
mg/day	O
1.8	O
(	O
N=773	O
)	O
5.4	O
(	O
N=723	O
)	O
5.4	O
(	O
N=425	O
)	O
FANAPT	O
20-24	O
mg/day	O
-3.6	O
(	O
N=34	O
)	O
-9.0	O
(	O
N=31	O
)	O
-18.0	O
(	O
N=20	O
)	O
Dyslipidemia	O
Undesirable	B
alterations	I
in	I
lipids	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
HORIZANT	O
in	O
the	O
treatment	O
of	O
RLS	O
was	O
studied	O
primarily	O
in	O
placebo-controlled	O
trials	O
(	O
n	O
=	O
642	O
)	O
,	O
and	O
in	O
long-term	O
follow-up	O
studies	O
.	O
	
It	O
is	O
unknown	O
whether	O
TRULICITY	O
will	O
cause	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
,	O
as	O
the	O
human	O
relevance	O
of	O
dulaglutide-induced	O
rodent	O
thyroid	B
C-cell	I
tumors	I
has	O
not	O
been	O
determined	O
.	O
	
Serious	O
adverse	O
reactions	O
reported	O
include	O
anaphylactic	B
shock	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
,	O
myelosuppression	B
,	O
gastrointestinal	B
toxicity	I
(	O
diarrhea	B
)	O
,	O
fluid	B
retention	I
,	O
hepatotoxicity	B
and	O
rash	B
.	O
	
Consider	O
measures	O
to	O
prevent	O
severe	O
reactions	O
,	O
including	O
antihistamines	O
,	O
antipyretics	O
and	O
corticosteroids	O
in	O
subsequent	O
cycles	O
in	O
patients	O
who	O
have	O
experienced	O
Grade	O
1	O
or	O
2	O
infusion	O
reactions	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
1	O
%	O
)	O
were	O
ingrown	B
toenails	I
,	O
application	B
site	I
dermatitis	I
,	O
application	B
site	I
vesicles	I
,	O
and	O
application	B
site	I
pain	I
.	O
	
The	O
mean	O
baseline	O
hemoglobin	O
value	O
was	O
approximately	O
14.1	O
g/dL	O
across	O
treatment	O
groups	O
.	O
	
The	O
population	O
was	O
19	O
to	O
97	O
years	O
old	O
,	O
64	O
%	O
were	O
female	O
,	O
and	O
84	O
%	O
were	O
Caucasian	O
;	O
64	O
%	O
were	O
undergoing	O
a	O
surgery	O
that	O
included	O
bowel	O
resection	O
.	O
	
The	O
average	O
age	O
was	O
55	O
years	O
(	O
range	O
from1	O
week	O
to	O
93	O
years	O
)	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
64	O
patients	O
(	O
37.2	O
%	O
)	O
treated	O
with	O
XALKORI	O
and	O
40	O
patients	O
(	O
23.4	O
%	O
)	O
in	O
the	O
chemotherapy	O
arm	O
.	O
	
(	O
5.1	O
)	O
Growth	O
of	O
Resistant	O
Organisms	O
with	O
Prolonged	O
Use	O
.	O
	
5.2	O
Spread	O
of	O
Toxin	O
Effect	O
Post-marketing	O
safety	O
data	O
from	O
DYSPORT	O
(	O
r	O
)	O
and	O
other	O
approved	O
botulinum	O
toxins	O
suggest	O
that	O
botulinum	O
toxin	B
effects	I
may	I
,	I
in	I
some	I
cases	I
,	I
be	I
observed	I
beyond	I
the	I
site	I
of	I
local	I
injection	I
.	O
	
The	O
forms	O
specifically	O
requested	O
information	O
on	O
occurrence	O
of	O
allergic	B
reactions	I
,	O
thrombotic	B
events	I
,	O
hemorrhagic	B
events	I
,	O
hepatobiliary	B
disorders	I
,	O
pancreatic	B
disorders	I
,	O
and	O
hyperglycemia	B
.	O
	
Monitor	O
ALT	O
,	O
AST	O
and	O
bilirubin	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
.	O
	
5.9	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
INVOKANA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Common	O
adverse	O
reactions	O
that	O
occurred	O
in	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
of	O
subjects	O
switching	O
to	O
STRIBILD	O
were	O
nausea	B
(	O
4	O
%	O
)	O
,	O
flatulence	B
(	O
2	O
%	O
)	O
,	O
and	O
headache	B
(	O
2	O
%	O
)	O
.	O
	
A	O
total	O
of	O
2,034	O
subjects	O
with	O
COPD	O
received	O
at	O
least	O
1	O
dose	O
of	O
BREO	O
ELLIPTA	O
100/25	O
,	O
and	O
1,087	O
subjects	O
received	O
a	O
higher	O
strength	O
of	O
fluticasone	O
furoate/vilanterol	O
.	O
	
Treatment	O
with	O
antibacterial	O
agents	O
alters	O
the	O
normal	O
flora	O
of	O
the	O
colon	O
and	O
may	O
permit	O
overgrowth	O
of	O
C	O
.	O
	
Administer	O
dexamethasone	O
prior	O
to	O
Kyprolis	O
to	O
reduce	O
the	O
incidence	O
and	O
severity	O
of	O
infusion	O
reactions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
Table	O
3	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=1	O
%	O
of	O
Subjects	O
on	O
OTEZLA	O
and	O
With	O
Greater	O
Frequency	O
Than	O
in	O
Subjects	O
on	O
Placebo	O
;	O
up	O
to	O
Day	O
112	O
(	O
Week	O
16	O
)	O
*	O
Two	O
subjects	O
treated	O
with	O
OTEZLA	O
experienced	O
serious	O
adverse	O
reaction	O
of	O
abdominal	B
pain	I
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Zylera	O
Pharmaceuticals	O
,	O
LLC	O
.	O
	
Exercise	O
caution	O
in	O
patients	O
with	O
known	O
hypersensitivity	O
to	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
ELIQUIS	O
can	O
cause	O
serious	O
,	O
potentially	O
fatal	B
bleeding	B
.	O
	
If	O
the	O
patient	O
is	O
known	O
or	O
strongly	O
suspected	O
of	O
having	O
had	O
a	O
hypersensitivity	O
reaction	O
to	O
DaTscan	O
,	O
the	O
decision	O
to	O
administer	O
DaTscan	O
should	O
be	O
based	O
upon	O
an	O
assessment	O
of	O
the	O
expected	O
benefits	O
compared	O
to	O
the	O
potential	O
hypersensitivity	O
risks	O
.	O
	
It	O
is	O
unknown	O
whether	O
TANZEUM	O
(	O
r	O
)	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
If	O
anticoagulation	O
with	O
ELIQUIS	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
These	O
studies	O
did	O
not	O
show	O
an	O
increase	O
in	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
antidepressant	O
use	O
in	O
patients	O
over	O
age	O
24	O
;	O
there	O
was	O
a	O
reduction	O
in	O
risk	O
with	O
antidepressant	O
use	O
in	O
patients	O
aged	O
65	O
and	O
older	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
As	O
such	O
,	O
reliability	O
in	O
estimating	O
their	O
frequency	O
or	O
in	O
establishing	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
is	O
not	O
always	O
possible	O
.	O
	
Additional	O
safety	O
information	O
was	O
collected	O
from	O
clinical	O
records	O
submitted	O
by	O
treating	O
physicians	O
.	O
	
Withhold	O
treatment	O
with	O
trametinib	O
and	O
continue	O
TAFINLAR	O
at	O
the	O
same	O
dose	O
if	O
absolute	O
LVEF	O
value	O
decreases	O
by	O
10	O
%	O
from	O
pretreatment	O
values	O
and	O
is	O
less	O
than	O
the	O
lower	O
limit	O
of	O
normal	O
.	O
	
If	O
an	O
infection	O
develops	O
,	O
monitor	O
carefully	O
,	O
and	O
stop	O
CIMZIA	O
if	O
infection	O
becomes	O
serious	O
(	O
5.1	O
)	O
*	O
Invasive	B
fungal	I
infections	I
-	O
for	O
patients	O
who	O
develop	O
a	O
systemic	O
illness	O
on	O
CIMZIA	O
,	O
consider	O
empiric	O
antifungal	O
therapy	O
for	O
those	O
who	O
reside	O
or	O
travel	O
to	O
regions	O
where	O
mycoses	O
are	O
endemic	O
(	O
5.1	O
)	O
*	O
Cases	O
of	O
lymphoma	B
and	O
other	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF	O
blockers	O
(	O
5.2	O
)	O
*	O
Heart	B
failure	I
,	I
worsening	I
may	O
occur	O
(	O
5.3	O
)	O
*	O
Anaphylaxis	B
or	O
serious	O
allergic	B
reactions	I
may	O
occur	O
(	O
5.4	O
)	O
*	O
Hepatitis	B
B	I
virus	I
reactivation	I
-	O
test	O
for	O
HBV	O
infection	O
before	O
starting	O
CIMZIA	O
.	O
	
All	O
patients	O
also	O
received	O
basiliximab	O
induction	O
,	O
mycophenolate	O
mofetil	O
,	O
and	O
corticosteroids	O
.	O
	
C.	O
difficile	O
produces	O
toxins	O
A	O
and	O
B	O
which	O
contribute	O
to	O
the	O
development	O
of	O
CDAD	O
.	O
	
Immunogenicity	O
assay	O
results	O
are	O
highly	O
dependent	O
on	O
several	O
factors	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Stroke	O
In	O
the	O
WHI	O
estrogen-alone	O
substudy	O
,	O
a	O
statistically	O
significant	O
increased	O
risk	O
of	O
stroke	B
was	O
reported	O
in	O
women	O
50	O
to	O
79	O
years	O
of	O
age	O
receiving	O
daily	O
conjugated	O
estrogens	O
(	O
CE	O
)	O
(	O
0.625	O
mg	O
)	O
-alone	O
compared	O
to	O
women	O
in	O
the	O
same	O
age	O
group	O
receiving	O
placebo	O
(	O
45	O
versus	O
33	O
per	O
10,000	O
women-years	O
)	O
.	O
	
In	O
the	O
extension	O
trial	O
,	O
cataracts	B
developed	O
or	O
worsened	O
in	O
4	O
%	O
of	O
patients	O
who	O
underwent	O
ocular	O
examination	O
prior	O
to	O
therapy	O
with	O
PROMACTA	O
.	O
	
5.10	O
Hyperprolactinemia	O
Like	O
other	O
drugs	O
that	O
antagonize	O
dopamine	O
D2receptors	O
,	O
SAPHRIS	O
can	O
elevate	B
prolactin	I
levels	I
,	O
and	O
the	O
elevation	O
can	O
persist	O
during	O
chronic	O
administration	O
.	O
	
In	O
the	O
two	O
controlled	O
clinical	O
trials	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
and	O
thrombocytopenia	O
,	O
cataracts	B
developed	O
or	O
worsened	O
in	O
8	O
%	O
patients	O
treated	O
with	O
PROMACTA	O
and	O
5	O
%	O
patients	O
treated	O
with	O
placebo	O
.	O
	
If	O
hemoglobin	O
is	O
less	O
than	O
10	O
g	O
per	O
dL	O
,	O
a	O
decrease	O
in	O
dosage	O
of	O
ribavirin	O
is	O
recommended	O
;	O
and	O
if	O
hemoglobin	O
is	O
less	O
than	O
8.5	O
g	O
per	O
dL	O
,	O
discontinuation	O
of	O
ribavirin	O
is	O
recommended	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
In	O
Phase	O
2	O
and	O
3	O
clinical	O
studies	O
the	O
following	O
adverse	O
reactions	O
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
and	O
in	O
more	O
than	O
one	O
subject	O
treated	O
with	O
doses	O
ranging	O
from	O
40	O
mg	O
to	O
240	O
mg	O
of	O
ULORIC	O
.	O
	
If	O
serum	O
calcitonin	O
is	O
measured	O
and	O
found	O
to	O
be	O
elevated	O
,	O
the	O
patient	O
should	O
be	O
further	O
evaluated	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
skin	B
reactions	I
have	O
been	O
reported	O
with	O
glycopeptide	O
antibacterial	O
agents	O
,	O
including	O
DALVANCE	O
;	O
exercise	O
caution	O
in	O
patients	O
with	O
known	O
hypersensitivity	O
to	O
glycopeptides	O
.	O
	
Some	O
of	O
these	O
events	O
were	O
reported	O
in	O
patients	O
without	O
known	O
underlying	O
renal	O
disease	O
.	O
	
Arthralgias	B
and	O
muscle	B
pain	I
have	O
also	O
been	O
reported	O
in	O
cases	O
of	O
proximal	B
renal	I
tubulopathy	I
.	O
	
The	O
effect	O
of	O
anti-brentuximab	O
vedotin	O
antibodies	O
on	O
safety	O
and	O
efficacy	O
is	O
not	O
known	O
.	O
	
5.3	O
Thrombotic/Thromboembolic	O
Complications	O
In	O
two	O
controlled	O
clinical	O
trials	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
and	O
thrombocytopenia	O
,	O
3	O
%	O
(	O
31/955	O
)	O
treated	O
with	O
PROMACTA	O
experienced	O
a	O
thrombotic	B
event	I
(	O
1	O
%	O
in	O
patients	O
treated	O
with	O
PROMACTA	O
versus	O
less	O
than	O
1	O
%	O
for	O
placebo	O
)	O
.	O
	
If	O
drug-induced	O
hemolytic	O
anemia	O
is	O
suspected	O
,	O
discontinuation	O
of	O
Teflaro	O
should	O
be	O
considered	O
and	O
supportive	O
care	O
should	O
be	O
administered	O
to	O
the	O
patient	O
(	O
i.e	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
Ophthalmologic	O
:	O
Non-arteritic	B
anterior	I
ischemic	I
optic	I
neuropathy	I
(	O
NAION	B
)	O
,	O
a	O
cause	O
of	O
decreased	B
vision	I
including	O
permanent	B
loss	I
of	I
vision	I
,	O
has	O
been	O
reported	O
rarely	O
post-marketing	O
in	O
temporal	O
association	O
with	O
the	O
use	O
of	O
phosphodiesterase	O
type	O
5	O
(	O
PDE5	O
)	O
inhibitors	O
.	O
	
The	O
detection	O
of	O
an	O
immune	O
response	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assays	O
used	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
initiated	O
was	O
22	O
cycles	O
for	O
the	O
KRd	O
arm	O
and	O
14	O
cycles	O
for	O
the	O
Rd	O
arm	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
,	O
age	O
>	O
60	O
years	O
,	O
diabetes	O
mellitus	O
or	O
chronic	O
hypertension	O
)	O
,	O
estimate	O
the	O
GFR	O
through	O
laboratory	O
testing	O
.	O
	
5.7	O
Plasmodium	O
vivax	O
Infection	O
Coartem	O
Tablets	O
have	O
been	O
shown	O
in	O
limited	O
data	O
(	O
43	O
patients	O
)	O
to	O
be	O
effective	O
in	O
treating	O
the	O
erythrocytic	O
stage	O
of	O
P.	O
vivax	O
infection	O
.	O
	
Treatment	O
with	O
SIMPONI	O
ARIA	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
with	O
an	O
active	O
infection	O
,	O
including	O
clinically	O
important	O
localized	O
infections	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Avoid	O
treatment	O
in	O
the	O
periocular	O
area	O
.	O
	
For	O
the	O
purposes	O
of	O
assessing	O
Response-Guided	O
Therapy	O
milestones	O
,	O
a	O
confirmed	O
``	O
detectable	O
but	O
below	O
limit	O
of	O
quantification	O
''	O
HCV-RNA	O
result	O
should	O
not	O
be	O
considered	O
equivalent	O
to	O
an	O
``	O
undetectable	O
''	O
HCV-RNA	O
result	O
(	O
reported	O
as	O
``	O
Target	O
Not	O
Detected	O
''	O
or	O
``	O
HCV-RNA	O
Not	O
Detected	O
''	O
)	O
.	O
	
One	O
additional	O
patient	O
's	O
death	B
was	O
attributed	O
to	O
neutropenia	B
without	O
a	O
documented	O
infection	B
.	O
	
Adverse	O
reactions	O
are	O
listed	O
according	O
to	O
MedDRA	O
version	O
15.0	O
system	O
organ	O
class	O
.	O
	
5.5	O
Effect	O
of	O
P-gp	O
Inducers	O
and	O
Inhibitors	O
on	O
Dabigatran	O
Exposure	O
The	O
concomitant	O
use	O
of	O
PRADAXA	O
with	O
P-gp	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
)	O
reduces	O
exposure	O
to	O
dabigatran	O
and	O
should	O
generally	O
be	O
avoided	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
?	O
	
at	O
1-866-416-9637	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
During	O
the	O
clinical	O
trials	O
,	O
0.1	O
%	O
(	O
1/1308	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
discontinued	O
treatment	O
due	O
to	O
depression	B
compared	O
with	O
none	O
in	O
placebo-treated	O
subjects	O
(	O
0/506	O
)	O
.	O
	
Of	O
the	O
1,039	O
subjects	O
,	O
60	O
%	O
were	O
female	O
and	O
88	O
%	O
were	O
white	O
;	O
the	O
mean	O
age	O
was	O
46	O
years	O
.	O
	
Increases	B
in	I
serum	I
creatinine	I
occurred	O
within	O
the	O
first	O
4	O
weeks	O
of	O
treatment	O
and	O
remained	O
stable	O
through	O
48	O
to	O
96	O
weeks	O
.	O
	
These	O
reactions	O
can	O
occur	O
immediately	O
following	O
or	O
up	O
to	O
24	O
hours	O
after	O
administration	O
of	O
Kyprolis	O
.	O
	
Serious	O
adverse	O
reactions	O
reported	O
with	O
alglucosidase	O
alfa	O
included	O
anaphylaxis	B
,	O
which	O
presented	O
as	O
angioedema	B
,	O
throat	B
tightness	I
and	O
chest	B
pain	I
.	O
	
Table	O
3	O
summarizes	O
the	O
most	O
common	O
adverse	O
reactions	O
that	O
occurred	O
in	O
at	O
least	O
3	O
%	O
of	O
alglucosidase	O
alfa-treated	O
patients	O
and	O
with	O
a	O
higher	O
incidence	O
than	O
the	O
placebo-treated	O
patients	O
during	O
the	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
described	O
above	O
.	O
	
Withhold	O
Kyprolis	O
for	O
pulmonary	O
hypertension	O
until	O
resolved	O
or	O
returned	O
to	O
baseline	O
and	O
consider	O
whether	O
to	O
restart	O
Kyprolis	O
based	O
on	O
a	O
benefit/risk	O
assessment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
In	O
a	O
combined	O
analysis	O
of	O
Studies	O
115	O
and	O
121	O
,	O
the	O
frequency	O
of	O
adverse	O
reactions	O
(	O
all	O
grades	O
)	O
was	O
24	O
%	O
in	O
subjects	O
switching	O
to	O
STRIBILD	O
compared	O
to	O
6	O
%	O
of	O
subjects	O
in	O
either	O
group	O
who	O
stayed	O
on	O
their	O
baseline	O
antiretroviral	O
regimen	O
,	O
RTV-boosted	O
PI	O
+	O
TRUVADA	O
or	O
NNRTI	O
+	O
TRUVADA	O
.	O
	
Pool	O
of	O
Placebo-Controlled	O
Trials	O
The	O
data	O
in	O
Table	O
1	O
is	O
derived	O
from	O
four	O
26-week	O
placebo-controlled	O
trials	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Laryngeal	O
attacks	O
:	O
Following	O
treatment	O
of	O
laryngeal	O
attacks	O
with	O
FIRAZYR	O
,	O
advise	O
patients	O
to	O
seek	O
immediate	O
medical	O
attention	O
.	O
	
Vascular	O
Disorders	O
superficial	B
phlebitis	I
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
SIMPONI	O
ARIA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
a	O
history	O
of	O
CHF	O
and	O
SIMPONI	O
ARIA	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
CHF	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
ENDOMETRIAL	B
CANCER	I
,	O
CARDIOVASCULAR	B
DISORDERS	I
,	O
AND	O
PROBABLE	O
DEMENTIA	B
WARNING	O
:	O
ENDOMETRIAL	B
CANCER	I
,	O
CARDIOVASCULAR	B
DISORDERS	I
,	O
AND	O
PROBABLE	O
DEMENTIA	B
*	O
Women	O
taking	O
DUAVEE	O
should	O
not	O
take	O
additional	O
estrogens	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
There	O
is	O
an	O
increased	O
risk	O
of	O
endometrial	B
cancer	I
in	O
a	O
woman	O
with	O
a	O
uterus	O
who	O
uses	O
unopposed	O
estrogens	O
.	O
	
In	O
most	O
cases	O
,	O
this	O
is	O
a	O
consequence	O
of	O
weakening	O
of	O
muscles	O
in	O
the	O
area	O
of	O
injection	O
that	O
are	O
involved	O
in	O
breathing	O
or	O
swallowing	O
.	O
	
The	O
incidence	O
of	O
non-hematologic	O
,	O
non-infectious	O
,	O
adverse	O
events	O
(	O
all	O
Grades	O
)	O
in	O
Study	O
1	O
,	O
Study	O
2	O
,	O
and	O
the	O
EMTP	O
trial	O
is	O
provided	O
in	O
Table	O
1	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bausch	O
&	O
Lomb	O
Incorporated	O
at	O
1-800-323-0000	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Topical	O
Ophthalmic	O
Use	O
Only	O
.	O
	
The	O
most	O
frequent	O
serious	O
adverse	O
reactions	O
reported	O
in	O
patients	O
treated	O
with	O
XALKORI	O
were	O
pneumonia	B
(	O
4.1	O
%	O
)	O
,	O
pulmonary	B
embolism	I
(	O
3.5	O
%	O
)	O
,	O
dyspnea	B
(	O
2.3	O
%	O
)	O
,	O
and	O
ILD	B
(	O
2.9	O
%	O
)	O
.	O
	
Among	O
the	O
patients	O
who	O
experienced	O
diarrhea	O
,	O
the	O
median	O
number	O
of	O
episodes	O
of	O
diarrhea	O
per	O
patient	O
during	O
treatment	O
with	O
BOSULIF	O
was	O
3	O
(	O
range	O
1-221	O
)	O
.	O
	
(	O
5.2	O
)	O
*	O
Lymphopenia	B
:	O
Obtain	O
a	O
CBC	O
including	O
lymphocyte	O
count	O
before	O
initiating	O
TECFIDERA	O
,	O
after	O
6	O
months	O
,	O
and	O
every	O
6	O
to	O
12	O
months	O
thereafter	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
in	O
Study	O
1	O
and	O
Study	O
2	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
thrombocytopenia	B
,	O
neutropenia	B
,	O
diarrhea	B
,	O
anemia	B
,	O
fatigue	B
,	O
musculoskeletal	B
pain	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
rash	B
,	O
nausea	B
,	O
and	O
pyrexia	B
.	O
	
Symptoms	O
include	O
fever	B
,	O
chills	B
,	O
pruritus	B
and	O
rash	B
.	O
	
7	O
)	O
]	O
EXCERPT	O
:	O
Cervical	O
Dystonia	O
Most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
5	O
%	O
of	O
patients	O
)	O
are	O
:	O
muscular	B
weakness	I
,	O
dysphagia	B
,	O
dry	B
mouth	I
,	O
injection	B
site	I
discomfort	I
,	O
fatigue	B
,	O
headache	B
,	O
neck	B
pain	I
,	O
musculoskeletal	B
pain	I
,	O
dysphonia	B
,	O
injection	B
site	I
pain	I
,	O
and	O
eye	B
disorders	I
.	O
	
Glucagon-like	O
peptide	O
(	O
GLP-1	O
)	O
receptor	O
agonists	O
have	O
induced	O
thyroid	B
C-cell	I
adenomas	I
in	O
mice	O
and	O
rats	O
at	O
clinically	O
relevant	O
exposures	O
.	O
	
Other	O
Adverse	O
Reactions	O
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
in	O
controlled	O
trials	O
of	O
Crohn	O
's	O
disease	O
were	O
described	O
above	O
.	O
	
BK	B
virus-associated	I
nephropathy	I
was	O
reported	O
in	O
6	O
NULOJIX	O
patients	O
(	O
4	O
of	O
which	O
resulted	O
in	O
graft	O
loss	O
)	O
and	O
6	O
cyclosporine	O
patients	O
(	O
none	O
of	O
which	O
resulted	O
in	O
graft	O
loss	O
)	O
by	O
Year	O
3	O
.	O
	
(	O
5.9	O
)	O
5.1	O
Cytokine	O
Release	O
Syndrome	O
Cytokine	B
Release	I
Syndrome	I
(	O
CRS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
Summary	O
of	O
Clinical	O
Trials	O
in	O
Chronic	O
Lymphocytic	O
Leukemia	O
The	O
safety	O
data	O
reflect	O
subject	O
exposure	O
to	O
Zydelig	O
from	O
Study	O
1	O
,	O
in	O
which	O
218	O
subjects	O
with	O
relapsed	O
CLL	O
received	O
up	O
to	O
8	O
doses	O
of	O
rituximab	O
with	O
or	O
without	O
Zydelig	O
150	O
mg	O
twice	O
daily	O
.	O
	
If	O
a	O
patient	O
is	O
exposed	O
to	O
measles	O
,	O
prophylaxis	O
with	O
pooled	O
intramuscular	O
immunoglobulin	O
(	O
IG	O
)	O
may	O
be	O
indicated	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=	O
0.1	O
%	O
of	O
subjects	O
treated	O
with	O
EOVIST	O
.	O
	
During	O
the	O
initial	O
phase	O
of	O
combination	O
antiretroviral	O
treatment	O
,	O
patients	O
whose	O
immune	O
system	O
responds	O
may	O
develop	O
an	O
inflammatory	B
response	I
to	O
indolent	O
or	O
residual	O
opportunistic	B
infections	I
(	O
such	O
as	O
Mycobacterium	B
avium	I
infection	I
,	O
cytomegalovirus	B
,	O
Pneumocystis	B
jiroveci	I
pneumonia	I
(	O
PCP	B
)	O
or	O
tuberculosis	B
)	O
,	O
which	O
may	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
collagenase	O
clostridium	O
histolyticum	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
The	O
most	O
frequent	O
serious	O
adverse	O
reactions	O
that	O
occurred	O
were	O
pneumonia	B
(	O
15	O
%	O
)	O
,	O
diarrhea	B
(	O
11	O
%	O
)	O
,	O
and	O
pyrexia	B
(	O
9	O
%	O
)	O
.	O
	
These	O
patients	O
should	O
also	O
be	O
instructed	O
to	O
carry	O
a	O
warning	O
card	O
indicating	O
that	O
they	O
may	O
need	O
supplementary	O
systemic	O
corticosteroids	O
during	O
periods	O
of	O
stress	O
,	O
a	O
severe	O
COPD	O
exacerbation	O
,	O
or	O
a	O
severe	O
asthma	O
attack	O
.	O
	
Grade	O
3-4	O
cardiac	B
failure	I
occurred	O
in	O
0.2	O
%	O
of	O
patients	O
taking	O
placebo	O
.	O
	
It	O
is	O
possible	O
that	O
systemic	O
corticosteroid	O
effects	O
such	O
as	O
hypercorticism	B
and	O
adrenal	B
suppression	I
(	O
including	O
adrenal	B
crisis	I
)	O
may	O
appear	O
in	O
a	O
small	O
number	O
of	O
patients	O
who	O
are	O
sensitive	O
to	O
these	O
effects	O
.	O
	
During	O
withdrawal	O
from	O
oral	O
corticosteroids	O
,	O
some	O
patients	O
may	O
experience	O
symptoms	O
of	O
systemically	O
active	O
corticosteroid	O
withdrawal	O
(	O
e.g.	O
,	O
joint	O
and/or	O
muscular	O
pain	O
,	O
lassitude	O
,	O
depression	O
)	O
despite	O
maintenance	O
or	O
even	O
improvement	O
of	O
respiratory	O
function	O
.	O
	
Monitor	O
and	O
treat	O
promptly	O
per	O
standard	O
of	O
care	O
until	O
signs	O
and	O
symptoms	O
resolve	O
(	O
5.4	O
)	O
.	O
	
This	O
reflects	O
its	O
alpha1-adrenergic	O
antagonist	O
properties	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
volume	B
depletion	I
(	O
including	O
reports	O
of	O
dehydration	B
,	O
hypovolemia	B
,	O
orthostatic	B
hypotension	I
,	O
or	O
hypotension	B
)	O
are	O
shown	O
in	O
Table	O
2	O
for	O
the	O
12-study	O
and	O
13-study	O
,	O
short-term	O
,	O
placebo-controlled	O
pools	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
reported	O
within	O
48	O
weeks	O
of	O
treatment	O
and	O
in	O
at	O
least	O
1	O
%	O
of	O
subjects	O
treated	O
with	O
JUBLIA	O
and	O
those	O
reported	O
in	O
subjects	O
treated	O
with	O
the	O
vehicle	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
the	O
postmarketing	O
use	O
of	O
NESINA	O
.	O
	
Cervical	O
Dystonia	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
DYSPORT	O
(	O
r	O
)	O
in	O
357	O
cervical	O
dystonia	O
patients	O
in	O
6	O
studies	O
.	O
	
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
(	O
2.3	O
)	O
]	O
5.2	O
Infections	O
Infection	B
,	O
including	O
pneumonia	B
,	O
sepsis	B
,	O
septic	B
shock	I
,	O
and	O
death	B
have	O
occurred	O
in	O
adult	O
and	O
pediatric	O
patients	O
in	O
clinical	O
trials	O
and	O
in	O
postmarketing	O
reports	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
in	O
children	O
(	O
>	O
12	O
%	O
)	O
are	O
pyrexia	B
,	O
cough	B
,	O
vomiting	B
,	O
anorexia	B
,	O
and	O
headache	B
.	O
	
If	O
skin	O
reactions	O
are	O
severe	O
or	O
progressive	O
,	O
withhold	O
or	O
discontinue	O
TREANDA	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Besivance	O
in	O
approximately	O
1,000	O
patients	O
between	O
1	O
and	O
98	O
years	O
old	O
with	O
clinical	O
signs	O
and	O
symptoms	O
of	O
bacterial	O
conjunctivitis	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
compared	O
directly	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Laboratory	O
abnormalities	O
are	O
described	O
separately	O
in	O
Table	O
11	O
.	O
	
This	O
drop	O
in	O
body	O
estrogen	O
levels	O
causes	O
the	O
``	O
change	O
of	O
life	O
''	O
or	O
menopause	O
(	O
the	O
end	O
of	O
monthly	O
menstrual	O
periods	O
)	O
.	O
	
(	O
5.1	O
)	O
*	O
Acute	B
Renal	I
Failure	I
:	O
Monitor	O
serum	O
creatinine	O
regularly	O
(	O
5.2	O
)	O
*	O
Tumor	B
Lysis	I
Syndrome	I
(	O
TLS	B
)	O
:	O
Administer	O
pre-treatment	O
hydration	O
.	O
	
(	O
5.13	O
)	O
*	O
Embryo-fetal	B
Toxicity	I
:	O
Kyprolis	O
can	O
cause	O
fetal	B
harm	I
.	O
	
Monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
cardiac	O
failure	O
throughout	O
treatment	O
with	O
INLYTA	O
.	O
	
At	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
,	O
withhold	O
GILENYA	O
and	O
perform	O
an	O
appropriate	O
diagnostic	O
evaluation	O
.	O
	
If	O
unexplained	O
or	O
clinically	O
significant	O
weight	O
loss	O
occurs	O
,	O
evaluate	O
weight	O
loss	O
and	O
consider	O
discontinuation	O
of	O
OTEZLA	O
(	O
5.2	O
)	O
*	O
Drug	O
Interactions	O
:	O
Use	O
with	O
strong	O
cytochrome	O
P450	O
enzyme	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
phenobarbital	O
,	O
carbamazepine	O
,	O
phenytoin	O
)	O
is	O
not	O
recommended	O
because	O
loss	O
of	O
efficacy	O
may	O
occur	O
(	O
5.3,7.1	O
)	O
5.1	O
Depression	O
Treatment	O
with	O
OTEZLA	O
is	O
associated	O
with	O
an	O
increase	O
in	O
adverse	O
reactions	O
of	O
depression	B
.	O
	
Therefore	O
,	O
if	O
ENTEREG	O
is	O
administered	O
to	O
these	O
patients	O
,	O
they	O
should	O
be	O
monitored	O
for	O
gastrointestinal	O
adverse	O
reactions	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
treatment	O
with	O
STRIBILD	O
,	O
the	O
RTV-boosted	O
PI	O
,	O
or	O
the	O
NNRTI	O
due	O
to	O
adverse	O
events	O
,	O
was	O
2	O
%	O
,	O
3	O
%	O
and	O
1	O
%	O
,	O
respectively	O
.	O
	
Reduce	O
or	O
withhold	O
dose	O
as	O
appropriate	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
If	O
CDAD	O
is	O
confirmed	O
,	O
discontinue	O
antibacterials	O
not	O
directed	O
against	O
C.	O
difficile	O
,	O
if	O
possible	O
.	O
	
5.8	O
Venous	O
Thrombosis	O
Venous	B
thromboembolic	I
events	I
(	O
including	O
deep	B
venous	I
thrombosis	I
and	O
pulmonary	B
embolism	I
)	O
have	O
been	O
observed	O
with	O
Kyprolis	O
.	O
	
Table	O
7	O
:	O
Bleeding	B
Results	O
in	O
the	O
AMPLIFY-EXT	O
Study	O
ELIQUIS	O
2.5	O
mg	O
bidN=840n	O
(	O
%	O
)	O
ELIQUIS	O
5	O
mg	O
bidN=811n	O
(	O
%	O
)	O
PlaceboN=826n	O
(	O
%	O
)	O
*	O
CRNM	B
=	O
clinically	B
relevant	I
nonmajor	I
bleeding.Events	O
associated	O
with	O
each	O
endpoint	O
were	O
counted	O
once	O
per	O
subject	O
,	O
but	O
subjects	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
endpoints	O
.	O
	
Patients	O
should	O
be	O
observed	O
for	O
an	O
appropriate	O
period	O
of	O
time	O
after	O
administration	O
of	O
KALBITOR	O
,	O
taking	O
into	O
account	O
the	O
time	O
to	O
onset	O
of	O
anaphylaxis	O
seen	O
in	O
clinical	O
trials	O
.	O
	
*	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Across	O
8	O
Phase	O
III	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
MTC	B
was	O
diagnosed	O
in	O
1	O
patient	O
receiving	O
TANZEUM	O
and	O
1	O
patient	O
receiving	O
placebo	O
.	O
	
JC	B
virus	I
infection	I
resulting	O
in	O
PML	B
and	O
death	B
can	O
occur	O
in	O
patients	O
receiving	O
ADCETRIS	O
(	O
5.9	O
,	O
6.2	O
)	O
.	O
	
5.11	O
Seizures	O
Seizures	B
were	O
reported	O
in	O
0	O
%	O
and	O
0.3	O
%	O
(	O
0/572	O
,	O
1/379	O
)	O
of	O
adult	O
patients	O
treated	O
with	O
doses	O
of	O
5	O
mg	O
and	O
10	O
mg	O
twice	O
daily	O
of	O
SAPHRIS	O
,	O
respectively	O
,	O
compared	O
to	O
0	O
%	O
(	O
0/503	O
,	O
0/203	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
in	O
short-term	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
,	O
respectively	O
.	O
	
Monitor	O
HBV	O
carriers	O
during	O
and	O
several	O
months	O
after	O
therapy	O
.	O
	
Routine	O
monthly	O
pregnancy	O
tests	O
must	O
be	O
performed	O
during	O
this	O
time	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
(	O
5.4	O
)	O
*	O
Renal	B
Impairment	I
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
reporting	O
severe	O
adverse	O
gastrointestinal	O
reactions	O
.	O
	
In	O
addition	O
,	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
severe	O
hypersensitivity	O
to	O
milk	O
proteins	O
.	O
	
*	O
Malignancies	B
-	O
More	O
cases	O
of	O
lymphoma	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF-blockers	O
compared	O
with	O
patients	O
in	O
the	O
control	O
groups	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Intensive	O
measures	O
may	O
be	O
required	O
for	O
severe	O
diarrhea	O
and	O
electrolyte	O
imbalance	O
.	O
	
Given	O
the	O
similar	O
structural	O
formula	O
of	O
atropine	O
to	O
aclidinium	O
,	O
patients	O
with	O
a	O
history	O
of	O
hypersensitivity	O
reactions	O
to	O
atropine	O
should	O
be	O
closely	O
monitored	O
for	O
similar	O
hypersensitivity	O
reactions	O
to	O
TUDORZA	O
PRESSAIR	O
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
Oral	O
contraceptives	O
containing	O
lower	O
doses	O
of	O
norethindrone	O
and	O
other	O
forms	O
of	O
hormonal	O
contraception	O
have	O
not	O
been	O
studied	O
or	O
are	O
contraindicated	O
.	O
	
Eye	O
Disorders	O
:	O
vision	B
blurred	I
.	O
	
Long-term	O
Safety	O
Trials	O
TUDORZA	O
PRESSAIR	O
was	O
studied	O
in	O
three	O
long	O
term	O
safety	O
trials	O
,	O
two	O
double	O
blind	O
and	O
one	O
open	O
label	O
,	O
ranging	O
from	O
40	O
to	O
52	O
weeks	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
COPD	O
.	O
	
Consider	O
the	O
potential	O
for	O
an	O
increased	O
risk	O
of	O
thromboembolism	O
when	O
administering	O
PROMACTA	O
to	O
patients	O
with	O
known	O
risk	O
factors	O
for	O
thromboembolism	O
(	O
e.g.	O
,	O
Factor	O
V	O
Leiden	O
,	O
ATIII	O
deficiency	O
,	O
antiphospholipid	O
syndrome	O
,	O
chronic	O
liver	O
disease	O
)	O
.	O
	
Both	O
patients	O
had	O
markedly	O
elevated	O
serum	O
calcitonin	O
levels	O
at	O
baseline	O
.	O
	
If	O
reactivation	O
occurs	O
,	O
stop	O
CIMZIA	O
and	O
begin	O
anti-viral	O
therapy	O
(	O
5.5	O
)	O
*	O
Demyelinating	B
disease	I
,	O
exacerbation	O
or	O
new	O
onset	O
,	O
may	O
occur	O
(	O
5.6	O
)	O
*	O
Cytopenias	B
,	O
pancytopenia	B
-	O
advise	O
patients	O
to	O
seek	O
immediate	O
medical	O
attention	O
if	O
symptoms	O
develop	O
,	O
and	O
consider	O
stopping	O
CIMZIA	O
(	O
5.7	O
)	O
*	O
Lupus-like	B
syndrome	I
-	O
stop	O
CIMZIA	O
if	O
syndrome	O
develops	O
(	O
5.9	O
)	O
5.1	O
Risk	O
of	O
Serious	O
Infections	O
[	O
see	O
Boxed	O
Warning	O
]	O
Patients	O
treated	O
with	O
CIMZIA	O
are	O
at	O
an	O
increased	O
risk	O
for	O
developing	O
serious	O
infections	B
involving	O
various	O
organ	O
systems	O
and	O
sites	O
that	O
may	O
lead	O
to	O
hospitalization	O
or	O
death	B
.	O
	
5.4	O
Hypersensitivity	O
Reactions	O
Across	O
8	O
Phase	O
III	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
a	O
serious	O
hypersensitivity	B
reaction	I
with	O
pruritus	B
,	O
rash	B
,	O
and	O
dyspnea	B
occurred	O
in	O
a	O
patient	O
treated	O
with	O
TANZEUM	O
.	O
	
Transplant	O
recipients	O
who	O
are	O
EBV	O
seronegative	O
,	O
or	O
with	O
unknown	O
serostatus	O
,	O
should	O
not	O
receive	O
NULOJIX	O
[	O
see	O
Boxed	O
Warning	O
and	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
*	O
Embryo-fetal	B
toxicity	I
:	O
Fetal	B
harm	I
can	O
occur	O
.	O
	
(	O
2.4	O
,	O
5.1	O
,	O
14.1	O
)	O
(	O
B	O
)	O
SPINAL/EPIDURAL	O
HEMATOMA	O
:	O
spinal	B
hematomas	I
may	O
occur	O
in	O
patients	O
treated	O
with	O
ELIQUIS	O
who	O
are	O
receiving	O
neuraxial	O
anesthesia	O
or	O
undergoing	O
spinal	O
puncture	O
.	O
	
Monitor	O
patients	O
for	O
visual	O
signs	O
and	O
symptoms	O
of	O
uveitis	O
(	O
e.g.	O
,	O
change	O
in	O
vision	O
,	O
photophobia	O
,	O
eye	O
pain	O
)	O
.	O
	
Non-infectious	B
pneumonitis	I
was	O
reported	O
in	O
up	O
to	O
19	O
%	O
of	O
patients	O
treated	O
with	O
AFINITOR	O
in	O
clinical	O
trials	O
.	O
	
Major	O
2	O
(	O
0.2	O
)	O
1	O
(	O
0.1	O
)	O
4	O
(	O
0.5	O
)	O
CRNM*	O
25	O
(	O
3.0	O
)	O
34	O
(	O
4.2	O
)	O
19	O
(	O
2.3	O
)	O
Major	O
+	O
CRNM	B
27	O
(	O
3.2	O
)	O
35	O
(	O
4.3	O
)	O
22	O
(	O
2.7	O
)	O
Minor	O
75	O
(	O
8.9	O
)	O
98	O
(	O
12.1	O
)	O
58	O
(	O
7.0	O
)	O
All	O
94	O
(	O
11.2	O
)	O
121	O
(	O
14.9	O
)	O
74	O
(	O
9.0	O
)	O
Adverse	O
reactions	O
occurring	O
in	O
>	O
=1	O
%	O
of	O
patients	O
in	O
the	O
AMPLIFY-EXT	O
study	O
are	O
listed	O
in	O
Table	O
8	O
.	O
	
Other	O
adverse	O
reactions	O
indicative	O
of	O
hypersensitivity	B
reactions	O
included	O
the	O
following	O
:	O
pruritus	B
(	O
5	O
%	O
)	O
,	O
rash	B
(	O
3	O
%	O
)	O
,	O
and	O
urticaria	B
(	O
2	O
%	O
)	O
.	O
	
Pneumonia	O
In	O
the	O
pool	O
of	O
7	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
the	O
adverse	O
reaction	O
of	O
pneumonia	B
was	O
reported	O
more	O
frequently	O
in	O
patients	O
receiving	O
TANZEUM	O
(	O
1.8	O
%	O
)	O
than	O
in	O
patients	O
in	O
the	O
all-comparators	O
group	O
(	O
0.8	O
%	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Biogen	O
at	O
1-800-456-2255	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
In	O
the	O
event	O
of	O
a	O
severe	O
reaction	O
,	O
discontinue	O
DIFICID	O
.	O
	
Permanently	O
discontinue	O
TAFINLAR	O
and	O
trametinib	O
for	O
life-threatening	O
PE	O
.	O
	
The	O
youngest	O
alglucosidase	O
alfa-treated	O
patient	O
was	O
16	O
years	O
of	O
age	O
,	O
and	O
the	O
youngest	O
placebo-treated	O
patient	O
was	O
10	O
years	O
of	O
age	O
.	O
	
In	O
the	O
combination	O
study	O
,	O
the	O
incidence	O
of	O
venous	B
thromboembolic	I
events	I
in	O
the	O
first	O
12	O
cycles	O
was	O
13	O
%	O
in	O
the	O
Kyprolis	O
combination	O
arm	O
versus	O
6	O
%	O
in	O
the	O
control	O
arm	O
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
discontinued	O
treatment	O
due	O
to	O
any	O
adverse	O
reaction	O
during	O
the	O
controlled	O
clinical	O
trials	O
was	O
6.2	O
%	O
for	O
patients	O
receiving	O
BENLYSTA	O
and	O
7.1	O
%	O
for	O
patients	O
receiving	O
placebo	O
.	O
	
Of	O
the	O
2,254	O
subjects	O
,	O
70	O
%	O
were	O
male	O
and	O
84	O
%	O
were	O
white	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Therefore	O
,	O
co-administration	O
of	O
KALYDECO	O
with	O
strong	O
CYP3A	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
St.	O
John	O
's	O
wort	O
)	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
While	O
receiving	O
study	O
drug	O
through	O
Week	O
144	O
,	O
an	O
additional	O
11	O
%	O
of	O
STRIBILD	O
subjects	O
were	O
started	O
on	O
lipid	O
lowering	O
agents	O
,	O
compared	O
to	O
13	O
%	O
of	O
ATRIPLA	O
and	O
12	O
%	O
of	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
subjects	O
.	O
	
The	O
patients	O
were	O
also	O
not	O
taking	O
any	O
immunosuppressive	O
or	O
immunomodulatory	O
medications	O
concomitantly	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Forest	O
Laboratories	O
,	O
LLC	O
.	O
	
(	O
5.5	O
)	O
*	O
Gastrointestinal	B
perforation	I
,	O
including	O
death	B
,	O
have	O
occurred	O
.	O
	
In	O
Study	O
1	O
and	O
Study	O
2	O
,	O
safety	O
information	O
was	O
prospectively	O
and	O
systematically	O
collected	O
.	O
	
Two	O
subjects	O
(	O
0.13	O
%	O
)	O
tested	O
positive	O
for	O
binding	O
antibodies	O
at	O
baseline	O
.	O
	
Patients	O
in	O
the	O
chemotherapy	O
arm	O
received	O
pemetrexed	O
unless	O
they	O
had	O
received	O
pemetrexed	O
as	O
part	O
of	O
first-line	O
or	O
maintenance	O
treatment	O
.	O
	
Hypersensitivity	B
reactions	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
5.2	O
Aerosolization	O
of	O
Capsaicin	O
Aerosolization	O
of	O
capsaicin	O
can	O
occur	O
upon	O
rapid	O
removal	O
of	O
Qutenza	O
patches	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Merck	O
Sharp	O
&	O
Dohme	O
Corp.	O
,	O
a	O
subsidiary	O
of	O
Merck	O
&	O
Co.	O
,	O
Inc.	O
,	O
at	O
1-877-888-4231	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
(	O
6.2	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Serious	O
Adverse	O
Reactions	O
The	O
following	O
serious	O
and	O
otherwise	O
important	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
labeling	O
:	O
*	O
Hypersensitivity	B
Reactions	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.3	O
)	O
]	O
.	O
	
5.6	O
Other	O
Malignancies	O
There	O
are	O
reports	O
of	O
malignant	B
diseases	I
that	O
have	O
developed	O
in	O
patients	O
who	O
have	O
been	O
treated	O
with	O
TREANDA	O
,	O
including	O
myelodysplastic	B
syndrome	I
,	O
myeloproliferative	B
disorders	I
,	O
acute	B
myeloid	I
leukemia	I
and	O
bronchial	B
carcinoma	I
.	O
	
Laboratory	O
Tests	O
No	O
clinically	O
meaningful	O
changes	O
in	O
hematology	O
,	O
serum	O
chemistry	O
or	O
urinalysis	O
were	O
observed	O
in	O
patients	O
treated	O
with	O
NESINA	O
.	O
	
The	O
patient	O
had	O
no	O
other	O
identified	O
systemic	O
medical	O
conditions	O
resulting	O
in	O
compromised	O
immune	O
system	O
function	O
and	O
had	O
not	O
previously	O
been	O
treated	O
with	O
natalizumab	O
,	O
which	O
has	O
a	O
known	O
association	O
with	O
PML	O
.	O
	
Life-threatening	O
or	O
fatal	B
CRS	B
was	O
infrequently	O
reported	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
5.1	O
IOP	O
Increase	O
Prolonged	O
use	O
of	O
corticosteroids	O
may	O
result	O
in	O
glaucoma	B
with	O
damage	B
to	I
the	I
optic	I
nerve	I
,	O
defects	B
in	I
visual	I
acuity	I
.	O
	
Fungal	O
culture	O
should	O
be	O
taken	O
when	O
appropriate	O
.	O
	
Elderly	O
patients	O
and	O
patients	O
with	O
impaired	O
renal	O
function	O
were	O
more	O
susceptible	O
to	O
these	O
adverse	O
reactions	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
Monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
TLS	O
.	O
	
Adverse	O
reactions	O
led	O
to	O
study	O
treatment	O
discontinuation	O
in	O
16	O
%	O
of	O
patients	O
receiving	O
COMETRIQ	O
and	O
in	O
8	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Table	O
2	O
Adjudicated	O
Major	O
Bleeding	B
Events	O
in	O
Treated	O
Patientsa	O
aPatients	O
during	O
treatment	O
or	O
within	O
2	O
days	O
of	O
stopping	O
study	O
treatment	O
.	O
	
However	O
,	O
by	O
the	O
end	O
of	O
the	O
third	O
year	O
,	O
the	O
cumulative	O
incidence	O
of	O
NODAT	B
was	O
8	O
%	O
(	O
24/304	O
)	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
and	O
10	O
%	O
(	O
29/280	O
)	O
in	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
regimen	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
The	O
Medicines	O
Company	O
at	O
1-888-977-MDCO	O
(	O
6326	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Teflaro	O
was	O
evaluated	O
in	O
four	O
controlled	O
comparative	O
Phase	O
3	O
clinical	O
trials	O
(	O
two	O
in	O
ABSSSI	O
and	O
two	O
in	O
CABP	O
)	O
which	O
included	O
1300	O
adult	O
patients	O
treated	O
with	O
Teflaro	O
(	O
600	O
mg	O
administered	O
by	O
IV	O
over	O
1	O
hour	O
every	O
12h	O
)	O
and	O
1297	O
patients	O
treated	O
with	O
comparator	O
(	O
vancomycin	O
plus	O
aztreonam	O
or	O
ceftriaxone	O
)	O
for	O
a	O
treatment	O
period	O
up	O
to	O
21	O
days	O
.	O
	
For	O
each	O
subject	O
in	O
whom	O
a	O
Week	O
12	O
sample	O
was	O
selected	O
,	O
the	O
corresponding	O
Week	O
6	O
,	O
18	O
,	O
24	O
,	O
and	O
52	O
samples	O
were	O
assayed	O
if	O
they	O
were	O
also	O
binding	O
antibody	O
positive	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trial	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Peripheral	O
Neuropathy	O
:	O
In	O
Study	O
1	O
,	O
17	O
%	O
of	O
enrolled	O
patients	O
had	O
Grade	O
1	O
peripheral	B
neuropathy	I
and	O
3	O
%	O
of	O
patients	O
had	O
Grade	O
2	O
peripheral	B
neuropathy	I
at	O
baseline	O
.	O
	
Patients	O
with	O
liver	O
metastases	O
were	O
excluded	O
if	O
AST	O
and/or	O
ALT	O
>	O
5*	O
ULN	O
.	O
	
If	O
anaphylaxis	O
occurs	O
,	O
immediately	O
and	O
permanently	O
discontinue	O
administration	O
of	O
ADCETRIS	O
and	O
administer	O
appropriate	O
medical	O
therapy	O
.	O
	
Adverse	O
Reactions	O
N	O
(	O
Percent	O
of	O
patients	O
)	O
Headache	B
10	O
(	O
1.8	O
%	O
)	O
Musculoskeletal	B
pain	I
4	O
(	O
0.7	O
%	O
)	O
Blood	B
pressure	I
increased	I
a	O
4	O
(	O
0.7	O
%	O
)	O
Nausea	B
4	O
(	O
0.7	O
%	O
)	O
Fatigue	B
3	O
(	O
0.5	O
%	O
)	O
Injection	B
site	I
reaction	I
b	O
3	O
(	O
0.5	O
%	O
)	O
Anxiety	B
2	O
(	O
0.4	O
%	O
)	O
Back	B
pain	I
2	O
(	O
0.4	O
%	O
)	O
Claustrophobia	B
2	O
(	O
0.4	O
%	O
)	O
Dizziness	B
2	O
(	O
0.4	O
%	O
)	O
Feeling	B
cold	I
c	O
2	O
(	O
0.4	O
%	O
)	O
Insomnia	B
2	O
(	O
0.4	O
%	O
)	O
Neck	B
pain	I
2	O
(	O
0.4	O
%	O
)	O
Other	O
adverse	O
reactions	O
occurred	O
at	O
lower	O
frequencies	O
and	O
included	O
infusion	B
site	I
rash	I
,	O
dysgeusia	B
,	O
pruritis	B
,	O
urticaria	B
,	O
and	O
flushing	B
.	O
	
As	O
with	O
other	O
antipsychotics	O
,	O
FANAPT	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
conditions	O
that	O
potentially	O
lower	O
the	O
seizure	O
threshold	O
,	O
e.g.	O
,	O
Alzheimer	O
's	O
dementia	O
.	O
	
5.6	O
Fungal	O
Infections	O
Fungal	B
infections	I
of	I
the	I
cornea	I
are	O
particularly	O
prone	O
to	O
develop	O
coincidentally	O
with	O
long-term	O
local	O
steroid	O
application	O
.	O
	
*	O
Perforations	B
and	O
Fistulas	B
:	O
Gastrointestinal	B
perforations	I
occurred	O
in	O
3	O
%	O
and	O
fistula	B
formation	I
in	O
1	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
genital	O
mycotic	O
infections	O
and	O
uncircumcised	O
males	O
were	O
more	O
likely	O
to	O
develop	O
genital	B
mycotic	I
infections	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Pre-medicate	O
in	O
subsequent	O
cycles	O
for	O
milder	O
reactions	O
.	O
	
Hematologic	O
nadirs	O
were	O
observed	O
predominantly	O
in	O
the	O
third	O
week	O
of	O
therapy	O
.	O
	
Monitor	O
ECGs	O
and	O
discontinue	O
SIRTURO	O
if	O
significant	O
ventricular	O
arrhythmia	O
or	O
QTcF	O
interval	O
>	O
500	O
ms	O
develops	O
.	O
	
Atypical	O
Subtrochanteric	O
and	O
Diaphyseal	O
Fractures	O
In	O
the	O
osteoporosis	O
clinical	O
trial	O
program	O
,	O
atypical	B
femoral	I
fractures	I
were	O
reported	O
in	O
patients	O
treated	O
with	O
Prolia	O
.	O
	
N**	O
=	O
Number	O
of	O
patients	O
at	O
risk	O
at	O
Baseline	O
with	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
The	O
changes	O
averaged	O
less	O
than	O
10	O
mm	O
Hg	O
,	O
although	O
some	O
patients	O
had	O
greater	O
increases	O
and	O
these	O
changes	O
lasted	O
for	O
approximately	O
two	O
hours	O
after	O
patch	O
removal	O
.	O
	
System	O
Organ	O
Class/	O
Preferred	O
Term	O
Placebo	O
N=378	O
%	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
N=274	O
%	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
N=208	O
%	O
All	O
SAPHRIS	O
S	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
N=572	O
%	O
Gastrointestinal	O
disorders	O
Constipation	B
6	O
7	O
4	O
5	O
Dry	B
mouth	I
1	O
3	O
1	O
2	O
Oral	B
hypoesthesia	I
1	O
6	O
7	O
5	O
Salivary	B
hypersecretion	I
0	O
<	O
1	O
4	O
2	O
Stomach	B
discomfort	I
1	O
<	O
1	O
3	O
2	O
Vomiting	B
5	O
4	O
7	O
5	O
General	O
disorders	O
Fatigue	B
3	O
4	O
3	O
3	O
Irritability	B
<	O
1	O
2	O
1	O
2	O
Investigations	O
Increased	B
weight	I
<	O
1	O
2	O
2	O
3	O
Metabolism	O
disorders	O
Increased	B
appetite	I
<	O
1	O
3	O
0	O
2	O
Nervous	O
system	O
disorders	O
Akathisia*	O
3	O
4	O
11	O
6	O
Dizziness	B
4	O
7	O
3	O
5	O
Extrapyramidal	B
symptoms	I
(	O
excluding	O
akathisia	B
)	O
7	O
9	O
12	O
10	O
Somnolence	B
?	O
	
Discontinuations	O
due	O
to	O
adverse	O
drug	O
reactions	O
(	O
ADRs	O
)	O
were	O
5.2	O
%	O
in	O
the	O
INTELENCE	O
(	O
r	O
)	O
arm	O
and	O
2.6	O
%	O
in	O
the	O
placebo	O
arm	O
.	O
	
Permanently	O
discontinue	O
XTANDI	O
in	O
patients	O
who	O
develop	O
a	O
seizure	O
during	O
treatment	O
.	O
	
Antipsychotic	O
treatment	O
itself	O
,	O
however	O
,	O
may	O
suppress	O
(	O
or	O
partially	O
suppress	O
)	O
the	O
signs	O
and	O
symptoms	O
of	O
the	O
syndrome	O
and	O
thereby	O
may	O
possibly	O
mask	O
the	O
underlying	O
process	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
dehydration	B
,	O
thrombotic	B
thrombocytopenic	I
purpura/hemolytic	O
uremic	B
syndrome	I
(	O
TTP/HUS	O
)	O
,	O
tumor	B
lysis	I
syndrome	I
including	O
fatal	B
outcomes	O
,	O
and	O
posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
.	O
	
This	O
may	O
require	O
protective	O
drops	O
,	O
ointment	O
,	O
therapeutic	O
soft	O
contact	O
lenses	O
,	O
or	O
closure	O
of	O
the	O
eye	O
by	O
patching	O
or	O
other	O
means	O
.	O
	
Hypersensitivity	B
reactions	I
and	O
acute	B
kidney	I
injury	I
are	O
described	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
and	O
(	O
5.3	O
)	O
]	O
.	O
	
Do	O
not	O
exceed	O
the	O
recommended	O
dosage	O
and	O
frequency	O
of	O
administration	O
of	O
DYSPORT	O
(	O
r	O
)	O
.	O
	
Keratitis	B
was	O
reported	O
in	O
5	O
(	O
2.2	O
%	O
)	O
patients	O
in	O
Study	O
1	O
,	O
with	O
Grade	O
3	O
in	O
1	O
(	O
0.4	O
%	O
)	O
.	O
	
Subjects	O
ranged	O
in	O
age	O
from	O
18	O
to	O
83	O
years	O
,	O
with	O
an	O
overall	O
median	O
age	O
of	O
46	O
years	O
.	O
	
If	O
the	O
diagnosis	O
is	O
suspected	O
,	O
stop	O
Kyprolis	O
and	O
evaluate	O
.	O
	
The	O
risks	O
and	O
benefits	O
of	O
treatment	O
should	O
be	O
considered	O
prior	O
to	O
prescribing	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
to	O
patients	O
who	O
are	O
carriers	O
of	O
HBV	O
.	O
	
Primary	O
prophylaxis	O
with	O
G-CSF	O
should	O
be	O
considered	O
in	O
patients	O
with	O
high-risk	O
clinical	O
features	O
(	O
age	O
>	O
65	O
years	O
,	O
poor	O
performance	O
status	O
,	O
previous	O
episodes	O
of	O
febrile	O
neutropenia	O
,	O
extensive	O
prior	O
radiation	O
ports	O
,	O
poor	O
nutritional	O
status	O
,	O
or	O
other	O
serious	O
comorbidities	O
)	O
that	O
predispose	O
them	O
to	O
increased	O
complications	O
from	O
prolonged	O
neutropenia	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
If	O
symptoms	O
are	O
moderate	O
,	O
consider	O
interrupting	O
therapy	O
until	O
symptoms	O
improve	O
.	O
	
In	O
clinical	O
trials	O
,	O
121	O
patients	O
who	O
received	O
one	O
(	O
n=99	O
)	O
,	O
two	O
(	O
n=21	O
)	O
,	O
or	O
three	O
(	O
n=1	O
)	O
doses	O
of	O
VORAXAZE	O
were	O
evaluated	O
for	O
anti-glucarpidase	O
antibodies	O
.	O
	
If	O
signs	O
or	O
symptoms	O
of	O
spinal	O
hematoma	O
are	O
suspected	O
,	O
initiate	O
urgent	O
diagnosis	O
and	O
treatment	O
including	O
consideration	O
for	O
spinal	O
cord	O
decompression	O
even	O
though	O
such	O
treatment	O
may	O
not	O
prevent	O
or	O
reverse	O
neurological	O
sequelae	O
.	O
	
EBV	O
seropositive	O
patients	O
are	O
defined	O
as	O
having	O
evidence	O
of	O
acquired	O
immunity	O
shown	O
by	O
the	O
presence	O
of	O
IgG	O
antibodies	O
to	O
viral	O
capsid	O
antigen	O
(	O
VCA	O
)	O
and	O
EBV	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
.	O
	
In	O
these	O
trials	O
,	O
891	O
patients	O
were	O
treated	O
with	O
TUDORZA	O
PRESSAIR	O
at	O
the	O
recommended	O
dose	O
of	O
400	O
mcg	O
twice	O
daily	O
.	O
	
Cardiac	O
Disorders	O
:	O
angina	B
pectoris	I
,	O
atrial	B
fibrillation	I
,	O
cardiac	B
murmur	I
,	O
ECG	B
abnormal	I
,	O
palpitations	B
,	O
sinus	B
bradycardia	I
,	O
tachycardia	B
.	O
	
5.5	O
Renal	O
Impairment	O
In	O
patients	O
treated	O
with	O
GLP-1	O
receptor	O
agonists	O
,	O
there	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
renal	I
failure	I
and	O
worsening	B
of	I
chronic	I
renal	I
failure	I
,	O
which	O
may	O
sometimes	O
require	O
hemodialysis	O
.	O
	
Patients	O
have	O
frequently	O
presented	O
with	O
disseminated	O
rather	O
than	O
localized	O
disease	O
.	O
	
Reproductive	O
System	O
and	O
Breast	O
Changes	O
:	O
breast	B
pain	I
,	O
erectile	B
dysfunction	I
,	O
gynecomastia	B
.	O
	
The	O
trial	O
excluded	O
patients	O
with	O
abnormal	O
left	O
ventricular	O
ejection	O
fraction	O
or	O
cardiac	O
valve	O
morphology	O
(	O
>	O
=Grade	O
2	O
)	O
,	O
corrected	O
QT	O
interval	O
>	O
=480	O
milliseconds	O
on	O
electrocardiogram	O
,	O
or	O
a	O
known	O
history	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
deficiency	O
.	O
	
Monitoring	O
of	O
orthostatic	O
vital	O
signs	O
should	O
be	O
considered	O
in	O
all	O
such	O
patients	O
,	O
and	O
a	O
dose	O
reduction	O
should	O
be	O
considered	O
if	O
hypotension	O
occurs	O
.	O
	
Women	O
taking	O
DUAVEE	O
should	O
not	O
take	O
progestins	O
,	O
additional	O
estrogens	O
or	O
additional	O
estrogen	O
agonist/antagonists	O
.	O
	
Excluded	O
from	O
this	O
list	O
are	O
those	O
events	O
that	O
were	O
minor	O
,	O
those	O
with	O
no	O
plausible	O
relation	O
to	O
drug	O
use	O
,	O
and	O
reports	O
too	O
imprecise	O
to	O
be	O
meaningful	O
.	O
	
The	O
demographic	O
and	O
baseline	O
characteristics	O
of	O
the	O
long	O
term	O
safety	O
trials	O
were	O
similar	O
to	O
those	O
of	O
the	O
placebo-controlled	O
trials	O
.	O
	
Conjugated	O
estrogens	O
are	O
a	O
mixture	O
of	O
sodium	O
estrone	O
sulfate	O
and	O
sodium	O
equilin	O
sulfate	O
and	O
other	O
components	O
,	O
including	O
sodium	O
sulfate	O
conjugates	O
,	O
17alpha-dihydroequilin	O
,	O
17alpha-estradiol	O
,	O
and	O
17beta-dihydroequilin	O
.	O
	
Pyrexia	B
,	O
chills	B
,	O
and	O
nausea	B
were	O
the	O
most	O
common	O
reasons	O
cited	O
for	O
dose	O
reductions	O
and	O
pyrexia	B
,	O
chills	B
,	O
and	O
decreased	B
ejection	I
fraction	I
were	O
the	O
most	O
common	O
reasons	O
cited	O
for	O
dose	O
interruptions	O
of	O
TAFINLAR	O
and	O
trametinib	O
when	O
used	O
in	O
combination	O
.	O
	
Blood	O
and	O
Lymphatic	O
System	O
Disorders	O
:	O
anemia	B
,	O
idiopathic	B
thrombocytopenic	I
purpura	I
,	O
leukocytosis/leukopenia	O
,	O
neutropenia	B
,	O
pancytopenia	B
,	O
splenomegaly	B
,	O
thrombocytopenia	B
.	O
	
The	O
risk	O
may	O
also	O
be	O
increased	O
by	O
traumatic	O
or	O
repeated	O
epidural	O
or	O
spinal	O
puncture	O
.	O
	
These	O
hematomas	B
may	O
result	O
in	O
permanent	B
paralysis	I
.	O
	
5.8	O
Musculoskeletal	O
Pain	O
In	O
post-marketing	O
experience	O
,	O
severe	O
and	O
occasionally	O
incapacitating	O
muscle	B
pain	I
has	O
been	O
reported	O
in	O
patients	O
taking	O
Prolia	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
for	O
FULYZAQ	O
that	O
occurred	O
in	O
at	O
least	O
2	O
%	O
of	O
patients	O
and	O
at	O
a	O
higher	O
incidence	O
than	O
placebo	O
are	O
provided	O
in	O
Table	O
1	O
.	O
	
The	O
use	O
of	O
corticosteroids	O
may	O
be	O
indicated	O
.	O
	
A	O
minority	O
of	O
patients	O
(	O
approximately	O
17	O
%	O
)	O
who	O
tested	O
positive	O
for	O
anti-albiglutide	O
antibodies	O
also	O
transiently	O
tested	O
positive	O
for	O
antibodies	O
to	O
human	O
albumin	O
.	O
	
For	O
patients	O
who	O
test	O
positive	O
for	O
hepatitis	O
B	O
surface	O
antigen	O
,	O
consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
hepatitis	O
B	O
is	O
recommended	O
before	O
initiating	O
TNF-blocker	O
therapy	O
.	O
	
G-CSF	O
may	O
be	O
administered	O
to	O
reduce	O
the	O
risks	O
of	O
neutropenia	O
complications	O
associated	O
with	O
JEVTANA	O
use	O
.	O
	
They	O
had	O
a	O
mean	O
age	O
of	O
62	O
years	O
and	O
an	O
average	O
smoking	O
history	O
of	O
44	O
pack-years	O
,	O
with	O
54	O
%	O
identified	O
as	O
current	O
smokers	O
.	O
	
A	O
similar	O
trend	O
was	O
also	O
seen	O
in	O
the	O
cUTI	O
trial	O
.	O
	
Withhold	O
GILOTRIF	O
during	O
evaluation	O
of	O
patients	O
with	O
suspected	O
keratitis	O
,	O
and	O
if	O
diagnosis	O
of	O
ulcerative	O
keratitis	O
is	O
confirmed	O
,	O
treatment	O
with	O
GILOTRIF	O
should	O
be	O
interrupted	O
or	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
No	O
hypersensitivity	B
or	O
anaphylactic	B
reactions	I
were	O
reported	O
with	O
FIRAZYR	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
were	O
lymphopenia	B
,	O
hyperglycemia	B
,	O
anemia	B
,	O
hypophosphatemia	B
,	O
and	O
hypercholesterolemia	B
.	O
	
For	O
patients	O
who	O
develop	O
prolonged	O
Grade	O
2	O
cutaneous	O
adverse	O
reactions	O
lasting	O
more	O
than	O
7	O
days	O
,	O
intolerable	O
Grade	O
2	O
,	O
or	O
Grade	O
3	O
cutaneous	O
reactions	O
,	O
withhold	O
GILOTRIF	O
until	O
the	O
adverse	O
reaction	O
resolves	O
to	O
Grade	O
1	O
or	O
less	O
,	O
and	O
resume	O
GILOTRIF	O
with	O
appropriate	O
dose	O
reduction	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Changes	O
from	O
baseline	O
in	O
total	O
cholesterol	O
,	O
HDL-cholesterol	O
,	O
LDL-cholesterol	O
,	O
and	O
triglycerides	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
Liver	B
chemistry	I
elevations	I
consistent	O
with	O
immune	B
reconstitution	I
syndrome	I
were	O
observed	O
in	O
some	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
C	O
at	O
the	O
start	O
of	O
therapy	O
with	O
TIVICAY	O
,	O
particularly	O
in	O
the	O
setting	O
where	O
anti-hepatitis	O
therapy	O
was	O
withdrawn	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Patients	O
with	O
pre-	O
existing	O
swallowing	O
or	O
breathing	O
difficulties	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
complications	O
.	O
	
Adverse	O
reactions	O
of	O
venous	B
thromboembolism	I
were	O
reported	O
in	O
0.0	O
%	O
of	O
patients	O
treated	O
with	O
DUAVEE	O
and	O
0.1	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
5.2	O
Pancreatitis	O
Pancreatitis	B
has	O
been	O
reported	O
in	O
4	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
The	O
effects	O
of	O
DYSPORT	O
(	O
r	O
)	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	I
produce	I
symptoms	I
consistent	I
with	I
botulinum	I
toxin	I
effects	I
.	O
	
Renal	B
insufficiency	I
adverse	I
events	I
(	O
renal	B
impairment	I
,	O
acute	B
renal	I
failure	I
,	O
renal	B
failure	I
)	O
have	O
occurred	O
with	O
an	O
incidence	O
of	O
approximately	O
8	O
%	O
in	O
a	O
randomized	O
controlled	O
trial	O
.	O
	
Mean	O
changes	B
(	I
percent	I
changes	I
)	I
from	I
baseline	I
in	I
non-HDL-C	I
relative	O
to	O
placebo	O
were	O
2.1	O
mg/dL	O
(	O
1.5	O
%	O
)	O
and	O
5.1	O
mg/dL	O
(	O
3.6	O
%	O
)	O
with	O
INVOKANA	O
100	O
mg	O
and	O
300	O
mg	O
,	O
respectively	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
*	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
labeling	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
(	O
NSF	B
)	O
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
other	O
drugs	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
in	O
pregnant	O
women	O
using	O
JEVTANA	O
.	O
	
The	O
adverse	O
reaction	O
most	O
commonly	O
(	O
>	O
=1	O
%	O
on	O
APTIOM	O
)	O
leading	O
to	O
discontinuation	O
was	O
hyponatremia	B
.	O
	
Fatal	B
and	O
serious	O
cases	O
of	O
renal	B
failure	I
have	O
occurred	O
with	O
IMBRUVICA	O
therapy	O
.	O
	
(	O
6.1	O
)	O
Upper	O
Limb	O
Spasticity	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
are	O
:	O
urinary	B
tract	I
infection	I
,	O
nasopharyngitis	B
,	O
muscular	B
weakness	I
,	O
musculoskeletal	B
pain	I
,	O
dizziness	B
,	O
fall	B
and	O
depression	B
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Pfizer	O
,	O
Inc	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Anaphylaxis	B
and	O
angioedema	B
:	O
Discontinue	O
and	O
do	O
not	O
restart	O
TECFIDERA	O
if	O
these	O
occur	O
.	O
	
Patients	O
should	O
have	O
baseline	O
ophthalmologic	O
testing	O
by	O
an	O
ophthalmic	O
professional	O
and	O
follow-up	O
testing	O
every	O
6	O
months	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contactJanssen	O
Biotech	O
,	O
Inc.	O
at	O
1-800-JANSSEN	O
(	O
1-800-526-7736	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Monitor	O
for	O
pulmonary	O
symptoms	O
and	O
bilateral	O
interstitial	O
infiltrates	O
.	O
